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1. What is breast cancer
Cancer is the uncontrolled growth of cells into a malignant tumor. Breast cancer usually 
begins in the lobules, ducts, or connective tissue of the breast. The lobules are the glands 
that produce milk in nursing women. The ducts are thin tubes that drain milk from the 
lobules to the nipple. The connective tissue, consisting of fibrous and fatty tissue holds 
everything together. Most breast cancers begin in the ducts called ductal carcinoma in 
situ (DCIS) or, less common, in the lobules (lobular carcinoma in situ). Non-invasive can-
cers are confined to the milk ducts or lobules in the breast and do not evade into normal 
tissues. The non-invasive cancers may be pre-cancer and are sometimes called stage-0 
breast cancer. Breast cancers become invasive when they grow into healthy tissue and 
can eventually spread outside the breast (metastasize) to other parts in the body through 
blood vessels and lymph vessels. Breast cancer diagnosed at an early stage when it has 
not spread, is more likely to be treated successfully. Vice versa, women’s chances of 
surviving breast cancer are much lower when the cancer has spread throughout the body 
and effective treatment becomes increasingly difficult.(1)
breast cancer staging
Breast cancer staging is used by doctors, hospitals, and others to characterize breast 
cancer upon diagnosis. Staging describes where the cancer is present in the body in 
relation to the primary tumor and in particular whether, and to what extent the cancer has 
spread. Staging is useful for guiding the treatment strategy and assessing the prognosis 
of the cancer. A widely used staging system for cancer is the tumor, node, metastasis 
(TNM) system.(2) The T refers to the size of the primary tumor from which the cancer 
Figure 1 Anatomy of the female breast
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originates. The number of nearby lymph nodes involved is indicated with N. The M refers 
to metastasis of cancer and indicates whether the cancer has spread from the primary 
tumor to other parts in the body.
A similar staging system used by the Surveillance, Epidemiology, and End Results 
(SEER) program is the local-regional-distant system. In situ; abnormal cells, which may 
be a precursor of cancer, are present but have not spread to nearby tissue. Localized; 
cancer is present, but only in the organ where it started. Regional; the cancer has spread 
to nearby lymph nodes or organs. Distant; the cancer has spread from the place of the 
primary tumor to distant parts of the body.
2. etiology and risk-factors of breast cancer
Research has identified hormonal, lifestyle, environmental and genetic factors that may 
increase the risk of developing breast cancer. (3) Breast cancer is likely caused by a 
complex interaction of genetic makeup and environment. While there are known risk 
factors, many women who develop breast cancer have no evident risk factors other than 
being women and in the age range of 50-74 when breast cancer incidence is the highest. 
As women get older, there are more opportunities for genetic damage in the breast and 
Figure 2 Ductal Carcinoma in Situ (DCIS) – non-invaiseve or pre-invasive breast cancer.
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the entire body. At the same time, the human body becomes less capable of repairing 
genetic damage that may cause cancer.
A previous breast biopsy, dense breasts, and a positive family history of breast cancer 
are strong risk factors for breast cancer. Inherited cases of breast cancer are often associ-
ated with mutations in genes BRCA1, BRCA2, ATM, CHEK2, and PALB2 which are known 
to increase breast cancer risk by a large factor.(4) Minor risk factors include reproductive 
factors such as low parity, and young age at first menarche which expose women to 
female hormones estrogen and progesterone that are linked to breast cancer onset and 
growth.(3) Breast cancer single nucleotide polymorphisms (SNPs) are common variations 
in the DNA sequence associated with small increases or decreases in breast cancer risk.
(5) Polygenic risk combines information from multiple SNPs and could potentially achieve 
a degree of risk discrimination useful for population screening and be suitable to stratify 
risk in women of all ages.(6) Several other risk factors are related to personal behaviors, 
such as lack of exercise, alcohol consumption, smoking, and an unhealthy diet. While 
Table 1 Overview of major and minor risk-factors of breast cancer.(3)
Breast cancer risk factors Relative risk Reference population
Personal information
Age 20-30 Breast cancer at age 20 vs. at age 70
Body Mass Index 2 Obesity (BMI>30) vs. no obesity
Alcohol consumption 1.28 4 glasses containing alcohol vs. none
Breast density 4-6 Extremely dense vs. fatty breast
Hormonal / reproductive risk factors
Age of first menarche 1.5 Before age 10 vs. after age 16
Age of menopause 2 After age 55 vs. before age 40
Age of first live birth 3 After age 35 vs. before age 19
Breast feeding 0.8 More than 4 years vs. No breast feeding
Use of hormonal replacement therapy 2 10 years usage vs. never
Family history of breast cancer
First degree family history of breast cancer 3.6 2 first degree with breast cancer vs. none
Second degree family history of breast cancer 1.5 Second degree with breast cancer vs. none
Age of breast cancer onset 3 Onset before age 50 in sister vs. none
Ovarian cancer 1.5 Ovarian cancer in family vs. none
Personal history with breast cancer
Atypical ductal hyperplasia 4 Ductal hyperplasia vs. no hyperplasia
Previous breast biopsy 2 No previous breast biopsy
Lobular carcinoma in situ (LCIS) 4 LCIS vs. no LCIS
Genetic breast cancer risk
Single Nucleotide Polymorphisms 10 Top 1% vs. bottom 1% based on 77 SNPs
Mutations in BRCA 1/2 15 Mutation in BRCA genes vs. no mutation
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Figure 3 Worldwilde female breast cancer incidence in 2012. All incidence rates are age-standard-
ized to the 1960 world population. Source: Ferlay J. Soerjomataram I, Ervik M, et al. GLOBOCAN 
2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11.
Figure 4 Worldwilde female breast cancer mortality in 2012. All mortality rates are age-standardized 
to the 1960 world population. Source: Ferlay J. Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 
v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11.
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many known factors increase the risk of developing breast cancer, a large part of breast 
cancers are due to random, unpredictable, mistakes in DNA copying which is essential 
for cell division and life itself.
3. breast cancer epidemiology
breast cancer incidence worldwide
Breast cancer is a major health problem with an estimated 2.1 million new cases and 
0.63 million breast cancer deaths worldwide in 2018. (Figure 1, 2) In many developed 
countries around 1 in 8 (13%) women are diagnosed with breast cancer in their lifetime. 
(7)
Age-specific breast cancer incidence
Breast cancer correlates strongly with age regardless of race or ethnicity. At age 50 
around which most women start screening, 200 cases per 100,000 women are observed 
in the United States. The peak in incidence lies between ages 70 and 80. This age-
specific pattern is seen in most western countries.
Breast cancer incidence over time
Invasive breast cancer incidence has seen a sharp increase in the United States up to the 
year 2000. (Figure 5) After 2000, there was a drop in incidence up to 2003 which was 
followed by a period of relatively stable incidence levels. These changes over time have 
been attributed to the increase in use- and performance of mammography, changes in 
hormone use after 2000, risk factor prevalence, and differential birth cohort effects. The 
use of Hormone Replacement Therapy (HRT) was reduced in 2000-2003 as it became 
apparent at the time that it was associated with increased risk of breast cancer.(8, 9) This 
led to a decrease in breast cancer incidence up to 2003.
Breast cancer mortality
Breast cancer mortality was relatively stable up to the mid-nineties of the 20th century 
and gradually declined thereafter. The decrease in breast cancer mortality has been at-
tributed to the increase in screening, better access to healthcare, and advances in breast 
cancer.(10, 11)
breast cancer survival
Survival rates are an estimate of the percentage of patients who survive for a given 
period of time after a cancer diagnosis. Relative breast cancer survival compares survival 
among women with breast cancer to women of the same age without breast cancer. 
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Based on data over a 14-year period from 2000 to 2014, the 10-year survival rate for 
U.S. women diagnosed with breast cancer was 83.3% and varied strongly by stage at 
diagnosis. (Figure 8)
4. primary prevention of breast cancer
Primary prevention aims to prevent disease before it begins. This is typically done by 
changing unhealthy behavior or prevent exposure to hazardous chemicals or situations. 
In breast cancer, the modifi able risk factors include postmenopausal obesity, alcohol 
consumption, physical inactivity, and exposure to radiation. A healthy bodyweight, bal-
anced diet and regular physical activity reduce breast cancer risk and improve general 
health as well. A balanced diet is one that consists of suffi cient fruit, fi bers, vegetables, 
healthy fats, proteins and preferably no or little red or processed meat and added salt. 
In a proper diet the total caloric intake should maintain a healthy body mass index to 
prevent obesity. Physical activity should ideally be at least 30 minutes of walking, biking 
Figure 5 U.S. BC incidence by age, 2011-2015. Figure 6 U.S. BC incidence - age-adjusted
Figure 7 U.S. BC mortality, age-standardized ‘75-’13 Figure 8 U.S. age-specifi c BC mortality ’11-‘15
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or other sports according to the world cancer research fund. Further, primary preven-
tion among high risk women may entail the use of medications that modulate estrogen 
receptors such as tamoxifen and raloxifene.
5. secondary prevention of breast cancer
Screening aims at finding breast cancer in early stages of the disease when tumors 
are less likely to have spread in the body. Screening can find in healthy, asymptomatic 
women in multiple different ways. For example, breast self-examination is a screening 
technique which allows women to examine their breast tissue at home for any physical or 
visual changes. More modern screening techniques include the use of digital mammog-
raphy, ultrasound, magnetic resonance imaging (MRI), or Tomosynthesis. Mammography 
is an X-ray image taken of the breasts called a mammogram which has relatively high 
sensitivity and specificity. (12) Mammograms and other medical imaging techniques, 
allow radiologists to look for changes in breast tissue that could be pre-cursor, or early 
stage breast cancer.
benefits of screening
True positives screening outcomes correctly identify abnormalities in the breast as cancer. 
True negatives correctly provide reassurance when no cancer is present in the breast. 
Chances of successful treatment and survival are higher for breast cancer diagnosed at 
Figure 9 U.S. Survival Rates by Time Since Breast Cancer Diagnosis, 2000-2014.
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an early (localized) stage. Screening increases the number of early stage breast cancer 
and thereby improves breast cancer survival of the majority of screen-detected cancers. 
Next to life years gained, averting breast cancer deaths is an important goal of screening. 
In the absence of screening, more cancers are diagnosed at a more advanced stage of 
breast cancer. Consequently, more advanced treatment is necessary and if the cancer is 
lethal, life years are lost or quality of life is significantly reduced. Overall, regular screening 
at the population level provides large benefits for a small number of women, and harms 
among the majority of women who undergo screening but never develop breast cancer.
Figure 10 Three possible life-history scenarios. A: women without breast cancer, B:women with 
breast cancer who are not screened, C: women with breast cancer who are screened. In scenario 
C, the pre-clinical phase is the period of time between tumor inception and clinical diagnosis in the 
absence of screening. The sojourn time for a screening test, e.g., mammography, is the period of 
time within the pre-clinical phase that a cancer can be screen-detectable; this period can also be 
termed the pre-clinical screen-detectable phase. The point when the cancer is detected by screen-
ing depends on when the screening test is performed and the sensitivity of the screening test. The 
period before the sojourn time represents a period in which the tumor is present but undetectable 
by mammography. Should the sensitivity of mammography improve, or new types of screening tests 
evolve, the point of screen-detectability would be closer to tumor inception.
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harms of screening
On mammograms, tissue may show up that looks like breast cancer, but may in fact be 
benign (non-cancerous) tissue. If the abnormalities are flagged as breast cancer and 
additional imaging shows that there is no cancer, this is called a false positive screening 
that may cause unnecessary anxiety and distress. One other important harm of breast 
cancer screening is over diagnosis. Overdiagnosis is the diagnosis of breast cancer by 
screening that would never have caused symptoms and be diagnosed in the absence of 
screening in a woman’s lifetime. Besides false positives and overdiagnoses, false nega-
tive screening outcomes can also be harmful. False negatives may provide a sense of 
false reassurance while in fact cancer is growing in the breast. Lastly, regular screening 
increased the overall exposure to ionizing radiation and could lead to radiation-induced 
breast cancer in some cases.
Quality of life
Through screening, cancer diagnoses are advanced in time and in the majority of 
cases treatment can be less invasive and still be curative. In general, this results in a 
better quality of life for women who are diagnosed with breast cancer. For the majority 
of women who will never be diagnosed with breast cancer, mammography screening 
involves planning, travel, and waiting time. Before the actual mammogram, women may 
feel anxious or worry about the possible abnormal outcomes of the screening. Undergo-
ing screening means that women have to undress from the waist up and may feel pain, 
pressure and discomfort in their breasts from the mammogram. After the examination, it 
takes some time before women are notified about the outcomes of the screening. This 
waiting period could be experienced as uncertain and stressful, but may be worth the 
reassurance, be it early diagnosis of breast cancer. Because women differ in their willing-
ness to accept the harms of screening for potential benefits, a personal consideration is 
advised before attending screening.
6. breast cancer treatment
The majority of breast cancers will eventually metastasize without treatment. To prevent 
breast cancer death after diagnosis, the tumor is surgically removed and the patient 
usually receives adjuvant treatment to help decrease the risk of breast cancer recurring. 
Effective adjuvant treatments are commonly called systemic treatment and include: ra-
diation, chemotherapy, and hormone therapy. There are additional supplemental treat-
ments which might increase the effectiveness of these three treatments, but chemical, 
radiation, and hormonal treatments are the first ones considered to successfully treat 
breast cancer.(13)
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If breast cancer is contained in the breast regions, localized treatment is considered. 
To help prevent local recurrence, a surgeon will try to remove the tumor, possibly with 
surrounding tissue, and treat the patient with radiation. The molecular nature of the 
tumor may also determine whether chemo- and/or hormonal therapy is used. Systemic 
treatment comes into play when breast cancer has spread or metastasized to the lymph 
nodes. In this stage of breast cancer, surgery alone is not curative anymore and systemic 
therapies are considered. Neoadjuvant breast cancer treatment is applied before surgical 
intervention aiming to stop the cancer growth and shrink the tumor size before surgical 
intervention.(14)
In the past, radical mastectomy of the breast was much more common. This involved 
surgery to remove the entire breast including the axillary lymph nodes and chest wall. 
Today, this medical procedure is less common and lumpectomy, i.e., breast conserving 
surgery, is more common. Lumpectomy aims to remove the cancer while preserving as 
much of the normal breast as possible.
7. evidence on breast cancer screening
Large randomized trials have been introduced in 1960’s and ‘70’s and conducted 
throughout to the early 2000’s. These include the New York Health Insurance Plan (HIP) 
(15), Malmö I and II (16), Swedish two county trial(17), Canada I and II (18), Göteborg (19), 
Stockholm(20), and the UK age trial(21). These trials compared breast cancer incidence 
and mortality among women invited to screening to women not invited to screening. 
While most studies found a reduction in breast cancer mortality from screening, contro-
versy about the harms of breast cancer screening remains. In 2013, an independent panel 
extensively reviewed published work about the evidence on breast cancer screening to 
reach conclusions about the benefits and harms.(22) They found that 43 breast cancer 
deaths are prevented and 129 cases are overdiagnosed per 10,000 women screened 
triennially for 20 years from age 50 onwards in the UK.
In 2014, the International Agency for Research on Cancer (IARC) convened 29 inde-
pendent experts from 16 countries to review the scientific evidence of various methods 
of screening for breast cancer.(23) The IARC concludes that women in the age range of 
50 to 69 invited to mammography screening have a 23% breast cancer mortality reduc-
tion. Older women, in age ranges 70-74 also observed a substantial reduction in risk 
of breast cancer death. The reduction in risk of breast cancer death in studies among 
women aged 40 to 49 was less pronounced. Estimates of the cumulative risk of false 
positive results differ between organized programs and opportunistic screening. The 
cumulative risk of having at least one false-positive is about 20% for a woman who had 
10 screens between the ages of 50 and 70 years. Overdiagnosis was estimated to be in 
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the range of %1 to 10% of all breast cancer diagnoses, with point estimate of 6.5% based 
on data from European studies that adjusted for both lead time and trends in incidence 
between screened and unscreened women.
8. current breast cancer screening guidelines
Breast cancer screening guidelines recommending who should undergo screening, how 
often and at what ages vary within and among developed countries. The United States 
Preventive Services Task Force (USPSTF) 2016 guidelines recommend that women aged 
50 to 74 years of age be screened with digital mammography every two years. According 
to the USPSTF, screening before age 50 is an individual decision women should make 
including their values about the (possible) harms and benefits of screening and attitude 
towards breast cancer risk.(24)
The American Cancer Society (ACS) recommends that women between ages 40 and 
45 should have the choice to be screened based on their own considerations. Women 
between ages 45 and 54 are recommended to undergo annual mammography, followed 
by biennial screening between ages 55 and 74.(25) The International Agency for Research 
on Cancer (IARC), part of the World Health Organization (WHO), recommends women 
aged 50 to 69 to be screened and is next to the USPSTF one of the least intensive 
screening guidelines.(23) Overall, these guidelines agree that women aged 50 to 69 
should be screened and vary to some extent in screening initiation and stopping age 
and screening interval.
9. moving toWards risk-based breast cancer screening
Historically, breast cancer screening guidelines have been age-based even though we 
know that at any given age there is variability in breast cancer risk due to earlier men-
tioned risk factors. By better understanding which women are at increased or decreased 
breast cancer risk, risk stratification can target screening to those who are most likely 
to benefit from different screening strategies than currently recommended. This could 
individualize breast cancer care and potentially reduce the population-level harms of 
screening and increase the benefits. Projections for groups of women differing in risk due 
to family history, breast density, polygenic risk, and other risk factors have been made 
under various screening and treatment interventions by breast cancer simulation models 
in the chapters of this thesis.
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10. the use of models next to randomized controlled trials
Randomized clinical trials (RCT) are considered the gold standard to assess the effec-
tiveness of breast cancer screening and treatment interventions. However, there are 
several reasons why modeling is essential to complement and extend the evidence from 
randomized trials. First, RCTs to assess screening and treatment interventions with cause 
of death as primary outcome are time consuming and relatively expensive to set up. Sec-
ond, lifetime follow-up is difficult logistically as participants may move abroad, are lost 
to follow-up, or decide to stop their participation. Consequently, the long-term benefits 
and harms of medical interventions such as screening are difficult to assess. Third, trials 
are usually set up to evaluate a limited number of interventions. In screening this would 
be different starting ages, intervals, and treatment regimens. Fourth, in RCTs ethical 
concerns have to be taken into account. If routine screening of healthy women is part 
of usual practice, it could be unethical to include a non-screening (control) group in the 
trial that is at increased risk of late stage cancer. Finally, trials usually provide outcomes 
in a specific setting, for a specific group of people in a certain region with screening and 
treatment methods available at that time. We know screening and treatments methods 
have improved since the large mammography trials and are likely to have a different 
impact on breast cancer detection and breast cancer mortality. Simulation models can 
synthesize data on breast cancer epidemiology, population demographics, screening 
accuracy, and treatment effectiveness from different sources and produce outcomes for 
multiple screening and treatment strategies among varying risk groups.
microsimulation model miscan-fadia
In this thesis, MISCAN-Fadia which is an acronym for Microsimulation Screening Analysis 
– Fatal Diameter is used to make predictions about breast cancer incidence and mortality 
following from varying screening and treatment strategies, Chapter 2 of this thesis (26). 
The model simulates individual life histories from birth to death, with and without breast 
cancer, in the presence and in the absence of screening and treatment. Life histories are 
simulated according to discrete events such as birth, tumor inception, metastasis, and 
death from breast cancer or death from other causes. The model consists of four main 
components: demography, natural history of breast cancer, screening, and treatment. 
The impact of screening on the natural history of breast cancer is assessed by simulating 
continuous tumor growth and the “fatal diameter” concept. This concept implies that 
tumors diagnosed at a size that is between the screen detection threshold and the fatal 
diameter are cured, while tumors diagnosed at a diameter larger than the fatal tumor 
diameter metastasize and lead to breast cancer death.
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collaborative modeling
Erasmus Medical Center part of a collaborative modeling initiative called the cancer 
intervention and surveillance modeling network (CISNET). We use statistical modeling 
to improve understanding of cancer control interventions in prevention, screening, and 
treatment and their effects on population trends in incidence and mortality. Models are 
used to guide public health research and priorities, and they can aid in the development 
of optimal cancer control strategies. Collaborative modeling can enhance the rigor of 
modeling research using multiple independent models to answer the same research 
question. Conclusions supported by multiple independently developed models provide 
greater credibility than conclusions obtained from a single model.
11. research Questions and thesis outline
This thesis consists of three main parts: 1. Breast cancer micro-simulation modeling, 
2.Quantification of current breast cancer screening practice among average-risk women 
in the United States. 3. Outcome projections of risk-based screening strategies. This 
thesis concludes with a discussion of the work in this thesis in relation to the field of 
breast cancer screening.
part 1: breast cancer microsimulation: model, methods, 
comparison, and validation
Research question 1: How can model description, comparison, and validation con-
tribute to a better understanding of model predictions?
Chapter 2 provides an overview of the past, current and future applications of breast 
cancer simulation model MISCAN-FADIA. In chapter 3, different approaches to model-
ing the natural history ductal carcinoma in situ are compared. Chapter 4 presents an 
external validation and comparison of CISNET models´ breast cancer incidence and 
mortality predictions to the observed clinical trial outcomes. Chapter 5 investigates the 
impact of model structure and model assumptions about tumor onset and progression 
on predictions of breast cancer incidence and mortality.
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part 2: Quantifying the harms and benefits of age-based 
breast cancer screening in the united states.
Research question 2: What are the benefits and harms of current age-based breast 
cancer screening in the United States?
In chapter 6, the contributions associated with screening and treatment to breast can-
cer mortality reductions by molecular subtype-specific breast cancer are evaluated. In 
chapter 7, six simulation models use U.S. national data on incidence, digital mammog-
raphy performance, treatment effects, and other-cause mortality to evaluate screening 
outcomes among average risk women. In chapter 8, we estimated the distributions of 
radiation-induced breast cancer incidence and mortality from digital mammography 
screening while considering exposure from screening and diagnostic mammography and 
dose variation among women.
part 3: projecting the harms and benefits of risk-based 
breast cancer screening in the united states
Research question 3: To what extent can risk-based breast cancer screening improve 
the harm-benefit ratio of current age-based screening guidelines?
In chapter 9, we estimated the outcomes for various screening strategies in the U.S. 
tailored to women aged 50 years or older with various combinations of breast density 
and relative risk. Chapter 10 assessed screening approaches using first-degree family 
history (FH) and polygenic risk scores (PRS) to identify women for risk-based screening.
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abstract
The MISCAN-Fadia microsimulation model uses continuous tumor growth to simulate 
the natural history of breast cancer and has been used extensively to estimate the impact 
of screening and adjuvant treatment on breast cancer incidence and mortality trends. 
The model simulates individual life histories from birth to death, with and without breast 
cancer, in the presence and in the absence of screening and treatment. Life histories are 
simulated according to discrete events such as birth, tumor inception, the tumor’s clinical 
diagnosis diameter in the absence of screening, and death from breast cancer or death 
from other causes. MISCAN-Fadia consists of four main components: demography, natu-
ral history of breast cancer, screening, and treatment. Screening impact on the natural 
history of breast cancer is assessed by simulating continuous tumor growth and the “fatal 
diameter” concept. This concept implies that tumors diagnosed at a size that is between 
the screen detection threshold and the fatal diameter are cured, while tumors diagnosed 
at a diameter larger than the fatal tumor diameter metastasize and lead to breast cancer 
death. MISCAN-Fadia has been extended by including a different natural history for mo-
lecular subtypes based on a tumor’s estrogen receptor (ER) status and human epidermal 
growth factor receptor 2 (HER-2) status. In addition, personalized screening strategies 
that target women based on their risk such as breast density have been incorporated into 
the model. This personalized approach to screening will continue to develop in light of 
potential polygenic risk stratification possibilities and new screening modalities.
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introduction
Randomized trials are considered the gold standard to assess the efficacy of cancer 
screening interventions. However, ethical concerns, participants lost to follow-up, 
feasibility issues regarding the number of evaluated screening strategies, and limited 
quantification abilities of the harms of screening such as overdiagnosis, emphasize the 
need for ways to complement randomized trials. The breast cancer models of the Cancer 
Intervention and Surveillance Modeling Network (CISNET) simulate the effects of screen-
ing and treatment for lifetime follow up, with varying compliance rates, for an unlimited 
number of screening strategies, and thereby extrapolate the findings from randomized 
trials.
MISCAN-Fadia, acronym for Micro Simulation Screening Analysis – Fatal Diameter, 
has been part of CISNET since its start in 2000, usually referred to as Model E (i.e., 
Erasmus Medical Center). Before the development of MISCAN-Fadia, a microsimula-
tion model with discrete tumor progression was developed at Erasmus already in the 
1980’s to evaluate the effects of breast cancer screening in the Netherlands [1]. However, 
compared to observed stage distribution data, the model over-estimated the number of 
early-stage cancers diagnosed at subsequent screens. Sensitivity analysis of screening 
sensitivity did not lead to better estimates [2]. Moreover, it was difficult to explore differ-
ent natural history assumptions because tumor progression was directly linked to discrete 
stages. MISCAN-Fadia, with continuous tumor growth, was initiated to overcome this 
rigid property. This model was developed with the intent of creating a more biologically 
oriented breast cancer model to evaluate the impact of screening and treatment on 
breast cancer incidence and mortality. Since tumor size is measurable and tumor growth 
is continuous, these properties form the biological approach to modeling the natural 
history of breast cancer. In the model, a distinction is made between tumor biology 
(growth function) and other model variables that are more likely to vary by calendar year 
and possibly differ between geographical areas such as access to screening facilities, 
screening equipment and consequently screening test sensitivity, clinical diagnosis in the 
absence of screening due to fewer breast self-examinations and less public awareness of 
breast cancer risk. Sensitivity of a screening test is translated into a diameter size at which 
tumors become screen detectable. In MISCAN-Fadia, ductal carcinoma in situ (DCIS) as 
well as invasive tumors are simulated. Tumor properties like exponential growth rate, 
clinical diagnosis diameter, minimal diameter for screen detection and fatal diameter are 
drawn from probability distributions to account for variability between tumors. The fatal 
diameter concept implies that available treatment only cures tumors that are diagnosed 
at a smaller diameter than the tumor’s fatal diameter. Available treatment options are 
not sufficient for tumors diagnosed past their fatal diameter and these tumors will cause 
breast cancer death.
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Disease processes such as the moment of onset of breast cancer and progression or 
regression of DCIS and breast cancer are unobservable in reality. These are nonetheless 
important determinants that influence the balance of harms and benefits of screening 
and treatment. Modeling allows us to explore the effect of changing one of these unob-
servable factors on modelled outcomes such as breast cancer incidence and mortality. 
Likewise, it is possible to study the effect of changing tumor onset and tumor growth 
while keeping all other parameters unchanged to gain insight into the natural history 
of breast cancer and its interaction with cancer control interventions. To quantify the 
harms and benefits of different screening and treatment strategies, the model simulates 
the same female population twice. First, a population is simulated in the absence of 
screening, and second, in the presence of screening. Key outcomes such as the number 
of breast cancers, the number breast cancer deaths and over diagnosed breast cancers 
can be calculated for lifetime follow-up for any possible screening strategy.
Population demography, natural history of breast cancer, screening and treatment are 
the four main parts of the model. All model inputs and model parameters belong to 
one of these components and are either calibrated to data from trials or are based on 
empirical research [3-5]. This paper presents the current model status and in particular 
the progress and extensions with respect to the first model paper [6], as well as the latest 
model applications that explore the possibilities of risk-based breast cancer screening.
methods
discrete event-driven microsimulation
Discrete event simulation implies that the model moves from the time of one event (e.g., 
birth) to the next event (e.g., tumor onset). The events in a woman’s lifetime are discrete 
and mutually exclusive. Microsimulation modeling entails simulation of independent life 
histories that can be aggregated to estimate the effects of screening and treatment at 
the population level. Life histories are simulated according to discrete events such as 
birth, a possible tumor inception, the diameter of the tumor when it would be clinically 
diagnosed in the absence of screening, a date of death from other causes, or, for woman 
with breast cancer, a date of breast cancer death. Events that affect the natural history 
of breast cancer, such as screening and treatment, are tied to the tumor’s continually 
growing diameter (i.e., screen detection of the tumor may take place from a certain 
tumor size and treatment may treat tumors successfully up to a certain tumor size). Each 
woman is simulated from birth and followed until death and time plays an essential role 
in the order of events in a woman’s life.
Microsimulation model MISCAN-Fadia 33
parallel universe approach
In randomized controlled trials, randomization of participants is a key step to reduce the 
chance of systematic differences between study participants in the intervention and con-
trol group. In MISCAN-Fadia, this is imitated by simulating the same female population 
twice. First, the population is simulated in a no screening world, then, the identical popu-
lation is simulated again and subjected to screening to evaluate the effects of screening 
and treatment on incidence and mortality. In microsimulation modeling this approach is 
often referred to as a parallel universe structure. Usually, populations of tens of millions 
of women are simulated with a model runtime of approximately fifteen minutes.
breast cancer onset
The risk of developing breast cancer increases as women get older, while at the same 
time breast cancer risk may differ by birth cohort [7, 8]. Therefore, breast cancer onset 
in Model E is mainly driven by an age risk factor combined with a birth cohort risk factor 
to account for variations in the prevalence of risk factors that are related to birth cohort. 
The model uses as input breast cancer incidence (invasive and DCIS) in the absence 
of screening to derive breast cancer onset probabilities that vary by age and cohort. 
Considering breast cancer incidence in the absence of screening has not been available 
at the population level in the U.S. since routine mammography screening started in the 
1980’s, most CISNET breast models used the breast cancer incidence in the absence of 
screening derived by Holford et al. [9]. Currently in Model E, the breast cancer onset 
parameters are calibrated to the U.S. incidence in the absence of screening that was 
derived and estimated by Gangnon et al. who extended the work by Holford by disen-
tangling breast cancer incidence by cohort- and age-related factors, and the impact of 
mammography screening dissemination in the U.S.. [10].
the continuous tumor growth natural history model
Among women who develop breast cancer, the natural history of the disease is simulated 
as a continuously growing tumor. At tumor inception, the tumor’s diameter is 0.1 millime-
ter and based on the time it takes for the tumor to double in size, (i.e., the tumor volume 
doubling time) it grows exponentially. The DCIS model was originally based on the DCIS 
model of the Erasmus MISCAN breast model [11]. Once a breast lesion emerges from 
normal breast tissue, a woman is in the pre-clinical undetectable DCIS phase (Figure 
1). The two possible transitions from there are either: pre-clinical screen-detectable 
DCIS, the state that all CISNET breast models that include DCIS have in common [12], 
or pre-clinical invasive breast cancer. From the pre-clinical screen-detectable state three 
different transitions are possible; regression to a breast cancer-free life, progression to 
pre-clinical invasive breast cancer, or progression to the clinical DCIS state. The duration 
(years) in each DCIS state is assumed to be exponentially distributed and transitions 
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between DCIS states happen at exponential rates. These transition rates were estimated 
using SEER American Joint Committee on Cancer (AJCC) data on stage distributions and 
age-specific DCIS and invasive incidence rates between 1975 and 1999 [3].
The tumor diameter at which available treatment options no longer result in cure is the 
fatal disease diameter and reflects the spread of breast cancer, i.e., distant metastasis. If 
the disease is fatal at the moment of diagnosis (i.e., the tumor diameter at diagnosis is 
larger than the tumor’s fatal diameter), the time until death from breast cancer is deter-
mined by a draw from the survival distribution at the moment the disease became fatal 
(Figure 2). Tumors that are diagnosed at a smaller diameter than their fatal diameter are 
surgically removed, possibly radiated and adjuvant treatment ensures the woman will not 
die of breast cancer. Each tumor is unique and has different diameter sizes for: clinical 
diagnosis, screen detectability and metastasis (fatal diameter). As listed under ‘the life 
course of a tumor’, these tumor properties are governed by probability distributions to 
bring about variation between tumors.
Figure 1 The Ductal Carcinoma in Situ sub-model in MISCAN-Fadia.
Once a breast lesion emerges from normal breast tissue, a woman is in the pre-clinical undetectable 
DCIS phase. The two possible transitions from there are either: pre-clinical screen detectable DCIS 
or pre-clinical invasive breast cancer. From the pre-clinical screen detectable DCIS phase the tumor 
may regress and the woman will end up in the ‘No Breast Cancer’ pool. However, from the pre-clini-
cal screen detectable DCIS phase the tumor may also progress to pre-clinical invasive breast cancer 
or the tumor may cause clinical symptoms and a DCIS case will be diagnosed as a result of clinical 
symptoms. If a tumor is in the pre-clinical invasive breast cancer state, the cancer may be screen 
detected or cause clinical symptoms that lead to a clinical breast cancer diagnosis. Depending on 
the moment of diagnosis and the type of treatment a women may cure or die from breast cancer.
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Our natural history approach makes a distinction between tumor biology (i.e., growth 
rate of the tumor) and variables that are more likely to change over time, by age, or differ 
by geographical region. The advantage of this approach is that it readily lends itself to 
define separate distributions for different parameters based on risk groups and molecular 
tumor subtypes for example [13, 14]. As such, adapting the model to simulate subgroups 
Figure 2 The MISCAN-Fadia breast cancer natural history model.
When a breast tumor is initiated in a simulated woman, values of six tumor characteristics are gener-
ated: growth rate of the tumor, the tumor’s fatal diameter that represents distant metastasis, survival 
time after reaching the fatal diameter, screen detectability diameter (threshold), and the clinical di-
agnosis diameter. The distribution curves on the y-axis demonstrate the probabilistic nature of the 
simulations and the variation between the screen-detection, fatal and clinical diagnosis diameter 
of tumors. The growth rate of the tumor determines the times since its initiation at which the tumor 
reaches the screen detectability diameter, the clinical diagnosis diameter, and the fatal diameter. If in 
the absence of screening the clinical diagnosis diameter is larger than the fatal diameter, the woman 
will die of breast cancer and the observed survival time is given as depicted in Figure 2. A woman 
will be cured if the breast cancer is detected, either clinically or through screening, before the fatal 
diameter is reached. Treatment (not shown in Figure 2) is modeled as a shift in fatal diameter and 
may affect survival and in the best scenario cause of death.
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of more aggressive and faster growing tumors (e.g., ER/HER2 molecular subtypes of 
breast cancer) was done by changing the growth rate of tumors while keeping other 
tumor aspects such as the clinical diagnosis diameter and tumor diameter threshold for 
screen detectability unchanged.
the life course of a tumor is described by
1. Tumor growth rate ~ Log Normal (μ1,σ1)
2. Fatal diameter of the tumor ~ Weibull (λ1,κ1)
3. Survival time after reaching fatal diameter ~ Log Normal (μ2,σ2)
4. Screen detectable (threshold) tumor diameter ~ Weibull (λ2,κ2)
5. Clinical diagnosis diameter of the tumor ~ Log Normal (μ3,σ3)
6. Clinical diagnosis of the tumor caused by distant metastasis. This is modeled as a 
constant fraction of the survival after reaching the tumor’s fatal diameter.
7. Correlation between tumor growth rate and the tumor’s clinical diagnosis diameter: 
ρ1
8. e.g., fast growing tumors are diagnosed at larger diameters.
9. Correlation between tumor growth rate and survival time after reaching the tumor’s 
fatal diameter: ρ2 e.g., fast growing tumors have a shorter survival.
10. Correlation between tumor diameter at clinical diagnoses and survival time after 
reaching the tumor’s fatal diameter: ρ3
11. e.g., tumors with a large size at clinical diagnosis have a shorter survival.
12. The tumor diameter at which N1 lymph node disease becomes detectable ~ Weibull 
(λ3,κ3)
13. Difference in tumor size at which N1 and N2 lymph node disease become detectable.
When a breast tumor is initiated in a simulated woman, values of the six (1-6) tumor 
variables are generated. For each simulated tumor, the clinical diagnosis diameter is 
determined by the smallest tumor diameter of either the diameter at clinical diagnosis or 
the diameter at clinical diagnosis because of fatal metastases. After tumor initiation, the 
growth rate of the tumor determines the times at which the tumor reaches the threshold 
diameter for detectability by screening, the clinical diagnosis diameter, and the fatal 
diameter. If the tumor diameter at diagnosis is larger than the fatal diameter, then the 
survival time after reaching the fatal diameter will give the time at which a woman will die 
of breast cancer. On the other hand, if a tumor is detected, either clinically or through 
screening, before the fatal diameter is reached, the woman will be cured of cancer and 
die of other causes. A graphical representation of how the natural history of breast cancer 
is modeled in MISCAN-Fadia is provided in Figure 2. In MISCAN-Fadia, initially, Weibull 
distributions were assumed for all variables. However, when it became apparent that 
correlations had to be assumed, the more convenient multivariate lognormal distribution 
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was used for three correlated variables. The main reason was to get a better fit on the 
data of the base-case analysis.
For the CISNET breast “Base Case” analysis [15, 16], the maximum likelihood estimates 
of MISCAN-Fadia for the natural history parameters were initially based on detailed data 
from the Swedish Two County Study [4, 5]. These included estimates for tumor growth, 
tumor fatal diameter, survival duration since fatal diameter, clinical diagnosis diameter, 
and screen detectability diameter. The tumor size distribution and number of screen de-
tected cancers and interval cancers per screening round were simulated and compared 
to the findings of the trial. A detailed description and estimation of these natural history 
parameters can be found elsewhere [6]. Since the base case analysis, the natural history 
parameters such as tumor growth rate, tumor fatal diameter, survival duration after reach-
ing the fatal diameter, and the threshold for screen detection have been re-estimated 
for the simulation of various breast cancer molecular subtype combinations of ER and 
HER2. [13, 14]
population demographics
MISCAN-Fadia can simulate one specific birth cohort, or, to account for varying demo-
graphic characteristics, a dynamic population consisting of multiple birth cohorts can be 
simulated. Certain birth cohorts may be assigned a different relative risk of developing 
breast cancer when cohort effects are present in the population. Nevertheless, each birth 
cohort is assigned an all-cause mortality table from which breast cancer as cause of death 
is removed. These mortality tables determine the date of non-breast cancer related 
death. A woman dies either from breast cancer or from other causes, whichever comes 
first. MISCAN-Fadia uses population parameters such as the number of birth cohorts and 
the proportion of each birth cohort in the overall U.S. population. These model inputs, as 
well as the other cause mortality tables are common CISNET model inputs [3].
screening and screen detection
Characteristics of organized screening programs, such as screening ages, intervals, 
screening modality, and attendance by first and subsequent screens can be inserted 
directly into the model. The mammography screening dissemination that reflects the 
historic opportunistic screening patterns observed in the U.S. can also be simulated [17, 
18]. Parameters to simulate screen detection, such as the sensitivity of the screening test, 
are translated into a diameter size at which tumors become screen detectable. By means 
of model calibration of tumor size distributions to observed tumor size distributions, 
the model estimates the screen detection (threshold) parameter. By varying of only the 
screen detection parameters, the model finds the parameter values that resemble the 
best match between the simulated data and observed data.
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If a woman is screened after a tumor onset, but before the threshold tumor diameter 
of screen-detectability, the result of the screening test is false negative. If that woman 
would be screened when the tumor diameter is larger than the tumor’s screen-detect-
ability diameter, the result of the screening test is true positive. This structure for screen 
detection implies that no false positives are registered as direct output from the model. 
The number of false positive mammograms is calculated based on the total number of 
mammograms performed in the model and the observed false positive rates. Screening 
sensitivity differences between screening modalities, as well as improvements in screen-
ing performance are modeled as a shift in the threshold diameter for screen-detectability. 
The advent of digital mammography between 2000 and 2010 has been incorporated 
into the model by calibrating the threshold to digital mammography data [19].
Overdiagnosis is defined as screen-detected DCIS or invasive breast cancer that would 
not have been diagnosed in a woman’s life in the absence of screening. The parallel 
universe approach; simulating the same population of women twice, implies that the 
women in the screened population are exactly the same women as in the unscreened 
population. This allows for exact quantification of overdiagnosis due to screening be-
cause of the lifetime follow-up of all women.
breast cancer staging
In MISCAN-Fadia, the severity of breast cancer is described by the diameter of the 
primary tumor and the extent to which the cancer has spread to lymph nodes or distant 
organs. This corresponds to the Tumor Node Metastasis (TNM) staging system that was 
developed and is maintained by the AJCC union that classifies tumors based on the size 
of the primary tumor (T), the nearby lymph nodes that are involved (N), and the spread 
of cancer as distant metastasis (M). To get to a stage at diagnosis, MISCAN-Fadia links 
tumor diameter to staging by including 3 parameters. First, continuous growth of the 
tumor diameter; the main concept of the natural history model, covers the T part of 
the staging system by the unique size of the tumor at diagnosis. Second, the lymph 
node status of tumors is covered by the inclusion of two parameters; N1: the size of the 
tumor that reflects the spread to 1-3 nearby lymph nodes, N2: the size of the tumor that 
corresponds to the diameter at which breast cancer has spread to 4 to 9 lymph nodes. 
This is modeled as a fixed diameter size larger than N1. Third, metastasis of the primary 
tumor is modeled and covered by the unique fatal diameter of each tumor. The values 
of N1 and N2 were calibrated to SEER data on stage at diagnosis of cancers diagnosed 
between 1975 and 2000 as part of the base-case analysis[6]. The definition of the AJCC 
staging system determines how cancers are staged at diagnosis; all DCIS diagnoses are 
staged as 0. Tumors smaller than 2 cm that have not spread to any nearby lymph nodes 
are staged as 1, tumors that are between 2 and 5 cm at diagnosis that have not spread 
to nearby lymph nodes are staged as 2a, and so on.
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adjuvant treatment
The benefit of adjuvant treatment is modeled as a shift in the fatal diameter. For each 
adjuvant treatment an age-specific cure proportion is estimated using the common 
CISNET model inputs [3] based on treatment effectiveness data from the meta-analyses 
by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) [20, 21]. The cure 
proportions are translated into tumor diameters so that more effective treatment can 
cure a larger tumor. Women diagnosed at a tumor diameter greater than the tumor’s fatal 
diameter, benefit from adjuvant treatment by a shift to a larger fatal disease diameter. If 
the new fatal diameter is larger than the diameter at diagnosis, the treatment results in 
cure and ultimately death from other causes. However, if the new fatal diameter is still 
smaller than the diameter at diagnosis, surgery and radiation combined with adjuvant 
treatment will not results in cure and the tumor will eventually cause breast cancer death. 
The dissemination of adjuvant treatment is modeled as the probability of being treated 
with a certain type of treatment (e.g. chemotherapy, tamoxifen) given stage at diagnosis, 
calendar year, age at diagnosis, ER and HER2 status.
parameter estimation
Parameter estimates are obtained by optimizing the goodness of fit between simulated 
data and observed data. The stochastic nature of the model output and duration of the 
model runs make the process of finding solid parameter estimates time-consuming. For 
selected starting values of the parameters, one microsimulation run will produce, for 
instance, age-specific breast cancer incidence trends over time, and compare it to the 
observed breast cancer incidence levels. Maximum likelihood estimates of the model 
parameters are obtained by repeated evaluation of the simulated breast cancer inci-
dence for different sets of parameter values. Parameters are estimated by minimizing the 
sum of squared differences between observed and simulated data. This weighted sum 
measures the goodness of fit of the simulation results and is defined as a chi-squared 
distributed statistic. [22]. Minimization of the goodness of fit statistic leads to the optimal 
parameters, but requires frequent, and time-consuming evaluations of the objective 
function. We used the Nelder and Mead Simplex (NMSM) algorithm [23], which has the 
advantage that it only uses the value of the objective function, i.e., the goodness of fit of 
the model, to find the minimum. In the NMSM approach, each step in the optimization 
algorithms is based on output from previous simulation runs in which large numbers of 
life histories have been simulated, and it performs quite well in locating the optimum.
Extensive model calibration for the CISNET base case analysis provided parameter 
estimates that resulted in a close match between the simulated U.S. incidence and mor-
tality over time and the observed trends in incidence and mortality from 1975 to 2000 
[16]. These parameter estimates from the base case analysis were only re-calibrated for a 
limited number of parameters at a time and within logical parameter bounds (e.g., new 
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screening modalities with higher sensitivity of screening correspond to, and resulted in, 
a smaller threshold diameter for screen-detectability).
validation
Establishing the degree to which MISCAN-Fadia is an accurate representation of the 
real world, is validation. Five types of validation [24] are addressed: face validity, internal 
validity, cross validity, external validity, and predictive validity. Face validity means the 
model makes sense at face value. MISCAN-Fadia’s structure with a biological entry of 
continuous tumor growth makes sense at face value. The model structure and data 
sources used as input lead to credible results that show no logical contradictions such 
as screening resulting in the diagnosis of more late stage tumors, or decreasing risk 
of developing breast cancer as women get older. Internal consistency, or verification, 
examines the mathematical calculations performed and its consistency with what could 
be expected based on the model’s specification. MISCAN-Fadia, programmed in Del-
phi, is a microsimulation model in which disease processes are mainly driven by clearly 
specified probability distributions that are widely used in modern programming software 
packages. Results of mathematical calculations for published parameter values can easily 
be verified when using these probability distributions.
Cross-validity covers the aspect of comparing model results to the results of other 
modeling groups. As MISCAN-Fadia has been part of CISNET since the start of its col-
laboration, this form of validation of the model has been done extensively [15, 25, 26]. 
External validity is the comparison of model outcomes to observed data that was not 
used for calibration and development of the model. MISCAN-Fadia is currently part of 
an independent external validation exercise wherefore we validated the results of five 
CISNET breast cancer models against the UK Age trial [27]. In the past, we conducted 
a dependent model validation against the UK Breast Screening Frequency trial [28]. UK 
specific breast cancer incidence and life tables were used, and the threshold diameter as 
well as the diameter of clinical diagnosis were re-estimated based on the trial’s data. The 
model accurately reproduced the cumulative incidence in the intervention and control 
groups. Also, the percentage of screen detected and clinically diagnosed breast cancers 
were similar to the observed percentages in both groups, as were the number of breast 
cancer deaths [29]. Predictive validation is done by making model predictions for future 
outcomes of, for example, patterns in incidence and mortality. MISCAN-Fadia has made 
predictions about future trends in incidence and mortality [30], but it still remains to be 
seen how these predictions unfold.
model input and output of miscan-fadia
Differences in patterns of breast cancer incidence and mortality can often be traced 
back to different screening and treatment regimens, adherence patterns, and different 
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underlying risks. To simulate the harms and benefits of screening and treatment at the 
population level, the model requires data for the four major model components: popula-
tion demographics, natural history of breast cancer, screening and treatment. A list of 
inputs of MISCAN-Fadia is provided and described as common CISNET model inputs [3].
The outcomes listed in Table 1 can be produced for any screening scenario with dif-
ferent start and stop ages of screening, screening frequency and screening modality. In 
addition to different screening strategies, the model output can also be broken down 
by: calendar year, age group, and by tumor size or breast cancer stage such as AJCC. 
By assigning health utilities to specific health states and unit costs to specific events, 
total costs and Quality Adjusted Life Years (QALYs) can be calculated. Consequently 
cost-effectiveness analyses can be performed [31]. In addition, radiation-induced breast 
cancers and breast cancer deaths can be calculated using model output together with 
radiation dose [32].
extensions and applications of the model
Targeting screening to women with the highest potential benefit and lowest potential 
harm can improve the overall balance between benefits and harms in the population. In 
recent years, we explored the effects of obesity and race on U.S. breast cancer mortality 
Table 1 Model output MISCAN-Fadia model
Output description
1 Invasive Breast cancer cases diagnosed clinically
2 Invasive Breast cancer cases diagnosed by screening
3 DCIS cases diagnosed clinically
4 DCIS cases diagnosed by screening
5 Life years in the absence of screening
6 Life years in the presence of screening
7 DCIS over diagnosed cases (in the presence of screening)
8 Invasive over diagnosed cases (in the presence of screening)
9 Breast cancer deaths in the absence of screening
10 Breast cancer deaths in the presence of screening
11 Deaths from other causes in the absence of screening
12 Deaths from other causes in the presence of screening
13 Number of mammograms
14 Number of cancers diagnosed in AJCC stage I, II, III, IV
15 Number of cancers diagnosed in SEER stage local, regional, distant
16 Number of cancers diagnosed by tumor size 0-20mm, 20-50mm, 50+ mm
17 Number of cancers treated with adjuvant treatment
18 Intervals between events, e.g., lead time (time between screen detection and diagnosis in the absence of 
screening), survival (time between diagnosis and death)
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[30, 33] as well as the cost effectiveness of ultrasonography screening [31]. In the past 
years, we also examined the contributions of screening and treatment to reduction in 
molecular subtype specific breast cancer mortality by evaluating different screening 
scenarios, including risk-based screening strategies. We present some examples of the 
model adaptations that formed the basis of these collaborative modeling studies.
personalizing screening
To evaluate screening outcomes while taking into account advances in mammography 
and treatment of breast cancer, several screening strategies were modeled differing by 
age at which screening starts and screening interval. Biennial screening from age 50 
to 74 years avoided a median of 7 breast cancer deaths per 1,000 women screened 
compared to no screening and is generally considered to have a favorable balance 
between benefits and harms. More intensive screening leads to more benefits (breast 
cancer deaths averted), but also to more harms (false-positives and over diagnosis). For 
example, annual screening from age 40 to 74 years avoided an additional 3 deaths, but 
yielded 1988 more false-positive results and 11 more over diagnosed cases per 1000 
women screened [26]. Women aged 40 with a two-fold risk (compared to average risk) 
can expect the same balance of benefits and harms as average-risk women who receive 
biennial screening starting from age 50 [25].
breast density and breast cancer
Breast density has been proposed to personalize mammography screening. Dense 
breast tissue is prevalent and associated with a higher risk of developing breast cancer 
[34]. Moreover, since breast density is relatively easy to measure on a mammogram, it 
can be used for risk stratification. Some studies have found that tumors in dense breasts 
(categorized as BI-RADS 3 and 4) may progress more rapidly than those in fatty breasts, 
categorized as BI-RADS 1 and 2 [35]. Based on this, breast density could be taken into 
account when personalizing a woman’s screening frequency. Breast density does not 
only affect risk of developing breast cancer, it also affects screening test sensitivity as 
dense breast tissue is comprised of less fat and more connective breast tissue which 
appears white on a mammogram. Moreover, cancer appears white on a mammogram 
and is therefore easier overlooked by radiologists, resulting in a lower screening test 
sensitivity.
breast density in miscan-fadia
Breast density has been incorporated into MISCAN-Fadia to assess the effects of person-
alized screening; breast density was assumed to influence the sensitivity of the screening 
test (threshold diameter) as well as the onset of breast cancer. We also incorporated the 
decrease in breast density as women age because mammographic density decreases 
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after the menopause when ovarian function declines. When modeling both risk and 
density, we found that average-risk women (low breast density) undergoing triennial 
screening and higher-risk women (high breast density) receiving annual screening will 
maintain a similar or better balance of benefits and harms compared to biennially screen-
ing average-risk women [36].
simulating molecular subtypes of breast cancer
It has been widely acknowledged that breast cancer is a heterogeneous disease and 
more knowledge is emerging on distinct molecular subtypes. Combinations of Estrogen 
Receptor (ER) and Human Epidermal Growth Factor Receptor 2 (HER-2) status have dif-
ferent tumor growth and are associated with different treatment responses that have 
been found to be important in targeting the treatment of breast cancer. To understand 
the relative contributions of screening and treatment to U.S. breast cancer mortality, first 
the major subtype combinations of ER positive and ER negative have been included 
in MISCAN-Fadia. Across CISNET models we found greater absolute breast cancer 
mortality declines in ER-positive cancers than among ER-negative cancers. The relative 
contribution of adjuvant treatment vs screening to breast cancer mortality reductions was 
higher for ER-positive cases; for ER-negative cases, the relative contributions were similar 
[13]. We have recently also included HER-2 in the model [14], as well as the treatment 
Trastuzumab (Herceptin) that is an antibody that interferes with the HER2 receptor.
future directions of miscan-fadia
Risk based screening based on genetic risk profile
Genomic discoveries of genes associated with breast cancer risk may have the potential 
to personalize screening based on a woman’s genetic risk profile. It is one of our primary 
goals in the upcoming years to continue our research on estimating the population 
impact of using polygenic risk to tailor screening strategies. A growing group of single 
nucleotide polymorphisms (SNPs) are discovered that are associated with an elevated 
risk for breast cancer [37]. Individual SNPs identify a small increase in risk, however, 
multiple SNPs combined together can be translated into a polygenic risk score to stratify 
women based on their polygenic risk. We divide the population into risk groups based 
on observed polygenic risk score distributions. For each risk group, the models simulate 
routine digital mammography screening strategies by varying starting and stopping ages 
of screening and screening frequency. To warrant a more intense screening scenario for 
high risk groups and a less intense screening strategy for low risk groups, we compare 
the benefits and harms of the different screening strategies. The polygenic risk distribu-
tion in the U.S. female population determines how many women are eligible for each 
selected screening strategy and what the overall harms and benefits of polygenic risk-
based screening will be.
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A simplified analysis of using polygenic risk to inform screening strategies, can be 
performed by dividing the population into three (low, median, high) risk groups with 
varying prevalence (Figure 3). Targeted screening based on polygenic risk leads to a 
redistribution of benefits and harms. A more in-depth analysis will be performed in the 
near future within CISNET. MISCAN-Fadia will be used to quantify the benefits such as 
the breast cancer deaths averted, quality-adjusted life years saved, breast cancer mortal-
ity reduction, costs, and harms such as the false positive mammograms, over diagnosed 
cases, unnecessary biopsies, false negatives.
strategies to reduce overtreatment of dcis
While early detection of breast cancer and consequently less invasive treatment are often 
mentioned as benefits of screening, overtreatment of DCIS lesions that otherwise would 
not have clinically surfaced without screening is an increasing harm of screening since 
DCIS rates have increased dramatically over the last 30 years. Studies have shown that an 
increase in breast cancer mortality reduction due to screening comes with a substantial 
increased number of over diagnosed DCIS cases [11, 38]. MISCAN-Fadia will be ex-
tended to investigate if, how, and to what extent the harms of screening and treatment 
Figure 3 Simulating a personalized approach to 
breast cancer screening based on genetic risk 
profile.
Genetic variants for breast cancer have different 
risk alleles. Multiple single nucleotide polymor-
phisms (SNPs) combined together can be trans-
lated into a polygenic risk score to stratify wom-
en based on their polygenic risk. In Figure 3, a 
simplified analysis of the potential population 
impact of using polygenic risk to inform screen-
ing strategies is demonstrated by dividing the 
population into three (low, median, high) risk 
groups with varying prevalence. In this simplified 
example 10% of the population has a low risk of 
developing breast cancer, 80% an average risk, 
and 10% a high risk. More frequent screening 
could be offered to the high risk group and less 
frequent screening (compared to average risk 
group) could be offered to the low risk group. 
With more risk groups, or even a continuous risk 
distribution we could potentially optimize the 
tailoring of screening strategies based on poly-
genic risk which would lead to a redistribution of 
benefits and harms compared to current prac-
tice. A more in depth analysis will be performed 
in the near future within CISNET.
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of DCIS can be reduced. By simulating ‘watchful waiting’ strategies and exploring risk 
factors for progression to invasive breast cancer such as cytological grade, ER status, age 
at diagnosis and ethnicity, MISCAN-Fadia will be used to assess how different screening 
strategies and treatment routines may affect incidence and mortality for varying progres-
sion and regression rates of DCIS.
conclusion
Trends in breast cancer incidence and mortality depend on many factors related to the 
biology and natural history of breast cancer. As tumor size is observable at diagnosis 
and tumors are considered to grow in continuous time rather than discrete time, these 
two aspects form MISCAN-Fadia’s biological entry to modeling the effects of screening 
and treatment on breast cancer incidence and mortality. The advantage of this biologi-
cally oriented approach is that it allows for simple hypothesis testing because the core 
biological mechanisms are separated from cancer control interventions. Changes or 
improvements in screening and treatment that may vary by age, or over time, can be 
implemented directly and be dealt with without changing breast cancer onset or tumor 
growth parameters. On the other hand, simulating less or even more aggressive tumor 
subtypes with a different growth function is also possible. Moreover, correlations that 
were added to the base case model in order to get a good overall fit with observed data, 
were plausible, and with a biological reasoning, intuitive to understand. In particular, one 
may expect faster growing tumors to be diagnosed at larger tumor diameters, and faster 
growing tumors to have a shorter survival as well as a larger clinical diagnosis diameter.
However, MISCAN-Fadia also has limitations and makes use of simplifying assump-
tions. We model only one tumor per woman while it may be possible that breast cancer 
develops in both breasts independently or at the same time, although such cancer devel-
opment is not prevalent. Also, recurrence of breast cancer is not simulated in our model. 
We do not model specific factors associated with an elevated risk for breast cancer such 
as reproductive history, alcohol use, hormone therapy use or familial risk. These different 
risk groups are assumed to be captured by the distribution we simulate tumors from. The 
spread between slower and faster growing tumors with unique tumor characteristics is 
assumed to capture the entire population risk profile.
Future development of the model will focus on evaluating the impact of using poly-
genic risk to inform screening strategies, evaluating the clinical management of screen-
detected DCIS, and incorporating alternative and emerging screening modalities such 
as breast MRI and tomosynthesis.
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abstract
Ductal carcinoma in situ (DCIS) can be a precursor of invasive breast cancer. Since the 
advent of screening mammography in the 1980’s, the incidence of DCIS has increased 
dramatically. The value of screen detection and treatment of DCIS is a matter of con-
troversy, since it is unclear to what extent detection and treatment of DCIS prevents 
invasive disease and reduces breast cancer mortality. The aim of this paper is to provide 
an overview of existing Cancer Intervention and Surveillance Modelling Network (CIS-
NET) modeling approaches for the natural history of DCIS, and to compare these to 
other modeling approaches reported in the literature. Five of the six CISNET models 
currently include DCIS. Most models assume that some, but not all, lesions progress to 
invasive cancer. The natural history of DCIS cannot be directly observed and the CISNET 
models differ in their assumptions and in the data sources used to estimate the DCIS 
model parameters. These model differences translate into variation in outcomes such as 
the amount of overdiagnosis of DCIS with estimates ranging from 34%-72% for biennial 
screening from age 50-74 years. The other models described in the literature also report 
a large range in outcomes with progression rates varying from 20%-91%. In the future, 
DCIS data by grade from active surveillance trials, development of predictive markers of 
progression probability, and evidence from other screening modalities, such as tomo-
synthesis, may be utilized to inform and improve the models’ representation of DCIS and 
might lead to convergence of the model estimates. Until then, the CISNET model results 
consistently show a considerable amount of overdiagnosis of DCIS, supporting the safety 
and value of observational trials for low-risk DCIS.
Key Words: Cancer simulation, breast cancer epidemiology, simulation models, ductal 
carcinoma in situ
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introduction
Ductal carcinoma in situ (DCIS) represents a spectrum of abnormal cells confined to 
the breast duct and is a risk factor for invasive breast cancer development [1]. Before 
the introduction of mammography screening, DCIS was not often diagnosed. Since the 
advent of screening mammography in the 1980s, the incidence of DCIS has increased 
dramatically. In the United States, the incidence of DCIS increased from 5.8 per 100,000 
women in 1975 to 68.9 per 100,000 women in 2010 [2-4]. By the year 2020, more than 
one million US women are expected to be living with and have been treated for a DCIS 
diagnosis [1].
The etiology of DCIS is presumably heterogeneous and its natural history is poorly 
understood as onset, progression and regression rates are not directly observable. Some 
DCIS lesions likely represent a precursor to subsequent invasive breast cancer, but DCIS 
may also remain indolent for sufficiently long that a woman dies of other causes [5-7]. 
The proportion of untreated DCIS that will progress to invasive breast cancer is unknown 
[1], and therefore, the impact of detecting and treating DCIS, particularly for any given 
woman, is unclear. Treating some DCIS lesions will probably prevent invasive disease, 
and consequently might reduce breast cancer mortality, thus can be considered a ben-
efit. Other lesions might remain indolent in the absence of treatment with only harms 
related to their treatment (representing overdiagnosis and overtreatment). Since we do 
not know which and how many DCIS lesions will progress, the value of screen detection 
and treatment of DCIS remains unknown and is a matter of considerable controversy.
Despite the uncertainty around the natural history of DCIS, some predictors for progres-
sion have been identified. For example, younger age at diagnosis and black ethnicity are 
associated with higher breast cancer-specific mortality among patients with DCIS [8, 9]. 
Other identified factors for progression include estrogen receptor (ER) negative status, 
larger DCIS tumor size, and comedonecrosis [9]. In addition, DCIS progression to inva-
sive breast cancer can be predicted by cytologic grade [5, 7, 9]. Pathologists use three 
grading categories: corresponding to well (grade 1), moderately (grade 2), and poorly 
(grade 3) differentiated DCIS [10], also referred to as “low grade”, “intermediate grade”, 
and “high grade”, respectively. Grade has been found to be associated with recurrence 
[11, 12] and the survival benefit of surgical treatment has been found to be lower for 
low-grade DCIS than that for intermediate or high-grade DCIS [13]. Furthermore, the 
DCIS Score, based on Oncotype DX, has been found to be associated with recurrence of 
DCIS (either as DCIS or invasive breast cancer) [14].
These identified prognostic factors for recurrence may enable physicians to tailor treat-
ment strategies. Specifically, recommending treatment that is less aggressive would be 
appropriate for DCIS that has a low risk for future recurrence, and predictors such as age, 
ER status, and/or grade might be used to identify low-risk lesions. Thus, understanding the 
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natural history of DCIS and its recurrence and progression predictors to guide treatment 
strategies is important for both clinical and public health decisions. However, investigat-
ing the natural history of DCIS is difficult as ideal high-quality data is lacking, given that 
progression paths are not directly observable. In addition, data are also limited because 
survival for women diagnosed with DCIS is very high and a trial would need to enroll very 
large numbers of women and follow them for a lifetime to be adequately powered to 
detect an impact of screening and treatment on mortality or other endpoints. Moreover, 
the natural history of DCIS is difficult to study because the standard of care is immediate 
treatment following diagnosis. In these instances (comparative) modeling can be useful, 
for example to provide a range of plausible DCIS progression and regression rates by 
evaluating what set of assumptions about these rates best fit the existing observable 
data. In addition, in natural history models, the difference in risk of progression based on 
age, grade and ER status can be included by allowing varying transition rates for these 
factors, which has already been done in a well-established microsimulation model to 
include grade [15].
Furthermore, within the Cancer Intervention and Surveillance Modelling Network 
(CISNET) comparative modeling work has been done. Previously, three CISNET models 
estimated the amount of DCIS overdiagnosis in women age 74 and older. The results 
indicated that at older ages harms began to outweigh benefits, largely as a consequence 
of the increasing amount of overdiagnosis of DCIS at older ages [16], which is partly due 
to the higher death rate from competing causes with aging. Together, these modeling 
papers, on one hand highlight the uncertainty regarding the natural history of DCIS, but 
also show the potential value of modeling in providing information where results are 
consistent.
The aim of this paper is to provide an overview of the ways CISNET models simulate 
the natural history of DCIS, illustrate how different assumptions affect results, to compare 
the CISNET models to other models described in the literature, and to highlight devel-
opments that might lead to model improvements or refinements.
cisnet models
CISNET DCIS models – model overview
CISNET is a consortium of National Cancer Institute (NCI)-sponsored investigators who 
use statistical modeling to improve our understanding of cancer control interventions in 
prevention, screening, and treatment and their effects on population trends in incidence 
and mortality. The CISNET breast models have been described in detail previously and 
recently updated descriptions have been given [17-22]. Briefly, the models are designed 
to match breast cancer incidence and mortality rates observed in the US. Four models 
are micro-simulation models (models developed by Erasmus MC, University Medical 
Center Rotterdam, model E; Georgetown University Medical Center, and Albert Einstein 
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College of Medicine, model G-E; MD Anderson Cancer Center, model M; and University 
of Wisconsin, Madison and Harvard Medical School, model W), one model uses an 
analytic approach (model developed by Dana-Farber Cancer Institute, model D), and 
the remaining model is a hybrid Monte Carlo simulation (model developed by Stanford 
University, model S). The micro-simulation models include natural history components 
that approximate tumor progression in size and stage (https://resources.cisnet.cancer.
gov/registry/site-summary/breast/). Five of the six CISNET models currently include DCIS 
(all except model S). Most models assume that some, but not all, lesions progress to 
invasive cancer, for example by including three different types of preclinical DCIS: DCIS 
that progresses to invasive disease during the preclinical phase, progressive DCIS that 
is diagnosed clinically, and DCIS that does not progress (and might regress). However, 
the models differ in natural history of DCIS (Table 1) and model structure (see Figure 1), 
with different pathways for the progression and regression of DCIS and breast cancer. 
For example, invasive cancer can either develop through pre-clinical screen-detectable 
DCIS (Figure 1C), or also develop directly from pre-clinical DCIS that is not detectable at 
screening (Figure 1A and 1B). In the models, DCIS can regress from pre-clinical screen-
detectable DCIS to pre-clinical undetectable DCIS (Figure 1A) or to an absorbing ‘no 
breast cancer’ state and disappear (“cease to exist”) (Figure 1B and 1C). One model 
(model W) allows regression of pre-clinical DCIS as well as invasive disease (Figure 1D). 
Although the regression of breast cancer, especially invasive disease, is controversial, 
there is some evidence supporting the possibility of regressing tumors, including epide-
miologic evidence [23] and a case report on regression of breast on imaging [24].
Most of the CISNET models have used data from the Surveillance, Epidemiology, and 
End Results (SEER) Program [25], typically age-specific incidence over time, combined 
with data from other sources (Wisconsin cancer registry for model W, Dutch data for 
model E) to estimate DCIS parameters, although one model used data from another 
source to develop their model (Norwegian data for model D) [26]. All CISNET models 
include a certain probability for mammography to detect DCIS at screening (Table 2). 
Specifically models D and GE use the same detection mechanism for DCIS as for invasive 
disease by including a sensitivity of screening. Model W uses the detection probability 
as a function of tumor size and because in situ lesions are small the likelihood of detect-
ing DCIS is lower than that for detecting invasive breast cancer. Model E includes two 
separate detection mechanisms; DCIS detection is modeled by including a sensitivity, 
whereas screen-detection of invasive disease is modeled by a threshold diameter. Thus, 
in some models the sensitivity of a screening test differs for DCIS and invasive cancer.
CISNET models – analysis
The CISNET models were recently applied to evaluate screening outcomes of various 
screening strategies differing by age at which screening starts (40, 45, or 50 years) and 
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screening interval (annual, biennial) for the US female population [27]. We assessed the 
results of those prior analyses by focusing on the (as yet unpublished) model-specific 
rates of DCIS detection and overdiagnosis of the five CISNET models that include DCIS 
[28]. Overdiagnosis was defined as the detection of tumors that would not have been 
detected in a woman’s lifetime in the absence of screening. We estimated the detection 
and overdiagnosis rate per 1000 women screened followed from age 40 over their life-
times. In addition, the percentage overdiagnosis was calculated by dividing the rate of 
overdiagnosed DCIS by the rate of detected DCIS. We focus on four screening scenarios: 
biennial screening from 50-74 years (base), more frequent screening (annual screening 
from age 50-74 years; A50-74), an earlier starting age (biennial screening from age 40-74 
years; B40-74), and later stopping age (biennial screening from age 50-84 years; B50-84).
Table 1 Natural history of DCIS in the CISNET models.
Model in situ or 
DCIS?*
Do all tumors start as 
in situ?
Progression/regression Model
structure
D DCIS only Yes, but some DCIS is 
not screen-detectable 
and assumed to progress 
to invasive directly
DCIS progress to clinical DCIS or invasive 
breast cancer at exponential rates with mean 
sojourn time of 1.5-3 years; DCIS may also go 
back to a state in which it is undetectable [19]
Figure 1A
E All in situ Yes DCIS progress to clinical or invasive breast 
cancer at an exponential rate with age and 
calendar year dependent sojourn times; DCIS 
may also regress [22]
Figure 1B
GE DCIS only Yes DCIS progress to clinical or invasive breast 
cancer at an exponential rate with mean 
sojourn time of 2.97 years; DCIS may also 
regress [21]
Figure 1C
M Model M is not a natural history model. It does not specify how tumors grow. It is an empirical model 
to describe screening, incidence, treatment and mortality. Under different screening scenarios, 
different stage distribution tables obtained from observed data [28] are used to assign tumor stages: 
DCIS, stages I, II, III or IV. DCIS patients are assumed to have the same survival as normal population, 
given age and birth year, no matter what treatments they receive.[18]
W All in situ. 
Model W also 
separated in 
situ into DCIS 
and non-DCIS 
in situ
Yes All tumors, including DCIS, progress 
according to a Gompertz-type growth 
function, where the growth parameter is a 
random variable distributed with Gamma. 
Small size defines in situ. All tumors grow 
until they reach a maximum size. All tumors 
progress although a subset with “limited 
malignant potential” (LMP) stop at early 
invasive. LMPs comprise approximately 30-
50% of all onset tumors [17]
Figure 1D
Model D: Dana-Farber Cancer Institute, Boston, Massachusetts. Model E: Erasmus MC, University 
Medical Center Rotterdam, Rotterdam, the Netherlands. Model GE: Georgetown University Medical 
Center, Washington, DC, and Albert Einstein College of Medicine, Bronx, New York. Model M: MD 
Anderson Cancer Center, Houston, Texas. Model W: University of Wisconsin, Madison, Wisconsin, 
and Harvard Medical School, Boston, Massachusetts.
* in situ: DCIS and lobular carcinoma in situ (LCIS)
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Figure 1A Model D
Normal Tissue Pre-clinical undetectable DCIS
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Figure 1B Model E
Figure 1 Schematic overview of models for the natural history of DCIS and invasive breast cancer. In-
vasive cancer can either develop through pre-clinical screening detectable DCIS (Figure 1C), or also 
develop directly from pre-clinical DCIS not detectable at screening (Figure 1A, 1B and 1D). Models 
include progression from preclinical screen-detectable DCIS to either clinical DCIS or preclinical 
invasive disease (Figure 1A, 1B, 1C, 1D), regression from preclinical DCIS to normal tissue (Figure 
1D), to pre-clinical undetectable DCIS (Figure 1A), or to a ‘no breast cancer’ (absorbing) state in 
which women are no longer at risk for developing DCIS or invasive breast cancer (Figure 1B and 1C). 
Regression from invasive disease is also possible (Figure 1D).
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Normal Tissue Pre-clinical Screen-detectable DCIS
Clinical DCIS with 
symptoms
Clinical IBC With 
Symptoms
Breast Cancer Death
Pre-clinical Screen-
detectable IBC
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Figure 1 Schematic overview of models for the natural history of DCIS and invasive breast cancer. In-
vasive cancer can either develop through pre-clinical screening detectable DCIS (Figure 1C), or also 
develop directly from pre-clinical DCIS not detectable at screening (Figure 1A, 1B and 1D). Models 
include progression from preclinical screen-detectable DCIS to either clinical DCIS or preclinical 
invasive disease (Figure 1A, 1B, 1C, 1D), regression from preclinical DCIS to normal tissue (Figure 
1D), to pre-clinical undetectable DCIS (Figure 1A), or to a ‘no breast cancer’ (absorbing) state in 
which women are no longer at risk for developing DCIS or invasive breast cancer (Figure 1B and 1C). 
Regression from invasive disease is also possible (Figure 1D).
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CISNET models – results and implications
For biennial screening between age 50 and 74 years, the five models that include DCIS 
predict that 154.4 women (median; range across five models 137.4 – 158.5; Table 3) are 
diagnosed with breast cancer per 1000 women followed from age 40 over their lifetimes. 
Of these women, 26.7 (25.8 – 32.3) are diagnosed with DCIS and 128.2 (110.7 – 131.8) 
with invasive disease. Of the women diagnosed with DCIS, 15.6 (9.0-18.8) are overdiag-
nosed, representing 51.3% (33.7%-71.8%) of the detected DCIS (Table 3). In contrast, for 
invasive disease, the models estimate that of the 128.2 (110.7-131.8) breast cancers de-
tected, 3.3 (1.8-15.4) are overdiagnosed, corresponding to 2.6% (1.5%-12.0%; Table 3). 
This means that 2.6% (1.5-12.0%) of the invasive breast cancers that are detected would 
not have been detected in the absence of screening and are overdiagnosed. There is no 
direct connection between the amount of overdiagnosis of DCIS and overdiagnosis of 
invasive disease in the models. For example, one model predicts relatively low overdiag-
nosis percentages for DCIS as well as invasive breast cancer (model GE), whereas another 
model predicts relatively high percentages for both (model M). In contrast, there are also 
models that have modest estimates of DCIS overdiagnosis combined with relatively high 
estimates of invasive disease overdiagnosis (model W) or the other way around (model E).
Table 2 Detection mechanism of DCIS in the CISNET models.
Model Clinical detection mechanism Screen detection 
mechanism
Detection mechanism DCIS vs. 
invasive cancer
D Some DCIS progress to clinical DCIS with 
symptoms - this rate matches age-specific 
incidence rate of DCIS in pre-screening era
Sensitivity varying by 
screening modality, 
age, calendar year
Same mechanism for DCIS and 
invasive cancer by test sensitivity
E Some DCIS progress to clinical DCIS with 
symptoms - this rate matches age-specific 
incidence rate of DCIS in pre-screening era
Sensitivity varying by 
calendar year
DCIS is detected by test sensitivity; 
invasive disease is detected using a 
threshold diameter
GE Progressive DCIS are clinically detected 
the same as more advanced lesions. Non-
progressive DCIS are NEVER clinically 
detected.
Sensitivity varying by 
screening modality, 
age, calendar year
Same mechanism for DCIS and 
invasive cancer by test sensitivity
M  Model M makes no explicit mechanism assumptions regarding DCIS detection.
W Some DCIS are clinically diagnosed similarly 
as more advanced lesions. Clinical detection 
probability is an increasing function of tumor 
size and varies by age and calendar year. 
Clinical detection probabilities are in general 
smaller than screen detection probabilities; 
therefore a tumor is less likely to be detected 
via clinical surfacing than by screening.
Sensitivity varying by 
is tumor size, age, 
calendar year
Detection probability is an 
increasing function of tumor size, 
thus because in situ are small by 
definition, likelihood of detection 
of DCIS is less than that for invasive 
cancer
Model D: Dana-Farber Cancer Institute, Boston, Massachusetts. Model E: Erasmus MC, University 
Medical Center Rotterdam, Rotterdam, the Netherlands. Model GE: Georgetown University Medi-
cal Center, Washington, DC, and Albert Einstein College of Medicine, Bronx, New York. Model M: 
MD Anderson Cancer Center, Houston, Texas. Model W: University of Wisconsin-Madison, Madison, 
Wisconsin, and Harvard Medical School, Boston, Massachusetts.
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When annual screening from age 50-74 years is simulated, the models estimate 0.1-
14.0 additional cases of DCIS being detected of which 0.1-13.7 are overdiagnosed (Table 
4). Also, the models differ for the source for additional DCIS cases. For Models D, M, the 
increase in detection of DCIS is entirely overdiagnosis, whereas in models E, GE, W it is 
combination of overdiagnosis and earlier detection of lesions with progressive potential.
In addition, the order of scenarios that have the largest increase in overdiagnosis of 
DCIS varies across models, as well as the magnitude of the increase. For example, for an-
nual screening the increase in overdiagnosis varies between 0.1 and 13.7 overdiagnosed 
DCIS cases across models. Some models estimate the largest change in detection and 
overdiagnosis when annual screening is considered (models E, M, W), whereas other 
models predict the largest increase when upper age of screening is extended to age 84 
(models D and GE).
For the biennial screening scenario from age 50-74 years, the highest percentage of 
overdiagnosis of DCIS and invasive breast cancer was estimated by model M followed by 
W. This can be explained by the modeling choice of model M to assume a rather stable 
trend in breast cancer incidence (background trend) over time and, therefore, assign 
more of the increase to overdiagnosis than other CISNET models. Model W assumes that 
some invasive disease is non-progressive, and consequently, has a higher estimate for 
overdiagnosis than the other three models, especially for invasive disease.
For the other scenarios, annual screening from age 50-74 years, biennial screening 
from age 40-74 years, and biennial screening from age 50-84 years, there are two clus-
ters of models: models D and M assign the increase in detection of DCIS when screening 
more intensively entirely to overdiagnosis. For model M that is again related to the stable 
background trend and for model D, the screen detectable period for DCIS is relatively 
Table 3 Detection and overdiagnosis of DCIS and invasive disease across the CISNET models for 
biennial screening from age 50-74 years.
Model DCIS 
dx per 
1000
DCIS 
overdx 
per 1000
%overdx 
DCIS
invasive 
dx per 
1000
invasive 
overdx per 
1000
%overdx 
invasive
total 
dx per 
1000
overdx 
per 1000
%overdx 
(DCIS + 
invasive)
D 30.2 15.5 51.3% 128.3 3.3 2.6% 158.5 18.8 11.9%
E 25.8 16.1 62.4% 131.8 2.0 1.5% 157.6 18.1 11.5%
GE 26.7 9.0 33.7% 110.7 1.8 1.6% 137.4 10.8 7.9%
M 26.2 18.8 71.8% 128.2 15.4 12.0% 154.4 34.2 22.2%
W 32.3 15.6 48.3% 114.8 9.9 8.6% 147.1 25.5 17.3%
Median 26.7 15.6 51.3% 128.2 3.3 2.6% 154.4 18.8 11.9%
Model D: Dana-Farber Cancer Institute, Boston, Massachusetts. Model E: Erasmus MC, University 
Medical Center Rotterdam, Rotterdam, the Netherlands. Model GE: Georgetown University Medi-
cal Center, Washington, DC, and Albert Einstein College of Medicine, Bronx, New York. Model M: 
MD Anderson Cancer Center, Houston, Texas. Model W: University of Wisconsin-Madison, Madison, 
Wisconsin, and Harvard Medical School, Boston, Massachusetts.
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short. The other three models (models E, GE, and W) only assign a proportion of the 
increase to overdiagnosis and a proportion to earlier diagnosis. Models E and GE assign 
most of the increase to overdiagnosis when moving to older ages and a smaller percent-
age when moving to younger ages.
literature
Description of other DCIS models in the literature
To improve the understanding of the natural history of DCIS, we conducted a literature 
search to identify DCIS models that have been described in the literature. We searched 
PubMed and JSTOR for “DCIS natural history modeling” and “DCIS progression”, and 
selected the articles that focus on the estimation of key DCIS natural history parameters, 
such as mean sojourn time for screen-detectable pre-clinical DCIS, and percent of DCIS 
cases that progress to either invasive cancer, clinical DCIS, or potentially regress. We 
identified 10 relevant studies, of which nine include DCIS natural history modeling (Table 
5). Among them, four studies use Markov models [29-32] and five use simulation models 
[15, 33-36], with parameters estimated with either maximum likelihood, Bayesian Gibbs 
sampling or least square methods, and varying assumptions about DCIS natural history 
pathways. Seven studies assumed that all invasive breast cancers progress through a 
pre-clinical in situ or DCIS state that can be detected at screening [15, 29, 32-34, 36], 
whereas the other two studies assumed that some DCIS or in situ lesions first become 
visible on mammograms as small invasive tumors [30, 35]. DCIS or in situ is assumed to 
have both progressive and non-progressive paths in eight studies [15, 29-34, 36], with 
one study also including non-progressive invasive cancers [36].
Table 4 Changes in DCIS detection and overdiagnosis of DCIS when moving from biennial 50-74 
years to other screening scenarios.
Model change in DCIS detection change in DCIS overdiagnosis change in DCIS overdx
change in DCIS detection
A50-74 B40-74 B50-84 A50-74 B40-74 B50-84 A50-74 B40-74 B50-84
D 0.1 0.0 2.8 0.1 0.1 2.8 100% N/A 100%
E 8.5 4.8 5.6 6.7 3.3 5.2 79% 69% 93%
GE 3.2 3.6 6.3 0.4 1.2 3.0 13% 33% 48%
M 13.6 5.0 5.5 13.7 5.1 5.6 101% 102% 102%
W 14.0 2.4 9.7 7.1 1.5 -1.1 51% 63% -11%
A50-74: annual screening from age 50-74 years.
B40-74: biennial screening from age 40-74 years.
B50-84: biennial screening from age 50-84 years.
Model D: Dana-Farber Cancer Institute, Boston, Massachusetts. Model E: Erasmus MC, University 
Medical Center Rotterdam, Rotterdam, the Netherlands. Model GE: Georgetown University Medi-
cal Center, Washington, DC, and Albert Einstein College of Medicine, Bronx, New York. Model M: 
MD Anderson Cancer Center, Houston, Texas. Model W: University of Wisconsin-Madison, Madison, 
Wisconsin, and Harvard Medical School, Boston, Massachusetts.
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These 10 studies used various data sources including different combinations of: i) data 
aggregated from population registries [15, 30, 35, 36], ii) observed national screening 
service program data [32, 33, 37], iii) detailed data from randomized screening trials [29, 
31, 32, 34] and iv) estimates made from previously reported studies including studies 
of DCIS first overlooked at mammography [30, 36]. Generally, more detailed screening 
data makes it possible to deduce more realistic natural history models, fitting the model 
using data from different screening rounds and screening histories [29, 32]. In addition to 
the different data sources, three studies include all in situ lesions [29, 31, 36], while seven 
others only include DCIS [15, 30, 32-35, 37].
Table 5 Overview of studies on modeling DCIS.
1st Author (Year), 
Journal
Paper title Approaches/Models for DCIS natural 
history
Data sources natural History assumptions
Yen (2003), Eur J 
Cancer. [32]
Quantifying the potential problem of 
overdiagnosis of ductal carcinoma in situ in 
breast cancer screening
Markov model Swedish two county trial, service 
screening programs from UK, US 
Netherlands, and Australia
Healthy cases can progress to pre-clinical screen detectable progressive 
or non-progressive DCIS; progressive DCIS progress to invasive breast 
cancer; non-progressive DCIS regress to a separate state where no tumor 
is apparent.
Ozanne (2011), 
Breast Cancer Res 
Treat. [35]
Characterizing the impact of 25 years of DCIS 
treatment
Simulation model US SEER (1975-2005) incidence The percentage of the DCIS lesions that are assumed to progress to 
invasive breast cancer varies between 0% and 100%. The initial assumption 
that DCIS is a short-term obligate precursor of invasive cancer must be 
reevaluated based on the results.
de Gelder (2011), 
Epi Rev. [33]
Interpreting overdiagnosis estimates in 
population-based mammography screening
Simulation model Dutch population data from public 
screening program
Healthy cases can progress to pre-clinical screen detectable DCIS or 
invasive breast cancers; pre-clinical screen detectable DCIS can regress, 
progress to clinical DCIS, or progress to invasive breast cancer.
Gunsoy (2012), 
Breast Cancer Res. 
[29]
Modeling the overdiagnosis of breast cancer 
due to mammography screening in women aged 
40-49 in the United Kingdom
Markov model UK Age trial Healthy cases can progress to pre-clinical screen detectable progressive 
in-situ or non-progressive in-situ; progressive in situ progress to invasive 
breast cancers
Tan (2013), Br J 
Cancer. [31]
Quantifying the natural history of breast cancer Markov model (Bayesian) Swedish randomized trials Healthy cases can progress to pre-clinical screen detectable progressive 
DCIS or non-progressive DCIS; progressive DCIS progress to invasive 
breast cancer.
Ryser (2016), J 
natl Cancer Inst. 
[30]
Outcomes of Active Surveillance for DCIS: A 
Computational Risk Analysis
Markov model US SEER (1999-2011) for 
cumulative mortality estimates and 
natural history model summarized 
from a variety of studies
Healthy cases can progress to the pre-clinical screen detectable 
progressive DCIS or non-progressive DCIS; progressive DCIS progress to 
localized invasive breast cancer.
Duffy (2016), 
Lancet Oncol. [37]
Screen detection of ductal carcinoma in situ and 
subsequent incidence of invasive interval breast 
cancers: a retrospective population-based study
Poisson regression UK National Health Service Breast 
Screening Program (NHSBSP)
Not specified.
de Koning (2006), 
Breast Cancer Res. 
[34]
Overdiagnosis and overtreatment of breast 
cancer: microsimulation modelling estimates 
based on observed screen and clinical data
Simulation model Dutch pilot studies in Utrecht & 
Nijmegen; EORTC
Healthy cases can progress to pre-clinical screen detectable DCIS; pre-
clinical screen detectable DCIS cases can progress to clinical DCIS or 
invasive breast cancer.
Seigneurin (2011), 
BMJ. [36]
Overdiagnosis from non-progressive cancer 
detected by screening mammography: 
stochastic simulation study with calibration to 
population based registry data
Simulation model (Bayesian) Isere, France incidence rates 
of breast cancer and DCIS 
(1991-2006) with some screening 
information
Healthy cases can progress to in situ; in situ cases can be non-progressive, 
progressive to clinical, and progressive to invasive; invasive cancer can also 
be non-progressive or progressive.
van Luijt (2016), 
Breast Cancer Res. 
[15]
The distribution of ductal carcinoma in situ 
(DCIS) grade in 4232 women and its impact on 
overdiagnosis in breast cancer screening
Simulation model Nationwide network and 
registry of histopathology and 
cytopathology in the Netherlands 
(PALGA) data
Healthy cases can progress to different grades of DCIS; lower grade DCIS 
can progress to higher grade DCIS and vice versa; each grade of DCIS can 
progress to invasive cancer that are charaterized by tumor stage.
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Parameters in the literature useful for DCIS modeling
The estimated proportion of DCIS progressing to invasive cancer varies widely in the 
literature (Table 5), mainly due to the available data, study-specific model assumptions, 
and different model structures. When all invasive breast cancer is assumed to go through 
a pre-clinical screen detectable DCIS state, the estimated progression rate of DCIS to 
invasive varies from 61% to 91% [15, 29, 31-34, 36]. When this assumption is not made, 
the estimated progression rate from DCIS to invasive varies from 20% to 24.4% [30, 35]. 
Some studies report a large proportion of progressive DCIS [31, 33, 34, 36], while other 
studies report that most DCIS cases do not progress to invasive cancer [30, 35]. When the 
Table 5 Overview of studies on modeling DCIS.
1st Author (Year), 
Journal
Paper title Approaches/Models for DCIS natural 
history
Data sources natural History assumptions
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screening programs from UK, US 
Netherlands, and Australia
Healthy cases can progress to pre-clinical screen detectable progressive 
or non-progressive DCIS; progressive DCIS progress to invasive breast 
cancer; non-progressive DCIS regress to a separate state where no tumor 
is apparent.
Ozanne (2011), 
Breast Cancer Res 
Treat. [35]
Characterizing the impact of 25 years of DCIS 
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Simulation model US SEER (1975-2005) incidence The percentage of the DCIS lesions that are assumed to progress to 
invasive breast cancer varies between 0% and 100%. The initial assumption 
that DCIS is a short-term obligate precursor of invasive cancer must be 
reevaluated based on the results.
de Gelder (2011), 
Epi Rev. [33]
Interpreting overdiagnosis estimates in 
population-based mammography screening
Simulation model Dutch population data from public 
screening program
Healthy cases can progress to pre-clinical screen detectable DCIS or 
invasive breast cancers; pre-clinical screen detectable DCIS can regress, 
progress to clinical DCIS, or progress to invasive breast cancer.
Gunsoy (2012), 
Breast Cancer Res. 
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Modeling the overdiagnosis of breast cancer 
due to mammography screening in women aged 
40-49 in the United Kingdom
Markov model UK Age trial Healthy cases can progress to pre-clinical screen detectable progressive 
in-situ or non-progressive in-situ; progressive in situ progress to invasive 
breast cancers
Tan (2013), Br J 
Cancer. [31]
Quantifying the natural history of breast cancer Markov model (Bayesian) Swedish randomized trials Healthy cases can progress to pre-clinical screen detectable progressive 
DCIS or non-progressive DCIS; progressive DCIS progress to invasive 
breast cancer.
Ryser (2016), J 
natl Cancer Inst. 
[30]
Outcomes of Active Surveillance for DCIS: A 
Computational Risk Analysis
Markov model US SEER (1999-2011) for 
cumulative mortality estimates and 
natural history model summarized 
from a variety of studies
Healthy cases can progress to the pre-clinical screen detectable 
progressive DCIS or non-progressive DCIS; progressive DCIS progress to 
localized invasive breast cancer.
Duffy (2016), 
Lancet Oncol. [37]
Screen detection of ductal carcinoma in situ and 
subsequent incidence of invasive interval breast 
cancers: a retrospective population-based study
Poisson regression UK National Health Service Breast 
Screening Program (NHSBSP)
Not specified.
de Koning (2006), 
Breast Cancer Res. 
[34]
Overdiagnosis and overtreatment of breast 
cancer: microsimulation modelling estimates 
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Simulation model Dutch pilot studies in Utrecht & 
Nijmegen; EORTC
Healthy cases can progress to pre-clinical screen detectable DCIS; pre-
clinical screen detectable DCIS cases can progress to clinical DCIS or 
invasive breast cancer.
Seigneurin (2011), 
BMJ. [36]
Overdiagnosis from non-progressive cancer 
detected by screening mammography: 
stochastic simulation study with calibration to 
population based registry data
Simulation model (Bayesian) Isere, France incidence rates 
of breast cancer and DCIS 
(1991-2006) with some screening 
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Healthy cases can progress to in situ; in situ cases can be non-progressive, 
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Breast Cancer Res. 
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progress to invasive cancer that are charaterized by tumor stage.
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proportion of progressive DCIS is reported by screening round, the subsequent screen-
ing rounds often reported smaller proportions of progressive DCIS [29, 32] compared to 
initial screening, as cases with a long sojourn time were diagnosed in earlier screening 
exams. High-grade DCIS cases have a larger proportion progressing to invasive than 
low-grade DCIS cases [15].
As for the mean sojourn time, when all invasive cancer are assumed to be screen 
detectable at a pre-clinical DCIS stage, the estimated mean sojourn time for progressive 
DCIS cases in the pre-clinical screen-detectable DCIS state are usually short varying from 
1 month to 5 years [29, 31, 32, 34, 35]. On the other hand, the sojourn time estimates 
are much longer if it is assumed that only a small fraction of invasive cancers comes from 
pre-clinical screen-detectable DCIS [30]. The estimated mean sojourn time in pre-clinical 
screen-detectable DCIS state for DCIS cases that progress to clinical DCIS or regress is 
in typically longer than the mean sojourn time of DCIS cases that progress to invasive 
cancer [29, 32].
1st Author (Year), Journal All invasive 
cancers progress 
through screening 
detectable DCIS?
Screening detectable 
DCIS might regress 
to a non-detectable 
stage
Regression Progression Mean sojourn time Mammography 
sensitivities to detect 
DCIS/in situ
Yen (2003), Eur J Cancer. 
[32]
Yes Yes 37% (19%-46%) at 1st screening; 
4% (3%-21%) at 2nd screening
To invasive: 100-%non-
progression
for non-progression: 30y (6y-37y), for 
progression to invasive: 3mo (2mo-5mo)
Not specified
Ozanne (2011), Breast 
Cancer Res Treat. [35]
No Not specified Not specified To invasive: 20% of progression 
rate matches SEER data best
Not specified Not specified
de Gelder (2011), Epi Rev. 
[33]
Yes Yes 11% of DCIS regress To clinical DCIS: 28% ;
To invasive: 61%
2.6y for DCIS: 72%
Gunsoy (2012), Breast 
Cancer Res. [29]
Yes No  Not specified To invasive: 45% (95%CI: 23%-
75%) at 1st screen, 60% (95%CI: 
40%-78%) at incidence screen
for pre-clinical non-progressive DCIS to clinical 
DCIS: 1.3y (95%CI: 0.4y-3.4y), for pre-clinical 
progressive DCIS: 0.11y (95%CI: 0.05y-0.19y).
for in situ: 82% (95%CI: 
43%-99%)
Tan (2013), Br J Cancer. [31] Yes Yes Not specified 91%(95%CI: 85%-97%) 
aggressive
for aggressive DCIS to invasive 0.5mo (95%CI: 
0-1mo)
for DCIS: 88% (95%CI: 
83%-92%)
Ryser (2016), J natl Cancer 
Inst. [30]
No Yes Not specified 24.4% (11.3%-67%) for progressive DCIS to localized invasive (did 
not specify whether to pre-clinical or clinical 
invasive): 9.8y (6.4y-13.5y)
for MRI: 84% (77%-100%); 
for mammography: 40% 
(33%-50%)
Duffy (2016), Lancet Oncol. 
[37]
Not specified Not specified Not specified 1 invasive interval cancer case is 
estimated to be avoided per 5 
DCIS cases
Not quantified, but short Not specified
de Koning (2006), Breast 
Cancer Res. [34]
No Yes Not specified To either invasive or clinical : 
90%
Dutch pilot study suggests 2.8y with 99% sensitivity. Nijmegen data suggests 
2.5y. EORTC trial suggests 5y with 40% sensitivity.
Seigneurin (2011), BMJ. [36] Yes Yes 6% non-progressive in situ 
(95%CI 0%--17%)
To invasive: 91% (95%CI: 84%-
97%)
Not specified Not specified
van Luijt (2016), Breast 
Cancer Res. [15]
Yes Yes 4% low, 2% intermediate, and 
1% for high grade DCIS
To invasive: 16% low, 31% 
intermediate, 53% for high 
grade DCIS
Not specified Not specified
Note: ranges present values estimated from different studies or data sources unless otherwise speci-
fied.
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The mammography sensitivity for DCIS varies from 40% to 99% [29, 31, 33, 34]. The 
mean sojourn time for progressive DCIS in the pre-clinical screen detectable DCIS state 
tends to be smaller when mammography sensitivity is high. These variations reveal the 
uncertainty regarding the natural history of DCIS, highlighting the need and potential 
directions of CISNET modeling.
discussion
While the CISNET models have generated relatively similar results and conclusions in 
most other respects, DCIS detection rates and overdiagnosis reveal more variation in 
results, with predicted DCIS incidence ranging from 25.8 – 32.3 per 1000 women age 
40 followed over their lifetimes, and estimates of DCIS overdiagnosis ranging from 
34%-72% for biennial screening from age 50 to 74 years. The large difference in the 
1st Author (Year), Journal All invasive 
cancers progress 
through screening 
detectable DCIS?
Screening detectable 
DCIS might regress 
to a non-detectable 
stage
Regression Progression Mean sojourn time Mammography 
sensitivities to detect 
DCIS/in situ
Yen (2003), Eur J Cancer. 
[32]
Yes Yes 37% (19%-46%) at 1st screening; 
4% (3%-21%) at 2nd screening
To invasive: 100-%non-
progression
for non-progression: 30y (6y-37y), for 
progression to invasive: 3mo (2mo-5mo)
Not specified
Ozanne (2011), Breast 
Cancer Res Treat. [35]
No Not specified Not specified To invasive: 20% of progression 
rate matches SEER data best
Not specified Not specified
de Gelder (2011), Epi Rev. 
[33]
Yes Yes 11% of DCIS regress To clinical DCIS: 28% ;
To invasive: 61%
2.6y for DCIS: 72%
Gunsoy (2012), Breast 
Cancer Res. [29]
Yes No  Not specified To invasive: 45% (95%CI: 23%-
75%) at 1st screen, 60% (95%CI: 
40%-78%) at incidence screen
for pre-clinical non-progressive DCIS to clinical 
DCIS: 1.3y (95%CI: 0.4y-3.4y), for pre-clinical 
progressive DCIS: 0.11y (95%CI: 0.05y-0.19y).
for in situ: 82% (95%CI: 
43%-99%)
Tan (2013), Br J Cancer. [31] Yes Yes Not specified 91%(95%CI: 85%-97%) 
aggressive
for aggressive DCIS to invasive 0.5mo (95%CI: 
0-1mo)
for DCIS: 88% (95%CI: 
83%-92%)
Ryser (2016), J natl Cancer 
Inst. [30]
No Yes Not specified 24.4% (11.3%-67%) for progressive DCIS to localized invasive (did 
not specify whether to pre-clinical or clinical 
invasive): 9.8y (6.4y-13.5y)
for MRI: 84% (77%-100%); 
for mammography: 40% 
(33%-50%)
Duffy (2016), Lancet Oncol. 
[37]
Not specified Not specified Not specified 1 invasive interval cancer case is 
estimated to be avoided per 5 
DCIS cases
Not quantified, but short Not specified
de Koning (2006), Breast 
Cancer Res. [34]
No Yes Not specified To either invasive or clinical : 
90%
Dutch pilot study suggests 2.8y with 99% sensitivity. Nijmegen data suggests 
2.5y. EORTC trial suggests 5y with 40% sensitivity.
Seigneurin (2011), BMJ. [36] Yes Yes 6% non-progressive in situ 
(95%CI 0%--17%)
To invasive: 91% (95%CI: 84%-
97%)
Not specified Not specified
van Luijt (2016), Breast 
Cancer Res. [15]
Yes Yes 4% low, 2% intermediate, and 
1% for high grade DCIS
To invasive: 16% low, 31% 
intermediate, 53% for high 
grade DCIS
Not specified Not specified
Note: ranges present values estimated from different studies or data sources unless otherwise speci-
fied.
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predicted amount of overdiagnosis of DCIS between models likely reflects the continued 
uncertainty about DCIS natural history, in particular the progression rates, which is also 
reflected in the results from other models described in the literature with reported pro-
gression rates varying from 20% to 91%.
In the literature outside of CISNET, several approaches have been proposed to model 
DCIS. The variations in model structure, assumptions and results make it challenging to 
deduce good overall estimates of key natural history parameters. Given the uncertainties 
in the DCIS models, a realistic approach to DCIS modeling is to adopt several plausible 
sets of model parameters and to evaluate a range of outcomes generated from the 
models. The CISNET models are well-suited for this type of analysis. CISNET models 
have the ability to project long-term implications for DCIS assumptions in terms of breast 
cancer outcomes such as life expectancy and overdiagnosis, and can thus assess how 
much early detection impacts breast cancer mortality. Also, moving forward, CISNET 
models are capable of utilizing multiple models and vary model parameters, to explore 
the impact of different DCIS assumptions on outcomes more systematically. In addi-
tion, both the impact of screening and treatment on DCIS-related outcomes can be 
systematically reviewed and compared. Although it remains to be seen to what extent 
these analyses will provide sufficiently accurate and consistent findings to inform clinical 
practice, the comparative modeling effort of the CISNET models will likely contribute to 
a greater understanding of DCIS.
Despite the large difference in the predicted amount of overdiagnosis of DCIS between 
models, all models indicated that the amount of overdiagnosis of DCIS is substantial 
(i.e., 34%-72% for biennial screening from age 50-74 years), indicating that per 1000 
women followed over their lifetimes 9-19 are overdiagnosed with DCIS and the majority 
of those women will undergo treatment for their non-invasive disease. Almost all women 
(98%) diagnosed with DCIS undergo a surgical procedure [13, 38] and recent work found 
an increase in the utilization of mastectomy with reconstruction and contralateral risk-
reducing mastectomy over time [39]. There was also an increase in the proportion of 
women undergoing adjuvant radiation therapy after surgery from 58.5% in 1998-1999 to 
70% during 2006-2011 [39].
Modeling estimates might improve and results might converge when new data 
becomes available. A unique opportunity to improve DCIS natural history modeling 
comes from trials on active surveillance. Several trials are currently underway to evaluate 
active surveillance approaches for DCIS. In the UK, the Low Risk DCIS Trial (LORIS), is 
comparing surgical excision to active surveillance without excision [40, 41]. Similarly, 
the European Organisation for Research and Treatment of Cancer (EORTC) has started 
a trial on the management of low-risk DCIS (LORD), which is a randomized, multicenter, 
non-inferiority trial, between standard therapy approach versus active surveillance [42]. 
In the US a prospective, randomized trial, Comparing Operative to Medical Endocrine 
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Therapy for low-risk DCIS (COMET), has recently been funded. Women diagnosed with 
low-risk DCIS will be randomized to receive either guideline-concordant care of surgical 
intervention, with or without radiation, or active surveillance of a mammogram every 6 
months for 5 years. Patients in both trial arms are free to choose endocrine therapy. Also, 
in the US, several research networks, called cooperative groups, that conduct cancer 
clinical research primarily under the sponsorship of the NCI, are presently testing the 
use of neo-adjuvant hormonal therapy in postmenopausal women with ER-positive DCIS 
prior to surgery; those with a complete response based on magnetic resonance imaging 
(MRI) will not receive additional therapy. However, it will take a long time before results 
are available, e.g., for LORIS initial results are expected in 2020 and for LORD the results 
are not expected before 2029. When they do become available these data present a 
unique opportunity to validate models by comparing the model projections to the final 
trial data.
In the meantime, thus, before final results from these trials become available, the mod-
els can be used to evaluate which assumptions affect outcomes most. Also, data from 
several different sources might be used and combined to compare model outcomes 
and see what model structure and progression rates fit the data best. For example, data 
from different screening modalities can inform models, as the ability to detect DCIS 
varies across modalities. Screening ultrasound is less likely to detect DCIS compared to 
mammography in the small number of controlled experiments available that make this 
comparison, because ultrasound is unlikely to detect micro-calcifications. MRI may be 
more sensitive than mammography [43, 44] by detecting the pathophysiologic proper-
ties like basement membrane permeability in DCIS [45] perhaps explaining the tendency 
of MRI to detect intermediate and high grade DCIS more readily than mammography. 
By using a particular set of parameters and modelling different screening modalities, it 
might become possible to narrow down the range of plausible progression parameters. 
Furthermore, data by ER and grade might be used to refine the models. Subsequently, 
the updated and refined models can be used to simulate active surveillance strategies 
and quantify the predicted outcomes for subgroups of women varying by age and with 
DCIS varying by grade and ER status.
Until then, the model results consistently show a considerable amount of over-
diagnosis of DCIS, which increases with more frequent screening. This indicates that 
women undergoing regular screening with a screen-detected DCIS are quite likely to be 
overdiagnosed. Thus, given the substantial amount of overdiagnosis estimated by the 
CISNET models for DCIS in general, the model results support the safety and value of 
observational trials for low-risk DCIS.
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abstract
background
The U.K. Age trial compared annual mammography screening of women ages 40 to 49 
to no screening and found a statistically significant breast cancer mortality reduction at 
10-year follow-up, but not at 17-year follow-up. The objective of this study was to com-
pare the observed Age trial results to the Cancer Intervention and Surveillance Modeling 
Network (CISNET) breast cancer model predicted results.
methods
Five established CISNET breast cancer models used data on population demographics, 
screening attendance, and mammography performance from the Age trial together with 
extant natural history parameters to project breast cancer incidence and mortality in the 
control and intervention arm of the trial.
results
The models closely reproduced the effect of annual screening from ages 40 to 49 on 
breast cancer incidence. Restricted to breast cancer deaths originating from cancers 
diagnosed during the intervention phase, the models estimated an average 15% (range 
across models 13% to 17%) breast cancer mortality reduction at 10-year follow-up com-
pared to 25% (95% CI 3% to 42%) observed in the trial. At 17-year follow-up, the models 
predicted 13% (range 10% to 17%) reduction in breast cancer mortality compared to the 
non-significant 12% (95% CI -4% to 26%) in the trial.
conclusions
Overall, the models captured the observed effect of screening from age 40 to 49 on 
breast cancer incidence and mortality in the U.K. Age trial, suggesting that the model 
structures, input parameters, and assumptions about breast cancer natural history are 
reasonable for estimating the impact of screening on mortality in this age group.
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introduction
The breast cancer models of the Cancer Intervention and Surveillance Modeling Network 
(CISNET) synthesize data on breast cancer epidemiology, population demographics, 
screening accuracy, and treatment to simulate the impact of screening and treatment 
interventions on breast cancer incidence and mortality. Prior comparative modeling 
studies, i.e., cross-validations [1], by the CISNET models have illustrated the ability of the 
models to reproduce the trends in breast cancer incidence and mortality in the United 
States. [2-4] The models generated similar rankings of the effects of different screening 
scenarios and the relative impact of screening and treatment on breast cancer mortality. 
Moreover, the simulation results provided quantitative information about the harms and 
benefits of various screening strategies not examined in randomized clinical trials, and 
have been used by policy makers to inform decisions about breast cancer screening 
guidelines. [3, 5]
The consistency of previous collaborative modeling research provides a level of 
evidence for cross-validation. However, none of the prior collaborative CISNET research 
by the Breast Working Group has included external model validation. The International 
Society for Pharmacoeconomics and Outcomes Research in collaboration with the Soci-
ety for Medical Decision Making (ISPOR-SMDM) recommends external model validation 
as part of good modeling practices, where external model validation is defined as, “the 
comparison of model predictions to observed event data not used in model develop-
ment”[1]. The purpose of this paper is to conduct an external validation and compare 
CISNET breast cancer incidence and mortality predictions to observed clinical trial results 
of mammography screening from ages 40 to 49.
To date, the model parameters were primarily developed based on U.S. data on breast 
cancer epidemiology, screening, treatment, and population demographics.[6] Outcomes 
of our simulations indicated that offering screening to women in their fifties results in a 
more favorable ratio of benefits and harms than offering screening to women in their 
forties. [3, 7] This difference between the benefits and harms between these age groups, 
corresponds to the available evidence of screening women aged 50 and older [8] and 
the uncertainty about screening women in their forties, considering the inconclusive evi-
dence from fewer studies, and the different guidelines for this age group [5, 9, 10]. Given 
the high prevalence of dense breast tissue, faster growing tumors, and inferior sensitivity 
of mammography in these younger women [11-13], it is important to validate the models 
for the effectiveness of screening in the forties. The U.K. ‘Age’ trial is a well-documented 
[14-20] trial, investigating the effect of annually screening women from ages 40 to 49 
compared to no screening, and provided a unique opportunity to externally validate the 
CISNET breast cancer models for screening in the forties.
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In this study, we present the first external validation performed by the CISNET breast 
cancer models that use different structures and assumptions about breast cancer natural 
history to project the impact of screening. We compare breast cancer incidence and 
mortality predictions to the observed results from the U.K. Age trial. The findings from 
this study are intended to inform CISNET model users as they can account for this infor-
mation when considering and interpreting future model outcomes.
methods
The U.K. Age trial was the only randomized controlled trial designed specifically to inves-
tigate the effect of annual mammography screening from ages 40 to 49. Between Octo-
ber 1990 and September 1997, 160,836 women aged 40-41 were randomly assigned in 
a ratio of 1 : 2 to either the intervention group or the control group. The 53,883 women in 
the intervention arm were offered annual screening by mammography, and the 106,953 
women in the control arm received usual care (no screening). We collaborated with the 
Age trial investigators to obtain the observed de-identified data from the trial.
simulation models
Five CISNET breast cancer models were included in this analysis: Model D (Dana-
Farber), Model E (Erasmus), Model M (MD Anderson), Model S (Stanford), and Model W 
(Wisconsin-Harvard). These models have been developed independently within CISNET 
over the past 15 years and are described in detail elsewhere [21-25]. Briefly, women are 
born in a breast cancer-free stage, some women develop a tumor that may progress to 
a pre-clinical stage where it could be screen-detected in its pre-clinical sojourn time, 
or be diagnosed with breast cancer due to clinical symptoms. Once diagnosed with 
breast cancer, women receive age-, stage-, and biomarker-specific treatment. Breast 
cancer incidence and mortality projections depend on age, start and stopping ages of 
screening, screening frequency, mammography screening performance, stage at diag-
nosis, estrogen receptor (ER) and Human Epidermal growth factor Receptor 2 (HER2) 
status of the tumor, breast cancer treatment, and factors related to the natural history 
of breast cancer (Tables 1 & 2). However, since the Age trial did not collect HER2 status, 
the models did not simulate HER2 specific molecular subtypes of breast cancer. The 
models adopt a ‘parallel universe’ approach; the same population of women is simulated 
twice: in one scenario women were invited to annual screening in the forties (intervention 
group), and in the second scenario women did not receive any screening in the forties 
(control group).
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Table 1 Key differences and similarities between the CISNET breast models.
Model D E M S W
Model type Analytic, Parallel 
universe
Simulation, 
Parallel universe
Bayesian, Parallel 
universe
Simulation,
Parallel universe
Simulation, 
Parallel universe
Natural history 
modeled as
State-transition Continuous tumor 
growth
Bayesian model Continuous tumor 
growth
Continuous tumor 
growth
Tumor inception Start of the 
sojourn time
Prior to start of 
sojourn time
N/A Prior to start of 
sojourn time
Start of the 
sojourn time
DCIS included Since 2014 Yes Yes No Yes
Tumor ER status Yes Yes Yes Yes Yes
Screen detection 
depends on
Modality,
age, density, 
frequency
Tumor size, 
modality, age, 
density, frequency
Modality, age, 
frequency
Tumor size, ER 
status, age, 
hormone repl., 
frequency
Tumor size, 
modality, age, 
density, frequency
Screening 
benefit
Stage shift Detection at 
smaller tumor size
Stage shift, 
beyond stage shift
Stage shift, 
smaller tumor size
Younger age, 
smaller tumor size
Estimation of 
over diagnosis
Difference 
screen &
no-screen
Difference screen 
&
no-screen
Difference screen 
&
no-screen
Difference screen 
&
no-screen
Difference screen 
&
no-screen
Treatment 
benefit
Hazard reduction Cure fraction, 
larger fatal 
diameter
Cure fraction, 
hazard reduction,
Hazard reduction, 
non-proportional
Cure fraction
Death from 
breast cancer 
determined by
Survival from BC 
< survival other 
cause mortality
Fatal diameter, 
survival from BC 
< survival other 
cause mortality
Survival from BC 
< survival other 
cause mortality
Survival from BC 
< survival other 
cause mortality
Survival from BC 
< survival other 
cause mortality
Model type
Analytic: Analytical approach to estimate the impact of mammography screening and treatment on 
incidence and mortality of breast cancer.
Simulation: Stochastic simulation is based on the Monte Carlo method and use of random numbers.
Bayesian: The model does not include a natural history and estimates prior probability distributions 
for all unknown parameters.
Parallel universe: Screening and treatment is modeled in a parallel universe, implying that the same 
population is simulated twice: once to determine the impact of breast cancer without screening, and 
once to determine the impact of breast cancer with screening.
Breast cancer natural history and breast cancer death
ER: Onset and progression of breast cancer is different for Estrogen Receptor positive and negative 
tumors.
Tumor stage transition: Tumor progression is modeled as transitions between different stages of 
breast cancer.
Continuous tumor growth: Tumors grow continuously after tumor onset.
Death from breast cancer: Once diagnosed with breast cancer, a survival until breast cancer death 
is competing with the other cause mortality survival. That is, breast cancer death occurs only if the 
patient does not die from other causes.
Screening & Treatment
Sensitivity: Sensitivity can be used directly or indirectly (e.g., when translated to tumor size).
Over diagnosis: The detection and diagnosis of a condition that would not go on to cause symptoms 
or breast cancer death in a woman’s lifetime.
Hazard reduction: Reduction in breast cancer mortality hazard, calculated by 1 minus the hazard ratio 
for the different treatment regimes.
Cure fraction: If hazard rate reduction is not a model input, it is translated into a cure fraction.
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As summarized in Table 1, the models differ in the ways they approximate unobservable 
events in the natural history of breast cancer. In model D, tumors progress via discrete 
state transitions [23], models E, S and W have continuous tumor growth [21, 22, 25], and 
model M uses Bayesian simulation [24] and does not have a natural history component. 
In models D and W, tumors are technically screen-detectable from the moment at tumor 
inception. Models E and S start simulating tumors at small tumor sizes, prior to the start 
of the sojourn time, when tumors are not yet screen-detectable by film or digital mam-
Table 2 Model inputs used for the Age trial simulation:
Model Input Description Source
Population demographics
Birth cohort Birth years of women participating in the Age trial Age trial
Life years Number of life years by trial arm by age Age trial
natural history of breast cancer
Incidence Control arm incidence (incidence in the absence of screening) Age trial
Tumor onset The moment tumors start to grow (tumor inception) CISNET1
Sojourn time Time between when a cancer is first screen-detectable and 
cancer diagnosis in the absence of screening.
CISNET2
Tumor progression Tumor growth, tumor progression and regression affect tumor 
sojourn times and breast cancer survival.
CISNET3
Estrogen receptor distribution Age-specific ER positive and ER negative distributions U.K.4
Breast cancer screening
Attendance Adherence to annual screening in the intervention arm Age trial
Sensitivity Probability that the screen will be positive among women with 
breast cancer by age, screening round (first vs. subsequent)
Age trial
Mammography Two-view mammography for first screens, for all subsequent 
screens one-view mammography
Age trial
Breast cancer treatment
Treatment dissemination Breast cancer treatment by age, stage and ER-status BASO5
Effectiveness Hazard reduction breast cancer mortality by age and ER-status EBCTCG6
Breast cancer survival
Survival Breast cancer survival by age, stage and ER-status CISNET7
Other-cause mortality Probability of dying from causes other than breast cancer U.K.8
1-3 Tumor onset, sojourn time and tumor progression are model-specific parameters. These, and 
other model-specific assumptions about breast cancer natural history are described elsewhere [6, 
21-25].
4 Estrogen receptor status comes from observed U.K. data [26].
5 The treatment dissemination was derived from BASO reports [26] published by the NHSBSP.
6 Treatment effectiveness / hazard reduction for breast cancer death was published by the Early 
Breast Cancer Trialists Collaborative Group (EBCTCG) that included the U.K. trials [27]
7 Breast cancer survival by age and ER status from the UK is not available for the time period of the 
trial, the existing survival in the models which is based on U.S. data was used.
8 Other cause mortality was taken from the Human Mortality Database [30] with breast cancer deaths 
removed.
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mography. Screening benefit in models D and M is modeled as a stage shift to earlier 
stage breast cancer, with the latter model including an additional benefit of screening 
beyond stage shift. The benefits of screening in models E, S and W are simulated by the 
detection of tumors at smaller sizes than at clinical diagnosis in the absence of screening. 
(Table 1)
model inputs
The Age trial data that the CISNET models obtained included control arm incidence in 
the absence of screening, mammography screening performance, screening attendance 
patterns, and demographic data such as life years and the distribution of birth years 
of women participating in the trial (Table 2). In the Age trial, data were not collected 
for breast cancer treatment. To fill this gap we modeled the breast cancer treatment 
dissemination between 1991 and 2006, the intervention period of the trial, based on 
reports from the British Association of Surgical Oncology [26]. The effectiveness of breast 
cancer treatment was taken from analyses by the Early Breast Cancer Trialists’ Collabora-
tive Group (EBCTCG) that included trials conducted in the U.K. [27]. Model parameters 
related to the natural history of breast cancer such as tumor onset and tumor growth 
were based on the original CISNET parameters and no calibration was performed to the 
results from the Age trial.
simulation of the age trial
The women who participated in the Age trial were born between 1950 and 1957, there-
fore, we simulated the 1950-1957 birth cohort. In the trial, two thirds of women aged 
40 to 41 were randomized to the control group and were not invited to any screening in 
their forties. The models simulated 2 to 10 million women in each arm of the trial as they 
were not limited by practical issues concerning invitations and the number of women 
who can be included in the simulation of the trial. (Table 3) Any unscheduled screening 
in the control group was primarily a consequence of clinical symptoms and not because 
of routine screening [17], so we did not model screening contamination in the control 
group explicitly.
We used the control arm incidence as model input for a baseline projection of breast 
cancer incidence in the absence of screening. The models then overlaid the screening 
parameters according to the observed screening attendance patterns of the 53,883 
women in the intervention group of the Age trial [18]. The percent uptake of invita-
tions increased by screening round while the absolute number of invitations sent to the 
women in the trial decreased by almost 50% near the end of the intervention period and 
consequently the absolute number of women who were screened decreased as well. [18] 
The models accounted for this by simulating the decrease in the number of women who 
were screened by age. The first analog mammogram in the trial included two views, and 
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all subsequent mammograms were single-view, similar to the standard practice in the 
U.K. at the time of the trial. Screen detection of pre-clinical breast cancer was modeled 
on the basis of observed sensitivity data published by the trial investigators [16].
The U.K. treatment dissemination developed for this project indicated whether 
a breast cancer is treated with hormone therapy and/or chemotherapy after surgical 
removal of the tumor. Overall, ER-positive breast cancers were primarily treated with 
hormone therapy and ER-negative breast cancers with chemotherapy. Since, the trial did 
not collect HER2 status, and Trastuzumab (Herceptin) was not yet disseminated in the 
U.K. at the time of the trial, it was not included in the treatment regimens.
analysis
Model predictions were compared to breast cancer incidence and mortality observations 
from the Age trial by arm without calibrating the natural history parameters of the models 
to the trial. In addition, we compared the number of mammograms in the intervention 
group to that of the Age trial to investigate whether any differences in model predictions 
were related to variations in the number of mammograms.
We compared model outcomes to those from the trial at 10-year and 17-year follow-
up, corresponding to the most recent analysis by the Age trial investigators [15]. The 
trial used ‘incidence based mortality’ to measure the effect of screening and treatment 
on breast cancer mortality. This implies, only counting cancer deaths that originated 
from cancers diagnosed during the intervention phase of the trial (ages 40 to 49). This is 
necessary because all women from both the intervention and control group ‘rolled’ into 
the national U.K. breast cancer screening program at age 50 and were invited to screen-
ing once every three years. For example, if at age 54 there would be fewer breast cancer 
deaths among women randomized to the intervention group than among the women 
Table 3 Number of women included in the control and intervention group
nr. of women in the control arm nr. of women in the intervention arm
Age trial 106,953 53,883
Model D N/A* N/A
Model E 10,000,000 10,000,000
Model M 4,000,000 4,000,000
Model S 5,000,000 5,000,000
Model W 2,000,000 2,000,000
All models simulated at least about 20 times as many women in the control group and 40 times as 
many women as in the intervention group. The number of women simulated was selected by each 
model to balance feasibility of simulation time with model output that yields relatively smooth inci-
dence and mortality curves.
*Model D uses entirely analytical formulations to evaluate the impact of screening and treatment 
on breast cancer incidence and mortality, i.e., the number of women simulated does not apply to 
Model D.
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in the control group, one could conclude that the intervention of annual screening in 
the forties effectively reduced breast cancer mortality at age 54. However, because all 
women ‘rolled’ into the national screening program at age 50, it may be the case that the 
breast cancer deaths prevented at age 54 were actually from breast cancers diagnosed 
by screening at age 50 as part of the national program and not by the trial’s annual 
screening intervention in the forties. Therefore, the trial and the models only used breast 
cancer deaths from cancers diagnosed during the intervention phase to measure the 
effect of annual screening in the forties on breast cancer mortality.
The confidence intervals associated with the mortality reduction observed in the Age 
trial at 10-and 17-year follow-up are useful as these are mainly influenced by the finite 
number of women included in the trial. The CISNET models have not included confi-
dence intervals on their results given the millions of women simulated per trial arm. The 
model estimates will have a negligible range, given that the model outcomes are based 
on simulations of millions of women, each with varying combinations of variables consti-
tuting the life history, and sampled across the distribution of each variable. However, the 
model results do have uncertainty due to assumptions about unobservable parameters 
and structural uncertainties that are addressed. The use of multiple models provides 
a range of results that captures this structural uncertainty and could be considered to 
provide information comparable conceptually to a confidence interval.
results
breast cancer incidence
The average simulated invasive breast cancer incidence among women aged 40 to 49 in 
the control arm was 131 per 100,000 women (range across models 124 - 138) compared 
to 132 observed in the Age trial (Figure 1). The modeled ductal carcinoma in situ (DCIS) 
incidence was 11 per 100,000 women on average (range across models 7 - 17), and 
equivalent to the 11 per 100,000 observed in the Age trial.
The average number of mammograms per woman in the intervention arm of the 
simulated trial was 5.2 (range across models 4.9 – 5.4) compared to 4.84 in the Age trial. 
Modeled invasive breast cancer incidence in the intervention arm increased by age and 
was an average of 135 per 100,000 among women aged 40 to 49 (range across models 
131 - 141). This is consistent with the pattern for the 139 invasive breast cancers diag-
nosed per 100,000 women in the trial (Figure 2). DCIS intervention arm incidence varied 
more across the models (range 18 - 38) and with 27 diagnoses on average, higher than 
the 21 DCIS diagnoses per 100,000 women in the trial. Models with continuous tumor 
growth (Models E and W) and models with tumor inception prior to the start of the tumor’s 
sojourn time (Model E) tend to have the highest incidence of screen-detected DCIS.
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Both the model results and the observed Age trial data included a small peak (Figure 
3) at age 40 in screen-detected breast cancers due to the detection of (prevalent) cases 
on the first mammogram, the only two-view mammogram in the trial with better sensitiv-
ity than subsequent screens (Table 4). This was the only age during the trial at which the 
rate of screen detected cancers was higher than the rate of clinically diagnosed cancers 
in the intervention group. The average rate of screen-detected DCIS and invasive breast 
cancers in the intervention arm in the age range 40 - 49 was 69 per 100,000 women in 
the Age trial, compared to the models’ average of 75 (range 63 - 89). The rate of clinically 
diagnosed cases (DCIS and invasive breast cancers) in the intervention arm was 97 in 
the trial and 93 in the models (range 82 - 99). Regardless of mode of detection, the rate 
of breast cancers diagnosed in the intervention arm between ages 40 - 49 was 161 per 
100,000 women on average (range across models 154 - 169) and similar to 162 in the 
Age trial.
Figure 1 Control group breast cancer incidence (DCIS and invasive separately) per 100,000 women, 
compared to the Age trial.
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breast cancer mortality
Among breast cancers diagnosed between ages 40 to 49, the Age trial found a total 
of 83 breast cancer deaths in the first 10 years of follow-up in the intervention arm (16 
breast cancer deaths per 100,000 women) and 219 breast cancer deaths in the control 
arm (21 per 100,000 women). At 10-year follow-up, the rate of breast cancer deaths 
per 100,000 women predicted by the models was 20 on average (range across models 
17 to 22) in the intervention arm, and 23 (range across models 20 to 25) in the control 
arm (Table 5). The number of breast cancer deaths predicted by the different models 
consistently somewhat higher in both arms than in the trial.
On average, the modeled breast cancer mortality reduction due to screening was 15% 
(range across models 13% to 17%) at 10-year follow-up vs. 25% (95% CI 3% to 42%) 
observed in the Age trial. At 17-year follow-up, the models predicted 13% (range across 
models 10 – 17%) breast cancer mortality reduction when restricted to breast cancer 
deaths that originated from breast cancers diagnosed during the intervention phase 
(incidence-based mortality) vs. 12% (95% CI -4% to 26%) observed in the trial (Table 6). 
Figure 2 Intervention group breast cancer incidence (DCIS and invasive separate) per 100,000 wom-
en, compared to the Age trial.
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Table 4 Sensitivity of screening in the Age trial and in the models.
First screen
(two view mammography)
Subsequent screens
(single view mammography)
Age trial 73.6 55.2
Model D 73.6 55.3
Model E 72.5 55.7
Model M* - -
Model S 75.5 59.0
Model W 67.7 59.6
*Model M is a Bayesian without a natural history part and a woman’s disease status is unknown. As 
a result sensitivity is not applicable. Model M simulates screen- and clinically-detected incidences 
without knowing the true disease status.
Sensitivity of screening and screen detection is modeled differently in various models. In the con-
tinuous tumor growth models E, S, and W screen detection of tumors is simulated by transforming 
sensitivity to a threshold tumor size at which tumors can be screen detected. On the other hand, 
model D uses sensitivity of screening by simulating a shift to a less-advanced stage of breast cancer.
Table 6 Breast cancer mortality outcomes at 17-years follow-up, restricted to breast cancer deaths 
that stem from cancers diagnosed during the intervention phase.
Mammograms 
per woman
Breast cancer deaths per 100,000 
women
Rate ratio 
BC deaths
Breast cancer ** 
mortality reduction
intervention group control group
Age trial 4.84 19 22 0.88 12% (-4 to 26%) *
Model average 5.23 20 23 0.87 13.2% [range 10 -17%]
Model D 5.30 20 22 0.90 9.7%
Model E 4.90 18 22 0.83 17.1%
Model M 5.43 20 24 0.85 15.2%
Model S 5.29 21 24 0.89 11.0%
Model W 5.23 18 21 0.86 13.7%
* 95% confidence interval in parentheses
Table 5 Breast cancer mortality outcomes at 10-years follow-up.
Mammograms 
per woman
Breast cancer deaths per 100,000 
women
Rate ratio 
BC deaths
Breast cancer ** 
mortality reduction
intervention group control group
Age trial 4.84 16 21 0.75 25% (3 to 42%) *
Model average 5.23 19 23 0.85 15.3% [range 13-17%]
Model D 5.30 17 20 0.83 17.0%
Model E 4.90 20 25 0.83 16.9%
Model M 5.43 20 23 0.86 13.6%
Model S 5.29 22 25 0.87 13.2%
Model W 5.23 19 22 0.84 16.0%
* 95% confidence interval in parentheses
** The Age trial measured the effect of annual screening of women aged 40 to 49 on breast cancer 
mortality. Therefore, the trial and the simulation models excluded breast cancer deaths that oc-
curred in women diagnosed with breast cancer before age 40 and after age 49.
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Figure 3 Intervention group (screen detected) breast cancer incidence per 100,000 women. Screen-
ing ceased at age 48 in the Age trial. 
Figure 4 Intervention group (clinically diagnosed) breast cancer incidence per 100,000 women.
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The models with either tumor onset at tiny tumor sizes prior to the start of the sojourn 
time and on average slow tumor progression (Model E), or with tumor cure fractions for 
treatment benefit (Models E, M and W) maintained their 10-year follow-up breast cancer 
mortality reduction prediction at 17-year follow-up, whereas mortality reduction in the 
trial decreased. Similar to the Age trial, the models showed a turning point around age 
50 where the increase in the cumulative number of breast cancer deaths averted started 
to diminish (Figure 5).
discussion
This is the first collaborative CISNET breast cancer study comparing model predictions 
to observed clinical trial results not used in the development of any model parameters. 
The results indicate that all five models estimate the long-term effect of annual screen-
ing between the ages of 40 to 49 well within the observed confidence intervals of the 
U.K. Age trial. The impact of screening on breast cancer mortality was also internally 
consistent with individual model structures regarding the natural history of breast cancer.
The ISPOR-SMDM Modeling Good Research Practices TaskForce-7 [1] states that pre-
dictive and external validation are the strongest forms of model validation as decision-
Figure 5 Cumulative breast cancer deaths averted per 100,000 women*. *Cumulative breast cancer 
deaths averted only using breast cancer deaths from cancers diagnosed in the intervention period 
per 100.000 women. Calculated by the rate of breast cancer deaths in the control group minus the 
rate of breast cancer deaths in the intervention group.
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makers can account for this information when considering model outcomes. In the past, 
the breast CISNET models have illustrated accurate predictions of molecular-subtype-
specific and overall U.S. breast cancer incidence and mortality trends. [3, 4, 28] This study 
extends these prior cross-validations by independently estimating the observed results 
from a U.K. randomized controlled trial.
All models reproduced the trend in control group breast cancer incidence from ages 
40 to 49, implying that the extant model structures and assumptions about the natural 
history of breast cancer in the absence of screening are reliable. Despite the intensive 
(annual) screening intervention, the models predicted more clinically diagnosed than 
screen-detected breast cancers in the intervention group. This was likely to be explained 
by the relatively low sensitivity of all subsequent single-view mammograms that followed 
after the more sensitive prevalent two-view mammogram, and the decrease in the num-
ber of women screened by screening round in the trial [18]. Although the models utilized 
different mechanisms such as a threshold tumor size (Models E, S, and W) or stage shift 
(Models D and M) to simulate screen detection of pre-clinical breast cancer, they were 
all able to accurately estimate the impact of screening from ages 40 to 49 on invasive 
breast cancer incidence.
The effect of screening and treatment on breast cancer mortality was underestimated 
by all models at 10-year follow-up compared to the reduction observed in the Age trial. 
Since all models accurately predicted breast cancer incidence, and the fact that the 
underestimation of the mortality reduction was present across all models, it might be 
explained by a common model input not related to screening. Specifically, the derived 
U.K. treatment dissemination may not represent the actual treatment received by women 
diagnosed with breast cancer in the trial. This is in line with the higher rate of breast 
cancer deaths predicted by the models in the control arm in the absence of screening.
After 10 years of follow-up, breast cancer mortality reduction observed in the trial 
decreased and lost significance, whereas most models predicted a fairly constant mor-
tality reduction between 10- and 17-year follow-ups. Previous analysis of the CISNET 
models [29] illustrated that Model D, with tumor inception at the start of the sojourn 
time, has fast tumor progression on average, and Model E, with tumor inception prior 
to the start of the sojourn time, has the slowest tumor progression on average. These 
individual model structures affect the pattern in breast cancer deaths averted after age 
49 when screening ceased, because cancers diagnosed in the control arm caused breast 
cancer death at a younger age in Model D and at a later age in Model E. Consequently, 
mortality reduction due to screening was greater at later ages (between 10- and 17-year 
follow-up) in Model E than in Model D. While the model structure of Model S is similar 
to that of Model E, Model S does not include DCIS, which implies no possible benefit 
in terms of mortality reduction from screen-detected DCIS. However, these otherwise 
screen-detected DCIS cases will likely be diagnosed as local stage small invasive tumors 
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(size <1 cm.) in Model S with relatively high, and similar survival as DCIS cases. Model W 
is unique in that it simulates tumors with a limited malignant potential [25]. This may have 
resulted in a substantial amount of screen-detected tumors that did not cause breast 
cancer death during the 17-year follow-up. Consequently, Model W’s mortality reduction 
decreased slightly after age 49 despite their high rate of screen-detected cancers in the 
forties.
In summary, at 10- and 17-year follow-up, the models reproduced the effects of annual 
screening in the forties on breast cancer mortality well within the trial’s confidence inter-
vals [15]. In terms of model validation, it can be questioned what these model outcomes 
imply, as it is quite common to have relatively wide confidence intervals in randomized 
trials on cancer screening. The wide confidence intervals in the trial are partly due to the 
limited number of women included and breast cancer deaths observed in the trial. The 
models’ outcomes may be less sensitive to the number of women that are simulated 
because they simulated at least 2 million women in each arm of the trial, notwithstanding 
the fact that the models are ultimately based on observed data as well.
The CISNET breast models used Age trial-specific model inputs and data sources ap-
plicable to the U.K., but we can still draw a comparison between the outcomes of this 
study and published results from a recent collaborative modeling study on screening in 
the United States [3]. In the U.S. study, we simulated annual screening from age 40 to 74 
and compared it to annual screening from age 50 to 74. This implies that the difference 
in breast cancer deaths averted between these two scenarios over the women’s lifetime, 
is due to the effect of annual screening in the forties. Similar to the results of this analysis, 
the outcomes indicated that Model M and E avert the most breast cancer deaths from 
annual screening in the forties followed by Models W, S and D. In other words, the 
ranking of the models is fairly consistent when applied in another country with different 
model inputs.
This study presented the first external comparison performed by multiple breast cancer 
simulation models applied in a different country and setting. A strength of this analysis 
is that we used detailed observed de-identified trial data as model inputs. Another im-
portant strength is that we performed an independent external validation [1] in which no 
model calibration was performed to ensure credibility of the model outcomes.
Although the CISNET breast models used Age trial-specific model inputs and data 
sources applicable to the U.K., there were several limitations in this analysis. The trial 
did not collect data on breast cancer molecular sub-type and treatment, these were 
estimated based on U.K. data. It is possible that these data underestimated the actual 
treatment patterns of trial participants. That this is the case is suggested by the fact 
that all models had estimates for mortality reduction that were consistently lower than 
the point estimate from the trial. Moreover, when the models simulated the Age trial 
assuming all women received the most effective therapy available, the average model 
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estimate was very close to trial result. [3] The lack of precision in being able to model the 
treatment of women in the Age trial is likely to have contributed more to the differences 
between model and trial results than the screening and natural history components of the 
models. Other limits include the fact that the models did not explicitly simulate screening 
in the control arm because the reported amount of unscheduled screening was low, and 
primarily due to symptomatic reasons. [17] While this may not affect conclusions of the 
simulations, it is a limitation.
The quantitative information in this study demonstrated how well the models repro-
duced the effects of annual screening from ages 40 to 49 on breast cancer incidence 
and mortality. In the future, the CISNET models could simulate the impact of what 
would have happened if two-view digital mammography had been used for all screen-
ing examinations in the Age trial, simulate the impact of different patterns of screening 
attendance, provide estimates on overdiagnosis, and estimate the lifetime effects of 
different screening programs offered to women in their forties. The demonstration that 
the models can reproduce observed external trial results should increase confidence in 
models results to inform policy decisions about breast cancer screening.
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abstract
background
Collaborative modeling has been used to estimate the impact of potential cancer screen-
ing strategies worldwide. A necessary step in the interpretation of collaborative cancer 
screening model results is to understand how model structure and model assumptions 
influence cancer incidence and mortality predictions. In this study we examined the rela-
tive contributions of the pre-clinical duration of breast cancer, the sensitivity of screening, 
and the improvement in prognosis associated with treatment of screen-detected cases 
to the breast cancer incidence and mortality predictions of five Cancer Intervention and 
Surveillance Modeling Network (CISNET) models.
methods
To tease out the impact of model structure and assumptions on model predictions, the 
Maximum Clinical Incidence Reduction (MCLIR) method compares changes in the number of 
breast cancers diagnosed due to clinical symptoms and cancer mortality between 4 simpli-
fied scenarios: 1) no-screening; 2) one-time perfect screening exam that detects all existing 
cancers and perfect treatment (i.e., cure) of all screen-detected cancers; 3) one-time digital 
mammogram and perfect treatment of all screen-detected cancers; and 4) one-time digital 
mammogram and current guideline-concordant treatment of all screen-detected cancers.
results
The five models predicted a large range in maximum clinical incidence (19%-71%) and in 
breast cancer mortality reduction (33%-67%) from a one-time perfect screening test and 
perfect treatment. In this perfect scenario, the models with assumptions of tumor incep-
tion prior to when it is first detectable by mammography predicted substantially higher 
incidence and mortality reductions than models with assumptions of tumor onset at the 
start of a cancer’s screen-detectable phase. The range across models in breast cancer 
clinical incidence (11%-24%) and mortality reduction (8%-18%) from a one-time digital 
mammogram at age 62 with observed sensitivity and current guideline-concordant treat-
ment was considerably smaller than achievable under perfect conditions.
conclusions
The timing of tumor inception and its effect on the length of the pre-clinical phase of breast 
cancer had substantial impact on the grouping of the models based on their predictions for 
clinical incidence and breast cancer mortality reduction. This key finding about the timing of 
tumor inception will be included in future CISNET breast analyses to enhance model trans-
parency. The MCLIR approach should aid in the interpretation of variations in model results 
and could be adopted in other disease screening settings to enhance model transparency.
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introduction
Collaborative modeling can enhance the rigor of modeling research through the use of 
multiple independent models to answer the same research question. The National Can-
cer Institute-funded Cancer Intervention and Surveillance Modeling Network (CISNET) 
was established in 2000 to use collaborative modeling to improve our understanding of 
the impact of cancer prevention, screening, and treatment dissemination on population 
trends in cancer incidence and mortality. The CISNET Breast Cancer Working Group 
includes six modeling teams: Dana-Farber (Model D) [1], Erasmus (Model E) [2], George-
town-Einstein (Model GE) [3], MD Anderson (Model M) [4], Stanford (Model S) [5], and 
Wisconsin-Harvard (Model W) [6]. The modeling groups have collaborated to estimate 
the effects of breast cancer prevention [7], mammography screening [8-11], and systemic 
adjuvant treatment on trends in breast cancer incidence and mortality [12, 13]. Prior 
research has also investigated the impact of different screening scenarios on the balance 
of population-level benefits and harms, and the results have been used by policymakers 
to inform breast cancer screening guidelines [9, 14, 15].
Each of the models is unique in its structure, assumptions, and methods of synthesiz-
ing data. Consequently, they are unique in how they project the impact of screening 
and treatment on breast cancer incidence and mortality. Results that are similar across 
multiple models despite differences in assumptions and modeling approach, enhance 
the credibility of the findings and are more likely to be robust than conclusions obtained 
from a single model. For instance, in prior analyses, the models all closely estimated 
observed trends in US breast cancer incidence and mortality and consistently agreed on 
the ranking of screening scenarios based on several metrics, including mortality reduc-
tions. [9, 15]
Despite the consistency of prior conclusions about the effects of screening across the 
models, there are variations in the magnitude of the effects. [9, 15] For the interpreta-
tion of collaborative modeling results, it is important to understand how different model 
structures and combinations of assumptions contribute to this variation. Detailed model 
descriptions (Table 1) are informative and contribute to model transparency. However, 
conveying between-model differences is not always straightforward for reasons related 
to the nature of modeling disease processes and their interaction with cancer control 
interventions. In particular, breast cancer modeling involves the representation of un-
observable aspects of natural history such as tumor onset and tumor progression upon 
which interventions (e.g., screening and treatment) are overlaid. To do so, models make 
assumptions about the timing of tumor inception, tumor progression (e.g., discrete or 
continuous tumor growth), and progression variability among tumors. These assump-
tions in conjunction with model structure impact the three key determinants of screening 
effectiveness: 1) pre-clinical duration of breast cancer, i.e., the time period during which 
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prevalent undiagnosed cancers could be detected by screening; 2) sensitivity of the 
screening test, i.e., the likelihood that cancers are detected at screening; and 3) improve-
ment in prognosis from treatment, e.g., whether (earlier) treatment reduces (more) breast 
cancer mortality.
Given the complexity of interpreting outcomes from multiple models in a collaborative 
setting, it can be useful to isolate portions of the models to gain greater insight into 
how model structure and natural history assumptions systematically affect model results. 
The maximum clinical incidence reduction (MCLIR) method can be used to isolate the 
effects of tumor onset, tumor progression, screening test sensitivity, and treatment by 
comparing model results before and after imposing a one-time screening intervention 
under varying assumptions about screening performance and treatment effectiveness.
In the absence of screening, breast cancers will only be diagnosed as a result of clinical 
symptoms, i.e., clinical incidence, which is defined as breast cancers diagnosed due to 
symptoms. Screening is assumed to detect some of these cancers prior to symptomatic 
diagnosis, thereby reducing clinical incidence, and possibly cancer mortality. The MCLIR 
method measures this reduction in breast cancer clinical incidence and mortality. While 
all models use the same data on screening sensitivity and breast cancer treatment, the 
implementation of screening and treatment in the models varies as model structures 
are different. Therefore, differences in clinical incidence reduction should reflect model-
specific choices in their portrayal of the pre-clinical detectable phase of breast cancer 
(tumor onset and progression) and mechanisms of screen detection (e.g., how they 
incorporate sensitivity). Differences in breast cancer mortality are expected to capture 
model-specific assumptions about tumor onset and progression and how the implemen-
tation of treatment affects the natural history.
To date, the MCLIR method has been applied to three CISNET colorectal cancer mod-
els to clarify the effect of natural history assumptions and model structure on colorectal 
cancer incidence predictions. [16] In this study, we extended the MCLIR method to 
understand how differences among the CISNET breast cancer models affect predictions 
for screening effectiveness by projecting the clinical incidence and mortality reductions 
after a one-time screening exam at age 62 among women without prior screening or 
a past breast cancer diagnosis. The results are intended to provide a greater under-
standing of how the CISNET breast models depict unobservable processes, and how 
those representations may systematically affect conclusions about screening effects on 
incidence and mortality.
Maximum Clinical Incidence Reduction 95
methods
This research was approved as exempt by the Georgetown Institutional Review Board 
based on use of de-identified, publically available data. Five of the six CISNET breast 
models (those with natural history components) participated in this analysis.
model overview
The general model structure of the five models involves the simulation of women who 
may develop breast cancer in the absence or presence of screening. In all models, the 
majority of women live a breast cancer-free life and eventually die of causes other than 
breast cancer (Figure 1, panel A). For women who develop breast cancer, tumor inception 
is simulated either prior to (models E and S) or at the start of (models D, GE, and W) the 
tumor’s sojourn time. We define the sojourn time as the portion of time in the pre-clinical 
phase between when a cancer can be first screen-detectable (e.g., by mammography) 
and when clinical cancer diagnosis would occur due to symptoms in the absence of 
screening.[17] Tumor sojourn time is also termed ‘pre-clinical screen-detectable phase‘ 
(Figure 1).
The point when a tumor becomes screen-detectable may depend on the sensitivity of 
the screening test, such that more sensitive tests can detect tumors closer to inception, 
and hence in earlier stages or at smaller tumor sizes. Tumor growth is simulated either 
continuously (models E, S, and W) or as movement through discrete stages (models D 
and GE). All models except model S include ductal carcinoma in situ (DCIS). Nonethe-
less, model S simulates the progression of breast cancers prior to clinical symptoms 
based on continuous tumor growth of invasive cancer (Table 1). [5]
In the absence of screening, the models assume that some cancers will eventually 
cause symptoms and be clinically diagnosed (Figure 1, panel B). If a woman participates 
in screening during the cancer’s sojourn time, the cancer may be screen-detected in an 
earlier stage or at a smaller size than would have occurred with clinical diagnosis in the 
absence of screening.
The time period between when a cancer is screen-detected and when it would have 
been clinically diagnosed in the absence of screening is referred to as the lead-time (Fig-
ure 1, panel C). The lead time is part of the sojourn time, and the duration of the sojourn 
time is an important unobservable determinant of screening effectiveness because a 
longer sojourn time implies a longer period during which a screening test can potentially 
detect cancer. The sojourn time is based on assumptions about tumor inception and 
tumor growth, and the start of the sojourn time is determined by the sensitivity of the 
screening test (Figure 1, panel C).
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Table 1 Overview of Key Differences and Similarities Between The CISNET Breast Models Structures 
and Key Model Components
Model D E GE S W
Model type Analytic, Parallel universe Simulation, Parallel universe Simulation, Parallel universe Simulation,
Parallel universe
Simulation, Parallel universe
Tumor progression modeled as State-transition Continuous tumor growth Stage-transition Continuous tumor growth Continuous tumor growth
Incidence in the absence of screening Age Period Cohort model Age Period Cohort model Age Period Cohort model Age Period Cohort model* Age Period Cohort model
DCIS included Yes Yes Yes No Yes
ER/HER2 Included Yes Yes Yes Yes Yes
Individual risk factors for breast cancer Breast density Breast density, obesity Breast density Hormone replacement Breast density
Screen detection conditioned on Modality, age, density, frequency Tumor size, modality, age, 
density, frequency
Modality, age, density, frequency Tumor size, ER status, age, 
hormone repl., frequency
Tumor size, modality, age, density, 
frequency
Implementation of
screen benefit
Stage shift Detection at smaller tumor size Younger age, earlier stage Stage shift, detect at smaller tumor 
size
Younger age, detect at smaller 
tumor size
Estimation of
over diagnosis
Difference screen &
no-screen
Difference screen &
no-screen
Difference screen &
no-screen
Difference screen &
no-screen
Difference screen &
no-screen
Implementation treatment benefit Hazard reduction Cure fraction, larger fatal 
diameter
Hazard reduction, cure fraction Hazard reduction, non-proportional Cure fraction
Death from breast cancer determined by Survival from BC < survival other 
cause mortality
Fatal diameter, survival from BC 
< survival OC mortality
Survival from BC < survival other 
cause mortality
Survival from BC < survival other 
cause mortality
Survival from BC < survival other 
cause mortality
SEER data used for calibration No Incidence, mortality, stage 
distribution
Incidence, stage distribution Incidence, stage distribution Incidence, mortality
Addition based on MCLIR analyses
Tumor inception point At the start of pre-clinical screen-
detectable phase
Prior to start of pre-clinical 
screen-detectable phase
At the start of the pre-clinical 
screen-detectable phase
Prior to start of the pre-clinical 
screen-detectable
At the start of the pre-clinical 
screen-detectable phase
* Model S uses background breast cancer incidence derived from the APC framework that explicitly 
considers the effects of screening and menopausal hormone replacement therapy. [5] Among the 
other modeling groups breast cancer incidence in the absence of screening is estimated starting 
from a common APC model. [19, 24]
Explanation of Terms Used in Table 1
Model type
Analytic: Analytical approach to estimate the impact of mammography screening and breast cancer 
treatment on incidence and mortality of breast cancer.
Simulation: Stochastic simulation is based on the Monte Carlo method and use of random numbers 
to evaluate the impact of screening on life histories, cancer incidence and mortality.
Parallel universe: Screening and treatment is modeled in a parallel universe, implying that the same 
population is simulated twice: once to determine the impact of breast cancer without screening, and 
once to determine the impact of breast cancer with screening.
natural history and factors affecting breast cancer onset
APC model: Breast cancer onset and breast cancer in the absence of screening was derived by Gan-
gnon et al. [23] and is driven by an age-period-cohort model:
Age: As women age, their risk of developing breast cancer increases.
Period: Onset of breast cancer is different in certain calendar time periods.
Cohort: Year of birth influences the risk of developing breast cancer.
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Explanation of Terms Used in Table 1
Model type
Analytic: Analytical approach to estimate the impact of mammography screening and breast cancer 
treatment on incidence and mortality of breast cancer.
Simulation: Stochastic simulation is based on the Monte Carlo method and use of random numbers 
to evaluate the impact of screening on life histories, cancer incidence and mortality.
Parallel universe: Screening and treatment is modeled in a parallel universe, implying that the same 
population is simulated twice: once to determine the impact of breast cancer without screening, and 
once to determine the impact of breast cancer with screening.
natural history and factors affecting breast cancer onset
APC model: Breast cancer onset and breast cancer in the absence of screening was derived by Gan-
gnon et al. [23] and is driven by an age-period-cohort model:
Age: As women age, their risk of developing breast cancer increases.
Period: Onset of breast cancer is different in certain calendar time periods.
Cohort: Year of birth influences the risk of developing breast cancer.
Breast density: Breast density is associated with different levels of risk for developing breast cancer 
and modifies the operating characteristics of breast cancer screening.
ER/HER2: Onset of breast cancer is different for molecular subtypes ER and HER2.
Tumor stage transition: Tumor progression is modeled as transitions between discrete stages.
Continuous tumor growth: Tumors grow continuously after tumor inception.
Screening mechanism
Sensitivity: Sensitivity can be used directly or indirectly (e.g., when translated to tumor size).
Overdiagnosis: The detection and diagnosis of a condition that would not go on to cause symptoms 
or breast cancer death in a woman’s lifetime in the absence of screening.
Duration of preclinical detectable phase: The period between tumor onset and the start of a cancer’s 
screen-detectable phase.
Treatment effect
Hazard reduction: Reduction in breast cancer mortality hazard, derived from the hazard ratio re-
ported for the different treatment regimens [19].
Cure fraction: If hazard rate reduction is not a direct model input, it can be translated into a cure 
fraction to implement breast cancer treatment.
Death from breast cancer: Once diagnosed with breast cancer, a survival until breast cancer death 
is competing with the other cause mortality survival. That is, breast cancer death occurs only if the 
patient does not die from other causes.
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Mortality reductions from screening may occur via improvements in survival related to 
the earlier stage or smaller tumor size at diagnosis of screened vs. unscreened women, 
given receipt of breast cancer treatment.
mclir analysis
To illustrate the effects of model structure and assumptions about tumor inception, tu-
mor progression, screening test ability to detect tumors, and treatment on breast cancer 
incidence and mortality predictions, the MCLIR analysis consists of comparisons between 
four scenarios. Three scenarios involve a one-time screening test at age 62 and the 
Figure 1 Three versions of a woman’s life history. A: without breast cancer, B: with breast cancer and 
without screening, C: with breast cancer and mammography screening.
In scenario C, the pre-clinical phase is the period of time between tumor inception and clinical diag-
nosis in the absence of screening. The sojourn time for a screening test, e.g., mammography is the 
period of time within the pre-clinical phase that a cancer can be screen detectable; this period can 
also be termed the pre-clinical screen-detectable phase. The point when the cancer is detected by 
screening depends on when the screening test is performed and the sensitivity of the screening test. 
The period before the sojourn time represents a period in which the tumor is present but undetect-
able by mammography. Should the sensitivity of mammography improve, or new types of screening 
tests evolve, the point of screen-detectability would shift to the left and tumors could be detected 
closer to tumor inception.
Maximum Clinical Incidence Reduction 99
remaining no-screening scenario serves as a comparator (Table 2). The study popula-
tion for each scenario is a cohort of average risk women born in 1965, that have never 
been screened or diagnosed with breast cancer prior to age 62. Age 62 was chosen to 
illustrate model differences because it is in the middle of the start and stop ages of the 
generally recommended mammography screening guidelines [14, 18] and there is suf-
ficiently high prevalence of breast cancer at this age to illustrate model differences. While 
all models have the capacity to include risk factors, to isolate model differences these 
analyses focused on the average risk population. Women were followed for 15 years (i.e., 
up to age 77) to capture the immediate and long-term effects of the intervention. Model 
outcomes were breast cancer clinical incidence and breast cancer mortality by age.
Table 2 Description of Maximum Clinical Incidence Reduction (MCLIR) Method
Scenarios Scenario Description Implication Analyses
no Screening
(Scenario 1)
No screening: no screening 
during a woman’s lifetime. 
Diagnosed breast cancers 
will be treated with current 
treatment*
All cancers diagnosed in 
this scenario are diagnosed 
due to clinical symptoms 
and will be treated with 
guideline-concordant 
treatment.
Comparator to calculate 
the screening effect in 
scenarios 2, 3, and 4.
Perfect screening
Perfect treatment
(Scenario 2)
A one-time perfect screen 
with 100% sensitivityᶲ at 
age 62, all screen-detected 
cancers are treated with 
perfect treatment ͌
All existing cancers at age 
62 will be screen-detected 
and cured by perfect 
treatment and will not lead 
to breast cancer death.
Comparison of Scenario 2 
to 1 isolates the effect of 
the pre-clinical detectable 
duration of breast cancer 
and provides the tumor 
progression distribution.
Current sensitivity
Perfect treatment
(Scenario 3)
One-time digital 
mammogram with current 
sensitivity^ at age 62, all 
screen-detected cancers 
are treated with perfect 
treatment
Some of the existing 
cancers at age 62 are 
screen-detected. All 
screen-detected cancers 
are cured and will not lead 
to breast cancer death.
The comparison of 
scenario 3 to 2 isolates 
the effect of digital 
mammography (non-
perfect) sensitivity on 
reductions in clinical 
incidence and breast 
cancer mortality.
Current sensitivity 
Current Treatment
(Scenario 4)
One-time digital 
mammogram with current 
sensitivity at age 62, all 
screen-detected cancers 
are treated with current 
treatment
Some of the existing 
cancers at age 62 are 
screen-detected. All 
screen-detected cancers 
are treated with guideline-
concordant treatment 
and some will not lead to 
breast cancer death.
Comparison of scenario 
4 to 3 isolates the effect 
of guideline-concordant 
(imperfect) treatment 
effectiveness on breast 
cancer mortality reduction.
* Current treatment: All diagnosed breast cancers receive guideline-concordant breast cancer treat-
ment with observed treatment effectiveness. [19]
ᶲ Perfect sensitivity: All existing breast cancers are screen-detected at screening (e.g., Sensitivity is 
100%). ͌ Perfect treatment: All diagnosed breast cancers are “cured” and women will not die of breast 
cancer.
^ Current sensitivity: Screening is performed with the observed sensitivity of digital mammography. 
[19]
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mclir scenarios
Scenario 1 is the baseline scenario without screening where all breast cancers will be 
diagnosed due to clinical symptoms. Upon diagnosis, cancers are treated according to 
current guideline recommended treatment. [19] Guideline concordant treatment roughly 
implies that, after surgical removal of the tumor, estrogen receptor (ER)-positive breast 
cancers are primarily treated with hormone therapy and advanced stage ER positive 
tumors may also receive chemotherapy. ER-negative breast cancers are treated with 
chemotherapy only. Tumors that are Human epidermal growth factor Receptor 2 (HER2) 
positive are also treated with Trastuzumab (Herceptin). The effectiveness of breast cancer 
Figure 2 The MCLIR Metrics Explained For Breast Cancer Incidence
Overall Reductions in Breast Cancer Incidence at 15-Year Follow-Up
The light gray area denoted by A is the overall clinical incidence reduction over the 15 years after the 
digital mammogram at age 62. The area B alone represents the proportion of clinical incidence that 
could not be reduced because of the non-perfect sensitivity of the digital mammogram. As a digital 
mammogram does not detect all tumors in existence, the area B provides a measure of the room 
to further reduce breast cancer clinical incidence if better (more sensitive) screening would become 
available. The 2 light gray areas combined (A and B) are the maximum clinical incidence reduction 
from perfect screening. The dark gray area denoted by C, is the proportion of clinical incidence that 
is not reducible by a perfect screen at age 62 because these clinical cancers had a tumor onset after 
age 62.
Age-Specific Reductions in Breast Cancer Incidence
Scenario 1, the no-screening scenario, serves as comparator from which the reductions, as measured 
on the y-axis, are calculated. Scenario 2 (dashed line) is the age-specific percent reduction in clinical 
incidence from one perfect screening test at age 62 with perfect sensitivity relative to the clinical 
incidence in the no-screening scenario. Scenario 4 (solid line) is the age-specific percent clinical inci-
dence reduction from one digital mammogram at age 62 relative to the no-screening scenario. Sce-
nario 3 (also solid line) uses sensitivity of current digital mammography and in contrast to scenario 4 
has perfect treatment effectiveness which only affects breast cancer mortality, and thus, scenario 3 
has the same impact on breast cancer incidence as scenario 4.
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treatment was based on the most recent meta-analyses of randomized clinical trials re-
ported by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). [20] Scenario 
1 provides baseline information about the number of cancers that will lead to symptoms 
and be clinically diagnosed as well as the number of breast cancer deaths occurring in 
the 15-year follow-up period.
Scenario 2 involves a one-time perfect screening test at age 62 and perfect treat-
ment. The hypothetical perfect screening test assumes that all tumors in existence are 
screen-detected, including those that may not be detectable by digital mammography. 
Perfect treatment means treatment is curative and that all women will be cured and 
will die from other causes than breast cancer. Comparing results from this scenario with 
the baseline (no-screening) scenario provides the maximum achievable clinical incidence 
and mortality reduction. It is a measure of the pool of cancers that technically could be 
screen-detected at age 62 and thus avoid clinical diagnoses of these cancers at a later 
age when they would cause symptoms. The change in the maximum achievable clinical 
incidence reduction over time as women age provides insight into the distribution of 
sojourn times of the existing tumors at age 62, i.e., key determinant 1 of screening ef-
fectiveness. The mortality results from this scenario provide information on how many of 
the breast cancer deaths between ages 62 and 77 stem from cancers that were present 
at age 62. Relative to the no-screening scenario, it is the maximum achievable mortal-
ity reduction from screening and treatment, and the converse (1 minus the maximum 
mortality reduction) is the portion of unavoidable breast cancer deaths because these 
cancers had tumor onset after age 62 when the screening test was done (Figure 3). The 
age-specific maximum achievable mortality reduction after the screen test at age 62 also 
provides insight into the survival time of pre-clinical cancers in existence at age 62.
Scenario 3 involves a one-time digital mammogram at age 62 with sensitivity based 
on observed mammography performance in the Breast Cancer Screening Consortium [9, 
19] and perfect treatment (i.e., cure) of screen-detected cancers. In this scenario, some 
of the cancers in existence at age 62 will be missed by screening and this will affect 
clinical incidence and mortality at later ages. Because scenarios 2 and 3 vary screening 
performance while holding the treatment effects constant, the comparison of these two 
scenarios isolates the impact of perfect vs. observed sensitivity of screening on reduc-
tions in clinical incidence and breast cancer mortality, i.e., key determinant 2 of screening 
effectiveness. This comparison also illustrates the room for improvement in terms of 
fewer clinically diagnosed cases and cancer deaths should the sensitivity of screening 
would improve (e.g., new radiology technology or circulating tumor DNA detection).
Scenario 4, the realistic scenario, involves a one-time digital mammogram at age 62 
and treatment according to current guidelines [19]. Because scenarios 3 and 4 vary treat-
ment effectiveness while holding the sensitivity of screening constant, the comparison of 
these scenarios isolates the impact of perfect vs. actual treatment effectiveness on breast 
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cancer mortality, i.e., key determinant 3 of screening effectiveness. This comparison 
isolates the portion of cancers that, despite earlier detection by screening, will not be 
cured with current guideline recommended treatment. Also, this provides insight into 
the room for improvement should breast cancer treatment improve in the future, given 
current performance of digital mammography.
For ease of comparison and interpretation of outcomes across the four scenarios for 
five different models, results are reported as percent reductions in clinical incidence and 
breast cancer mortality relative to each model’s clinically diagnosed breast cancers and 
breast cancer deaths in the absence of screening (Figure 2 & 3).
results
The results for each scenario for the impact of a one-time screen at age 62 among women 
with no prior screening or past diagnosis of breast cancer are presented separately for 
incidence and mortality.
breast cancer incidence
Tumor Onset and Progression
The maximum achievable clinical incidence reduction from a perfect screening test at 
age 62 (scenario 2) relative to the no-screening scenario (scenario 1) illustrates the impact 
of natural history assumptions such as tumor onset and tumor progression on screening 
effectiveness. The maximum clinical incidence reduction ranged from 19% to 71% across 
the five models with models D, GE, and W grouping towards the lower end of the range 
and models E and S towards the top of the range (Table 3). This wide variation was the 
result of differences in the modeling of the timing of tumor inception relative to the start 
of the sojourn time. For example, Model E’s assumption of tumor onset long before 
the start of the sojourn time led to a large screening effect when the perfect screening 
test was applied that detects all tumors from their inception even before the pre-clinical 
screen-detectable phase begins. The majority (71%) of the cancers in this model had an 
onset prior to age 62 and were therefore screen-detected by a perfect screening test 
at age 62, avoiding clinical diagnoses at a later age. The remaining (29%) of cancers 
had an onset after age 62. Model S makes similar assumptions about tumor onset and 
growth as Model E, and has fairly similar patterns in their results as Model E. In contrast, 
in Models D, GE, and W, which simulate tumor inception at the start of the pre-clinical 
screen-detectable phase, only 19% to 27% of cancers were in existence at age 62, lead-
ing to a lower maximum clinical incidence reduction from a perfect screening test than 
Models E and S.
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Figure 3 The MCLIR Metrics Explained For Breast Cancer Mortality
Overall Reductions in Breast Cancer Mortality at 15-Year Follow-Up
The light gray area denoted by A is the overall breast cancer mortality reduction over the 15 years 
after one digital mammogram at age 62 and guideline recommended treatment with observed 
treatment effectiveness. The area B alone represents the proportion of breast cancer mortality that 
could not be reduced because of the non-perfect treatment effectiveness of current guideline rec-
ommended treatment. Since guideline recommended treatment does not cure all screen-detected 
cancers, B provides a measure of the room to further reduce breast cancer mortality if better (more 
effective) treatment would become available.
The area C alone represents the proportion of breast cancer mortality that could not be reduced 
because of the non-perfect sensitivity of currently available digital mammography. As a digital mam-
mogram does not detect all tumors in existence, B provides a measure of the room to further reduce 
breast cancer mortality if better (more sensitive) screening would become available. The 3 areas 
combined (A, B and C) are the maximum mortality reduction from perfect screening and perfect 
treatment where B + C represent the maximum room to further reduce breast cancer mortality if 
screening sensitivity and treatment effectiveness would become improve. The dark gray area, de-
noted by D, is the proportion of breast cancer deaths that is not reducible by a perfect screen at age 
62 and perfect treatment because these breast cancer deaths had tumor onset after age 62.
Age-Specific Reductions in Breast Cancer Mortality
Scenario 1, the no-screening scenario, serves as comparator from which the reductions, as mea-
sured on the y-axis, are calculated. Scenario 2 (dashed line) is the age-specific percent breast cancer 
mortality reduction from one perfect screening test with perfect sensitivity and perfect treatment 
relative to the breast cancer mortality in the no-screening scenario. Scenario 3 (dotted line) is the 
age-specific percent breast cancer mortality reduction from one digital mammogram at age 62 and 
perfect treatment relative to the no-screening scenario. Scenario 4 (solid line) is the age-specific 
percent mortality reduction from one digital mammogram at age 62 and guideline-concordant treat-
ment with observed treatment effectiveness in screen-detected cases relative to the no-screening 
scenario.
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The shape of the maximum clinical incidence reduction curve provides insight into 
the variability of tumor growth and disease progression of tumors in existence at age 62 
(Figure 4). In models D, GE and W, the age-specific clinical reductions from the perfect 
screen declined more rapidly in the first five years than in the other two models, indi-
cating the presence of more quickly progressing tumors relative to the other models. 
The non-steep and slower linear decline of the age-specific maximum clinical incidence 
reduction in Models E and S is the consequence of greater variability in tumor progres-
sion and overall slower tumor growth among the tumors in existence at age 62 than seen 
in the other models.
The models have structural differences in the timing of tumor inception relative to the 
sojourn time and they had the same calibration targets (observed trends in U.S. breast 
cancer incidence and mortality) in their development phase. This explains why Models E 
and S with tumor inception long before the start of the sojourn time have slower overall 
tumor progression and Models D, GE, and W with tumor inception at the start of the 
sojourn time have faster progressing tumors.
Screening Sensitivity
Reductions in clinical incidence based on the observed sensitivity of digital mammogra-
phy varied less across models than when assuming perfect sensitivity, with ranges of 11% 
to 24%. Since assumptions about tumor onset and progression differ, how the models ar-
rive at this result differs and is illustrated by comparison to their predictions for maximum 
reductions achievable (Scenario 3 vs 2). In models D, GE, and W, the differences in clini-
cal incidence reduction were 2%, 3%, and 8%, respectively, and in models E and S these 
were 56% and 27%. While models E and S have more tumors in existence at age 62, the 
majority of tumors were in their pre-sojourn period and not yet screen-detectable with 
Table 3 Percent Reductions in Breast Cancer Incidence after One Mammography Screen at Age 62 
over a 15-Year Follow-Up, %
Scenario Intervention D E GE S W
2 100% screening
sensitivity and 100% treatment 
effectiveness
(vs. no screening)
23 71 27 43 19
4 Current screening
sensitivity and current treatment 
effectiveness
(vs. no screening)
21 15 24 16 11
4 vs. 2 Breast cancer clinical incidence 
not reduced because of imperfect 
(current) screening sensitivity
2 56 3 27 8
Scenario 3 is not shown because this scenario has the same screening sensitivity (digital mammogra-
phy) as scenario 4 and hence has the same clinical incidence reduction as scenario 4.
Maximum Clinical Incidence Reduction 105
a digital mammogram having actual observed sensitivity. On the other hand, in models 
D, GE, and W, the majority of tumors in existence at age 62 were in their sojourn period 
and could be detected by the digital mammogram. Thus, the variations between model 
clusters E and S vs. D, GE, and W indicate that modeling assumptions about the timing 
of tumor inception in relation to the implementation of digital mammography can have 
substantial impact on screen detection and reductions in clinical breast cancer incidence.
breast cancer mortality
Tumor Onset and Progression
Based on one perfect screening test at age 62 and perfect treatment for screen-detected 
cancers, the maximum reductions in breast cancer mortality relative to the no-screening 
scenario ranged from 33% to 67% over 15 years of follow-up (Table 4). Similar to the 
impact of tumor onset on clinical incidence reductions, Models D, GE and W had a 
higher percent (55% to 67%) of breast cancer deaths stemming from cancers with onset 
after age 62 than Models E and S (33% to 38%). These variations reflect interactions 
between assumptions about tumor onset and survival times.
Table 4 Percent Reduction in Breast Cancer Mortality after One Digital Mammography Screen at 
Age 62 with 15-Year Follow-Up, %
Scenario Intervention D E GE S W
2 100% screening sensitivity and 100% 
treatment effectiveness (vs. no 
screening)
40 67 45 62 33
% Breast cancer deaths with onset 
after age 62.*
60 33 55 38 67
3 Current screening sensitivity and 
100% treatment effectiveness (vs. no 
screening)
37 23 40 31 23
3 vs. 2 Breast cancer mortality not reduced 
because of imperfect (current) 
screening sensitivity
3 44 5 31 10
4 Current screening sensitivity and 
current treatment effectiveness (vs. 
no screening)
17 8 17 18 8
4 vs. 3 Breast cancer mortality not reduced 
because of imperfect (current) 
treatment effectiveness
20 15 23 13 15
4 vs. 2 Breast cancer mortality not reduced 
because of imperfect screening 
sensitivity and imperfect treatment 
effectiveness
23 59 23 44 25
* The percent breast cancer deaths that stem from cancers with onset after age 62 is given by 100% 
minus the cancer deaths from cancers with onset before age 62 (Scenario 2).
Scenarios 3 vs. 2, 4 vs. 3, and 4 vs. 2, show the percentage point breast cancer mortality that is not 
reduced due to imperfect screening sensitivity and/or imperfect treatment effectiveness.
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The steep declines of the maximum mortality reduction curves (Figure 4, right panels) 
of models D, GE and W reveal that, on average breast cancers in these models have 
shorter survival times and less variability in survival times relative to models E and S. 
These results for average survival times correspond to the findings about tumor progres-
sion in the models: the relatively slow tumor progression, based on earlier inception of 
tumors, in models E and S relate to longer survival times, and the faster tumor progres-
sion in Models D, GE and W arising from tumor inception at the beginning of the sojourn 
period ultimately lead to shorter survival times on average.
Figure 4 Age-Specific Reductions In Breast Cancer Clinical Incidence And Mortality Over 15 Years 
After A One-Time Screening Test At Age 62 By Model 
The percent marks in the panels of Figure 4 represent the cumulative outcomes for the 15-year 
follow-up period from age 62 to age 77.
The line at the top in the breast cancer incidence panels on the left of Figure 4 is the maximum clini-
cal incidence reduction from a screening test at age 62 with 100% sensitivity and perfect treatment of 
screen-detected cancers (Scenario 2). Just after the screening test, the reduction in clinical incidence 
(panels on the left) is highest and decreases by age as it becomes less likely that clinical cancers at 
later ages were already in existence at age 62 and could have been prevented by a screening test 
at that age.
The percentages in the left-panel figures represent, for example for Model S: 57% of the cancers that 
are clinically diagnosed in the absence of screening between ages 62 and 77 have an onset after age 
62, this implies that 100-57=43% (Scenario 2, Table 3) of the cancers diagnosed in the absence of 
screening could be prevented from becoming clinical diagnosis at later ages by a perfect screening 
test at age 62. The solid line below the dashed line is the clinical incidence reduction from a digital 
mammography screening test: 16% of clinical diagnoses could be prevented by a one-time digital 
mammogram at age 62 (Scenario 3, Table 3). This implies that 27% of clinical incidence between ages 
62 and 77 was not reduced by the one-time digital mammogram at age 62 (Scenario 3 vs 2).
The dashed line at the top in the breast cancer mortality panels on the right of Figure 4 is the maxi-
mum achievable mortality reduction from a screening test with 100% sensitivity combined with per-
fect treatment in screen-detected cases (Scenario 2). The dotted line below the top line represents 
the breast cancer mortality reduction over the 15-years after a current digital mammogram at age 62 
and perfect treatment in the screen-detected cases (Scenario 3). The solid line at the bottom is the 
reduction in breast cancer mortality from a current screening test combined with current treatment 
(Scenario 4).
The percentages in these figures are, for example for Model S: 38% of breast cancer deaths observed 
in the scenario without screening stem from cancers with onset after age 62 and could therefore not 
be screen-detected and prevented from breast cancer death by screening at age 62. This implies that 
100-38=42% of breast cancer deaths could be reduced by perfect screening and perfect treatment of 
screen-detected cases (Scenario 2, Table 4). However, 31% of breast cancer deaths are not prevented 
due to lack of screen-detection if screening is performed with a digital mammogram (Scenario 3 vs 
2, Table 4), and 13% of breast cancer deaths is not prevented because current guideline-concordant 
treatment lacks the effectiveness to cure those screen-detected breast cancers (Scenario 4 vs 3). The 
18% mortality reduction follows from current screening and current treatment (Scenario 4).
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Screening sensitivity
Compared to the maximum achievable mortality reduction, a one-time digital mammo-
gram having actual observed sensitivity missed between 3% (Model D) to 44% (Model E) 
of the avoidable cancer deaths. Overall, the mortality reduction from a one-time digital 
mammogram at age 62 and perfect treatment relative to no-screening (scenario 3 vs. 1) 
was 23% to 40% across models (Table 4, Figure 4). The ability to detect lethal tumors by 
mammography screening was higher among the models (D, GE, and W) with assump-
tions of tumor onset at the start of the sojourn time than the models (E and S) with tumor 
onset prior to the start of the sojourn time.
Treatment effectiveness
Assuming observed guideline-concordant treatment effectiveness in screen-detected 
cancers (scenario 4), the percent breast cancer mortality that was not reduced compared 
to Scenario 3 with perfect treatment was 13% to 23% (Table 4, Figure 4). The difference 
between scenario 3 and 4 show that Models E and GE, have a relatively high percentage 
of cancer deaths that were not averted in the first 3 years after the screen at age 62. This 
illustrates the substantial portion of cancers screen-detected at a relatively advanced 
stage that was not curable with current treatment effectiveness. These findings showed 
that the lethality of the cancers found at screening impacts breast cancer mortality differ-
ently over time and in magnitude by model.
Sensitivity and Treatment
The combination of screening with a digital mammogram at age 62 and guideline-
concordant treatment with current treatment effectiveness (Scenario 4 vs. Scenario 1) 
provides insight into how assumptions about currently available screening and treatment 
interact with breast cancer natural history to affect breast cancer mortality. Models E, W 
and S grouped towards the lower end and models D and GE towards the higher end of 
the clinical incidence reductions (Table 3). But for breast cancer mortality slightly differ-
ent groupings of models were seen: Models D, GE and S predicted 17 to 18% breast 
cancer mortality reduction relative to the no-screening scenario, whereas models E and 
W predicted 8% breast cancer mortality reduction (Table 4).
The lower breast cancer mortality reductions predicted by models E and W were pri-
marily the result of a low screen-detection rate of lethal cancers and the lack of improving 
prognosis with treatment of screen-detected cases: in both models 23% of the cancers 
destined to cause breast cancer death were screen-detected (Scenario 3), and of those 
detected only one-third (8 out of 23; Scenario 4 vs. Scenario 3, Table 4) were cured.
Models D and S predicted a similar 17 and 18% mortality reduction as model GE, 
also due to a combination of relatively high screen-detection and high improvement 
of prognosis from treatment. However, the shape of the mortality reduction curve of 
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Model GE, relative to other models, was distinct. The inverted shape of model GE can be 
explained by the presence of more advanced-stage cancers at screen detection, where 
breast cancer death could not be avoided.
discussion
This study is the first to apply the maximum clinical incidence reduction (MCLIR) method 
to illustrate how model structure and assumptions impact both clinical incidence and 
cancer mortality predictions. To understand variations in model estimates of screening 
effects, the analysis decomposed the relative contributions of model-specific structures 
and assumptions regarding the pre-clinical duration of breast cancer, the ability of a 
screening test to detect cancers, and breast cancer treatment to breast cancer incidence 
and mortality predictions. The results illustrated that models with similar predictions 
for screening effectiveness may use differing assumptions about screening, treatment, 
tumor onset, and tumor progression. Altogether, the key finding was that assumptions 
about the timing of tumor inception and its effect on the pre-clinical duration of breast 
cancer had the greatest impact on the model groupings on predicted clinical breast 
cancer incidence and mortality reductions. As a result of this finding, we now include this 
model-specific tumor attribute in our CISNET model comparison table (Table1).
The MCLIR scenarios showed that models E and S simulate the longest pre-clinical 
duration of breast cancer. While this implies a longer period to detect cancers by screen-
ing and possibly avert cancer deaths, these models showed the greatest difference in 
breast cancer mortality reduction between the scenarios with perfect detection to those 
with (realistic) digital mammography . Again, this was related to those models’ assump-
tions about early tumor onset prior to the start of a cancer’s sojourn time. The loss in 
breast cancer mortality reduction due to digital mammography (imperfect) screening 
provides information about the further reductions in breast cancer mortality should 
screening sensitivity improve in the future, given the current state of the models. On 
the other hand, models D, GE and W had similar and relatively short pre-clinical dura-
tions due to their assumptions of tumor inception at the start of the sojourn time and 
therefore ultimately predicted smaller losses in breast cancer mortality reduction due 
to digital mammography screening. The effect of guideline-concordant treatment with 
actual observed treatment effectiveness on breast cancer mortality reduction differed by 
model structure. In general, greater breast cancer mortality reductions were predicted 
by models that use a hazard-reduction treatment structure than the models with cure 
fractions to implement breast cancer treatment. These types of insights from the MCLIR 
results provide further clarity on the differences and similarities across models and can be 
used to interpret variations in model outcomes.
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The MCLIR analyses also illustrated model variation in the distributions for tumor 
progression assumed in the models, with models D, GE, and W tending to have faster 
progressing tumors than models E and S. This knowledge about the models can help 
interpret model differences in predictions of screening effectiveness by screening 
frequency. For example, one would expect more cancers to be diagnosed with more 
frequent screening in models that have relatively faster tumor progression on average 
and vice versa. This was confirmed in a recent analysis of the impact of screening in-
tervals on breast cancer mortality, with Models D, GE, and W showing greater benefits 
(breast cancer deaths averted preceded by more cancer diagnoses) from more frequent 
screening than models E and S. [9]
The MCLIR methodology was first used to evaluate differences in the CISNET colorectal 
cancer screening models. [16] The colorectal cancer findings indicated that assumptions 
about the duration between adenoma onset and clinical diagnosis were an important 
factor in explaining colorectal cancer model differences. The results of this study were 
similar in demonstrating that models with long pre-clinical durations of breast cancer and 
relatively low screen detection rates project similar screening effects as models with a 
shorter pre-clinical durations and higher screen detection rates.
Usually, models are characterized by describing modeling approach, model inputs and 
assumptions. [19,21,22] In this research, we examined model outcomes to drill down 
to the mechanics of incidence and mortality predictions. There are several caveats that 
should be considered in evaluating this method. First, the effect of a single screen on 
breast cancer incidence and mortality is not the same as the effect of routine screening 
from age 50 to 74. The results in this study are therefore not directly translatable to pro-
jections of the effects of a periodic screening program on overall breast cancer incidence 
and mortality. Second, it was beyond the scope of this paper to perform and evaluate 
the MCLIR scenarios at different ages or at multiple ages across five different models. 
Evaluating the MCLIR scenarios at different ages would provide insight into age-specific 
and between-model differences in tumor inception, progression, and test-characteristics 
and the impact of these on breast cancer incidence and mortality. Third, the MCLIR 
methodology employed did not explicitly allow for formal assessments of the factors 
that account for differences in rates of over-diagnosis. This will be an interesting area for 
future research and extended use of the MCLIR method.
CISNET collaborative modeling predictions are increasingly used by policy makers to 
inform screening guidelines [9, 14], evaluate screening and treatment programs [12, 13], 
and can be used by clinicians to assist in decision-making about breast cancer screening. 
[23] How different models arrive at their predictions of harms and benefits of screening 
and treatment may be perceived as opaque due to the complexity of the models. This 
study complements model descriptions [1-6] by using MCLIR analyses to illustrate and 
compare which structural differences and natural history assumptions may be important 
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to consider by policy makers when using collaborative modeling outcomes. The MCLIR 
approach could be adopted in other comparative modeling research to improve model 
transparency.
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abstract
importance
Given recent advances in screening mammography and adjuvant therapy, quantifying 
their separate and combined effects on US breast cancer mortality reductions by molecu-
lar subtype could guide future decisions to reduce disease burden.
objective
To evaluate the contributions associated with screening and treatment to breast cancer 
mortality reductions by molecular subtype based on estrogen-receptor (ER) and human 
epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu).
design, setting and participants
Six Cancer Intervention and Surveillance Network (CISNET) models simulated US breast 
cancer mortality from 2000 to 2012 using national data on plain-film and digital mam-
mography patterns and performance, dissemination and efficacy of ER/ERBB2-specific 
treatment, and competing mortality. Multiple US birth cohorts were simulated.
exposures
Screening mammography and treatment.
main outcomes and measures
The models compared age-adjusted, overall, and ER/ERBB2-specific breast cancer 
mortality rates between 2000 and 2012 for women aged 30 to 79 years relative to the 
estimated mortality rate in the absence of screening and treatment (baseline rate); mor-
tality reductions were apportioned to screening and treatment.
results
In 2000, the estimated reduction in overall breast cancer mortality rate was 37% (model 
range, 27%-42%) relative to the estimated baseline rate in 2000 of 64 deaths (model 
range, 56-73) per 100 000 women: 44% (model range, 35%-60%) of this reduction was 
associated with screening and 56% (model range, 40%-65%) with treatment. In 2012, 
the estimated reduction in overall breast cancer mortality rate was 49% (model range, 
39%-58%) relative to the estimated baseline rate in 2012 of 63 deaths (model range, 54-
73) per 100 000 women: 37% (model range, 26%-51%) of this reduction was associated 
with screening and 63% (model range, 49%-74%) with treatment. Of the 63% associated 
with treatment, 31% (model range, 22%-37%) was associated with chemotherapy, 27% 
(model range, 18%-36%) with hormone therapy, and 4% (model range, 1%-6%) with 
trastuzumab. The estimated relative contributions associated with screening vs treatment 
Breast cancer mortality by molecular subtype 119
varied by molecular subtype: for ER+/ERBB2−, 36% (model range, 24%-50%) vs 64% 
(model range, 50%-76%); for ER+/ERBB2+, 31% (model range, 23%-41%) vs 69% (model 
range, 59%-77%); for ER−/ERBB2+, 40% (model range, 34%-47%) vs 60% (model range, 
53%-66%); and for ER−/ERBB2−, 48% (model range, 38%-57%) vs 52% (model range, 
44%-62%).
conclusions and relevance
In this simulation modeling study that projected trends in breast cancer mortality rates 
among US women, decreases in overall breast cancer mortality from 2000 to 2012 were 
associated with advances in screening and in adjuvant therapy, although the associations 
varied by breast cancer molecular subtype.
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introduction
Breast cancer mortality rates have been steadily declining over time in the United States 
(US).1 Simulation models developed within the Cancer Intervention and Surveillance Net-
work (CISNET) estimated that screening mammography and adjuvant therapy (treatment) 
contributed approximately equally to the reduction in breast cancer mortality from 1975 
to 2000.2 Since then, mammography has transitioned from plain-film to digital technol-
ogy optimized for tumor detection.3,4 At the same time, there have been advances in 
molecularly-targeted treatments based on expression of estrogen-receptor (ER) and hu-
man epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu), including 
aromatase inhibitors for ER+, and trastuzumab for ERBB2+ cancers. In addition, there 
have been advances in chemotherapy, particularly increasing use of taxanes.5,6
It is not known how screening and treatment advances have contributed to recent 
population-level, molecular subtype-specific breast cancer mortality rates. No single 
national registry contains sufficient information to assess this progress. Moreover, 
most clinical trials do not consider both screening and treatment effects, and do not 
readily translate to population effect. Given these circumstances, simulation modeling 
can be useful to integrate high-quality data from randomized-controlled trials, large 
observational studies, and population registries to estimate the relative contributions of 
advances on population-level mortality.2
In this report, six CISNET models compared the separate and combined contribution 
associated with screening and treatment on US breast cancer mortality rates by molecu-
lar subtype from 2000 and 2012.
methods
The Institutional Review Board at Georgetown University, the site of the CISNET Breast 
Cancer Coordinating Center, approved the study as exempt based on the use of de-
identified data. The 6 CISNET models were Dana-Farber Cancer Institute (model D)7, E 
Erasmus Medical Center (model E)8, Georgetown University-Albert Einstein College of 
Medicine (model G-E)9, MD Anderson Cancer Center (model M),10 Stanford University 
(model S),11,12 and University of Wisconsin-Harvard (model W-H).13 Compared to earlier 
analyses2,14,15 the models portray ER/ERBB2-specific subtypes,11 include digital screen-
ing3,4 and recent treatment advances,16 and have updated incidence17 and competing 
non-breast cancer mortality.18 The modeling approach is summarized below; additional 
details are available in the Supplement and online.19
The models incorporated updated estimates of breast cancer incidence17 and ER/
ERBB2-specific survival trends in the absence of screening or treatment and then incorpo-
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rated information on screening use and molecular subtype-specific treatment patterns to 
reproduce observed US incidence and mortality trends.1,20,21 Screen-detection during the 
preclinical screen-detectable period could result in diagnosis of earlier-stage or smaller 
tumors than diagnosed via symptomatic detection. This could translate into lower breast 
cancer mortality. Molecular subtype, age-specific, and stage-specific treatment could 
reduce the hazards of breast cancer death (models D, GE, M, and S) or result in cure for 
some cases (models E and W-H).
model input parameters
Each group used a common set of inputs 22 based on their specific model structure, 
prior research,15 and assumptions to best reproduce US breast cancer incidence and 
mortality trends (Supplemental Table 1).5,6,10-17,22-27 Five models used age-period-cohort 
(APC) analyses to estimate 1975-2012 breast cancer incidence rates in the absence of 
screening (baseline incidence rate)17,25; model M applied a Bayesian approach to extend 
1975-1979 Surveillance Epidemiology and End Results (SEER) rates forward in time with 
a 4% (SD 0.2%) annual increase. Plain-film and digital mammography sensitivity data 
from the Breast Cancer Surveillance Consortium (BCSC) for 1994-2012 were used to 
estimate sensitivity for detection of invasive and DCIS cancers by age group, first vs 
subsequent screen, and time since last mammogram.
Screening dissemination was derived from national survey data for age at first screen 
and subsequent screening frequency by birth cohort.23,24 Plain-film mammography was 
assumed before 2000. Digital mammography was phased-in starting in 2001 based on 
data from the BCSC (unpublished data) and the US Food and Drug Administration Mam-
mography Quality Standards Act and Program.28
Molecular subtype-specific treatment dissemination was based on SEER patterns-of-
care special studies for 1975-199626,27 and the National Comprehensive Cancer Network 
data for 1997 onwards14,19. Tamoxifen was used in the 1980s; aromatase inhibitor use 
began in 1997; taxanes in 1998; and trastuzumab in 2006. Treatment effectiveness was 
conditioned on stage and ER/ERBB2 status (and age, if applicable), based on clinical 
trials; all estimates assumed local therapy.16
analyses
Each model simulated mortality rates under four intervention scenarios: 1) no screen-
ing or treatment (the baseline mortality rate); 2) screening alone; 3) treatment alone; 
and 4) combined screening and treatment. Rates were age-adjusted using the 2000 US 
Standard Population29 and outcomes were reported for women ages 30-79.
The absolute mortality reductions associated with screening alone, treatment alone, 
or the combination in a given calendar year were calculated as the difference between 
the age-adjusted mortality rates predicted with intervention (scenarios 2, 3, or 4) and 
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the baseline mortality rate in that year (scenario 1). The percent mortality reduction 
(hereafter referred to as mortality reduction) in a given calendar year was calculated as 
this difference divided by the baseline mortality rate in that calendar year (scenario 1; 
Supplemental Table 2).
ER/ERBB2-specific mortality rates were computed by dividing the number of women 
who died of breast cancer with that subtype by the total breast cancer population at 
risk. In this manner, rates of all subtypes sum to the overall age-adjusted breast cancer 
mortality rate.
To estimate the separate contributions associated with screening and treatment to 
mortality reductions, we considered the modeled effects of screening alone and of treat-
ment alone as a fraction of the combined modeled effect in each calendar year.
The relative contribution associated with screening versus treatment to the combina-
tion of both was computed as the ratio of the screening alone effect to the sum of 
the screening alone effect and the treatment alone effect; the relative contribution of 
treatment was calculated similarly. Alternative approaches for computing these relative 
contributions were considered, and the main conclusions were unchanged (Supplemen-
tal Methods and Supplemental Table 3).
When considering the mortality reductions associated with each treatment interven-
tion (eg, chemotherapy, hormonal therapy, and trastuzumab) to their combination, the 
relative contribution associated with the various treatments were decomposed by first 
considering the chemotherapy contribution; then the hormonal therapy contribution for 
ER+ cases, given chemotherapy contributions; and lastly, the contribution associated 
with trastuzumab for ERBB2+ cases, given the other therapies.
To estimate relative contributions associated with the most recent advancements, we 
compared the mortality reduction from 2000 and 2012. We focused on this difference to 
remove the modeled effect of changes in the baseline rate during this period.
uncertainty analysis
All results were reported by model and summarized as the mean and range across 
models. The range provided a measure of uncertainty because each model has different 
assumptions and structures to represent unobservable factors such as baseline incidence 
rate and breast cancer natural history. Results consistent across models were considered 
robust.
results
Rates of mammography increased over time (Figure 1A), and plain-film was rapidly 
replaced by digital mammography starting in 2001 (Figure 1B). Treatment use varied by 
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Figure 1 Dissemination of Screening Mammography, Type of Mammography, and Adjuvant Therapy 
1975-2012
Panel A shows use of screening among US women ages 30-79 by calendar year based on data from 
multiple rounds of the National Health Interview Survey over time and Breast Cancer Surveillance 
Consortium (BCSC) data from 1994-2012. These observed data were used a targets in modeling 
dissemination of screening and intervals between screens. Note that the rate of never screened 
includes women ages 30-39.
Panel B illustrates the transition to use of digital vs. plain-film mammography over time using MQSA 
data on digital mammography facilities from the FDA and the BCSC, which includes over 2.3 million 
women, aged 30-79, with over 9.5 million mammograms, 95,000 breast cancer cases and 180,000 
breast biopsies.
Panel C depicts use of adjuvant systemic treatment dissemination from 1975-2012 for an exemplar 
stage and set of molecular markers (node positive AJCC 6 stage 2b, ER+/ERBB2-) among women 
50 to 69 years of age at diagnosis based on data from SEER special patterns of care studies and the 
National Comprehenisve Cancer Network. These data were used for all other combinations of ages, 
stages, and molecular subtypes.
Models used 2010 treatment dissemination data for subsequent years (indicated by dashed seg-
ments).
In general, in the 1980’s and early 1990’s multi-agent chemotherapy included primarily cytoxan, 
methotrexate, and 5-flourouricil (CMF) regimens; starting in the mid-1990’s anthracycline-based regi-
mens were included and increased in use, and in 1997 taxanes could be added to those regimens. 
Hormonal therapy began with tamoxifen in the 1980’s and starting in 1997 also included aromatase 
inhibitors. Hormonal therapy could be used alone or in combination with multi-agent chemotherapy. 
Over time, there was an increasing use of both multi-agent chemotherapy and hormonal therapy. 
For women diagnosed with ERBB2+ tumors (not shown in this example), trastuzumab was dissemi-
nated independently of other treatments and, based on its immediate rapid uptake, all ERBB2+ 
patients were modeled as receiving trastuzumab beginning in year 2006.
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molecular subtype, age, and stage, with high rates of dissemination of recent advances 
(Figure 1C). Incorporating these observed screening and treatment patterns, the models 
reproduced observed age-adjusted incidence (Supplemental Figure 1) and breast cancer 
mortality trends from 1975 to 2012 (Figure 2A). Predicted mortality trends for a represen-
tative model (Model G-E) illustrate that the mortality reduction associated with treatment 
alone increased faster than that associated with screening alone over time (Figure 2B).
overall breast cancer mortality in 2012
With the observed changes in screening technology and treatment regimens, we es-
timated a 49% (model range: 39%-58%) decrease in overall breast cancer mortality in 
2012 relative to the estimated baseline rate in 2012 of 63 deaths (model range, 54-73) 
per 100,000 women (Table 1, Column 4; Supplemental Table 2). The estimated screening 
contribution to this mortality reduction was 37% (model range, 26%-51%), while treat-
ment was 63% (model range, 49%-74%). The larger contribution associated with treat-
ment vs. screening in 2012 was predicted in five of six models (Table 1, Columns 7-8).
The estimated 63% (model range, 49%-74%) relative contribution associated with 
treatment in 2012 consisted of 31% (model range, 23%-37%) from chemotherapy, 27% 
(model range, 18%-36%) from hormone therapy, and 4% (model range, 1%-6%) from 
trastuzumab (Table 2).
molecular subtype-specific breast cancer mortality in 2012
The ER+/ERBB2- subtype was estimated to be associated with 64% (model range, 61%-
70%) of the overall mortality reduction in 2012 because it was the most common subtype 
(Supplemental Table 7).
Within-subtype analyses demonstrated significant variations in breast cancer mortality 
reduction in 2012 (vs estimated subtype-specific baseline rates; Table 1, Column 4). The 
estimated mortality reduction was largest for the ER+/ERBB2+ subtype at 58% (model 
range, 46%-71%), followed by the ER+/ERBB2- subtype at 51% (model range, 42%-55%), 
and the ER-/ERBB2+ subtype at 44% (model range, 33%-55%). The lowest mortality 
reduction was estimated for the ER-/ERBB2- subtype at 37% (model range, 27%-46%).
The estimated relative contributions associated with screening vs treatment also 
varied by molecular subtype, ranging from 31% (model range, 23%-41%) versus 69% 
(model range, 59%-77%) for the ER+/ERBB2+ subtype to 48% (model range, 38%-57%) 
versus 52% (model range, 43%-62%) for the ER-/ERBB2- subtypes, respectively (Table 1, 
Columns 7-8). The estimated relative contributions associated with specific treatments 
varied by subtype (Table 2). For example, for the ER+/ERBB2+ subtype, of the 69% 
(model range, 59%-77%) relative contribution associated with treatment, 26% (model 
range, 15%-32%) was associated with chemotherapy, 29% (model range, 23%-36%) with 
hormone therapy, and 14% (model range, 9%-18%) with trastuzumab (Table 2). For the 
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ER-/ERBB2- subtype, the 52% (model range, 43%-62%) relative contribution associated 
with treatment was associated with chemotherapy alone.
Figure 2 Age-Adjusted Breast Cancer Mortality From 1975-2012 by Model
Panel A compares the predictions the six models for rates of overall breast cancer mortality (all 
molecular subtypes) to actual US breast cancer mortality among the US population ages 30-79 from 
1975 to 2012.
Panel B illustrates predicted breast cancer mortality rates in the US population ages 30-79 from 1975 
to 2012 in the absence of screening and adjuvant treatment, presence of screening alone, presence 
of adjuvant treatment alone, and combination of screening and adjuvant treatment for a representa-
tive model (Model Georgetown-Einstein).
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contribution of screening and treatment advances between 2000 and 
2012
The estimated overall breast cancer mortality reduction in 2000 was 37% (model range, 
27%-42%) relative to the estimated baseline rate in 2000 of 64 deaths (model range, 
56-73) per 100,000 women (Table 3, Column 2; Supplemental Table 2). The estimated 
overall breast cancer mortality reduction in 2000 was 49% (model range, 39%-58%) rela-
tive to the estimated baseline rate in 2012 of 63 deaths (model range, 54-73) per 100,000 
women (Table 3, Column 3; Supplemental Table 2). Hence, the estimated difference in 
the overall breast cancer mortality reduction in 2012 vs. 2000 was 12% (model range, 
10%-16%) (Table 3, Column 4; Supplemental Table 5). The estimated relative contribu-
tion associated with screening advances to this difference was 17% (2%-31%) (Table 2, 
Column 5); treatment advances were 83% (69%-98%) (Table 3, sum of Columns 6-8). 
Of the 83% (69%-98%) treatment-related advances, 38% (model range, 21%-54%) was 
associated with advances in chemotherapy, largely taxanes; 29% (model range, 9%-44%) 
was associated with advances in hormone therapy, largely the addition of aromatase 
inhibitors, and 15% (model range, 4%-25%) with the introduction of trastuzumab (Table 
3, Columns 6-8).
Within each molecular subtype, the estimated difference in the breast cancer mortality 
reductions between 2012 and 2000 was largest for the ER+/ERBB2+ subtype at 19% 
(model range, 17%-25%) and the smallest for the ER-/ERBB2- subtype at 8% (model 
range, 5%-11%) (Table 3, Column 4). The estimated relative contribution of screening 
and treatment to these differences also varied by subtype: the relative contribution of 
trastuzumab was 41% (model range, 27%-58%) in the ER+/ERBB2+ subtype and 57% 
(model range, 35%-78%) in the ER-/ERBB2+ subtype (Table 3, Column 8).
To complement the above analysis, we decomposed the overall mortality reduction in 
2012 in terms of the contributions associated with advances before 2000 and after 2000 
(Supplemental Table 6). Of the 37% (model range, 27%-42%) mortality reduction associ-
ated with screening in 2012, 33% (model range, 29%-48%) was associated with screening 
advances before 2000 and 4% (model range, 1%-8%) after 2000, largely digital mam-
mography. The introduction of trastuzumab was associated with 15% of overall mortality 
reduction between 2000 and 2012. Of the 31% (model range, 23%-37%) associated 
with chemotherapy, 22% (model range, 15%-30%) was associated with chemotherapy 
advances before 2000 and 9% (model range, 7%-14%) after 2000, largely taxanes. Of 
the 27% mortality reduction (model range, 18%-36%) associated with hormone therapy, 
20% (model range, 15%-27%) was associated with advances in hormone therapy before 
2000 and 7% (model range, 2%-12%) after 2000, largely from aromatase inhibitors. 
Supplemental Table 6 provides subtype-specific results.
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Table 1 Overall And Subtype-Specific Breast Cancer Mortality Reductions in 2012 Associated with 
Screening, Treatment, Or Both by Model*
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Operation** A B C A/C B/C A/(A+B) B/(A+B)
Model Overall
Dana-Farber 29 28 49 59 57 51 49
Erasmus 18 30 43 41 70 37 63
Georgetown-Einstein 25 37 53 47 69 40 60
MD Anderson 17 29 39 44 73 38 62
Stanford 18 37 50 36 74 33 67
Wisconsin-Harvard 17 49 58 30 84 26 74
Mean 21 35 49 43 71 37 63
ER+, ERBB2- Subtype
Dana-Farber 30 30 52 59 58 50 50
Erasmus 18 34 46 39 73 35 65
Georgetown-Einstein 26 39 54 48 71 40 60
MD Anderson 17 31 42 42 75 36 64
Stanford 19 41 53 35 77 31 69
Wisconsin-Harvard 16 51 59 27 86 24 76
Mean 21 38 51 42 73 36 64
ER+, ERBB2+ Subtype
Dana-Farber 27 38 57 46 67 41 59
Erasmus 20 42 52 39 82 32 68
Georgetown-Einstein 24 43 58 41 74 36 64
MD Anderson 18 38 46 38 82 32 68
Stanford 17 58 66 26 88 23 77
Wisconsin-Harvard 19 62 71 26 87 23 77
Mean 21 47 58 36 80 31 69
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Table 1 Overall And Subtype-Specific Breast Cancer Mortality Reductions in 2012 Associated with 
Screening, Treatment, Or Both by Model* (continued)
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ER-, ERBB2+ Subtype
Dana-Farber 25 28 49 52 58 47 53
Erasmus 17 28 41 40 68 37 63
Georgetown-Einstein 25 32 52 48 62 43 57
MD Anderson 15 23 33 45 70 39 61
Stanford 17 25 40 42 63 40 60
Wisconsin-Harvard 23 43 55 41 79 34 66
Mean 20 30 45 45 67 40 60
ER-, ERBB2- Subtype
Dana-Farber 26 20 40 66 50 57 43
Erasmus 17 22 35 47 64 43 57
Georgetown-Einstein 24 29 46 53 63 45 55
MD Anderson 18 14 27 65 52 56 44
Stanford 18 17 33 53 50 52 48
Wisconsin-Harvard 18 30 42 43 70 38 62
Mean 20 22 37 55 58 48 52
* The column labels are defined as follows: (A) mortality reduction associated with screening alone, 
relative to the estimated baseline mortality in 2012; (B) mortality reduction associated with treatment 
alone relative to the estimated baseline mortality in 2012; (C) mortality reduction associated with 
combined screening and treatment alone, relative to the estimated baseline mortality in 2012 (“com-
bined mortality reduction”); (D) percentage of combined mortality reduced captured by screen-
ing alone; (E) percentage of combined mortality reduction captured by treatment alone; (F) relative 
contribution of screening to combined mortality reduction; (G) relative contribution of treatment to 
combined mortality reduction. Note: Columns F and G sum to 100%.
** Operation refers to the calculation of the result in the table. For example, column D (Percentage 
of Mortality Reduction Captured by Screening Alone) is calculated as the result in column A for 
screening alone divided by the result in column C for the combined mortality reduction with both 
screening and treatment.
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Table 2 Relative Contributions of Treatments to Mortality Reduction in 2012
  Relative Contribution 
Associated with 
Chemotherapy, %
Relative Contribution 
Associated with Hormone 
Therapy, %
Relative Contribution 
Associated with 
Trastuzumab, %
Model Overall
Dana-Farber 23 24 2
Erasmus 37 25 1
Georgetown-Einstein 37 18 4
MD Anderson 22 34 6
Stanford 34 28 5
Wisconsin-Harvard 33 36 5
Mean 31 27 4
ER+, ERBB2- Subtype
Dana-Farber 25 25 0
Erasmus 30 35 0
Georgetown-Einstein 34 24 0
MD Anderson 21 42 0
Stanford 33 36 0
Wisconsin-Harvard 29 47 0
Mean 29 35 0
ER+, ERBB2+ Subtype
Dana-Farber 24 23 12
Erasmus 28 30 10
Georgetown-Einstein 32 23 9
MD Anderson 15 36 18
Stanford 30 30 17
Wisconsin-Harvard 25 34 18
Mean 26 29 14
ER-, ERBB2+ Subtype
Dana-Farber 36 0 16
Erasmus 45 0 18
Georgetown-Einstein 43 0 11
MD Anderson 24 0 29
Stanford 35 0 25
Wisconsin-Harvard 42 0 23
Mean 37 0 21
ER-, ERBB2- Subtype
Dana-Farber 43 0 0
Erasmus 57 0 0
Georgetown-Einstein 53 0 0
MD Anderson 42 0 0
Stanford 48 0 0
Wisconsin-Harvard 62 0 0
Mean 51 0 0
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Table 3 Relative Contributions Associated with Advances In Screening and Treatment to The Differ-
ence In The Mortality Reduction Between 2000 and 2012
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Operation* B-A D+E+F+G = 100%
Model Overall
Dana-Farber 39 49 10 13 34 44 10
Erasmus 32 43 10 31 32 33 4
Georgetown-Einstein 39 53 14 21 54 9 15
MD Anderson 27 39 13 23 21 37 18
Stanford 40 50 10 14 41 20 25
Wisconsin-Harvard 42 58 16 2 48 31 18
Mean 37 49 12 17 38 29 15
ER+, ERBB2- Subtype
Dana-Farber 43 52 9 14 39 47 0
Erasmus 34 46 13 21 14 64 0
Georgetown-Einstein 41 54 13 29 62 9 0
MD Anderson 29 42 13 24 25 50 0
Stanford 45 53 8 19 46 35 0
Wisconsin-Harvard 45 59 14 3 49 48 0
Mean 39 51 12 19 39 42 0
ER+, ERBB2+ Subtype
Dana-Farber 41 57 17 10 19 29 42
Erasmus 33 52 19 24 8 41 27
Georgetown-Einstein 41 58 17 14 46 16 24
MD Anderson 28 46 18 17 6 32 45
Stanford 47 66 19 4 23 14 58
Wisconsin-Harvard 46 71 25 0 29 20 51
Mean 39 58 19 12 22 25 41
ER-, ERBB2+ Subtype
Dana-Farber 33 49 16 11 37 0 52
Erasmus 26 41 15 13 37 0 50
Georgetown-Einstein 33 52 19 21 44 0 35
MD Anderson 20 33 13 20 3 0 78
Stanford 26 40 14 0 30 0 70
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Table 3 Relative Contributions Associated with Advances In Screening and Treatment to The Differ-
ence In The Mortality Reduction Between 2000 and 2012 (continued)
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Wisconsin-Harvard 33 55 22 0 42 0 58
Mean 29 45 15 11 32 0 57
ER-, ERBB2- Subtype
Dana-Farber 34 40 6 13 87 0 0
Erasmus 26 35 10 34 66 0 0
Georgetown-Einstein 35 46 11 14 86 0 0
MD Anderson 22 27 5 41 59 0 0
Stanford 27 33 7 23 77 0 0
Wisconsin-Harvard 32 42 10 9 91 0 0
Mean 29 37 8 22 78 0 0
* Operation refers to the calculation of the results in the table for each column. The column labels (A 
through G) are included with each column title.
Details on the computations are included in the Supplemental methods. Briefly, the estimated mean 
overall mortality reduction associated with combined screening and treatment in 2012 relative to the 
estimated baseline mortality rate in 2012 (Table 3, Column B) was 49% and in 2000 (Table 3, Column 
A) it was 37%. Thus, there was an additional 12% mortality reduction in 2012 compared to 2000 (Table 
3, Column C).
In 2000, the estimated relative contribution of screening to the mortality reduction associated with 
combined screening and treatment was 44% (Supplemental Table 4, Row D), hence the mortality 
reduction associated with screening is 44% of 37% = 16%.
In 2012, the estimated relative contribution of screening to the mortality reduction associated with 
combined screening and treatment was 37% (Table 1 and Supplemental Table 4, Row M), hence the 
mortality reduction associated with screening is 37% of 49% = 18%.
The difference in the mortality reduction associated with screening between 2012 and 2000 is 18%-
16% = 2%. Hence, the relative contribution of screening advances to the difference in the mortal-
ity reduction associated with combined screening and treatment was 2% divided by 12% (Table 3, 
Column C), giving 17% (Column D). The remainder (83%) is associated with treatment advances. This 
83% is distributed by treatment type in columns E-G. Columns D to G total 100%.
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discussion
This model-based analysis provides clinically relevant insights about the separate and 
combined population contributions associated with screening and treatment advances 
on reducing breast cancer mortality by molecular subtype. Six independent models 
found that both screening and treatment were associated with overall and subtype-
specific breast cancer mortality declines over time. Between 2000 and 2012, advances 
in treatment were associated with a larger contribution than screening to overall US 
breast cancer mortality decreases and for all molecular subtypes except ER-/ERBB2-, the 
subtype that also had the lowest modeled mortality reduction.
These results build upon past CISNET analyses and other studies that have examined 
the period before 20002,30-32 or considered the role of ER-status.15,33 The current analysis 
considered the study period from 2000 to 2012. In this period, digital mammography 
increased screening sensitivity compared with plain-film mammography, especially for 
women younger than 50 years and women with dense breasts,34 and has increased 
somewhat the number of breast cancer deaths averted with screening.35 The current 
results support findings that advances in mammography continue to contribute to reduc-
ing breast cancer mortality. It will be important to update the analysis when there is 
sufficient evidence about the benefits of tomosynthesis or other emerging screening 
approaches.36,37
Even with the recent screening advances, findings from this model-based analysis 
demonstrate a shift in the relative contributions associated with screening and treatment 
to breast cancer mortality, with greater contributions associated with treatment in 2012. 
Recent observational analyses have also found stage-specific survival improvements 
related to current treatment.33 The results from this model analysis confirm the benefits 
at the population level from the discovery and rapid dissemination over this past decade 
of several new classes of molecularly-targeted therapies, improvements in delivery of 
standard regimens, and refinements in therapy based on molecular subtype based by 
ER and ERBB2 status.
A unique contribution of this population-level analysis is how the relative contributions 
associated with screening and treatment varied by molecular subtype. In 2012, when 
gains from treatment alone were estimated, treatment alone could have provided roughly 
70% of the predicted mortality reduction achieved with both screening and treatment for 
the all the subtypes expressing the ER and/or ERBB2 receptors. However, screening is 
likely to remain important even if future treatments could cure all breast cancers, because 
screening can detect disease at earlier stages where there is less surgical and treatment-
related morbidity compared to that with therapy for more advanced stages.
Among the advances in recent adjuvant treatments, advances in chemotherapy with 
the addition of taxanes were associated with roughly 37% of the difference in overall 
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breast cancer mortality reduction from 2000 to 2012. Advances in hormone therapy 
with the addition of aromatase inhibitors had comparable contribution associated with 
mortality reduction. The contribution associated with trastuzumab was smaller on overall 
breast cancer mortality (13%), because ERBB2+ cases only account for approximately 
20% of all newly diagnosed breast cancers.38 However, trastuzumab was associated with 
more than 40% of the difference in mortality reduction between 2000 and 2012 among 
the ERBB2+ subtypes.
All of the models concluded that the ER-/ERBB2- subtype had the lowest overall mod-
eled mortality reduction over time, although the relative contributions associated with 
screening and treatment varied somewhat by model, with three of the six models esti-
mating a modestly higher contribution associated with treatment compared to screening 
in 2012. Prior analysis of SEER data have similar results, with greater mortality declines 
for those with ER+ vs. ER-tumors.15,39 Given that treatment advancements are lagging for 
ER-/ERBB2- cancers, more intensive screening approaches, or screening with different 
modalities, might be considered for groups at highest risk for this subtype, including 
African American women. Continued investments to discover molecularly-targeted treat-
ments for the ER-/ERBB2- subgroup remain important to continue to lower breast cancer 
death rates.
Overall, the models projected that screening and treatment each were associated with 
continued reductions in breast cancer mortality, but in 2012 treatment was associated 
with a larger relative proportion than screening of the mortality reductions overall and 
for all subtypes, except the ER-/ERBB2-. Because ER+ cancers are most prevalent and 
this group is expected to increase with time,40 additional advances for this subtype could 
have the largest impact on reducing the overall population burden of breast cancer. 
Looking ahead, model-based approaches may continue to be important to evaluate 
continued population-level progress in reducing the burden of breast cancer through a 
combination of continued discovery and dissemination of effective molecularly-targeted 
therapies, invention of novel screening technologies to optimize early detection of 
aggressive cancer subtypes, and greater ability to identify risk of developing specific 
molecular subtypes to permit tailored prevention and early detection.
This study has several strengths. First, by synthesizing national and clinical trial data, 
the results fill an important knowledge gap, especially because current surveillance 
data systems do not contain information on both screening and treatment. Second, the 
main findings were robust across six independent models, despite differences in model 
structures and assumptions. Third, the validity of this comparative modeling approach 
is supported by the consistency of conclusions across models, and the ability of each 
model to closely replicate the patterns of observed trends in incidence and mortality.
This research also has several limitations. First, the accuracy of model results depends 
on the availability of good quality data for input parameters and reasonable assumptions 
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about unobservable events. For instance, because there are limited long-term clinical 
trial or registry data on survival by ERBB2 status, the models extrapolated long-term 
survival. Second, modeled treatment effects were based on efficacy in trials included in 
the Oxford Overview,16 so could have slightly over-estimated actual population treat-
ment effects, and the relative contribution of treatment to mortality reductions. Third, 
each model also made different assumptions about the baseline incidence and natural 
history of breast cancer, leading to variability in the magnitude of results. Fourth, the 
models considered only five years of hormonal therapy since recommendations to 
consider 10-years among women at high-risk of late recurrence were just recently in-
troduced and have not yet been uniformly applied. Future modeling could incorporate 
the population-level dissemination and effectiveness of longer-term hormonal therapy. 
Fifth, progesterone-receptor status was not explicitly modeled since it is missing from 
many data sources. Sixth, subtype results for various racial/ethnic subgroups were not 
modeled. Understanding interactions between race, ethnicity, and subtype-specific 
outcomes represents an important future direction.41 Seventh, the effect of screening 
and subtype-specific treatment on morbidity and all-cause mortality was not evaluated. 
Eighth, modeling was based on estimates until 2012, and it is uncertain whether or how 
well these estimates reflect current breast cancer screening, treatment, or outcomes after 
2012. 
conclusions
In this simulation modeling study that projected trends in breast cancer mortality rates 
among US women, decreases in overall breast cancer mortality from 2000 to 2012 were 
associated with advances in screening and in adjuvant therapy, although the associations 
varied by breast cancer molecular subtypes.
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eMethods 
 
Computing the Relative Contributions Associated with Screening and Treatment  
     In the main text, the relative contribution associated with screening versus treatment to 
the combination was computed as the ratio of the screening alone mortality reduction 
divided by the sum of the screening alone mortality reduction and treatment alone 
mortality reduction; similarly for the relative contribution associated with treatment. 
Herein, we refer to this approach as “Method A.” Two alternative approaches for 
computing the relative contributions associated with screening and treatment were also 
considered.  In “Method B,” we evaluated the relative contributions associated with 
screening and treatment by first quantifying the contributions associated with screening 
alone and assigning the remainder of the combined effect to treatment.  In “Method C”, 
we evaluated the relative contributions associated with screening and treatment by first 
quantifying the contributions associated with treatment alone and assigning the remainder 
of the combined effect to screening.  A comparison of all three approaches to compute 
the relative contributions associated with screening and treatment on overall breast cancer 
mortality is provided in Supplemental eTable 3.  All three approaches provide the same 
ranking of relative contributions, but results differ because the combination associated 
with  screening and treatment is less than the sum of the contributions associated with 
screening alone and treatment alone.  If the combination was equal to the sum of 
screening alone and treatment alone, all three methods would give the same result.  
Because Method A provided a result that was “in-between” Methods B and C, we choose 
it for the primary analysis.  
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Computing the Relative Contributions Associated with Screening and Treatment to the 
Difference in the Reduction Between 2000 and 2012  
In Table 3 of the main text, the relative contribution associated with screening and 
treatment advances to the different in the mortality reduction between 2000 and 2012 are 
provided.  The results in Table 3 are based on the difference in breast cancer mortality 
reduction in 2012 and breast cancer mortality reduction 2000.  Note that the mortality 
reduction in 2012 is computed relative to the estimated baseline breast cancer mortality in 
2012, where the estimate baseline mortality rate in a given calendar year is defined as the 
estimate mortality rate in that calendar year had there never been screening or adjuvant 
therapy. Similarly, the mortality reduction in 2000 is computed relative to the estimated 
baseline breast cancer mortality in 2000. By computing the difference between 2000 and 
2012, the baseline effect is removed and the difference estimates the effect of screening 
and treatment only (not the baseline effect) over this time period.  If we did not 
remove the effect of baseline then the difference in the mortality rate between 2012 and 
2000 could be associated with changes in the baseline as well as changes in screening and 
treatment.  Removing the estimated baseline trend provides more robust results for the 
relative contributions associated with screening and treatment.  
To understand how the relative contributions associated with screening and 
treatment to the difference in the mortality reduction between 2000 and 2012 is 
computed, we describe the calculations based on overall mortality using the mean results 
in Table 3. The overall mortality reduction associated with combined screening and 
treatment was estimated as 37% in 2000 and 49% in 2012, yielding a difference of 12% 
between 2000 and 2012. In 2000, the relative contribution associated with screening to 
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the overall mortality reduction was 44% (based on Method A in Supplemental eTable 3), 
so the mortality reduction associated with screening (vs. baseline) was 44% of 37% = 
16% in 2000.  In 2012, the relative contribution associated with screening to the overall 
mortality reduction was 37% (based on Method A in Supplemental Table 3), so the 
mortality reduction associated with screening (vs. baseline) was 37% of 49% = 18%.  The 
difference in the mortality reduction associated with screening between 2012 and 2000 
was 18%- 16% = 2%.  This was associated with screening advances (in this case the 
conversion to digital mammography because the dissemination of screening had not 
significantly changed). Hence the relative contribution of screening advances to the 
difference in the mortality reduction associated with combined screening and treatment 
was estimated as 2% divided by 12%, giving 17%. This leaves 83% associated with 
treatment advances. Supplemental eTable 5 provides the results of these calculations for 
each model, and the mean across the models.  
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eTable 1. Model Parameters 
Parameters Data Data Source* 
Common Model Parameters 
Incidence in the 
absence of screening 
An age-period-cohort model is used as a 
starting point for most models (except 
Model M) 
Ref. 1,2 
Mammography 
dissemination 
Screening dissemination is based on the age 
at first screening and frequency by birth 
cohort derived from BCSC and NHIS data 
through 2012 
Ref.3,4  
Proportion of plain 
film vs. digital 
mammograms by year 
Estimated percent of mammograms in the 
US that are digital by year from 
FDA MQSA and BCSC data 
Ref.5,6  
BCSC 
(unpublished 
data) 
Mammography 
performance 
By age, type of screen (initial vs. 
subsequent), screen interval, and plain film 
vs. digital  
BCSC 
(unpublished 
data) 
Distribution of 
ER/ERBB2-status by 
age and stage  
The probability of ER/ERBB2 conditional 
on age and stage at diagnosis 
BCSC 
(unpublished 
data) 
Survival in the 
absence of screening 
and treatment, Overall 
and by ER/ERBB2 
26-year breast cancer survival before 
adjuvant treatment by joint ER/ERBB2 
status, age group, and AJCC/SEER stage or 
tumor size 
Ref.18 
ER/ERBB2 specific 
treatment 
dissemination by year 
Based on observed dissemination in the 
population over time from SEER and the 
NCCN Outcomes Database (1997-2012)  
Ref. 5,7,8 
NCCN 
Outcomes 
Database 
(unpublished 
data) 
ER/ERBB2-specific 
treatment efficacy 
Meta-analyses of clinical trial results Ref.9  
Non-cancer competing 
causes of death 
Age- and cohort-specific all-cause mortality 
rates by year 
Ref. 10  
Model-specific Parameters 
Tumor sojourn time 
(or mean tumor 
doubling time)  
Sojourn time by joint ER/ERBB2 status and 
age group 
Ref.18  
Proportion of DCIS 
that progresses to 
invasive cancer 
Varies by model Ref.5,11-16  
Mean stage dwell 
time** or tumor 
growth rates or both 
Varies by models based on model structure; 
can vary by age and/or ER/ERBB2 status 
Ref.11-17  
Screening effects Stage-shift or change in tumor size between 
screened and unscreened populations 
Ref.11-16  
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* All reference citations refer to those in the main text. 
** The mean stage well time is defined as the average time a tumor spends in each stage 
before progressing to the next. 
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eTable 5. Relative contributions associated with screening and treatment advances on the difference 
in the breast cancer mortality reduction between 2000 and 2012* 
       Model**  
Year Metric Row 
ID 
Operation D E G-E M S W-H Mean 
2000 Mortality Reduction in 2000 Relative to 
Baseline in 2000, Screening Alone, % 
A A 27 14 21 13 17 17 17 
Mortality Reduction in 2000 Relative to 
Baseline in 2000, Treatment Alone, % 
B B 18 22 23 17 28 30 23 
Mortality Reduction in 2000 Relative to 
Baseline in 2000, Combined Screening and 
Treatment, % 
C C 39 32 39 27 40 42 37 
Relative Contribution Associated with 
Screening, % 
D A/(A+B) 60 39 48 44 38 35 44 
Relative Contribution Associated with 
Treatment, % 
E B/(A+B) 40 61 52 56 62 65 56 
Mortality Reduction Associated with 
Screening given Combination, % 
F D*C 24 13 19 12 15 15 16 
Mortality Reduction Associated with 
treatment given combination, % 
G E*C 16 20 21 15 25 27 21 
2012 Mortality Reduction Relative to Baseline, 
Screening Alone, % 
H H 29 18 25 17 18 17 21 
Mortality Reduction Relative to Baseline, 
Treatment Alone, % 
I I 28 30 37 29 37 49 35 
Mortality Reduction Baseline, Combined 
Screening and Treatment, % 
J J 49 43 53 39 50 58 49 
Relative Contribution Associated with 
Screening, % 
K H/(H+I) 51 37 40 38 33 26 37 
Relative Contribution Associated 
Treatment, % 
L I/(H+I) 49 63 60 62 67 74 63 
Mortality Reduction Associated with 
Screening given Combination, % 
M K*J 25 16 22 15 16 15 18 
Mortality Reduction associated with 
Treatment given Combination, % 
N L*J 24 27 32 24 34 43 31 
2000 
vs 
2012 
Difference in Mortality Reduction Between 
2000 and 2012, % 
Q J-C 10 10 14 13 10 16 12 
Difference in the Mortality Reduction 
Associated with Screening Advances 
Between 2000 and 2012, % 
O M-F 1 3 3 3 1 0 2 
Difference in the Mortality Reduction 
Associated with Treatment Advances 
Between 2000 and 2012, % 
P N-G 9 7 11 10 9 15 10 
Relative Contribution Associated with 
Screening Advances Between 2000 and 
2012, % 
R O/Q 13 31 21 24 14 2 17 
Relative Contribution Associated with  
Treatment Advances Between 2000 and 
2012, % 
S P/Q 87 69 79 76 86 98 83 
© 2018 American Medical Association. All rights reserved. 
* See Supplemental Methods subsection “Computing the Relative Contributions of Screening and 
Treatment to the Difference in the Reduction Between Two Calendar Years” for description of these 
calculations.  
** Abbreviations: Model D is Dana Farber; Model E is Erasmus; Model G-E is Georgetown-
Einstein; Model M is MD Anderson; Model S is Stanford; Model W-H is Wisconsin-Harvard.  
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eTable 6. Relative contributions associated with screening, chemotherapy, hormone therapy and 
trastuzumab to breast cancer mortality reduction in 2012, broken down by advances before and after 
2000*  
Relative Contributions Associated with Mortality Reduction in 2012, Percent 
  Screening  
Advances 
before 
2000 
Screening 
Advances 
after 
2000 
Chemo-
therapy 
Advances 
before 
2000 
Chemo-
therapy 
Advances 
after 
2000 
Hormone 
Therapy 
Advances 
before 
2000 
Hormone 
Therapy  
Advances 
after 2000 
Trast-
uzumab 
Model Overall 
Dana-Farber 48 3 16 7 15 9 2 
Erasmus 29 8 30 8 17 8 1 
Georgetown-
Einstein 
35 5 23 14 16 2 4 
MD Anderson 30 8 15 7 22 12 6 
Stanford 30 3 26 8 24 4 5 
Wisconsin-Harvard 26 1 20 13 27 9 5 
Mean 33 4 22 9 20 7 4 
 ER+, ERBB2- Subtype 
Dana-Farber 48 2 19 6 17 8 0 
Erasmus 29 6 26 4 17 18 0 
Georgetown-
Einstein 
35 6 21 13 22 2 0 
MD Anderson 29 8 13 8 27 16 0 
Stanford 28 3 26 7 30 5 0 
Wisconsin-Harvard 23 1 17 12 35 11 0 
Mean 32 4 20 8 25 10 0 
 ER+, ERBB2+ Subtype 
Dana-Farber 38 3 18 6 15 8 12 
Erasmus 23 9 25 3 15 15 10 
Georgetown-
Einstein 
32 4 19 14 19 5 7 
MD Anderson 25 7 12 2 23 13 18 
Stanford 22 1 24 7 26 4 17 
Wisconsin-Harvard 23 0 14 10 27 7 18 
Mean 27 4 19 7 21 9 14 
 ER-, ERBB2+ Subtype 
Dana-Farber 44 4 25 12 0 0 16 
Erasmus 32 5 31 13 0 0 18 
Georgetown-
Einstein 
38 7 30 14 0 0 11 
MD Anderson 34 8 25 1 0 0 32 
Stanford 40 0 24 11 0 0 25 
Wisconsin-Harvard 34 0 25 17 0 0 24 
Mean 37 4 27 11 0 0 21 
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eTable 6 (Continued). Relative contributions associated with screening, chemotherapy, hormone 
therapy and trastuzumab to breast cancer mortality reduction in 2012, broken down by advances 
before and after 2000*  
 
Relative Contributions Associated with Mortality Reduction in 2012, Percent 
 Screening  
Advances 
before 
2000 
Screening 
Advances 
after 
2000 
Chemo-
therapy 
Advances 
before 
2000 
Chemo-
therapy 
Advances 
after 
2000 
Hormone 
Therapy 
Advances 
before 
2000 
Hormone 
Therapy  
Advances 
after 2000 
Trast-
uzumab 
 ER-, ERBB2- Subtype 
Dana-Farber 55 2 30 13 0 0 0 
Erasmus 34 9 40 18 0 0 0 
Georgetown-
Einstein 
43 3 35 19 0 0 0 
MD Anderson 46 10 28 15 0 0 0 
Stanford 47 5 33 15 0 0 0 
Wisconsin-Harvard 36 2 39 23 0 0 0 
Mean 44 5 34 17 0 0 0 
*Row sum is 100%, within rounding error.  
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eTable 7. Breakdown of overall breast cancer mortality reduction in 2012 by molecular subtype* 
   
Model 
ER+/ERBB2- 
Subtype 
ER+/ERBB2+ 
Subtype 
ER-/ERBB2+ 
Subtype 
ER-/ERBB2- 
Subtype 
Dana-Farber 70 13 6 11 
Erasmus 62 17 10 12 
Georgetown-Einstein 62 15 9 14 
MD Anderson 61 17 9 13 
Stanford 65 16 8 11 
Wisconsin-Harvard 66 15 8 11 
Mean 64 16 8 12 
*Row sum is 100%.  
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eFigure 1. Comparison of model projections to actual US breast cancer incidence, for women ages 30-79, 
invasive cancer only 
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eFigure 2. Comparison of model projections for ER-/ ERBB2-specific breast cancer mortality trends between 
1975-2012, for women ages 30-79,  by molecular subtype.  (Upper left) ER+/ERBB2-, (upper right) 
ER+/ERBB2+, (lower left) ER-/ERBB2+, (lower right) ER-/ERBB2- subtypes.  
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eFigure 3. Individual model projections for overall US breast cancer incidence and mortality (vs. SEER) and 
ER/ERBB2-subtype-specific mortality from 1975-2012, for women ages 30-79* 
 
Model Dana-Farber 
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Model Erasmus 
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Model Georgetown-Einstein 
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Model MD Anderson 
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Model Stanford 
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Model Wisconsin-Harvard 
 
* Legend for Supplemental Figure 3: (upper two panels) Individual model projections of breast cancer 
incidence and mortality rates vs. SEER rates to 2012, with modeled incidence reported in the presence and 
absence of screening; (lower four panels) Individual model projections by ER/ERBB2 under 4 scenarios: (i) no 
screening and treatment, (ii) screening alone, (iii) treatment alone, (iv) screening and treatment combined. 
Subtype-specific comparison to SEER is not possible because ER and ERBB2 status were not jointly reported 
over this period. 
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abstract
background
Controversy persists about optimal mammography screening strategies.
objective
To evaluate screening outcomes, taking into account advances in mammography and 
treatment of breast cancer.
design
Collaboration of six simulation models using national data on incidence, digital mam-
mography performance, treatment effects, and other-cause mortality.
setting and patients
The average-risk US female population and sub-groups with varying risk, breast density, 
or comorbidity.
setting
Unites States
patients
Average-risk U.S. female population and subgroups with varying risk, breast density, or 
comorbidity
interventions
Eight strategies differing by age at which screening starts (40, 45, 50 years) and screen-
ing interval (annual, biennial, and hybrid [annual in the 40s and biennial thereafter]); all 
strategies assumed 100% adherence and stopped at age 74.
measurements
Benefits (breast cancer-specific mortality reduction, breast cancer deaths averted, 
life-years and quality-adjusted life years); number of mammograms used; harms (false-
positive results, benign biopsies, and overdiagnosis); and ratios of harms (or use) and 
benefits (efficiency) per 1000 screens.
results
Biennial strategies were consistently the most efficient for average-risk women. Biennial 
screening from ages 50-74 avoided a median of 7 breast cancer deaths vs. no screening; 
annual screening from ages 40-74 years avoided an additional 3 deaths, but yielded 
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1988 more false-positives and 7 more overdiagnoses per 1,000 women screened. Annual 
screening from ages 50-74 was inefficient (similar benefits but more harms than other 
strategies). For groups with a 2- to 4-fold increased risk, annual screening from age 40 
had similar harms and benefits as screening average-risk women biennially from 50-74. 
For groups with moderate or severe comorbidity, screening could stop at age 66 to 68 
years.
limitations
Other imaging technologies, polygenic risk, and nonadherence were not considered.
conclusion
Biennial screening for breast cancer is efficient for average-risk populations. Decisions 
regarding starting ages and intervals will ultimately depend on population characteristics 
and the decision-makers’ weight given to the harms and benefits of screening.
primary funding source
National Institutes of Health
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InTRODUCTIOn
Despite decades of mammography screening for early breast cancer detection, there 
is no consensus on optimal strategies, target populations, or the magnitude of harms 
and benefits.(1-11) The 2009 US Preventive Services Task Force recommended biennial 
film mammography from ages 50-74, and suggested shared decision-making about 
screening in the 40’s.(12) Since that recommendation was formulated, there have been 
some new data regarding screening benefits,(2,6,8,9,11,13,14) digital mammography 
has essentially replaced plain film,(15) and increasingly effective breast cancer systemic 
treatment regimens have become standard.(16) There has also been growing interest 
in consumer preferences and personalized screening approaches.(17-20). These factors 
could each affect the outcomes of breast cancer screening programs and/or alter policy 
decisions about population screening strategies.(17)
Modeling can inform screening policy decisions since it uses the best available evi-
dence to evaluate a wide range of strategies, while holding selected conditions (e.g., 
treatment effects) constant, facilitating strategy comparisons.(21,22) Modeling also 
provides a quantitative summary of outcomes in different groups and assesses how 
preferences affect results. Collaboration of several models provides a range of plausible 
effects and illustrates the impact of differences in model assumptions on results.(1,7,23)
We used six well-established simulation models to synthesize current data to examine 
the outcomes of digital mammography screening at various starting ages and intervals 
among average-risk women. We also examined how breast density, risk, or comorbidity 
levels affect results, and whether preferences for health states related to screening and 
its downstream consequences affected conclusions.
methods
strategies
We evaluated eight strategies that varied by starting age (40, 45, 50) and interval (an-
nual, biennial, and hybrid [annual in the 40’s and biennial thereafter]); all strategies stop 
screening at age 74. We included “no screening” as a baseline.
model descriptions
The models used to evaluate the screening strategies were developed within the Cancer 
Intervention and Surveillance Modeling Network (CISNET) (24-30) and the research was 
institutional review board approved. The models included model D (Dana-Farber Cancer 
Institute, Boston, Massachusetts), model E (Erasmus Medical Center, Rotterdam, the 
Netherlands), model GE (Georgetown University Medical Center, Washington, DC and 
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Albert Einstein College of Medicine, Bronx, New York), model M (MD Anderson Cancer 
Center, Houston, Texas), model S (Stanford University, Stanford, California), and model 
W (University of Wisconsin, Madison, Wisconsin and Harvard Medical School, Boston, 
Massachusetts).
Since earlier analyses,(1) the models have undergone substantial revision to reflect 
advances in breast cancer control, including portrayal of molecular subtypes based on 
estrogen receptor (ER) and human epidermal growth factor-2 receptor (HER2) status;(23) 
current population incidence (31) and competing non-breast cancer mortality; digital 
screening; and the most current therapies.(32) All models except model S include ductal 
carcinoma in-situ (DCIS).
The general modeling approach is summarized below; full details including approach, 
construction, data sources, assumptions, and implementation are available at: https://
resources.cisnet.cancer.gov/registry and at (33). Additional information is available on 
request and the models are available for use via collaboration.
The models begin with estimates of breast cancer incidence (31) and ER/HER2-specific 
survival trends without screening or adjuvant treatment and then overlay data on screen-
ing and molecular subtype-specific adjuvant treatment to generate observed US popula-
tion incidence and breast cancer-specific mortality trends.(1,7,17,23,34) Breast cancers 
have a distribution of preclinical screen-detectable periods (sojourn time) and clinical 
detection points. Digital mammography performance characteristics depend on age, first 
vs. subsequent screen, time since last mammogram, and breast density. ER/HER2 status 
is assigned at diagnosis based on stage and age. Molecular subtype- and stage-specific 
treatment reduces the hazard of breast cancer death (models D, GE, M, and S) or results 
in a cure for some cases (models E and W). Women can die of breast cancer or other 
causes. Screen detection of cancer during the preclinical screen-detectable period can 
result in the identification (and treatment) of earlier-stage or smaller tumors than might 
occur via clinical detection, with a corresponding reduction in breast cancer mortality.
We used a cohort of women born in 1970 with average-risk and average breast density 
and follow them from age 25 (since breast cancer is rare before this age [0.08% of cases]) 
until death or age 100.
model input parameters
The models used a common set of age-specific variables for breast cancer incidence, 
digital mammography performance, treatment effects, and average and comorbidity-
level specific-non-breast cancer causes of death.(20,33,35) The parameter values are 
available at: http://www.uspreventiveservicestaskforce.org/Page/Document/modeling-
report-collaborative-modeling-of-us-breast-cancer-1/breast-cancer-screening1.(33) 
In addition, each group included model-specific inputs (or intermediate outputs) to 
represent preclinical detectable times, lead-time, and age- and ER/HER2-specific stage 
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distribution in screen- vs. non-screen-detected women on the basis of their specific 
model structure.(1,7,23-30) These model-specific parameters were based on assump-
tions about combinations of values that reproduced US trends in incidence and breast 
cancer-specific mortality, including proportions of DCIS that were nonprogressive and 
would not be detected without screening. Models M and W also assumed some small 
nonprogressive invasive cancers. The models adopted an age-period-cohort modeling 
approach to project breast cancer incidence rates in the absence of screening;(31,36) 
Model M used 1975-79 SEER rates. The models assumed 100% adherence to screening 
and receipt of the most effective treatment to isolate the effect of varying screening 
strategies.
Four models used age-specific digital mammography sensitivity values observed in 
the Breast Cancer Surveillance Consortium (BCSC) for detection of invasive and DCIS 
cancers combined (model S only uses data for invasive cancers). Separate values were 
used for initial and subsequent mammography by screening interval using standard 
BCSC definitions: annual includes data from screens occurring within 9-18 months of the 
prior screen and biennial includes data on screens within 19-30 months.(37,38) Model 
D used these data as input variables (28) and models GE, S, and W used the data for 
calibration.(24,25,27) Models E and M fit estimates from the BCSC and other data.(26,29)
Women with ER-positive tumors received five years of hormonal therapy and an an-
thracycline-based regimen accompanied by a taxane. Women with ER-negative invasive 
tumors received anthracycline-based regimens with a taxane. Those with HER2-positive 
tumors also received trastuzumab. Women with ER-positive DCIS received hormonal 
therapy.(16) Treatment effectiveness was based on clinical trials and was modeled as 
a reduction in breast cancer-specific mortality risk or increase in the proportion cured 
compared to ER/HER2-specific survival in the absence of adjuvant treatment.(32)
benefits
Screening benefits (vs. no screening or incremental to other strategies) included percent 
breast cancer mortality reduction, breast cancer deaths averted, and life-years (LYs) and 
quality-adjusted life-years (QALYs) gained because of averted or delayed breast cancer 
death. Benefits (and harms) were accumulated from ages 40-100 years to capture the 
lifetime impact of screening.
We considered preferences, or utilities to account for morbidity from screening and 
treatment. A disutility for age- and gender-specific general population health was first 
applied to quality-adjust life years.(39) These were further adjusted to account for ad-
ditional decrements in life years related to undergoing screening (-0.006 for one week), 
evaluation of a positive screen (-0.105 for five weeks), undergoing initial treatment by 
stage (for the first 2 years after diagnosis), and experiencing distant disease (for the last 
year of life for all women who die of breast cancer) (see Supplement Table 1).(33,40,41)
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use and harms
Use of services focused on the number of mammograms required for the screening strat-
egy. Harms included false-positive mammograms, benign biopsies, and overdiagnosis. 
False-positive mammogram rates were calculated as mammograms read as abnormal 
or needing further work-up in women without cancer divided by the total number of 
screening mammograms. Benign biopsies were defined as biopsies among women with 
false-positive screening results; we assume 100% compliance with biopsy recommenda-
tions.(42) Overdiagnosis was defined as all cases that would not have been clinically 
detected in the absence of screening because of lack of progressive potential or death 
from competing non-breast cancer mortality. The impact of overdiagnosis on QALYs was 
captured by the disutility of being treated for cancer but dying of other causes.
statistical analysis
For each model, strategies were ranked by the number of mammograms performed. 
We report the median use, benefits, and harms and range across models. We also 
obtained an efficiency frontier by plotting the sequence of points that represent the 
largest incremental percent breast cancer mortality reduction (or LYs or QALYs) per mam-
mogram performed or harm entailed. Screening strategies that fell on this frontier were 
considered the most efficient (i.e., have the steepest slope such that no alternative exists 
that provides more benefit with less use/fewer harms).
Three models (E, GE, and W) also evaluated results based on combinations of breast 
cancer risk and density. Risk levels included: 1.3 (e.g., nulliparity or age at first live birth 
>30); (18,43) 2.0 (e.g., family history of one first degree relative); (18) or 4.0 times higher 
than average-risk (e.g., 2 or more first degree relatives).(18,44) Greater risk levels, such 
as seen with BRCA 1/2 mutations, were not considered since such groups have specific 
screening guidelines. We made the simplifying assumption that risk affected incidence, 
but not other aspects of disease.
Breast density was modeled as entirely fatty (“a”), scattered density (“b”), heteroge-
neously dense (“c”) and extremely dense (“d”). Based on observed age-specific preva-
lence rates, density was assigned at age 40, and remained the same or decreased by 
one level at age 50 and again at age 65.(45) Density modified mammography sensitivity 
and specificity based on age, interval, and first vs. subsequent screening.(33) Density 
also modified the age-group specific (40-49, 50-64, and 65+) risk of developing breast 
cancer compared to average population density in the age-group (BCSC unpublished 
data).(44,46) Density was assumed to not affect molecular subtype or disease natural 
history. Density results were grouped into low (“a and b”) and high density (“c and d”) 
for presentation. The risk- and density-specific results were also compared to those for 
screening average-risk and density groups biennially from 50-74, since many guideline 
groups accept the latter.
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In other analyses, two models (model E and GE) examined the impact of comorbidity 
on screening cessation using comorbidity-specific life expectancy. Examples of condi-
tions that placed women in severe and moderate comorbidity groups included conges-
tive heart failure and diabetes, respectively; the specific conditions and their associated 
life expectancies have been previously reported.(20,35,47) We compared results for 
continuing to screen biennially past age 74 among women with no or low comorbidity 
or stopping earlier than 74 for those with moderate or high comorbidity. These analyses 
included women who survived and were breast cancer-free up until the point where 
screening was to be extended or stopped.
Four models evaluated whether high disutility values would eliminate screening ben-
efits. Finally, we evaluated the ability of the models to independently predict external 
trends and results (Supplement Figure 1 and Supplement Table 2).
Role of the Funding Source
We worked with US Preventive Services Task Force and Agency for Healthcare Research 
and Quality to develop the research questions. NCI investigators (KC, EF) collaborated 
in their role as scientific project officers. The agencies had no role in the study conduct 
or decision to submit the manuscript for publication.
results
benefits in the average-risk population
The models produced consistent rankings of the screening strategies (Table 1). For 
instance, biennial screening from ages 50 to 74 yielded a median 25.8% reduction in 
breast cancer mortality compared to no screening (range: 24.1%-31.8). Annual screening 
led to slightly greater reductions in mortality than biennial strategies. However, biennial 
strategies maintained a median of 79.8%-81.3% of the breast cancer-specific mortality 
reduction of annual screening (range 68.3-98.9%) (Supplement Table 3).
Biennial screening also maintained the majority of annual benefits for LYS and QALYs 
and quality-adjustment did not change the ranking of strategies. Across all strategies, 
the largest decrement from quality-adjustment to life years was related to declines in 
general health as women aged; smaller decrements occurred due to the disutility of 
undergoing diagnostic evaluation of an abnormal screening exam and for having cancer. 
The disutility associated with screening itself had minimal impact on QALYs. (see 33)
The incremental benefits of initiating screening at age 40 were slightly greater than 
starting at age 50 in terms of breast cancer deaths averted with both annual and bien-
nial screening (median 1.3 [range: 1.1-1.7] and 1.0 [0.8-1.7] per 1000 women screened, 
respectively) (Table 3). Initiating screening at age 45 yielded benefits intermediate be-
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Table 1 Ranking of Benefits (Percent Breast Cancer Mortality Reduction, LYs, QALYs) by Model and 
Screening Strategy Per 1000 Women Screened
Strategies Results per 1000 Women Screened
# of 
screens*
Percent breast cancer mortality reduction (vs. no 
screening) by model1
Median
(range across 
models)D E G-E M S W
B 50-74 11,127 25.6% 26.0% 31.8% 26.8% 24.1% 25.4% 25.8% (24.1-31.8)
B 45-74 13,212 26.6% 27.6% 33.9% 28.4% 25.9% 26.7% 27.2% (25.9-33.9)
H 45-74 15,966 27.7% 29.7% 35.9% 29.2% 27.3% 30.1% 29.5% (27.3-35.9)
B 40-74 16,013 28.3% 30.3% 35.9% 31.9% 28.2% 30.5% 30.4% (28.2-35.9)
H 40-74 20,884 29.0% 32.3% 37.9% 31.7% 29.3% 32.8% 32.0% (29.0-37.9)
A 50-74 21,318 32.1% 33.9% 37.6% 27.1% 29.1% 35.3% 33.0% (27.1-37.6)
A 45-74 26,136 34.2% 37.6% 41.6% 29.4% 32.3% 39.1% 35.9% (29.4-41.6)
A 40-74 31,038 35.5% 40.1% 43.6% 32.5% 34.4% 42.6% 37.8% (32.5-43.6)
1Without screening, the median probability of dying of breast cancer is 2.50% (range 1.50-3.20%). 
Thus, if a particular screening strategy leads to a 30% reduction in breast cancer mortality, this means 
that the probability of breast cancer mortality was reduced from 2.50% to 1.75%. This translates into 
7.5 deaths averted per 1000 women screened. The absolute reduction in breast cancer deaths (i.e., 
deaths averted) vs. no screening for each strategy is included in Table 2.
Strategies Results per 1000 Women Screened
# of 
screens*
Years of Life Gained (vs. no screening) by model Median
(range across 
models)
D E G-E M S W
B 50-74 11,127 153.8 94.0 140.5 146.5 104.2 74.6 122.4 (74.6-153.8)
B 45-74 13,212 168.4 107.7 161.2 171.3 115.2 84.0 138.2 (84.0-171.3)
H 45-74 15,966 175.3 117.9 170.2 171.4 125.1 95.7 147.7 (95.7-175.3)
B 40-74 16,013 183.7 123.7 172.4 194.8 131.6 98.8 152.0 (98.8-194.8)
H 40-74 20,884 191.1 137.6 187.2 211.5 141.0 110.9 164.1 (110.9-211.5)
A 50-74 21,318 180.0 125.9 167.3 156.3 133.3 104.3 144.8 (104.3-180.0)
A 45-74 26,136 201.3 149.3 196.7 177.8 154.2 123.0 166.0 (123.0-201.3)
A 40-74 31,038 217.1 168.8 213.5 218.1 170.1 140.5 191.8 (140.5-218.1)
Strategies Results per 1000 Women Screened
# of 
screens*
QALYs Gained (vs. no screening) by model Median
(range across 
models)
D E G-E M S W
B 50-74 11,127 114.5 67.3 100.1 109.6 71.9 47.1 86.0 (47.1-114.5)
B 45-74 13,212 123.8 75.6 114.4 129.4 78.8 51.9 96.6 (51.9-129.4)
H 45-74 15,966 126.6 80.9 118.3 128.5 84.5 58.3 101.4 (58.3-128.5)
B 40-74 16,013 133.7 85.4 120.1 148.1 89.1 60.4 104.6 (60.4-148.1)
H 40-74 20,884 134.2 91.0 126.1 159.4 92.5 64.8 109.3 (64.8-159.4)
A 50-74 21,318 127.0 84.1 111.4 113.2 87.5 62.4 99.5 (62.4-127.0)
A 45-74 26,136 138.9 97.3 129.5 129.4 99.5 71.7 114.5 (71.7-138.9)
A 40-74 31,038 146.6 107.3 137.2 160.6 107.6 80.0 122.4 (80.0-160.6)
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tween beginning at 40 and 50, although there were slightly greater incremental benefits 
when starting at age 45 (vs. 50) than starting at age 40 (vs. 45) (e.g., 10.6 vs. 8.0 and 15.4 
vs. 7.9 QALYs for biennial and annual strategies, respectively) (Table 1).
harms in the average-risk population
All models projected more false-positive results, benign biopsies, and overdiagnosed 
cases under annual vs. biennial schedules and starting earlier than age 50 (Table 2). For 
instance, if biennial screening began at age 40 instead of age 50, for every 1000 women 
screened there would be a median of 1 more death averted, but 576 more false-positive 
results, 58 benign biopsies, and 2 additional overdiagnosed cases. Compared to screen-
ing initiation at age 45, starting screening at age 40 had 1 or fewer added deaths averted 
depending on interval, but more incremental harms.
efficiency frontiers for average-risk populations
Efficiency frontier plots were used to graphically depict the balance between the number 
of mammograms and benefits (life years gained) of screening strategies. Biennial strate-
gies starting at either age 40, 45, and 50 were all efficient (Figure 1, Supplemental Figure 
2). Points that were close to, but fell below the frontier were less efficient than those on 
the frontier line. For example, compared to the point on the efficient frontier for biennial 
screening at age 45, the hybrid strategy of annual screening at 45 was less efficient 
than biennial screening starting at 40. This is because the hybrid strategy at 45 would 
require 405.8 more mammograms to gain an additional life year for every 1000 women 
screened compared to biennial screening at 45, while biennial screening starting at 40 
only requires 189.5 extra mammograms to gain an additional life year.
Finally, annual screening from ages 50 to 74 was consistently inferior to other strate-
gies (i.e., was inefficient, or dominated) since it yielded the same or fewer benefits than 
the next least intensive strategy depending on the measure of benefits, but required 
A=Annual B=Biennial H=Hybrid
*Strategies are ranked from the least to the most mammograms, where the number of mammo-
grams is the median across models. Not all possible mammograms in the age interval are obtained 
since some women die from other causes before screening would occur.
†Model Group Abbreviations: D (Dana Farber Cancer Center), E (Erasmus Medical Center), G-E 
(Georgetown U. –Einstein COM.), M (M.D. Anderson Cancer Center), S (Stanford U.), W (University 
of Wisconsin/Harvard)
‡Grey shaded areas in the table show strategies that are inferior or inefficient (“dominated”) within a 
specific model; a strategy is classified as inferior or inefficient if there is another strategy that results 
in an equal or higher benefit (either percent mortality decline; LYG; or QALYs) with fewer harms (e.g., 
average screening exams).
§QALYs are adjusted for general health, diagnosis, screening and treatment.
||100% of women receive adjuvant systemic therapy based on recommended stage, ER/HER2-specif-
ic adjuvant therapy for pre- and post-menopausal women.
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Table 2 Lifetime Benefits and Harms of Screening Strategies based on Starting Ages and Screening 
Intervals
Strategy Median number (range across models) per 1000 women screened (vs. no screening)*
Screens Breast cancer 
deaths 
averted
False-positive 
screens
Benign breast 
biopsies
Over-diagnosed 
cases (invasive 
and DCIS) † ‡
Percent of all 
cases over-
diagnosed † ‡
Biennial          
50-74 11,127 7 (4-9) 953 (830-1325) 146 (120-205) 19 (11-34) 12% (8–22)
45-74 13,212 8 (4-9) 1220 (930-1599) 168 (120-221) 19 (11-34) 12% (8–22)
40-74 16,013 8 (5-10) 1529 (1100-1976) 204 (140-264) 21 (12-38) 13% (9–24)
Hybrid
45-74 15,966 8 (5-9) 1520 (1160-1968) 190 (140-250) 21 (12-40) 13% (8–25)
40-74 20,884 9 (5-10) 2106 (1480-2623) 245 (170-309) 23 (12-44) 14% (9–27)
Annual
50-74 21,318 9 (5-10) 1798 (1706-2445) 228 (219-317) 25 (12-68) 15% (8–36)
45-74 26,136 9 (6-11) 2355 (2185-3087) 247 (230-329) 28 (12-74) 17% (9–38)
40-74 31,038 10 (6-11) 2941 (2550-3742) 303 (260-388) 30 (13-77) 18% (9–39)
*In all scenarios, 100% of women receive adjuvant systemic therapy based on recommended stage, 
ER/HER2-specific adjuvant therapy for pre- and post-menopausal women.
†Over-diagnosed cases are defined as cases that would not have been clinically detected in the 
absence of screening
(i.e., cases that do not die from breast cancer because of lack of progressive potential or death from 
competing non-breast cancer mortality). The result includes DCIS and invasive overdiagnosis. Over-
diagnosis is calculated by comparing cases detected in the screening scenario to those detected 
in the non-screened scenario. Model S is excluded since it does not include DCIS. The percent 
overdiagnosis is calculated as the percent of all cases detected in the screening strategy that are 
overdiagnosis.
‡The upper range for all over diagnosis estimates is based on model M results. Model M gener-
ates very high overdiagnosis based on the assumption that incidence in the absence of screening 
has essentially remained flat since 1975-79, with virtually all of the increases over time attributable 
to screening. The other models use some form of an age-period-cohort model for incidence in the 
absence of screening, where some of the increases in incidence are due to screening and some to 
changes in risk factors (e.g., use of hormone replacement therapy), generating lower rates of overdi-
agnosis. Other sources of variation across models are related to assumptions about the proportions 
of DCIS cases that never progress to invasive cancer or the number of early invasive cancers that 
might be nonprogressive. Generally, models that assume higher proportions of DCIS and/or invasive 
cancer to be nonprogressive generate higher estimates of overdiagnosis than models that assume 
less nonprogressive disease. Unfortunately, the underlying incidence in the absence of screening 
and the proportion and types of tumors that are nonprogressive are unknown and unobservable. 
Therefore, the different results across models based on their respective assumptions provide a range 
of possible overdiagnosis.
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more mammograms or entailed more harms. These above patterns were generally seen 
with other harm and benefit metrics (see Supplement Figure 2).
sensitivity analyses for average-risk populations
Varying the disutilities for usual health, screening, diagnosis, and treatment did not af-
fect strategy rankings for average-risk populations and QALY gains persisted under all 
screening strategies, although their magnitude decreased.
Figure 1 Efficiency frontier for life-years gained versus mammograms performed per 1000 women in 
model D (Dana-Farber Cancer Institute).
Legend for Figure 1. Efficiency Frontier
Efficiency frontier graphs for all models are shown in Appendix Figure 2 (available at ww.annals.
org). This graph plots the average gain in life-years per additional mammogram performed per 1000 
women for each screening strategy (vs. no screening) in model D. Biennial strategies are indicated 
with a square; hybrid strategies (annual in the 40s followed by biennial from 50 to 74 years of age) 
with a triangle; and annual strategies with a circle. Efficient strategies were plotted (i.e., those in 
which increases in mammography use resulted in greater life-years gained than the next less inten-
sive strategy). The line represents the “efficiency frontier” by joining efficient strategies in which 
increases in mammography use resulted in greater life-years gained than the next less intensive 
efficient strategy. Strategies on this line would be considered efficient because they achieve the 
greatest gain in benefit (life-years gained) per harm or use of mammograms. Strategies that use 
more mammograms but still have small benefits (i.e., a shallower slope than the next best strategy) 
are considered to be less efficient (i.e., weakly dominated). When and if the slope in the efficiency 
frontier plot levels off, it means that the additional life-years gained per increase in mammography 
are small relative to the previous strategies and could indicate a point at which additional screening 
might be considered as having a low return (or additional benefit). There is no definitive inflection 
point across the models for the strategies or metrics evaluated. Black strategies are efficient; gray 
strategies close to the efficiency frontier are less efficient; and open gray strategies are inefficient (in-
ferior, or dominated). Reference (33) provides efficiency frontiers for other harm and benefit metrics.
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harms and benefits by risk level
The balance of harms and benefits differed by risk group, with women who had higher-
risk having lower rates of false-positives and higher gains from screening than lower-risk 
groups. Screening higher-risk women also yielded a lower proportion of overdiagnosed 
cases per breast cancer death averted than screening average-risk women. However, 
annual screening from ages 50 to 74 had the same or less benefit and more harms than 
other strategies at all risk levels.(33)
For women with a 2- to 4-fold increase in risk, annual screening starting at age 40 
or 45 had similar or more favorable harm-to-benefit ratios (based on false-positives) 
as biennial screening of average-risk women from 50-74. For instance, for every 1000 
average-risk women screened biennially from 50-74, there would be 226.5 (range: 169.9-
267.0) false-positives per death averted. If women with a two-fold increase in risk began 
annual screening at age 40, their corresponding ratio would be slightly more favorable at 
200.7 (range: 177.5-232.2). For women with a 1.3-fold increase in risk, biennial screening 
starting at age 40 had similar harm-to-benefit ratios as biennial screening of average-risk 
women from ages 50-74.
benefits and harms by breast density group
Breast density (low vs. high) changed absolute benefits, but annual screening from 50-74 
remained inefficient across breast density groups. Women in the low-density group had 
a greater proportion of their cancers detected due to greater digital mammography 
sensitivity, and therefore a greater breast cancer-specific mortality reduction than the 
high-density group. However, women in the high-density group had a greater absolute 
Table 3 Incremental Changes in Breast Cancer Deaths Averted by Interval, Age of Screening Initia-
tion, and Model
  Annual Biennial
number of breast cancer deaths averted/1000 women (% breast cancer mortality reduction)
Model Start at 40 vs. 50 Start at 45 vs. 50 Start at 40 vs. 50 Start at 45 vs. 50
D 1.1 (3.4%) 0.6 (2.1%) 0.9 (2.7%) 0.3 (1.0%)
E 1.5 (6.2%) 0.9 (3.6%) 1.0 (4.3%) 0.4 (1.6%)
G-E 1.5 (6.0%) 1.0 (4.0%) 1.0 (4.1%) 0.5 (2.2%)
M 1.7 (5.3%) 0.7 (2.3%) 1.7 (5.1%) 0.5 (1.6%)
S 1.1 (5.2%) 0.7 (3.1%) 0.9 (4.1%) 0.4 (1.7%)
W 1.1 (7.3%) 0.6 (3.8%) 0.8 (5.1%) 0.2 (1.3%)
Median 1.3 (5.7%) 0.7 (3.4%) 1.0 (4.2%) 0.4 (1.6%)
*Incremental difference between starting at age 40 or 45 vs. 50. Annual is comparing A40-74
(or 45-74) to A50-74; biennial is comparing B40-74 (or 45-74) to B50-74. Hybrid strategies are com-
pared to B50-74, therefore for those incremental comparisons the hybrid results are the same as the 
annual results
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number of cancers detected because their risk of cancer was higher, leading to more life 
years saved among women in the high-density than the low-density group (33)).
benefits and harms by comorbidity
For women with no comorbidity, biennial screening could continue to age 78 or 80 and 
still have similar harm-to-benefit ratios as screening women with average non-breast 
cancer mortality biennially from 50-74. However, for women with moderate to severe 
comorbidity, the comparable ratios were equivalent at about age 68 (33).
discussion
This study used six established models to estimate the potential efficacy of different US 
breast cancer screening strategies. All six models demonstrated that screening initiation 
at age 40 has some benefits for average-risk populations, but also higher levels of harms 
than strategies starting at age 50. The findings also suggest that comorbidity levels could 
be used to tailor the age of screening cessation. Biennial screening strategies were the 
most efficient, but annual screening could be considered from ages 40-74 in groups with 
a two to four-fold higher than average-risk.
Results from all models indicated that digital mammography screening of average-
risk women in their 40’s modestly lowers breast cancer-specific mortality and extends 
the length and quality of life, even after considering disutilities related to the screen-
ing process. The absolute benefits of starting screening in the 40’s varied somewhat 
based on model structure and assumptions, but were consistent with observations from 
randomized trials.(6) However, starting at age 40 vs. 45 was associated with increasing 
incremental harms relative to the increase in benefits. Thus, decisions about initiating 
screening before age 50 may depend on the weight attached to screening benefits and 
harms.
Consistent with other analyses of screening upper age limits,(20,48-50) and other 
recommendations,(12,51) our results suggested that the balance of harms and benefits 
of screening was affected by competing non-breast cancer mortality, so that age of 
screening cessation could be tailored by comorbidity levels.
Similar to our 2009 analysis,(1) biennial strategies are most consistently efficient. 
Screening annually from ages 50-74 had the same or fewer benefits for any given harm 
for all population groups in virtually all models, and would be considered inefficient. 
However, annual screening in the 40’s followed by biennial screening at age 50, or the 
most intensive schedule evaluated (annual screening 40-74) were also efficient or close 
to being efficient. Additionally, annual screening of women with a two- to four-fold 
increased risk (e.g., due to non-BRCA related family history) from ages 40-74 had com-
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parable harm-to-benefit ratios as did biennial screening from age 50 to 74 in average-risk 
populations.
The results also suggest that benefits of screening vary by breast density, at least 
when grouped into low/high categories. Women with dense breasts have a higher risk 
of developing cancer and absolute detection rate, but lower relative detection. (19,52) 
This is because digital sensitivity, while optimized for density, is still lower in women 
with dense than non-dense breasts.(53-56) Improving outcomes for women with dense 
breasts (55) may require new innovations in imaging (57-60) or identification of risk 
biomarkers.(61,62)
This analysis extends our prior work by explicitly considering overdiagnosis as a 
screening harm. Depending on screening strategy, the models estimated that 2-12% of 
invasive and 30% to 50% of DCIS cases might represent overdiagnosis. While the models 
differed in absolute estimates, they agreed on how overdiagnosis affected the ranking 
of strategies and the finding that the majority of overdiagnosed cases were DCIS. The 
model results for overdiagnosis are not directly comparable to other published estimates 
(8,63) since the models followed women for their entire lives. The models also made as-
sumptions about unobservable input parameters related to natural history. While there is 
no agreement on methods to estimate overdiagnosis (64) or on its true rate,(65,66) there 
is agreement that it is an important harm. Active surveillance for DCIS with a low risk of 
progression is one potential future approach to reduce harms from DCIS overdiagnosis. 
More information is also needed on consumer knowledge of and willingness to risk 
overdiagnosis.(67)
Overall, this study has several important strengths including collaboration of six 
long-established, independent modeling groups, use of well-calibrated models that 
reproduce temporal epidemiological trends and a screening trial result, inclusion of 
digital technology, incorporation of increasingly effective treatments, and consideration 
of quality of life, risk factors, breast density, and comorbidity.(68) The conclusions about 
the ranking of screening strategies are robust and should provide greater credibility than 
inferences based on one model alone.
Our study also had limitations. First, to evaluate program efficacy we assumed 100% 
adherence to screening, prompt evaluation of abnormal results, and full use of opti-
mal treatment. Actual benefits will fall short of our projected results since adherence 
is not perfect. Second, we only focused on hybrid strategies for women in their 40’s. 
Alternative hybrid strategies may be important to examine in future research. Third, the 
analysis also did not consider other imaging technologies for average-risk populations 
or for groups with high breast density, such as ultrasound, (69) computer-aided detec-
tion,(70) tomosynthesis, or magnetic resonance imaging (MRI). Data on tomosynthesis 
performance and needs for radiologist re-training are still emerging.(58) Fourth, we did 
not model any radiation-induced breast cancers due to more intensive mammography 
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schedules.(71) Fifth, we assumed that risk factors influenced the incidence of disease, but 
not its natural history. Sixth, certain risk factors, such as family history, are age-dependent 
in their effects.(18,72) Since we held relative risk levels constant over age, our benefit 
estimates could be over- or under-estimated for specific risk factors.(17) Seventh, we 
did not consider polygenic risk,(73,74) or explicitly model menopausal status; we used 
age 50 as a proxy for the average age of menopause. Additionally, the analysis did 
not include screening program costs or utility estimates specific to some of the newest 
treatments. Finally, compared to our earlier research,(1) the models all estimated similar, 
but somewhat greater breast cancer-specific mortality reductions (for example, a median 
22% vs. 25.8% reduction with biennial screening from 50-74 in 2009 vs. current models, 
respectively). The primary reasons for this modeled improvement relate to the increased 
sensitivity of digital vs. film mammography, advances in molecular-targeted therapies, 
and changes in underlying breast cancer trends.
Overall, the six models conclude that biennial screening strategies are the most ef-
ficient. Choices about optimal ages of initiation (and cessation) and screening intervals 
will ultimately depend on program goals, the weight attached by the decision-maker to 
screening harms and benefits,(75) and considerations of efficiency.
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Appendix Model validation
Each model has a different structure and assumptions and some varying input variables, 
so no single method can be used to validate results against an external standard. 
Therefore, we used several approaches. First, considering actual screening and treat-
ment patterns instead of the efficacy strategies simulated in the base case, we compared 
model projections of incidence, breast cancer–specific mortality, and stage distribution 
with those reported by the Surveillance, Epidemiology, and End Results program for 
1975 to 2010. In our previous work, results of each model accurately projected trends for 
incidence and breast cancer–specific mortality by ER status for 1975 to 2000 (23). Next, 
we approximated the Age screening trial (6), assuming perfect adherence to invitations 
for annual screening with 13-year follow-up of women aged 40 to 49 years (6). Finally, we 
examined the consistency of results across models. Using inputs for actual dissemination 
of screening and treatment in the United States, the models captured the major trends in 
incidence and the general shape of breast cancer–specific mortality decreases over time 
(Appendix Figure 1). They also closely matched current stage distribution (not shown) 
and the Age trial results (Appendix Table 2) (6, 33). Thus, the models replicated patterns 
of observed US incidence and breast cancer–specific mortality over time. The models 
also estimated similar breast cancer–specific mortality reduction as that observed among 
women aged 40 to 49 years who actually attended screening in the Age trial, although 
the model results are slightly more optimistic than the trial because the models assume 
100% screening and use of the most effective systemic regimens (6). Overall, use of 
6 models to project a range of plausible screening outcomes provides implicit cross-
validation, with the range of results from the models as a measure of uncertainty.
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D = Dana-Farber Cancer Institute; E = Erasmus Medical Center; GE = Georgetown University Medi-
cal Center and Albert Einstein College of Medicine; M = MD Anderson Cancer Center; S = Stanford 
University; W = University of Wisconsin and Harvard Medical School. * Projection of relative risk of 
breast cancer death with annual screening from age 40 to 49 y; biennial at age 50 and 52 y versus a 
control group with biennial screening at age 50 and 52 y. Because the models are estimating mortal-
ity reduction with actual screening, model estimates are most comparable to the Age trial results (6) 
among women who actually attended screening. Model results show more benefit than observed in 
the trial because the models assume that 100% of women complied with the trial-specified screening 
schedule. In reality, not all women who were invited attended screening, and among those who at-
tended, many did not attend all scheduled screening rounds. In addition, the models assumed 100% 
receipt of the most effective treatments. † Age trial invitation results (intention to treat): relative risk, 
0.83 (95% CI, 0.66–1.04). Age trial results for women who actually were screened: relative risk, 0.76 
(CI, 0.51–1.01).
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The models closely estimate observed U.S. trends in incidence of invasive disease (top), incidence 
of invasive disease and DCIS (middle)*, and breast cancer–specific mortality (bottom). Using inputs 
for actual dissemination of screening and treatment in the United States, the models all captured 
the major trends in incidence over time. Early increases with the advent of mammography in the 
mid-1980s are seen, followed by a downturn in the 2000s and then a leveling off. The models also 
captured the general shape of decreases in breast cancer–specific mortality over time. All models 
show an increase in incidence with the introduction of mammography screening. Model GE has a 
steep peak in incidence in 2005 owing to the specific method for capturing the transition from plain 
film to digital mammography, because digital mammography has higher sensitivity and detection of 
ductal carcinoma in situ than plain film mammography; other models include a more gradual transi-
tion surrounding this period. D = Dana- Farber Cancer Institute; DCIS = ductal carcinoma in situ; E 
= Erasmus Medical Center; GE = Georgetown University Medical Center and Albert Einstein Col-
lege of Medicine; M = MD Anderson Cancer Center; QALY = quality-adjusted life-year; S = Stanford 
University; SEER = Surveillance, Epidemiology, and End Results; W = University of Wisconsin and 
Harvard Medical School. * Model S does not include DCIS.
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D = Dana-Farber Cancer Institute; E = Erasmus Medical Center; GE = Georgetown University Medi-
cal Center and Albert Einstein College of Medicine; M = MD Anderson Cancer Center; S = Stanford 
University; W = University of Wisconsin and Harvard Medical School. * Model M does not include 
a natural history component. On the basis of a combination of assumptions about underlying inci-
dence trends in the absence of screening, it essentially yields a long lead time for invasive cancer; 
thus, all cancers found with annual screening can also be detected with biennial screening. † Per-
centage of reduction with annual screening in women aged 50-74 y that is maintained by bien-
nial screening in women aged 50-74 y is calculated as the percent mortality reduction with biennial 
screening in women aged 50-74 y divided by the percent mortality reduction with annual screening 
in women aged 50-74 y. § Percentage of reduction with annual screening in women aged 45-74 y 
that is maintained by biennial screening in women aged 45-74 y is calculated as the percent mortality 
reduction with biennial screening in women aged 45-74 y divided by the percent mortality reduction 
with annual screening in women aged 45-74 y. § Percentage of reduction with annual screening in 
women aged 40-74 y that is maintained by biennial screening in women aged 40-74 y is calculated 
as the percent mortality reduction with biennial screening in women aged 40-74 y divided by the 
percent mortality reduction with annual screening in women aged 40-74 y.
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The average gain in life-years per additional mammogram performed per 1000 women for each 
screening strategy (vs. no screening). Biennial strategies are indicated with a square; hybrid strate-
gies (annual in the 40s followed by biennial from 50 to 74 years of age) with a triangle; and annual 
strategies with a circle. Efficient strategies were plotted (those in which increases in mammogra-
phy use resulted in greater life-years gained than the next least-intensive strategy). The line rep-
resents the “efficiency frontier” by joining efficient strategies in which increases in mammography 
use resulted in greater life-years gained than the next less intensive efficient strategy. Strategies on 
this line would be considered efficient because they achieve the greatest gain in benefit (life years 
gained) per harm or use of mammograms. Strategies that use more mammograms but still have 
small benefits (i.e., a shallower slope than the next best strategy) are considered to be less efficient 
(i.e., weakly dominated). When and if the slope in the efficiency frontier plot levels off, it means that 
the additional life-years gained per increase in mammography are small relative to the previous 
strategies and could indicate a point at which additional screening might be considered as having 
a low return (or additional benefit). There is no definitive inflection point across the models for the 
strategies or metrics evaluated. Black strategies are efficient; gray strategies close to the efficiency 
frontier are less efficient; and open gray strategies are inefficient (inferior, or dominated). Reference 
33 provides efficiency frontiers for other harm and benefit metrics. D = Dana-Farber Cancer Institute; 
E = Erasmus Medical Center; GE = Georgetown University Medical Center and Albert Einstein Col-
lege of Medicine; M = MD Anderson Cancer Center; QALY = quality-adjusted life-year; S = Stanford 
University; W = University of Wisconsin and Harvard Medical School.
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abstract
background
Estimates of risk for radiation-induced breast cancer from mammography screening have 
not considered variation in dose exposure or diagnostic work-up after abnormal screen-
ing results.
objective
To estimate distributions of radiation-induced breast cancer incidence and mortality from 
digital mammography screening, considering exposure from screening and diagnostic 
mammography and dose variation across women.
design
Two simulation-modeling approaches.
setting
U.S. population.
patients
Women aged 40-74 years.
interventions
Annual or biennial digital mammography screening from age 40, 45, or 50 years until 
age 74 years.
measurements
Lifetime breast cancer deaths averted (benefits) and radiation-induced breast cancer 
incidence and mortality (harms) per 100,000 women screened.
results
Annual screening of 100,000 women aged 40 to 74 years was projected to induce 
125 breast cancers (95% confidence interval [CI]=88–178) leading to 16 deaths (95% 
CI=11–23) relative to 968 breast cancer deaths averted by early detection from screening. 
Women exposed at the 95th percentile were projected to develop 246 radiation-induced 
breast cancers leading to 32 deaths per 100,000 women. Women with large breasts 
requiring extra views for complete breast examination (8% of population) were projected 
to have higher radiation-induced breast cancer incidence and mortality (266 cancers, 35 
deaths per 100,000 women), compared to women with small or average breasts (113 
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cancers, 15 deaths per 100,000 women). Biennial screening starting at age 50 reduced 
risk of radiation-induced cancers 5-fold.
limitations
Life-years lost from radiation-induced breast cancer could not be estimated.
conclusions
Radiation-induced breast cancer incidence and mortality from digital mammography 
screening are affected by dose variability from screening, resultant diagnostic work-up, 
initiation age, and screening frequency. Women with large breasts may have a greater 
risk for radiation-induced breast cancer. 
funding source
Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force, Na-
tional Cancer Institute.
Primary research and data collection for the American College of Radiology Imaging 
Network (ACRIN) Digital Mammographic Imaging Screening Trial (DMIST) were sup-
ported by the National Cancer Institute (U01 CA80098, U01 CA80098-S1, U01 CA79778, 
and U01 79778-S1).
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introduction
Exposure to ionizing radiation from repeated mammography examinations may increase 
breast cancer risk (1, 2). Radiation-induced breast cancer incidence and mortality associ-
ated with recommended screening strategies are suggested to be low relative to breast 
cancer deaths prevented (3-5). However, prior projected population risks were based on 
exposure from screening only and assumed only four standard views per screen at the 
mean radiation dose. Evaluations of screening programs should consider full episodes of 
care including diagnostic work-up prompted by an abnormal screening result (6). False-
positive recalls, breast biopsies, and short-interval follow-up examinations are relatively 
common in the United States and add radiation exposure from diagnostic mammog-
raphy (7). Some subgroups of women, such as obese women and women with dense 
breasts, are more likely to have additional evaluations (7-9), which may increase their risk 
for radiation-induced cancer.
When risk for radiation-induced breast cancer is being evaluated, it may also be impor-
tant to consider variation in radiation dose from a single examination. Examinations vary 
in the number of views performed and dose per view; therefore, some women receive 
more than the mean dose. The American College of Radiology Imaging Network DMIST 
(Digital Mammographic Imaging Screening Trial) found an average radiation dose to the 
breast of 1.86 mGy to the breast from a single digital mammography screening view 
(10), but dose per view varied widely from 0.15 to 13.4 mGy (Supplemental Content) 
and 21% of digital screening examinations used more than four views (10). Radiation 
dose is strongly correlated with compressed breast thickness; thus, women with large 
breasts women tend to receive higher doses per view and may require more than four 
views for complete examination (10, 11). Women with breast augmentation receive 
implant-displacement views in addition to standard screening views, which doubles their 
radiation dose (12). Woman may have repeated views because of movement artifacts or 
improper breast positioning.
We estimated the distribution of cumulative radiation dose and associated breast 
cancer risk from full screening episodes to identify subgroups of women who may have 
a greater risk for radiation-induced cancer because they have factors contributing to 
greater doses per examination or frequent false-positive screening results that lead to 
additional radiation exposure from subsequent diagnostic work-up. Using population-
based data from the Breast Cancer Surveillance Consortium (BCSC) (13), we estimated 
the probability of a false-positive screening result followed by additional imaging evalua-
tion, short-interval follow-up, or biopsy. We used data from the BCSC, DMIST, and other 
sources in 2 simulation models to estimate radiation exposure and radiation-induced 
breast cancer incidence and mortality associated with 8 potential screening strategies 
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with different starting ages (40, 45, or 50 years) and screening intervals (annual, biennial, 
or a hybrid strategy).
methods
screening strategies
We used 2 complementary stochastic modeling approaches to evaluate the following 8 
strategies for screening with digital mammography:
1. Annual screening from ages 40-74, 45-74, and 50-74 years.
2. Biennial screening from ages 40-74, 45-74, and 50-74 years.
3. Hybrid strategy of annual screening from ages 40-49 or 45-49 and biennial screening 
from ages 50-74 years.
We included the hybrid strategies because more frequent screening has been advocated 
for younger and premenopausal women due to their greater prevalence of dense breasts 
and more aggressive tumors, resulting in a greater risk for interval cancer, than older 
women (14-17). Outcomes were breast cancer deaths averted (benefits) and radiation-
induced breast cancer incidence and mortality (harms) associated with a lifetime of 
mammography screening relative to no screening.
simulation modeling approaches
Figure 1 summarizes our approach. We used 2 complementary stochastic modeling 
approaches to simulate mammography events associated with radiation exposure and 
outcomes for a population adherent with each of the 8 screening strategies. The first ap-
proach used the Microsimulation of Screening Analysis–Fatal Diameter (MISCAN-Fadia) 
model (18), which is a detailed natural history model of breast cancer. This approach 
provided estimates of breast cancer incidence and mortality with and without screening 
to contextualize estimates of radiation-induced breast cancer cases. Although MISCAN-
Fadia models the average effects of screening on a population level, it does not model 
correlation among repeated mammography results in individual women or the specific 
types of work-up after an abnormal screening result; thus, it cannot be used to estimate 
the distribution of cumulative radiation exposure from both screening mammography 
and subsequent diagnostic work-up among women. Therefore, we developed a new 
simulation model that provides woman-level exposure histories that were not available 
from the MISCAN-Fadia model. This new model captures exposure heterogeneity by 
simulating mammography results and subsequent work-up in each woman and allowing 
for variability in radiation exposure and breast size.
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miscan-fadia simulation model
The MISCAN-Fadia microsimulation model simulates individual life histories of women with 
and without breast cancer in the presence and absence of screening from birth to death 
from breast cancer or other causes. The model has been described in detail elsewhere 
(18) and information about the model can be found online (http://cisnet.cancer.gov/); in-
puts and assumptions are described in our report for the draft USPSTF recommendations 
(19). In brief, on the basis of BCSC data on sensitivity of digital mammography screen-
ing, cancer detection rates, and cancer stage at detection, we estimated thresholds at 
which tumors become screen-detectable. Screening sensitivity and specificity depended 
on age, breast density, and screening interval. Breast cancer risk depended on age and 
breast density. The effect of screening on breast cancer natural history was assessed by 
modeling continuous tumor growth, in which tumors detected before they reached their 
fatal diameter were cured and those detected past their fatal diameter led to breast cancer 
death. We assumed that all women received the mean dose per screening examination 
and, if recalled, the mean dose associated with diagnostic work-up after a false-positive 
screening result, both of which were estimated from the radiation exposure model. We 
also projected breast cancer incidence and mortality with and without screening.
radiation exposure simulation model
Full details including approach, data sources, and assumptions are available in the 
Supplemental Content. In brief, for each of the 8 screening strategies, we simulated 
woman-level factors and screening-related events for 100 000 women.
Woman-level factors: Each woman was assigned a compressed breast thickness from 
the DMIST distribution (Supplemental Table 2). Women with a compressed breast 
thickness of 7.5 cm or greater (8% of DMIST population) were assumed to have large 
breasts that required extra views for complete examination. On the basis of distributions 
seen in the BCSC, each woman was assigned a baseline Breast Imaging Reporting and 
Data System (12) density at the start of screening, which could potentially decrease by 1 
category at ages 50 and 65 years (20) (Supplemental Table 4).
Evaluation of a positive screening exam: For each screening strategy, we simulated 
events after a positive screening result that did not lead to a diagnosis of breast cancer 
(Figure 2) to focus on risk for first breast cancer induced by radiation. We modeled the 
probability of each event by using data from digital mammography done at BCSC facili-
ties from 2003 to 2011 on women aged 40 to 74 years without a history of breast cancer 
or cancer diagnosed within 1 year after the examination. At each screening, a woman’s 
probability of recall for additional imaging was based on age, breast density, screening 
interval, prior screening results, and a woman-specific random effect. If recalled, the 
probability of referral to biopsy, short-interval follow-up, or return to routine screening 
was based on age, breast density, and screening interval.
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Radiation dose: For each screening and diagnostic event, we sampled the number of 
screening mammography views from the DMIST distribution (Supplemental Table 1) 
and number of views for diagnostic work-up on the basis of expert opinion, conditional 
on compressed breast thickness (Supplemental Table 3). assumed different distributions 
of views for women with and without large breasts. We randomly sampled the radia-
tion dose per view on the basis of the DMIST distribution conditional on the woman’s 
compressed breast thickness (Supplemental figure 1). For each age, we calculated total 
breast-level dose by multiplying half the number of views of both breasts by the dose 
per view. We report the mean and the 5th, 25th, 75th, and 95th percentiles (to quantify 
exposure leading to increased risk for radiation induced breast cancer) for the number 
of mammography views and associated dose from each screening examination and all 
follow-up mammograms within 1 year of a screening examination Supplemental Table 9.
radiation-induced breast cancer incidence and mortality
We estimated radiation-induced breast cancer incidence using the excess absolute risk 
model from pooled analysis of four cohorts by Preston and colleagues (1), the preferred 
model for estimating radiation-induced breast cancer incidence (2, 21). Details are 
provided in the Supplemental Content. Women in these cohorts received cumulative 
radiation doses of 20 mGy or greater. This level of cumulative radiation exposure is 
reached after 2 to 4 years of mammography screening and diagnostic work-up (Supple-
mental Table 9). This model assumes that excess risk of radiation-induced breast cancer 
increases linearly with increasing radiation dose within the exposure ranges from mam-
mography. In addition, risk decreases with increasing age at exposure, especially after 
Figure 2 Screening mammography process.
Short-interval follow-up (SIFU) examinations included unilateral diagnostic views on the recalled 
breast at 6 mo after the initial SIFU recommendation. The examinations included unilateral diag-
nostic views on the recalled breast plus bilateral routine screening views at 12 and 24 mo after the 
initial SIFU recommendation for women who received annual screening and 24 mo after the initial 
SIFU recommendation for those who received biennial screening. The routine screening views could 
result in recall for additional imaging to work up a new finding, followed by a recommendation for 
another SIFU examination or tissue biopsy.
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age 50 (a surrogate for menopause) and increases with age, the highest incidence of ra-
diation-induced breast cancer late in life. We modeled the latency period for developing 
radiation-induced breast cancer using a logistic function that phases in increased breast 
cancer risk between 4 and 11 years after exposure (21). We estimated radiation-induced 
breast cancer mortality by multiplying radiation-induced breast cancer incidence by the 
age-specific case-fatality rates derived from MISCAN-Fadia and assuming 100% adher-
ence to screening and available treatment. We assumed that breast cancers induced by 
radiation is screen-detected at the same rate as non-induced cancer. We approximated 
Confidence Intervals (CI) by re-estimating risk using the upper and lower 95% CIs for the 
risk coefficient, β, because this uncertainty dominates the uncertainty in estimated risk 
(2, 21).
The MISCAN-Fadia model was programmed in Delphi (Borland). All other analyses 
were done in R, version 3.1.0 (R Foundation for Statistical Computing) and SAS version 
9.4 (SAS Institute).
role of the funding source
This study was funded by the Agency for Healthcare Research and Quality under a con-
tract to support the work of the U.S. Preventive Services Task Force and by the National 
Cancer Institute. Investigators worked with Task Force members and Agency staff to 
develop the scope, analytic framework, and key questions. The funding source had no 
role in model input selection, data synthesis, or data analysis. Agency staff provided proj-
ect oversight and reviewed the report to ensure that the analysis met methodological 
standards. The authors are solely responsible for the content and the decision to submit 
the manuscript for publication.
results
radiation exposure
Most radiation exposure from screening and subsequent diagnostic work-up was due 
to the screening examination (Supplemental Table 9). Diagnostic work-up accounted 
for only 10% of the mean annual radiation dose but 24% of the dose for women with 
exposure at the 95th percentile. On average, women with large breasts were exposed to 
2.3 times more radiation than those with small or average-sized breasts.
radiation-induced breast cancer incidence and breast cancer death
Risk estimates corresponding to mean exposures were similar for the 2 modeling ap-
proaches (Table 1); therefore, we focus on results from the radiation exposure model. 
We projected that annual screening and diagnostic work-up of 100 000 women aged 
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40 to 74 years (35 screening examinations per woman) would induce an average of 125 
breast cancer cases (95% CI, 88 to 178), resulting in 16 deaths (CI, 11 to 23) (Table 1). Risk 
projections varied widely, with 100 000 women exposed at the 5th percentile projected 
to develop 64 radiation-induced cancer cases (CI, 44 to 90), resulting in 8 deaths (CI, 6 
to 12), and 100 000 women exposed at the 95th percentile projected to develop 246 
radiation-induced cases of cancer (CI, 171 to 349), resulting in 32 deaths (CI, 22 to 45). 
Women with large breasts requiring extra views for complete examination had more 
than twice as many cases of radiationinduced breast cancer (mean, 266 cases [CI, 186 to 
380]) and breast cancer deaths (mean, 35 deaths [CI, 24 to 50]) than women with small 
or average-sized breasts (113 breast cancer cases [CI, 79 to 161] and 15 breast cancer 
deaths [CI, 10 to 21]) (Table 2). Starting screening at age 50 years and following a biennial 
Table 1 Comparison of lifetime attributable risks of radiation-induced breast cancer and breast can-
cer death (per 100,000 women) from two modeling approaches.
Screening 
Strategy
MISCAn-Fadia Model   Radiation-Exposure Model
Mean
(95% CI)
Mean
(95% CI)
5th percentile
(95% CI)
95th percentile 
(95% CI)
  Lifetime Attributable Risk of Radiation-Induced Breast Cancer (Per 100,000 Women)
Biennial screening
Ages 50-74 y 28 (20, 40) 27 (19, 38) 13 (9, 19) 55 (39, 78)
Ages 45-74 y 44 (31, 62) 45 (31, 64) 21 (15, 30) 92 (65, 130)
Ages 40-74 y 67 (47, 96) 68 (48, 97) 33 (23, 47) 138 (97, 196)
Hybrid strategy
A45-49 y, B50-74 y 57 (40, 81) 59 (41, 84) 29 (20, 41) 118 (82, 168)
A40-49 y, B50-74 y 101 (71, 143) 89 (62, 126) 44 (31, 62) 177 (125, 251)
Annual screening
Ages 50-74 y 54 (39, 75) 49 (34, 69) 25 (17, 35) 97 (68, 139)
Ages 45-74 y 85 (59, 121) 81 (57, 115) 41 (29, 58) 159 (111, 226)
Ages 40-74 y 129 (90, 183) 125 (88, 178) 64 (44, 90) 246 (171, 349)
Lifetime Attributable Risk of Radiation-Induced Breast Cancer Death (Per 100,000 Women)
Biennial screening
Ages 50-74 y 5 (3, 7) 4 (3, 6) 2 (2, 3) 9 (6, 13)
Ages 45-74 y 8 (5, 11) 8 (5, 11) 4 (3, 5) 16 (11, 22)
Ages 40-74 y 12 (8, 17) 12 (8, 17) 6 (4, 8) 24 (17, 34)
Hybrid strategy
A45-49 y, B50-74 y 10 (7, 14) 10 (7, 14) 5 (3, 7) 20 (14, 29)
A40-49 y, B50-74 y 18 (13, 25) 15 (11, 22) 8 (5, 11) 31 (22, 44)
Annual screening
Ages 50-74 y 7 (5, 10) 7 (5, 9) 3 (2, 5) 13 (9, 19)
Ages 45-74 y 11 (8, 16) 11 (8, 15) 5 (4, 8) 21 (15, 30)
Ages 40-74 y 16 (12, 23)   16 (11, 23) 8 (6, 12) 32 (22, 45)
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strategy (13 screening examinations) greatly reduced risk for radiation-induced breast 
cancer and breast cancer death (Table 1). Compared with annual screening from age 
40 to 74 years, biennial screening from age 50 to 74 years was projected to cause ap-
proximately one fifth of the radiation-induced breast cancer cases (mean, 125 cases [CI, 
88 to 178] vs. 27 cases [CI, 19 to 38] per 100 000 women, respectively, and 266 cases [CI, 
186 to 380] vs. 57 cases [CI, 40 to 82] per 100 000 women with large breasts) (Table 2).
breast cancer deaths averted per radiation-induced cancer:
From the MISCAN-Fadia model, we projected that 16 947 breast cancer cases would 
be diagnosed from age 40 years through death per 100 000 women screened annually 
Table 2 Mean, 5th percentile, and 95th percentile (95% confidence intervals) of lifetime attributable 
risks (per 100,000 women) of radiation-induced breast cancer and breast cancer death, by breast size, 
for different screening strategies.
Screening Strategy Small or average breasts Large breasts
Mean
(95% CI)
5th 
percentile 
(95% CI)
95th 
percentile 
(95% CI)
Mean
(95% CI)
5th 
percentile 
(95% CI)
95th 
percentile 
(95% CI)
  Lifetime Attributable Risk of Radiation-Induced Breast Cancer (Per 100,000 Women)
Biennial screening
Ages 50-74 y 24 (17, 35) 13 (9, 18) 43 (30, 61) 57 (40, 82) 28 (19, 40) 108 (77, 154)
Ages 45-74 y 40 (28, 57) 21 (15, 30) 72 (50, 102) 95 (67, 135) 46 (32, 65) 181 (128, 259)
Ages 40-74 y 61 (43, 87) 33 (23, 46) 107 (76, 152) 144 (100, 205) 71 (49, 101) 266 (188, 384)
Hybrid strategy
A45-49 y, B50-74 y 53 (37, 75) 29 (20, 41) 91 (64, 130) 125 (87, 178) 60 (43, 88) 233 (162, 335)
A40-49 y, B50-74 y 80 (56, 114) 43 (31, 62) 137 (96, 195) 189 (132, 269) 95 (65, 134) 351 (244, 495)
Annual screening
Ages 50-74 y 44 (31, 62) 25 (17, 35) 74 (52, 105) 104 (73, 149) 53 (37, 76) 187 (131, 267)
Ages 45-74 y 73 (51, 103) 40 (28, 57) 122 (85, 174) 173 (121, 245) 88 (62, 126) 315 (221, 445)
Ages 40-74 y 113 (79, 161) 63 (44, 89) 189 (133, 268) 266 (186, 380) 136 (95, 193) 487 (339, 700)
Lifetime Attributable Risk of Radiation-Induced Breast Cancer Death (Per 100,000 Women) 
Biennial screening
Ages 50-74 y 4 (3, 6) 2 (1, 3) 7 (5, 10) 10 (7, 14) 5 (3, 7) 18 (13, 26)
Ages 45-74 y 7 (5, 10) 4 (3, 5) 12 (9, 17) 16 (11, 23) 8 (5, 11) 31 (22, 44)
Ages 40-74 y 11 (7, 15) 6 (4, 8) 19 (13, 26) 25 (17, 35) 12 (8, 17) 46 (33, 67)
Hybrid strategy
A45-49 y, B50-74 y 9 (6, 13) 5 (3, 7) 16 (11, 22) 21 (15, 31) 10 (7, 15) 40 (28, 57)
A40-49 y, B50-74 y 14 (10, 20) 8 (5, 11) 24 (17, 34) 33 (23, 47) 16 (11, 23) 61 (42, 86)
Annual screening
Ages 50-74 y 6 (4, 9) 3 (2, 5) 10 (7, 14) 14 (10, 20) 7 (5, 10) 25 (18, 36)
Ages 45-74 y 10 (7, 14) 5 (4, 8) 16 (11, 23) 23 (16, 33) 12 (8, 17) 42 (29, 59)
Ages 40-74 y 15 (10, 21) 8 (6, 12) 25 (17, 35)   35 (24, 50) 18 (12, 25) 63 (44, 91)
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from age 40 to 74 years (data not shown). The number of breast cancer deaths averted 
ranged from 627 per 100 000 women screened biennially from age 50 to 74 years to 968 
per 100 000 women screened annually from age 40 to 74 years (Table 3). For biennial 
screening from age 50 to 74 years, we projected a mean of 23 breast cancer deaths 
averted for each radiation-induced case of breast cancer (CI, 16 to 33) (5th percentile, 
48; 95th percentile, 11) and 140 breast cancer deaths averted for each radiation induced 
breast cancer death (CI, 98 to 199) (5th percentile, 289; 95th percentile, 68). For annual 
screening from age 40 to 74 years, these ratios were lower, at 8 breast cancer deaths 
Table 2 Mean, 5th percentile, and 95th percentile (95% confidence intervals) of lifetime attributable 
risks (per 100,000 women) of radiation-induced breast cancer and breast cancer death, by breast size, 
for different screening strategies.
Screening 
Strategy
Small or average breasts  
 
Large breasts
Mean
(95% CI)
5th 
percentile 
(95% CI)
95th 
percentile 
(95% CI)
Mean
(95% CI)
5th 
percentile 
(95% CI)
95th 
percentile 
(95% CI)
  Lifetime Attributable Risk of Radiation-Induced Breast Cancer (Per 100,000 Women)
Biennial screening
Ages 50-74 y 24 (17, 35) 13 (9, 18) 43 (30, 61) 57 (40, 82) 28 (19, 40) 108 (77, 154)
Ages 45-74 y 40 (28, 57) 21 (15, 30) 72 (50, 102) 95 (67, 135) 46 (32, 65) 181 (128, 259)
Ages 40-74 y 61 (43, 87) 33 (23, 46) 107 (76, 152) 144 (100, 205) 71 (49, 101) 266 (188, 384)
Hybrid strategy
A45-49 y, B50-74 y 53 (37, 75) 29 (20, 41) 91 (64, 130) 125 (87, 178) 60 (43, 88) 233 (162, 335)
A40-49 y, B50-74 y 80 (56, 114) 43 (31, 62) 137 (96, 195) 189 (132, 269) 95 (65, 134) 351 (244, 495)
Annual screening
Ages 50-74 y 44 (31, 62) 25 (17, 35) 74 (52, 105) 104 (73, 149) 53 (37, 76) 187 (131, 267)
Ages 45-74 y 73 (51, 103) 40 (28, 57) 122 (85, 174) 173 (121, 245) 88 (62, 126) 315 (221, 445)
Ages 40-74 y 113 (79, 161) 63 (44, 89) 189 (133, 268) 266 (186, 380) 136 (95, 193) 487 (339, 700)
Lifetime Attributable Risk of Radiation-Induced Breast Cancer Death (Per 100,000 Women) 
Biennial screening
Ages 50-74 y 4 (3, 6) 2 (1, 3) 7 (5, 10) 10 (7, 14) 5 (3, 7) 18 (13, 26)
Ages 45-74 y 7 (5, 10) 4 (3, 5) 12 (9, 17) 16 (11, 23) 8 (5, 11) 31 (22, 44)
Ages 40-74 y 11 (7, 15) 6 (4, 8) 19 (13, 26) 25 (17, 35) 12 (8, 17) 46 (33, 67)
Hybrid strategy
A45-49 y, B50-74 y 9 (6, 13) 5 (3, 7) 16 (11, 22) 21 (15, 31) 10 (7, 15) 40 (28, 57)
A40-49 y, B50-74 y 14 (10, 20) 8 (5, 11) 24 (17, 34) 33 (23, 47) 16 (11, 23) 61 (42, 86)
Annual screening
Ages 50-74 y 6 (4, 9) 3 (2, 5) 10 (7, 14) 14 (10, 20) 7 (5, 10) 25 (18, 36)
Ages 45-74 y 10 (7, 14) 5 (4, 8) 16 (11, 23) 23 (16, 33) 12 (8, 17) 42 (29, 59)
Ages 40-74 y 15 (10, 21) 8 (6, 12) 25 (17, 35)   35 (24, 50) 18 (12, 25) 63 (44, 91)
CI, confidence interval; y, years; A, annual screening at ages 40-50 or 45-50 and B, biennial screening 
at 50-74 years.
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averted per radiation-induced case of breast cancer (CI, 5 to 11) (5th percentile, 15; 95th 
percentile, 4) and 59 breast cancer deaths averted per radiation-induced breast cancer 
death among all women (CI, 42 to 85) (5th percentile, 117; 95th percentile, 30). For 
annual screening from age 40 to 74 years of women with large breasts, ratios were even 
lower, at 4 breast cancer deaths averted per radiation-induced case of breast cancer (CI, 
3 to 5) and 28 per radiation induced breast cancer death (CI, 20 to 40).
Table 3 Number of breast cancer deaths averted by screening 100,000 women and ratio of number 
of breast cancer deaths averted per number (mean, 5th percentile, and 95th percentile) of radiation-
induced breast cancers and of radiation-induced breast cancer deaths.
Strategy number 
of breast 
cancer deaths 
averted by 
screening
Overall Small or 
average 
breasts
Large 
breasts
Mean
(95% CI)
5th
Percentile
(95% CI)
95th 
Percentile
(95% CI)
Mean
(95% CI)
Mean
(95% CI)
   Ratio of Breast Cancer Deaths Averted per Radiation-Induced Breast Cancer
Biennial screening
Ages 50-74 y 627 23 (16, 33) 48 (34, 69) 11 (8, 16) 26 (18, 37) 11 (8, 16)
Ages 45-74 y 666 15 (10, 21) 31 (22, 45) 7 (5, 10) 17 (12, 24) 7 (5, 10)
Ages 40-74 y 732 11 (8, 15) 22 (16, 32) 5 (4, 8) 12 (8, 17) 5 (4, 7)
Hybrid strategy
A45-49 y, B50-74 y 717 12 (9, 17) 25 (17, 35) 6 (4, 9) 14 (10, 19) 6 (4, 8)
A40-49 y, B50-74 y 780 9 (6, 13) 18 (12, 25) 4 (3, 6) 10 (7, 14) 4 (3, 6)
Annual screening
Ages 50-74 y 819 17 (12, 24) 33 (23, 47) 8 (6, 12) 19 (13, 27) 8 (6, 11)
Ages 45-74 y 907 11 (8, 16) 22 (16, 32) 6 (4, 8) 12 (9, 18) 5 (4, 8)
Ages 40-74 y 968 8 (5, 11) 15 (11, 22) 4 (3, 6) 9 (6, 12) 4 (3, 5)
  Ratio of Breast Cancer Deaths Averted per Radiation-Induced Breast Cancer Death
Biennial screening
Ages 50-74 y 627 140 (98, 199) 289 (203, 415) 68 (48, 97) 155 (109, 221) 66 (46, 93)
Ages 45-74 y 666 87 (61, 125) 184 (130, 263) 43 (30, 60) 97 (68, 139) 41 (29, 59)
Ages 40-74 y 732 62 (44, 89) 128 (90, 183) 31 (22, 44) 69 (48, 98) 29 (21, 42)
Hybrid strategy
A45-49 y, B50-74 y 717 71 (50, 102) 145 (102, 207) 35 (25, 51) 79 (56, 113) 33 (23, 48)
A40-49 y, B50-74 y 780 51 (36, 72) 102 (72, 146) 25 (18, 36) 56 (40, 80) 24 (17, 34)
Annual screening
Ages 50-74 y 819 123 (86, 176) 242 (171, 346) 62 (43, 89) 136 (96, 195) 58 (40, 83)
Ages 45-74 y 907 84 (60, 121) 167 (118, 239) 43 (30, 61) 94 (66, 134) 39 (28, 57)
Ages 40-74 y 968 59 (42, 85) 117 (82, 167) 30 (21, 43)   66 (46, 94) 28 (20, 40)
CI, confidence interval; y, years; A, annual screening at ages 40-50 or 45-50 and B, biennial screening 
at 50-74 years.
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discussion
We improved previous estimates of the potential harms from radiation exposure of 
screening strategies for breast cancer by using methods that more fully represent the 
experience of women who have routine digital screening mammography. Our models in-
cluded radiation exposure from diagnostic evaluations prompted by abnormal screening 
results and incorporated variation in dose at each screening and diagnostic examination. 
In addition to the mean, we reported the 5th and 95th percentiles of the population 
distribution to highlight that some women have risk that is substantially lower or higher 
than average because of variation in radiation exposure. Most of the increased risk was 
due to screening examinations with more than 4 views and higher-than-average doses 
per view. We used DMIST data to model the number of views per screening examination 
and to incorporate the increased radiation dose per view for thicker compressed breasts. 
However, even for a given compressed breast thickness, some women received greater 
doses than others, which was probably due to greater breast density that required more 
radiation for penetration. Because women with large breasts may require more views per 
examination and tend to receive a greater dose per view, breast size was an important 
factor in determining radiation exposure and associated risk. Another reason for greater 
radiation exposure is false-positive results; additional imaging performed to work up 
false-positive results accounted for one fourth of the radiation dose received by women 
at the 95th percentile compared with only one tenth of the radiation dose received by 
women at the mean.
Relative to a projected 16 947 breast cancer cases diagnosed per 100 000 women 
aged 40 years or older with annual screening, we estimate that the number of breast 
cancer cases induced by screening is probably very small, even for women with the 
greatest radiation exposures. However, relative to the number of breast cancer deaths 
averted with screening, radiation induced breast cancer incidence is not trivial. Most 
concerning are numbers projected for annual screening and screening before age 50 
years of women with large breasts requiring extra views for complete examination, who 
have more than twice the risk for radiation induced breast cancer as women with small 
or average-sized breasts. Although we did not model this explicitly, women with breast 
augmentation should also have twice the risk for radiation-induced breast cancer be-
cause they receive implant-displacement views in addition to standard screening views, 
resulting in a minimum of 8 views per examination compared with the standard 4 views 
(12).
The benefit–harm ratio in terms of breast cancer deaths averted per radiation-induced 
case of breast cancer could be improved by initiating screening at age 50 years instead 
of 40 years, thereby reducing risk for radiation-induced breast cancer by 60%, or by using 
biennial screening, which would cut the risk in half compared with annual screening. 
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Doing both (screening biennially from age 50 to 74 years) would reduce the risk almost 
5-fold compared with annual screening from age 40 to 74 years. Several steps should be 
taken to further improve the benefit–harm ratio. Current efforts to reduce the radiation 
dose per view should continue. Radiology staff should strive to minimize the number of 
additional views performed and to reduce false-positive rates, which are much higher in 
the United States than many other countries, suggesting room for improvement (22-25). 
Radiation doses from diagnostic mammography could be avoided for certain screen-
detected masses amenable to ultrasonography work-up alone. In addition, facilities 
should ensure that large breasts are imaged using larger detector sizes to minimize the 
need for extra views for complete examination.
Hendrick (3) also estimated incidence and mortality of radiation-induced breast cancer 
using DMIST data but used the mean dose for 4 views without accounting for additional 
radiation exposure from additional screening views received by 21% of women or from 
diagnostic follow-up imaging. He projected that annual screening of 100 000 women 
from age 40 to 80 years with an examination-level dose of 3.7 mGy would induce 72 
breast cancer cases leading to 20 deaths. For women screened annually from age 40 
to 74 years, we estimated fewer breast cancer deaths (16 deaths per 100 000 women), 
despite more radiation-induced breast cancer cases (125 cases per 100 000 women), 
because we optimistically assumed 100% adherence to the screening regimen and use 
of available treatments. In particular, we assumed that 10% to 19% of women diagnosed 
with breast cancer between ages 40 and 74 years would die of the disease (depending 
on the screening scenario) compared with recent estimates of more than 23% (26). Thus, 
we may have underestimated the number of radiation-induced breast cancer deaths. 
Yaffe and Mainprize (4) projected that screening 100 000 women annually from age 40 to 
55 years and biennially thereafter to age 74 years with a dose of 3.7 mGy would induce 
86 breast cancer cases and 11 deaths. In comparison, we projected that screening 100 
000 women annually from age 40 to 49 years and biennially thereafter to age 74 years 
would induce 89 breast cancer cases and 15 deaths. Our estimates are probably greater 
because we accounted for some screening examinations having more than 4 views and 
for radiation exposure from diagnostic work-up.
Doses from current digital mammography systems may be lower than doses from 
older DMIST units. Nevertheless, DMIST doses may still be conservative because, similar 
to most prior studies, dose estimates assumed breast compositions of 50% glandular 
tissue, which probably underestimates dose by 8% to 18% (27, 28). Although Mammog-
raphy Quality Standards Act inspections suggest that doses for a digital mammography 
view decreased 2.5% between 2007 and 2009 (29), these doses were measured with 
phantoms simulating breasts with a compressed breast thickness at the 30th percentile in 
DMIST. Radiation dose is highly correlated with compressed breast thickness, which may 
increase over time with increasing population body mass index (BMI) (30).
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The use of digital breast tomosynthesis for screening is increasing in the United States 
(31). Doses from breast tomosynthesis vary by the strategy; however, the 3-dimen-
sional acquisition results in a radiation dose similar to or slightly greater than standard 
digital mammography (28, 32, 33). Most U.S. practices offering screening tomosynthesis 
combine it with digital mammography, which at least doubles doses and the risk for 
radiation-induced breast cancer. Software approved by the U.S. Food and Drug Admin-
istration to generate synthetic 2-dimensional views from tomosynthesis acquisitions will 
probably eliminate the need for standard digital mammography views and their associ-
ated radiation exposure (34); however, the rate at which this software will diffuse into 
clinical practice is unknown. Estimating radiation-induced cancer risks associated with 
tomosynthesis screening is further complicated by the expectation that this method will 
decrease recall rates and potentially eliminate the need for diagnostic mammography to 
work up some imaging findings (35-41).
Our study had several limitations. We had inadequate information on the percentage 
of women requiring more than 4 views for complete breast examination. In DMIST, 21% 
of women required more than 4 screening views (10), although most received only 1 or 
2 extra views, probably because of patient movement or poor positioning. On the basis 
of the observed distribution of compressed breast thickness and number of views, we 
assumed that 8% of women received extra views because they had large breasts. Of 
note, the early generation mammography systems used in DMIST had smaller image 
detectors (10). Most modern units have larger detectors; therefore, the percentage of 
women requiring extra views because of large breast size is probably less than 8%.
We could not calculate life-years lost due to radiation-induced breast cancer, which 
may occur later in life than deaths prevented from screening. Because of lack of data, we 
did not model the association between breast size and the probability of a false-positive 
result; thus, we may have underestimated exposure from additional work-up in women 
with large breasts because obese women may be 20% more likely than normal-weight 
women to have false-positive results (9). We also assumed that the number of breast 
cancer deaths averted with screening did not vary by breast size; however, screening 
may prevent more deaths among postmenopausal obese women (who tend to have 
large breasts) because they have a greater risk for advanced disease (42). In addition, 
we did not model the association between breast density and radiation dose per view 
because of lack of representative data. Probabilities for events after screening mam-
mography were based on point estimates from models that used the best available data 
and did not account for uncertainty due to model misspecification or inherent variability 
in parameter estimates. We could not estimate 95% CIs for deaths averted with screen-
ing because of the computational complexity of the MISCAN-Fadia model and because 
many input parameters of the model (such as tumor growth rate) are unobservable and 
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therefore have unknown distributions. We also made several simplifying assumptions 
(supplementary material).
In conclusion, population projections of radiation induced breast cancer incidence and 
mortality from mammography screening are affected by variability in doses from screen-
ing and resultant diagnostic examinations, age at screening initiation, and screening 
frequency. Our study suggests that women with large breasts or breast augmentation 
receive greater radiation doses and may have a greater risk for radiation induced breast 
cancer and breast cancer death. Radiology practices should strive to ensure that large 
breasts are imaged with large detectors with the fewest number of views possible.
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Supplemental Table 1 Comparison of lifetime attributable risks of radiation-induced breast cancer 
and breast cancer death (per 100,000 women) from two modeling approaches
Strategy MISCAn-Fadia Radiation Exposure Model
Mean
(95% CI)
Mean
(95% CI)
  Lifetime Attributable Risk of Breast Cancer (Per 100,000 Women)
Biennial screening
Ages 50-74 y 28 (20, 40) 27 (19, 38)
Ages 45-74 y 44 (31, 62) 45 (31, 64)
Ages 40-74 y 67 (47, 96) 68 (48, 97)
Hybrid strategy
A45-49 y, B50-74 y 57 (40, 81) 59 (41, 84)
A40-49 y, B50-74 y 101 (71, 143) 89 (62, 126)
Annual screening
Ages 50-74 y 54 (39, 75) 49 (34, 69)
Ages 45-74 y 85 (59, 121) 81 (57, 115)
Ages 40-74 y 129 (90, 183) 125 (88, 178)
  Lifetime Attributable Risk of Breast Cancer Death (Per 100,000 Women)
Biennial screening
Ages 50-74 y 5 (3, 7) 4 (3, 6)
Ages 45-74 y 8 (5, 11) 8 (5, 11)
Ages 40-74 y 12 (8, 17) 12 (8, 17)
Hybrid strategy
A45-49 y, B50-74 y 10 (7, 14) 10 (7, 14)
A40-49 y, B50-74 y 18 (13, 25) 15 (11, 22)
Annual screening
Ages 50-74 y 7 (5, 10) 7 (5, 9)
Ages 45-74 y 11 (8, 16) 11 (8, 15)
Ages 40-74 y 16 (12, 23) 16 (11, 23)
CI, confidence interval; y, years; A, annual screening at ages 40-50 or 45-50 and B, biennial screening 
at 50-74 years.
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Supplement. Supplemental Material 
Radiation Exposure Model 
For each screening strategy, we simulated screening-related events for 100,000 women from starting age through 74. For each woman, we: 
1. Randomly sampled breast density, compressed breast thickness, and a woman-specific random effect for false-positive mammogram 
probabilities. Determined breast size from compressed breast thickness. 
2. Randomly sampled screening results and resulting diagnostic events, conditional on age, breast density, current screening interval, prior 
screening results, and the woman-specific random effect. 
3. Randomly sampled number of views per screening examination and, if recalled, diagnostic events, conditional on breast size, and randomly 
sampled breast dose per view conditional on compressed breast thickness. 
4. Summed the number of mammographic views across events and calculated total dose based on sampled dose per view for each year of age. 
5. Estimated radiation-induced breast cancer incidence and mortality through age 100 or death based on total dose at each age. 
Data sources 
Data were from the Breast Cancer Surveillance Consortium (BCSC) and the American College of Radiology Imaging Network (ACRIN) digital 
mammographic imaging screening trial (DMIST). The BCSC (13) (http://breastscreening.cancer.gov) has prospectively collected data including 
patient characteristics and radiology information from community-based facilities since 1994. Characteristics of women are comparable to the 
US population (43). Breast cancer diagnoses and tumor characteristics are obtained by linking to pathology databases; regional Surveillance, 
Epidemiology, and End Results (SEER) programs; and state tumor registries. 
ACRIN DMIST was powered to compare the screening accuracy of digital and screen-film mammography (44, 45). For this paired trial, 
49,528 women provided informed consent to receive both modalities between October 2001 and November 2003. For quality assurance, 
compressed breast thickness, breast dose, and number of additional views performed were recorded on a subset of examinations at 33 sites. 
The ACRIN coordinating center provided the distribution for number of views for 5,021 digital examinations and the joint distribution between 
dose and compressed breast thickness for 19,205 digital mammography views from 4,876 digital examinations. 
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Breast Size, Compressed Breast Thickness, And Number Of Views Per Examination 
We estimated the percentage of women with large breasts based on the number of views and compressed breast thickness observed in DMIST 
(Appendix Tables 1 and 3). Based on expert opinion, we assumed all women with 5 views and a portion of women with 6 views received these 
extra views due to issues with positioning or movement. In contrast, we assumed a portion of women with 6 views and all women with 7 or 
more views received extra views because they had large breasts. To estimate the percentage of women with large breasts, we chose a threshold 
of compressed breast thickness 7.5 cm or larger, consistent with the percentage of women having 6 or more views. This resulted in 8.1% of 
women having large breasts and 35% of examinations with 6 views being performed in women with large breasts. 
DMIST has information only on number of views for screening examinations. For diagnostic examinations and procedure types, we 
obtained the typical number of views from expert opinion of a radiologist who specializes in breast imaging and scaled the distribution for 
screening examinations from DMIST based on the typical number of views for that diagnostic exam or procedure type relative to the typical 
number of screening views. For numbers of rescaled views that were not integers (e.g., 5 views /4 views = 1.3 views), we reassigned women into 
adjacent groups so the resultant mean number of views was unchanged (e.g., for 1.3 views, we assumed 70% received 1 view and 30% received 
2 views). For example, the typical number of screening views is 4 (2 per breast). From DMIST, we estimated that 86% of women without large 
breasts received 4 views, 9% received 5 views, and 5% received 6 views. Typically, two magnification views are used for an additional evaluation 
of a positive screening mammogram. Thus, to calculate the distribution of diagnostic views, we halved the number of views from the screening 
distribution. This resulted in 86% of women receiving 2 views, 9% receiving 2.5 views, and 5% receiving 3 views. We reassigned the 9% of women 
with 2.5 views to half receiving 2 and half receiving 3. This gave a final distribution for number of magnification views of 91% receiving 2 views 
and 9% receiving 3 views. Distributions are in Appendix Table 4. 
Breast density 
We assigned a baseline Breast Imaging-Reporting and Data System (BI-RADS) (12) density at the start of screening according to distributions 
observed in the BCSC (20) (Appendix Table 2). At age 50 and 65 years, we allowed breast density to potentially decrease by one category based 
on transition probabilities that maintain the marginal distributions of density by age (Appendix Table 2). We did not account for the inverse 
relationship between breast density and breast size due to lack of information on the association between event probabilities (i.e., short interval 
follow-up (SIFU) examinations) and breast size. 
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Radiation Dose 
Radiation dose depends on compressed breast thickness, which depends on breast size. For each woman, we sampled a dose per view based on 
the distribution observed in DMIST given her compressed breast thickness (Appendix Figure). Magnification views have higher radiation dose 
than standard mammography views (46, 47); however, only part of the breast is typically irradiated (48). Therefore, we assumed the same dose 
for all views. This assumption is supported by data from Boone, Nosratieh, and Seibert in the 2013 Society for Breast Imaging newsletter 
(http://www.sbi-online.org/NEWS.aspx). For women with large breasts who receive extra views, most glandular tissue is irradiated on all views; 
therefore, summing the doses per view for an exam-specific dose for each breast was reasonable (10, 11). We assumed the total bilateral dose 
per view was half the dose per single breast, as in Law and Faulkner (48). Thus, to calculate the total bilateral dose at each year of age, we 
summed the total number of views on both breasts from screening and associated diagnostic work-up within the following year, and divided in 
half. 
Events following A Positive Screening exam 
Figure 2 in manuscript summarizes possible events following a screening mammogram (12). At each screening mammogram, a woman’s 
probability of recall for additional imaging was based on age, breast density, screening interval, prior screening mammogram results, and a 
woman-specific random effect. If recalled, the probability of referral to biopsy, short interval follow-up (SIFU), or return to routine screening was 
based on age, breast density, and screening interval. Following BI-RADS guidelines (12), women recommended for SIFU received diagnostic 
views at 6, 12, and 24 months after screening mammogram, regardless of screening interval. At each SIFU exam, the probability of a biopsy 
recommendation was based on age and breast density. Women with a SIFU recommendation also continued to receive bilateral screening views 
according to their screening schedule with recall and subsequent follow-up recommendations assigned using the probabilities for all BCSC 
screening exams. A woman assigned to SIFU following recall from screening views restarted the SIFU sequence; otherwise, she continued 
according to her assigned SIFU schedule. Biopsy type was randomly assigned based on BCSC distributions to be fine needle aspiration, core 
biopsy, excisional biopsy, or core and excisional biopsy, based on age and breast density. Fine needle aspirations resulted in no additional 
mammography. For core and excisional biopsies, we randomly assigned ultrasound or stereotactic guidance based on proportions observed in 
BCSC. Women returned to routine screening following a benign biopsy based on suggestions that 6-month follow-up imaging after biopsy has no 
benefit (49). 
We modeled the probability of events following a screening mammogram using BCSC data. We included digital mammograms of women 
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aged 40-74 without a history of breast cancer or cancer diagnosed within 1 year after the exam and without breast augmentation. Most analyses 
included mammograms conducted from 2003 to 2011 with at least one year of complete cancer capture available following the screening exam. 
Mammograms were classified as screening or SIFU based on the indication given by the radiologist or technologist. For screening mammograms, 
we excluded unilateral exams and exams performed less than 9 months after a prior mammogram or breast ultrasound exam to avoid 
misclassifying diagnostic exams as screens. Screening mammograms were classified as annual exams if the previous mammogram was 9–18 
months prior and as biennial if 19–30 months prior. We excluded screening mammograms conducted more than 30 months after a prior 
mammogram because we were interested in estimating events in annual and biennial screeners. 
To estimate the recall rates for additional imaging, we included 613,797 digital screening mammograms with sufficient information on 
prior false-positive results. We defined a recall based on a positive initial BI-RADS assessment (12, 50). We estimated the probability of being 
recalled for additional views on a screening mammogram using logistic regression including age at exam; BI-RADS breast density; mammogram 
number (first, second, or third or more); and screening interval for subsequent screens (annual vs. biennial). For second exams, we also included 
the prior screening result and for third or subsequent exams, we included the prior two screening results. We included a woman-specific random 
effect to allow for additional correlation of recall across a woman’s entire screening regimen and report results for a random effect of 0, 
corresponding to median rates. Results are in Supplement Table 1. To evaluate the model fit, we compared results to prior estimates of 
cumulative false-positive rates after 10 rounds of screening using a different method (51) and got similar results. 
To estimate the probability of events following an abnormal mammogram, we included 725,433 digital mammograms with information 
on the specific type of recommendation at the end of all imaging work-up. We estimated the probability of recommended follow-up (either 
return to routine screening, SIFU, or biopsy) after recalled screening mammogram using multinomial logistic regression including age at exam, 
BI-RADS breast density, and screening interval as predictors. Results are in Supplement Table 2. 
We estimated the probability of a biopsy recommendation following a SIFU exam using 21,124 SIFU exams. We classified exams as 
having a biopsy recommendation based on the final BI-RADS assessment and recommendations at the end of all imaging work-up. We fit a 
logistic regression model including BI-RADS density and age at exam as predictors. Results are in Supplement Table 3. 
To estimate the distribution for type of biopsy following a positive screening mammogram or SIFU exam, we included 2,284 women with 
biopsies within 100 days following a positive screening or SIFU conducted in the most recent years available (2010 and 2011), because use of 
core biopsy instead of excisional biopsy has increased over time. We grouped biopsy events as core biopsy (no excisional, may also include fine 
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needle aspirations), excisional biopsy (no core biopsy, may also include fine needle aspirations), core and excisional (may also include fine needle 
aspirations), and fine needle aspiration only. We modeled biopsy type using multinomial logistic regression, including BI-RADS density and age at 
mammogram as predictors. To estimate the type of biopsy guidance distributions, we selected all biopsies within 100 days of a positive final 
assessment of a screening or SIFU mammogram. Given inconsistencies in excisional biopsy guidance records, we limited our data to core 
biopsies only and calculated the proportion of ultrasound and stereotactic biopsies in this sample. Results are in Supplement Table 4. 
Simplifying Assumptions 
Radiation dose depends on the mammography machine used (10), but we could not include this factor in our modeling due to lack of data. 
Estimates of the U.S. distribution of manufacturers are protected market share information. However, the majority of digital machines used by 
BCSC facilities are Hologic, which had the highest dose per view but the fewest exams with more than 4 views in DMIST (10). The majority of 
machines used in DMIST were not Hologic. Thus, if the BCSC is reflective of the U.S., we would likely have underestimated dose for women with 
small or average breasts but may have overestimated dose for women with large breasts because they would be less likely to need extra views 
for complete breast examination. We may have slightly underestimated dose due to diagnostic imaging for several reasons. Our estimates of the 
number of views used for diagnostic evaluations may be conservative, because we assumed that every abnormal screening examination 
identified only one finding needing diagnostic views and we did not include repeat whole breast views. Also, the chance of repeat images is likely 
higher for diagnostic spot magnification views for subtle calcifications or masses, and for large-breasted women. In these instances, the 
technologist may require several images to position small or subtle findings within the field of view. Moreover, magnification spot views require 
greater exposure time for optimal image resolution, making patient movement more likely. 
Radiation-Induced Breast Cancer Incidence And Mortality 
The incidence of radiation-induced breast cancer was modeled using the excess absolute risk model from pooled analysis of four cohorts by 
Preston et al.(1), the preferred model for estimating radiation-induced breast cancers (2, 21). The model formula from page 234 of Preston et al. 
(1) is 
𝛽𝛽𝛽𝛽𝛽𝛽𝛽𝛽exp(𝑎𝑎𝑎𝑎/50)𝜂𝜂𝜂𝜂 
where β is the risk coefficient per 10,000 person years-Gy, estimated as 10 with 95% confidence interval (CI) 7.0–14.2. D is dose in Gy, e is age at 
exposure; a is attained age; and η is 3.5 for a ≤ 50 and 1.0 otherwise. Similar to Berrington et al. (21), we modeled the latency period for 
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developing radiation-induced breast cancer using a logistic function with shape parameter 0.75, which phases in increased breast cancer risk 
between 4 and 11 years after exposure. We did not apply a dose and dose-rate effectiveness factor (2) because the Preston 2002 model (1) 
included data from two cohorts with radiation exposures from high-dose-rate X-rays similar to those used for mammography screening. Also, 
Preston et al. (1) found no evidence that fractionated exposures result in lower breast cancer risk than acute exposures. We adjusted for 
competing causes of death using US general population life tables for women (52). Radiation-induced breast cancer mortality was estimated by 
multiplying radiation-induced breast cancer incidence by the non-radiation induced breast cancer age-specific case-fatality rates derived from 
MISCAN-Fadia assuming 100% adherence to screening and current treatment. We assumed that breast cancers induced by radiation are screen 
detected at the same rate as non-induced cancers. Uncertainty ranges were estimated by re-estimating radiation-induced breast cancer risk 
using the upper and lower 95% CIs for the risk coefficient, β, given this uncertainty dominates the uncertainty in estimated risk (2, 21). 
Supplemental Results 
From the radiation exposure model simulation results, women who obtained screening annually from ages 40-74 years received an average of 
5.0 mammography views (5th percentile=4 views, 95th percentile=9 views) and a dose of 4.8 mGy (5th percentile=2.3 views, 95th 
percentile=10.7 mGy) from each screening exam and all diagnostic work-up prompted by that screen within a 1-year period (Appendix Table 5). 
The mean dose from screening views was 4.3 mGy (5th percentile=2.2 views, 95th percentile=8.3 mGy), and the mean dose from all diagnostic 
work-up among women with a false-positive screen was 4.5 mGy (5th percentile=1.7 views, 95th percentile=10.7 mGy). Women with large 
breasts undergoing annual screening received a mean of 8.4 views (5th percentile=6.0 views, 95th percentile=14.0) and mean dose of 10.0 mGy 
(5th percentile=4.6 views, 95th percentile=20.8 mGy) from each screening exam plus all diagnostic work-up prompted by that screen, compared 
to 4.7 views (5th percentile=4 views, 95th percentile=8 views) and 4.3 mGy (5th percentile=2.2 mGy, 95th percentile=8.4 mGy) for women 
without large breasts. 
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Supplement Table 1. Probability of a false-positive recall (median and interquartile range) by age, BI-RADS breast density, screening round, and prior 
screening results among women aged 40-74 years with digital mammography from 2003-2011 and no cancer diagnosis within 1-year follow-up period, 
estimated from the Breast Cancer Surveillance Consortium. 
   Screening Schedule = Annual Screening Schedule = Biennial 
Screening round and prior 
screening results 
Age, 
years 
Almost 
entirely fat 
Scattered 
fibro. 
densities 
Hetero. 
dense 
Extremely 
dense 
Almost 
entirely fat 
Scattered 
fibro. 
densities 
Hetero. 
dense 
Extremely 
dense 
  Probability of False-Positive Screening Mammogram, Median (Interquartile Range) 
Round 1 40-44 13 (8,20)% 19 (12,29)% 23 (15,35)% 19 (12,28)% 13 (8,20)% 19 (12,29)% 23 (15,35)% 19 (12,28)% 
 
45-49 18 (11,28)% 27 (18,39)% 32 (21,45)% 26 (17,38)% 18 (11,28)% 27 (18,39)% 32 (21,45)% 26 (17,38)% 
 
50-54 15 (9,23)% 22 (14,33)% 27 (17,39)% 21 (14,32)% 15 (9,23)% 22 (14,33)% 27 (17,39)% 21 (14,32)% 
Round 2  
           No prior FP 40-49 7 (4,11)% 11 (6,17)% 13 (8,21)% 10 (6,16)% 7 (4,12)% 12 (7,18)% 14 (9,22)% 11 (7,18)% 
 
50-59 5 (3,9)% 9 (5,14)% 11 (7,17)% 8 (5,14)% 6 (3,10)% 9 (6,15)% 12 (7,19)% 9 (5,15)% 
 
60-74 5 (3,8)% 8 (5,13)% 10 (6,16)% 7 (4,12)% 5 (3,9)% 8 (5,14)% 10 (6,17)% 8 (5,13)% 
  Prior FP 40-49 6 (4,10)% 10 (6,16)% 12 (7,19)% 9 (6,15)% 7 (4,11)% 11 (6,17)% 13 (8,21)% 10 (6,16)% 
 
50-59 5 (3,8)% 8 (5,13)% 10 (6,16)% 8 (5,12)% 5 (3,9)% 9 (5,14)% 11 (6,17)% 8 (5,13)% 
 
60-74 4 (3,7)% 7 (4,11)% 9 (5,14)% 7 (4,11)% 5 (3,8)% 8 (4,12)% 9 (6,15)% 7 (4,12)% 
Round 3+ 
           Past two results TNs 40-49 5 (3,8)% 8 (5,13)% 10 (6,16)% 7 (4,12)% 5 (3,9)% 8 (5,14)% 10 (6,17)% 8 (5,13)% 
 
50-59 4 (2,6)% 6 (4,10)% 8 (5,13)% 6 (3,10)% 4 (2,7)% 7 (4,11)% 8 (5,14)% 6 (4,11)% 
 
60-74 3 (2,6)% 5 (3,9)% 7 (4,11)% 5 (3,9)% 4 (2,6)% 6 (3,10)% 7 (4,12)% 6 (3,9)% 
  Past two results TN then FP 40-49 6 (4,10)% 10 (6,16)% 12 (7,20)% 9 (6,15)% 7 (4,11)% 11 (6,17)% 13 (8,21)% 10 (6,16)% 
 
50-59 5 (3,8)% 8 (5,13)% 10 (6,16)% 8 (5,13)% 5 (3,9)% 9 (5,14)% 11 (7,17)% 8 (5,14)% 
 
60-74 4 (3,7)% 7 (4,12)% 9 (5,14)% 7 (4,11)% 5 (3,8)% 8 (5,13)% 10 (6,16)% 7 (4,12)% 
  Past two results FP then TN 40-49 6 (4,10)% 10 (6,16)% 12 (7,20)% 9 (6,15)% 7 (4,11)% 11 (6,17)% 13 (8,21)% 10 (6,16)% 
 
50-59 5 (3,8)% 8 (5,13)% 10 (6,16)% 8 (5,13)% 5 (3,9)% 9 (5,14)% 11 (7,17)% 8 (5,13)% 
 
60-74 4 (3,7)% 7 (4,12)% 9 (5,14)% 7 (4,11)% 5 (3,8)% 8 (5,12)% 10 (6,15)% 7 (4,12)% 
  Past two results FPs 40-49 18 (11,27)% 26 (17,38)% 31 (21,44)% 25 (16,37)% 19 (12,29)% 28 (18,40)% 33 (22,46)% 27 (18,39)% 
 
50-59 14 (9,23)% 22 (14,33)% 27 (17,39)% 21 (13,32)% 16 (10,24)% 24 (15,35)% 28 (19,41)% 23 (14,34)% 
  60-74 13 (8,20)% 20 (12,30)% 24 (15,35)% 19 (12,29)% 14 (8,22)% 21 (13,32)% 26 (17,37)% 20 (13,31)% 
BI-RADS = Breast Imaging Reporting and Data Systems; FP, false positive; Fibro = fibroglandular; Hetero = heterogeneously 
Estimates are based on a mixed effects logistic regression model, and the interquartile range reflects heterogeneity among women based on quartiles of the 
woman-specific random effect distribution. 
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Supplement Table 2. Probability of subsequent events given a false-positive recall, by age and BI-RADS breast density, among 
women aged 40-74 years with digital mammography from 2003-2011 and no cancer diagnosis within 1-year follow-up period, 
estimated from the Breast Cancer Surveillance Consortium. 
   Screening Schedule = Annual Screening Schedule = Biennial 
 
Age, 
years 
Almost 
entirely fat 
Scattered 
fibro. 
densities 
Hetero. 
dense 
Extremely 
dense 
Almost 
entirely fat 
Scattered 
fibro. 
densities 
Hetero. 
dense 
Extremely 
dense 
Recommendation after false-positive screening mammogram  
  Return to normal interval follow-up 
    Round 1 40-44 52% 56% 55% 50% 52% 56% 55% 50% 
 
45-49 43% 47% 46% 41% 43% 47% 46% 41% 
 
50-54 46% 50% 49% 43% 46% 50% 49% 43% 
    Round 2+ 40-49 69% 72% 72% 67% 64% 68% 67% 62% 
 
50-59 66% 70% 69% 64% 61% 65% 64% 58% 
 
60-74 66% 70% 69% 64% 61% 65% 64% 59% 
Short interval follow-up 
     Round 1 40-44 32% 30% 29% 29% 32% 30% 29% 29% 
 
45-49 38% 36% 34% 34% 38% 36% 34% 34% 
 
50-54 29% 28% 26% 26% 29% 28% 26% 26% 
    Round 2+ 40-49 20% 19% 18% 19% 23% 21% 20% 21% 
 
50-59 21% 20% 19% 20% 24% 22% 21% 22% 
 
60-74 22% 20% 19% 20% 24% 22% 21% 22% 
  Biopsy 
             Round 1 40-49 16% 14% 16% 21% 16% 14% 16% 21% 
 
50-59 19% 17% 20% 25% 19% 17% 20% 25% 
 
60-74 25% 22% 25% 31% 25% 22% 25% 31% 
    Round 2+ 40-49 11% 9% 10% 14% 13% 11% 13% 17% 
 
50-59 12% 11% 12% 16% 15% 13% 15% 20% 
  60-74 12% 10% 12% 16% 15% 13% 15% 19% 
BI-RADS = Breast Imaging Reporting and Data Systems; FP = false positive; Fibro = fibroglandular; Hetero = heterogeneously 
Due to rounding, some percentages may not add to 100%. 
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Supplement Table 2. Probability of subsequent events given a false-positive recall, by age and BI-RADS breast density, among 
women aged 40-74 years with digital mammography from 2003-2011 and no cancer diagnosis within 1-year follow-up period, 
estimated from the Breast Cancer Surveillance Consortium. 
   Screening Schedule = Annual Screening Schedule = Biennial 
 
Age, 
years 
Almost 
entirely fat 
Scattered 
fibro. 
densities 
Hetero. 
dense 
Extremely 
dense 
Almost 
entirely fat 
Scattered 
fibro. 
densities 
Hetero. 
dense 
Extremely 
dense 
Recommendation after false-positive screening mammogram  
  Return to normal interval follow-up 
    Round 1 40-44 52% 56% 55% 50% 52% 56% 55% 50% 
 
45-49 43% 47% 46% 41% 43% 47% 46% 41% 
 
50-54 46% 50% 49% 43% 46% 50% 49% 43% 
    Round 2+ 40-49 69% 72% 72% 67% 64% 68% 67% 62% 
 
50-59 66% 70% 69% 64% 61% 65% 64% 58% 
 
60-74 66% 70% 69% 64% 61% 65% 64% 59% 
Short interval follow-up 
     Round 1 40-44 32% 30% 29% 29% 32% 30% 29% 29% 
 
45-49 38% 36% 34% 34% 38% 36% 34% 34% 
 
50-54 29% 28% 26% 26% 29% 28% 26% 26% 
    Round 2+ 40-49 20% 19% 18% 19% 23% 21% 20% 21% 
 
50-59 21% 20% 19% 20% 24% 22% 21% 22% 
 
60-74 22% 20% 19% 20% 24% 22% 21% 22% 
  Biopsy 
             Round 1 40-49 16% 14% 16% 21% 16% 14% 16% 21% 
 
50-59 19% 17% 20% 25% 19% 17% 20% 25% 
 
60-74 25% 22% 25% 31% 25% 22% 25% 31% 
    Round 2+ 40-49 11% 9% 10% 14% 13% 11% 13% 17% 
 
50-59 12% 11% 12% 16% 15% 13% 15% 20% 
  60-74 12% 10% 12% 16% 15% 13% 15% 19% 
BI-RADS = Breast Imaging Reporting and Data Systems; FP = false positive; Fibro = fibroglandular; Hetero = heterogeneously 
Due to rounding, some percentages may not add to 100%. 
 
 
Supplement Table 3. Probability of a biopsy at a short-
interval follow-up (SIFU) exam among women aged 40-74 
years with SIFU exam from 2003-2011 and no cancer 
diagnosis within 1-year follow-up period, estimated from 
the Breast Cancer Surveillance Consortium. 
BI-RADS breast density 
Age, 
years 
Probability 
of biopsy at 
SIFU exam 
Almost entirely fat 40-49 2.8% 
 50-59 2.9% 
 60-74 2.9% 
Scattered fibro. densities 40-49 3.3% 
 50-59 3.5% 
 60-74 3.4% 
Heterogeneously dense 40-49 5.0% 
 50-59 5.2% 
 60-74 5.2% 
Extremely dense 40-49 6.2% 
 50-59 6.6% 
  60-74 6.5% 
BI-RADS = Breast Imaging Reporting and Data Systems;  
SIFU = short interval follow-up; Fibro = fibroglandular   
222 Chapter 8
 
Supplement Table 4. Distribution of type of biopsy, by BI-RADS breast density and age, among 
women aged 40-74 years with a biopsy recommendation from a digital mammography 
examination from 2003-2011 and no cancer diagnosis within 1-year follow-up period, 
estimated from the Breast Cancer Surveillance Consortium. 
  
Type of biopsy (row %) 
BI-RADS Density 
Age, 
years Core Excisional 
Core + 
excisional 
Fine needle 
aspiration only 
Almost entirely fat 40-49 71% 3% 3% 23% 
 50-59 70% 3% 3% 24% 
 60-74 71% 3% 5% 21% 
Scattered fibro. densities 40-49 73% 9% 5% 13% 
 50-59 74% 7% 5% 14% 
 60-74 73% 8% 7% 13% 
Heterogeneously dense 40-49 74% 10% 6% 10% 
 50-59 75% 8% 6% 11% 
 60-74 73% 8% 9% 9% 
Extremely dense 40-49 72% 13% 6% 9% 
 50-59 73% 11% 6% 9% 
  60-74 71% 12% 9% 8% 
BI-RADS = Breast Imaging Reporting and Data Systems; Fibro = fibroglandular  
Due to rounding, some percentages may not add to 100%. 
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abstract
background
Biennial screening is generally recommended for average-risk women aged 50 to 74 
years, but tailored screening may provide greater benefits.
objective
To estimate outcomes for various screening intervals after age 50 based on breast density 
and risk for breast cancer.
design
Collaborative simulation modeling using national incidence, breast density, and screen-
ing performance data.
setting
United States
patients
Women aged 50 years or older with various combinations of breast density and relative 
risk (RR) of 1.0, 1.3, 2.0, or 4.0.
interventions
Annual, biennial, or triennial digital mammography screening from ages 50 to 74 years 
(vs. no screening) and ages 65 to 74 years (vs. biennial digital mammography from ages 
50 to 64 years)
measurements
Lifetime breast cancer deaths, life expectancy and quality-adjusted life-years (QALYs), 
false-positive mammograms, benign biopsy results, overdiagnosis, cost-effectiveness, 
and ratio of false-positive results to breast cancer deaths averted
results
Screening benefits and overdiagnosis increase with breast density and RR. False-positive 
mammograms and benign results on biopsy decrease with increasing risk. Among 
women with fatty breasts or scattered fibroglandular density and an RR of 1.0 or 1.3, 
breast cancer deaths averted were similar for triennial versus biennial screening for both 
age groups (50 to 74 years, median of 3.4 to 5.1 vs. 4.1 to 6.5 deaths averted; 65 to 74 
years, median of 1.5 to 2.1 vs. 1.8 to 2.6 deaths averted). Breast cancer deaths averted 
increased with annual versus biennial screening for women aged 50 to 74 years at all 
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levels of breast density and an RR of 4.0, and those aged 65 to 74 years with heteroge-
neously or extremely dense breasts and an RR of 4.0. However, harms were almost 2-fold 
higher. Triennial screening for the average-risk subgroup and annual screening for the 
highest-risk subgroup cost less than $100 000 per QALY gained
limitations
Models did not consider women younger than 50 years, those with an RR less than 1, or 
other imaging methods.
conclusions
Average-risk women with low breast density undergoing triennial screening and higher-
risk women with high breast density receiving annual screening will maintain a similar 
or better balance of benefits and harms than average-risk women receiving biennial 
screening.
primary funding source
National Cancer Institute
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introduction
Debate surrounding breast cancer screening for women in their 40s continues; however, 
there is a greater consensus about U.S. guidelines for average-risk women 50 or older 
(1, 2), with groups now recommending biennial mammography from ages 50 or 55 to 74 
years (3, 4). Biennial screening is supported by clinical trials (5, 6), observational studies 
(5, 7), and modeling results (8). Present recommendations also acknowledge that imple-
menting screening in clinical practice should involve shared decision making to consider 
preferences, risk levels, and breast density (3, 4). However, data to guide clinicians and 
women in making personalized decisions about screening intervals based on such factors 
are limited.
Observational data (7, 9) and modeling studies (10, 11) suggest that annual screening 
may be more effective than biennial screening for women at high risk for breast cancer 
due to dense breasts and other risk factors, further, triennial screening may retain most 
of the benefit of biennial screening but may be less harmful and more cost-effective for 
low-risk women with low density. However, past empirical research on alternative screen-
ing intervals did not include mortality outcomes (12). Moreover, most prior modeling 
studies have relied on single models (10, 11), data on film-screen mammography and 
older treatment regimens (10, 11, 13), and did not consider changes in breast density as 
women age (10), or triennial intervals (8).
To fill this gap, the Cancer Intervention and Surveillance Modeling Network (14) 
collaborating with the Breast Cancer Surveillance Consortium (BCSC) (a longstanding 
network of 6 U.S. breast imaging registries with links to tumor and pathology registries 
(15)), used 3 well-established models to evaluate various screening intervals for digital 
mammography among subgroups of women based on age, risk, and breast density. 
Outcomes were projected for women aged 50 (or 65) years who were deciding whether 
to initiate (or continue) biennial screening until age 74 years or to have annual or triennial 
screening. Study results are intended to inform discussions about implementing tailored 
breast cancer screening intervals to maximize screening benefits while minimizing harms.
methods
overview of breast cancer screening strategies
The study included the following 3 microsimulation models: Model E (Erasmus Medical 
Center, Rotterdam, Netherlands), Model GE (Georgetown University Medical Center, 
Washington, DC; and Albert Einstein College of Medicine, Bronx, New York), and Model 
W (University of Wisconsin–Madison, Madison, Wisconsin; and Harvard Medical School, 
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Boston, Massachusetts). These models were either exempt from human subjects review 
or approved by review boards at each institution.
The models used a lifetime horizon to evaluate screening strategies for 2 populations, 
women aged 50 years who were starting screening for the first time and those aged 65 
years who had received biennial screening from ages 50 to 64 years. We selected these 
populations because there is a consensus on screening women in their 50s and because 
at age 65 years, increases in competing mortality risks and decreases in breast density 
might alter the balance of benefits and harms.
Strategies for each age group varied by screening interval (annual, biennial, and trien-
nial) and were compared with no screening. These intervals were applied to population 
subgroups based on combinations of the following 4 breast density levels, as defined by 
the American College of Radiology’s Breast Imaging Reporting and Data System: almost 
entirely fat (“a”), scattered fibroglandular density (“b”), heterogeneously dense (“c”), or 
extremely dense (“d”) (16)], and 4 exemplar relative risk (RR) levels, which incorporated 
risk factors other than breast density. These levels represent common risk factors consid-
ered alone or in combination: 1.0 (average), 1.3 (for example, postmenopausal obesity) 
(17-27), 2.0 (for example, history of benign breast biopsy results), and 4.0 (history of 
lobular carcinoma in situ) (25-29) (Appendix Table 1). Populations with risk suggestive 
of mutations in breast cancer susceptibility genes 1 and 2 were not included in these 
analyses.
model overview
The models shared common inputs but used different structures and underlying assump-
tions (Appendix Table 2) (8, 14). They started with estimates of age-specific breast can-
cer incidence (31) and survival trends specific to breast cancer stage, estrogen receptor 
(ER) status, and human epidermal growth factor receptor 2 (HER2) status (30) all without 
screening or adjuvant treatment. Incidence in the absence of screening was calibrated 
from an age–period–cohort model that accounted for changes in underlying risk (for 
example, secular patterns in postmenopausal hormone use) (31). Tumors had a range 
of preclinical periods during which they could be detected by screening (that is, sojourn 
times). Data on screening and ER/HER2-specific adjuvant treatment were added to gen-
erate breast cancer–specific incidence and mortality (14). Models have been validated 
using data from the U.K. Age trial During the preclinical detectable period, screening 
could result in the identification and treatment of earlier-stage or smaller tumors and 
lead to a reduction in breast cancer mortality reduction (Appendix Figure 1). All models 
assumed that a portion of ductal carcinoma in situ lesions was non-progressive and 
nonlethal; model W also considered that some types of small invasive cancer would not 
progress.
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model input parameters
The models used a common set of age-specific variables for population demographics 
(32), breast cancer natural history and risk (30, 31, 33-36), digital mammography (37, 38), 
breast density, treatment (39-41), mortality (30), costs (42, 43), and quality of life (Table 1 
and Appendix Table 2) (14, 44-46). Each model also included parameters to represent 
preclinical detectable times, lead time, and age- and ER/HER2-specific stage distribution 
in screen- versus non–screendetected cancer based on each model’s specific structure. 
These model-specific parameters were based on assumptions about combinations of 
values that reproduced U.S. trends in breast cancer incidence and breast cancer–specific 
mortality from 1975 to 2010 in the SEER (Surveillance, Epidemiology, and End Results) 
program (47). To isolate the effect of various screening strategies, all models assumed 
100% adherence to screening and receipt of the most effective treatment. The population 
included women born in 1970 and followed until death. This birth cohort was chosen be-
cause these women experience modern conditions (for example, digital mammography 
performance, treatment effectiveness, and competing mortality) and for consistency with 
recent collaborative modeling reports (8). In each simulation, subgroups of women were 
followed from age 25 years until death or age 100 years. Subgroups were defined on the 
basis of combinations of 4 RR levels (1.0, 1.3, 2.0, and 4.0) and 4 breast density levels, 
with the combination of breast density levels and other factors treated multiplicatively. 
The risk level modified the underlying breast cancer incidence in the absence of screen-
ing. We assumed that risk level was constant over age and did not affect other model 
parameters. Women were assigned to either the same breast density category or the 
next lower category at ages 50 and 65 years based on observed age-specific prevalence 
in the BCSC(27, 48). Density also affected mammography performance (Table 1 and 
Appendix Table 3).
Digital mammography sensitivity and specificity were based on age, initial or subse-
quent screening, screening interval, and breast density using BCSC data (Table 1 and 
Appendix Table 3). Models GE and W used these data for calibration, and model E 
fit estimates from the BCSC and other sources Specificity data were used to estimate 
rates of false-positive mammograms. The BCSC rates of biopsy recommendations were 
applied to these estimates to calculate the number of benign biopsy results. Treatment 
effectiveness was based on clinical trials and modeled as a reduction in mortality risk 
(model GE) or an increase in the proportion cured (models E and W) compared with age-, 
stage-, and ER/HER2- specific survival in the absence of therapy (39). Women died of 
either breast cancer or other causes.
screening outcomes
Primary outcomes were lifetime benefits and harms; secondary outcomes were use of 
services and costs. Benefits included breast cancer deaths averted and life-years and 
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Table 1 Model Input Parameters
Parameter Description Data Source
Population Demographics
Birth cohorts 1970 birth cohort (32)
natural History of Breast Cancer
Incidence in the 
absence of screening
An age-period-cohort model is used as a starting point for 
calibration to observed SEER Program rates.
(31)
Stage distribution Stage distribution among clinically-detected and digital screen-
detected women by age group (<50, 50–64, ≥65 years), screening 
round (first, subsequent), and screening interval (annual, biennial, 
triennial).
BCSC data from 
1994–2013 (digital 
from 2003–2013)
ER/HER2 joint 
distribution
Probability of ER/HER2 conditional on age and stage at 
diagnosis.
BCSC
Sojourn time Sojourn time by joint ER/HER2 status and age. (30)
Mean stage dwell 
time/tumor growth 
rates
Varies by models; can vary by age and/or ER/HER2 status. (33-35)
Breast Cancer Screening
Mammography use Assume all women are screened by digital mammography. (37, 38)
Sensitivity/
detection rates of 
digital screening
Sensitivity of initial and subsequent digital mammography by age 
group, screening interval (annual, biennial, triennial), and breast 
density. See Appendix Table 3.
BCSC
Specificity False-positive mammograms are calculated as the difference 
between the overall number of positive mammograms in a 
screening scenario minus the number of positive mammograms 
among breast cancer cases.
BCSC
Prevalence of breast 
density
Prevalence of breast density (BI-RADS a, b, c, d) by age group. 
Density is assigned at age 40 years and can decrease by one level 
or remain the same at age 50 years and again at age 65 years.
BCSC
Risk levels for density Risk of breast cancer based on BI-RADS relative to average 
density by age group.
BCSC
Risk levels for factors 
other than density
RR=1 is used at the referent for average population. RR=1.3, 2.0, 
and 4.0 are used as levels associated with common risk factors.
(36)
Breast Cancer Treatment
Treatment use Assume receipt of and adherence to the most effective available 
treatment specific to age, stage and ER/HER2 status.
1997–2010 (40, 41)
Treatment effects Meta-analyses of clinical trial results. (39)
Survival
Breast cancer survival 26-year breast cancer survival before adjuvant treatment by joint 
ER/HER2 status, age group, and AJCC/SEER stage or tumor size
(30)
Non-breast cancer 
mortality
Age- and cohort-specific all-cause mortality rates by year. Vanness D, Personal 
communication, 2015
Costs
Screening 
mammogram
$138.28 Medicare 
reimbursement
Work-up after false-
positive mammogram
Imaging costs: $141.42 (all ages). Biopsy costs by age: $1,354.05 
for ages 50-64; $1,361.39 for ages 65-74; and $1,442.19 for ages 
75-100. Biopsies applied to 10.6% of women screened within each 
age group.
(42)
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quality-adjusted life-years (QALYs) gained. The QALYs were based on utilities for the 
general U.S. population estimated both with and without adjustments for having a 
screening examination (0.006 for 1 week per examination = –1 hour per examination) 
and having a positive screening result and undergoing diagnostic evaluation (0.0105 for 
5 weeks = –8.8 hours). We also adjusted for breast cancer treatment (Table 1).
Harms included false-positive mammograms, benign biopsies, and overdiagnosis. The 
rate of false-positive mammograms was the number read as abnormal in women without 
cancer divided by the total. Benign biopsies were defined as a biopsy recommendation 
among women with false-positive screening results (49). Overdiagnosis was defined as 
screen-detected cancer that would not have been diagnosed in a woman’s lifetime in the 
absence of mammography (14, 50).
Costs (reported in 2014 U.S. dollars) were estimated based on the number of mam-
mograms; evaluation of positive mammograms, including additional imaging or biopsy 
among women with cancer and those with false-positive mammograms; and stage-
specific cancer treatments based on Medicare reimbursement schedules and published 
studies (Table 1).
Table 1 Model Input Parameters (continued)
Parameter Description Data Source
Work-up after true 
positive mammogram
By age: $2,154.58 for ages 50-64; $2,166.52 for ages 65-74; and 
$1,826.80 for ages 75-100.
(42)
Breast cancer 
treatment
By stage during initial treatment: $13,695.67 for DCIS and local 
stage; $25,893.77 for regional stage; and $39,990.86 for distant 
stage. During the last year of life among women with cancers that 
were not cured/progressed, depending on stage at diagnosis: 
$37,070.10 for DCIS and local stage; $43,878.64 for regional 
stage; and $61,544.91 for distant stage.
(43)
Utilities
Healthy women Age-specific quality of life utilities among women without breast 
cancer.
(45)
Screening 
mammogram
0.994 for 1 week (44)
Diagnostics after 
positive mammogram
0.895 for 5 weeks (44)
Cancer treatment By stage: 0.9 for 2 years for DCIS and local stage; 0.75 for 2 years 
for regional stage; and 0.6 until death for distant stage.
(46)
Abbreviations: AJCC, American Joint Committee on Cancer; BCSC, Breast Cancer Surveillance Con-
sortium; BI-RADS, Breast Imaging Reporting and Data System; DCIS, ductal carcinoma in situ; ER, 
estrogen receptor; HER2, human epidermal growth factor 2; RR, relative risk; SEER, Surveillance, 
Epidemiology, and End Results.
Note: Not all models use all parameters; some models use parameters as direct inputs and others 
use them as a target for calibration or other estimation (See Appendix Table 2).
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Table 2 Lifetime benefits of screening annually, biennially or triennially per 1000 women screened by 
relative risk, breast density, and age group across 3 models.
Density
Breast cancer deaths averted vs. no 
screening, median (range across models)
Life years gained vs. no screening, 
median (range across models) *
RR Triennial Biennial Annual Triennial Biennial Annual
Ages 50-74†
A
lm
o
st
 
en
tir
el
y 
fa
tt
y 1 3.4 (1.8-3.6) 4.1 (2.4-4.3) 4.7 (3.2-5.6) 50 (35-64) 64 (47-73) 84 (62-85)
1.3 4.4 (2.4-4.6) 5.3 (3.1-5.5) 6.0 (4.1-7.1) 64 (46-82) 82 (60-94) 108 (80-109)
2 6.4 (3.6-7.0) 8.0 (4.8-8.0) 9.1 (6.2-10.3) 94 (69-124) 120 (92-142) 159 (122-163)
4 11.0 (7.2-13.1) 13.8 (9.2-15.0) 17.2 (12.0-17.7) 164 (136-235) 209 (177-269) 277 (233-309)
Sc
at
te
re
d
 
fib
ro
g
la
nd
ul
ar 1 4.0 (2.9-5.9) 5.2 (3.8-6.8) 6.9 (5.1-7.9) 59 (56-107) 77 (74-123) 106 (101-143)
1.3 5.1 (3.7-7.5) 6.5 (4.9-8.7) 8.7 (6.6-10.1) 75 (72-137) 97 (95-158) 134 (129-184)
2 7.2 (5.6-11.2) 9.2 (7.4-12.9) 12.3 (9.9-15.0) 109 (107-204) 144 (139-236) 194 (191-275)
4 11.5 (10.8-20.2) 14.7 (13.9-23.3) 19.4 (18.4-27.0) 207 (175-372) 269 (227-430) 360 (308-502)
H
et
er
o
-
g
en
eo
us
ly
 
d
en
se
1 4.8 (3.3-8.4) 6.3 (4.4-9.8) 8.4 (6.1-11.7) 72 (64-149) 94 (86-175) 130 (122-210)
1.3 6.0 (4.2-10.7) 7.7 (5.6-12.4) 10.4 (7.8-14.8) 90 (82-190) 117 (110-223) 161 (155-267)
2 8.3 (6.3-15.5) 10.6 (8.3-18.1) 14.3 (11.6-21.6) 124 (122-278) 162 (162-326) 230 (224-392)
4 12.4 (11.4-26.5) 15.8 (15.1-31.0) 21.0 (20.8-37.1) 221 (192-485) 294 (248-568) 411 (338-685)
Ex
tr
em
el
y 
d
en
se
1 5.1 (3.1-9.9) 6.5 (4.2-11.7) 8.9 (6.0-14.4) 75 (61-174) 98 (82-206) 138 (121-255)
1.3 6.2 (4.0-12.5) 8.0 (5.4-14.7) 10.9 (7.7-18.1) 93 (79-219) 122 (106-261) 170 (155-323)
2 8.4 (5.9-17.9) 10.8 (7.9-21.1) 14.7 (11.4-26.0) 127 (115-317) 166 (155-376) 231 (226-468)
4 12.0 (10.4-29.3) 15.4 (14.0-34.7) 20.5 (20.2-42.9) 204 (187-534) 277 (242-634) 402 (332-789)
Ages 65-74‡
A
lm
o
st
 
en
tir
el
y 
fa
tt
y 1 1.5 (0.8-1.6) 1.8 (1.0-2.0) 2.3 (1.4-2.4) 16 (11-21) 19 (15-26) 26 (21-31)
1.3 1.9 (1.0-2.0) 2.3 (1.4-2.6) 3.0 (1.9-3.1) 20 (14-27) 24 (19-34) 34 (27-40)
2 2.7 (1.5-3.0) 3.2 (2.1-3.9) 4.3 (2.8-4.4) 28 (20-40) 33 (29-50) 47 (41-59)
4 4.2 (2.6-5.4) 5.1 (3.8-7.0) 6.8 (5.0-8.0) 44 (37-71) 54 (52-92) 73 (73-107)
Sc
at
te
re
d
 
fib
ro
g
la
nd
ul
ar 1 1.7 (1.1-2.3) 2.1 (1.6-2.9) 3.0 (2.2-3.4) 18 (17-30) 23 (22-39) 33 (32-45)
1.3 2.1 (1.5-2.9) 2.6 (2.1-3.7) 3.6 (2.9-4.3) 22 (21-38) 30 (27-49) 42 (39-58)
2 2.9 (2.1-4.2) 3.5 (3.0-5.4) 4.9 (4.1-6.3) 30 (29-55) 43 (36-71) 60 (53-84)
4 4.0 (3.6-7.2) 5.3 (4.9-9.4) 7.2 (6.8-10.9) 50 (41-96) 74 (50-124) 102 (73-146)
H
et
er
o
-
g
en
eo
us
ly
 
d
en
se
1 2.0 (1.2-3.6) 2.5 (1.8-4.7) 3.6 (2.5-5.7) 21 (17-47) 26 (25-62) 38 (37-75)
1.3 2.5 (1.5-4.5) 3.0 (2.2-5.9) 4.3 (3.2-7.1) 26 (21-59) 32 (31-77) 47 (47-95)
2 3.2 (2.2-6.4) 3.9 (3.2-8.4) 5.5 (4.6-10.1) 33 (31-84) 46 (40-111) 66 (60-135)
4 4.0 (3.6-10.1) 5.4 (4.8-13.3) 7.6 (6.7-16.1) 50 (40-134) 76 (49-176) 109 (72-216)
Ex
tr
em
el
y 
d
en
se
1 2.0 (1.1-4.3) 2.5 (1.7-5.9) 3.6 (2.4-7.3) 21 (16-57) 26 (24-77) 39 (36-97)
1.3 2.4 (1.4-5.4) 3.0 (2.1-7.3) 4.3 (3.1-9.1) 25 (20-72) 31 (30-96) 46 (45-122)
2 3.0 (2.0-7.5) 3.7 (3.0-10.1) 5.3 (4.4-12.6) 31 (29-99) 43 (38-134) 64 (57-170)
4 3.5 (3.3-11.2) 4.9 (4.3-15.1) 7.3 (6.0-18.9) 46 (36-149) 70 (43-202) 105 (64-257)
Abbreviations: RR, relative risk.
* Life years gained are undiscounted.
† Screening is initiated at age 50.
‡ Women who are currently 65 and have been screened biennially from 50-64.
236 Chapter 9
statistical analysis
For each age group modeled (≥50 and ≥65 years), there were 16 possible population 
subgroups based on combinations of breast cancer risk and density. Benefits and harms 
for each strategy were compared with no screening for every 1000 women screened. No 
screening was assumed to occur before age 50 years in all analyses. Screening strategies 
for women aged 65 to 74 years assumed that they received biennial mammography dur-
ing ages 50 to 64 years. We report the median benefits and harms and the range across 
models as a measure of uncertainty. In secondary analyses, the ratio of false-positive 
mammograms to breast cancer deaths averted was calculated as a metric of the tradeoffs 
of harms to benefits. We also estimated the incremental costs per QALY for each strategy 
and population risk–density subgroup. For this estimate, the change in cost was divided 
by the change in benefit (for example, QALYs) when each more costly screening strategy 
was compared with the strategy with the next lowest cost within the subgroup. Costs and 
QALYs were discounted at 3% per year, and QALYs included screening and work-up ad-
justments. Screening strategies were considered cost-effective with a common threshold 
of $100 000 per QALY gained (51).
role of the funding source
The National Cancer Institute funded this research but had no role in the design or 
conduct of the study; collection, management, analysis, or interpretation of the data; 
preparation, review, or approval of the manuscript; or the decision to submit the manu-
script for publication.
results
The results of all 3 models illustrate that across intervals and age groups, screening (vs. 
no screening) (Appendix Table 4, available at www.annals.org) had a greater absolute 
benefit in terms of breast cancer deaths averted, life-years gained, and QALYs gained 
among 2 groups of women: those with dense breasts and those at higher RR within each 
breast density group (Tables 2 and 3). Adjustments for screening harms did not affect the 
ordering of screening strategies by QALY.
Women starting screening at age 50
For all screening intervals, as risk and breast density increased, the benefits (breast 
cancer deaths averted, life-years gained, and QALYs gained) of screening increased and 
the harms (false-positive mammograms and benign biopsy results but not overdiagnosis) 
decreased with greater risk (Tables 2 to 4).Among average-risk women with fatty breasts 
(RR, 1.0 or 1.3), biennial screening, compared with no screening, in women aged 50 to 74 
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Table 3 Lifetime QALY benefits of screening annually, biennially or triennially per 1000 women 
screened by relative risk, breast density, and age group with and without screening and work-up 
adjustments.
Density RR
QALYs gained with screening and work-up 
adjustments vs. no screening, median 
(range across models) *
QALYs gained without screening and work-
up adjustments vs. no screening, median 
(range across models)*
Triennial Biennial Annual Triennial Biennial Annual
Ages 50-74†
A
lm
o
st
 
en
tir
el
y 
fa
tt
y 1 32 (21-44) 41 (29-49) 51 (36-51) 37 (26-50) 48 (35-58) 63 (47-66)
1.3 43 (29-59) 54 (39-66) 69 (50-71) 47 (34-65) 61 (45-75) 80 (61-86)
2 65 (46-93) 82 (63-105) 106 (81-116) 70 (52-99) 89 (69-114) 118 (93-131)
4 118 (98-183) 150 (128-209) 194 (168-234) 123 (103-190) 157 (135-217) 206 (180-249)
Sc
at
te
re
d
 
fib
ro
g
la
nd
ul
ar 1 36 (35-76) 47 (47-86) 60 (60-92) 43 (43-85) 57 (56-99) 78 (78-115)
1.3 48 (47-101) 63 (62-114) 82 (81-126) 55 (55-110) 73 (72-127) 99 (98-148)
2 75 (71-155) 100 (92-178) 132 (123-200) 83 (78-164) 110 (102-190) 149 (140-222)
4 153 (122-292) 199 (158-336) 264 (212-386) 160 (129-301) 209 (168-349) 280 (228-407)
H
et
er
o
-
g
en
eo
us
ly
 
d
en
se
1 44 (40-110) 57 (55-126) 75 (73-143) 52 (49-120) 69 (66-141) 95 (94-169)
1.3 57 (54-143) 74 (74-165) 100 (98-190) 65 (63-153) 85 (85-180) 120 (119-216)
2 86 (83-215) 114 (108-249) 159 (145-292) 94 (91-225) 125 (119-263) 178 (165-317)
4 164 (133-384) 220 (173-448) 305 (233-533) 172 (141-394) 230 (184-461) 322 (251-556)
Ex
tr
em
el
y 
d
en
se
1 47 (40-131) 62 (54-154) 84 (77-185) 54 (47-140) 71 (64-166) 100 (94-206)
1.3 60 (54-169) 79 (73-199) 108 (104-240) 67 (61-177) 88 (82-211) 124 (120-261)
2 85 (83-248) 112 (112-293) 161 (153-358) 92 (90-257) 121 (121-305) 176 (169-379)
4 154 (129-425) 210 (169-503) 302 (231-622) 161 (136-433) 218 (178-514) 317 (246-641)
Ages 65-74‡
A
lm
o
st
 
en
tir
el
y 
fa
tt
y 1 9 (6-15) 11 (8-18) 15 (11-20) 11 (8-16) 13 (10-21) 19 (15-24)
1.3 12 (8-19) 15 (11-24) 20 (16-27) 14 (10-21) 17 (14-27) 24 (20-31)
2 18 (13-30) 22 (19-38) 29 (26-42) 20 (15-31) 24 (21-40) 34 (30-47)
4 30 (25-55) 37 (36-71) 50 (49-81) 32 (27-57) 39 (38-73) 54 (53-85)
Sc
at
te
re
d
 
fib
ro
g
la
nd
ul
ar 1 10 (10-21) 13 (12-27) 18 (17-29) 13 (13-23) 17 (16-30) 24 (23-36)
1.3 13 (13-28) 18 (16-35) 25 (22-39) 16 (15-30) 22 (19-39) 31 (28-46)
2 19 (19-42) 28 (23-53) 38 (32-60) 21 (21-44) 31 (26-57) 44 (38-67)
4 35 (28-75) 52 (33-96) 71 (47-111) 37 (30-77) 55 (37-99) 77 (53-117)
H
et
er
o
-
g
en
eo
us
ly
 
d
en
se
1 12 (10-35) 15 (14-45) 20 (20-52) 15 (13-38) 19 (18-49) 27 (27-60)
1.3 15 (13-45) 20 (18-58) 27 (26-68) 18 (16-47) 24 (22-62) 35 (33-76)
2 21 (20-65) 30 (25-85) 43 (36-100) 24 (23-67) 34 (29-89) 50 (43-108)
4 35 (27-105) 54 (33-138) 76 (46-167) 38 (30-107) 57 (36-142) 82 (52-174)
Ex
tr
em
el
y 
d
en
se
1 12 (10-44) 15 (15-58) 21 (21-72) 15 (12-46) 18 (18-62) 27 (27-78)
1.3 15 (13-55) 20 (18-74) 28 (27-91) 18 (15-57) 23 (21-77) 34 (32-98)
2 20 (20-78) 29 (24-104) 43 (35-130) 22 (22-80) 32 (27-107) 48 (41-136)
4 33 (24-118) 51 (29-159) 76 (43-201) 35 (26-120) 53 (32-162) 80 (47-206)
Abbreviations: QALY, quality-adjusted life year; RR, relative risk.
* QALYs gained are undiscounted.
† Screening is initiated at age 50.
‡ Women who are currently 65 and have been screened biennially from 50-64.
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Table 4 Lifetime harms of screening annually, biennially or triennially per 1000 women screened by 
relative risk, breast density, and age group
Density 
and RR
False-positives vs. no screening,
median (range across models)
Benign biopsies vs. no screening,
median (range across models)
Over-diagnosis vs. no screening, median (range 
across models)*
Triennial Biennial Annual Triennial Biennial Annual Triennial Biennial Annual
Ages 50-74†
Almost entirely fatty
1 489 (424-616) 618 (613-858) 1101 (1094-1548) 79 (68-106) 91 (91-136) 127 (127-191) 11 (9-17) 12 (11-20) 17 (12-24)
1.3 484 (420-611) 612 (606-851) 1089 (1081-1536) 78 (67-106) 91 (90-135) 126 (125-190) 12 (11-21) 15 (11-26) 21 (12-31)
2 471 (412-600) 598 (590-836) 1062 (1051-1507) 76 (66-104) 89 (88-133) 123 (122-187) 17 (11-31) 22 (11-37) 30 (12-44)
4 438 (390-571) 564 (547-794) 996 (972-1429) 71 (63-99) 84 (81-126) 116 (113-177) 27 (11-53) 35 (11-63) 49 (12-75)
Scattered areas of fibroglandular density
1 781 (693-935) 1009 (991-1326) 1806 (1776-2440) 126 (111-158) 150 (147-206) 209 (206-296) 13 (11-22) 17 (11-27) 23 (12-35)
1.3 767 (683-922) 994 (972-1309) 1776 (1740-2406) 123 (110-156) 148 (144-203) 206 (202-292) 16 (11-28) 20 (11-34) 29 (12-44)
2 734 (662-894) 963 (929-1267) 1714 (1659-2329) 118 (107-152) 143 (138-197) 199 (193-283) 21 (10-39) 28 (11-48) 39 (12-62)
4 649 (613-818) 888 (818-1158) 1568 (1452-2123) 105 (99-140) 132 (122-181) 183 (169-259) 31 (11-60) 40 (12-74) 56 (13-95)
Heterogeneously dense
1 917 (822-1064) 1197 (1171-1524) 2123 (2080-2829) 163 (146-195) 178 (174-235) 266 (261-365) 16 (10-20) 20 (11-26) 28 (12-38)
1.3 894 (807-1043) 1174 (1141-1493) 2078 (2023-2771) 159 (144-191) 174 (169-230) 261 (254-358) 19 (10-25) 24 (11-32) 34 (12-46)
2 842 (775-995) 1125 (1073-1424) 1984 (1896-2642) 150 (138-183) 167 (160-220) 249 (238-342) 25 (10-34) 32 (11-44) 45 (13-63)
4 715 (703-875) 1016 (906-1248) 1778 (1585-2308) 128 (126-162) 152 (136-194) 224 (200-301) 32 (11-49) 41 (12-63) 57 (14-89)
Extremely dense
1 732 (652-849) 939 (925-1200) 1668 (1647-2225) 130 (116-156) 139 (137-185) 209 (206-288) 16 (10-17) 21 (11-22) 31 (12-32)
1.3 712 (638-827) 917 (898-1169) 1626 (1597-2167) 127 (113-152) 136 (133-181) 204 (200-281) 19 (10-21) 26 (11-27) 37 (12-39)
2 666 (608-780) 872 (839-1102) 1540 (1487-2039) 119 (108-144) 129 (125-171) 193 (186-265) 26 (10-26) 34 (11-35) 47 (13-53)
4 555 (543-663) 776 (697-933) 1359 (1223-1719) 99 (97-123) 116 (104-146) 171 (154-225) 32 (10-37) 41 (12-49) 56 (15-74)
Ages 65-74‡
Almost entirely fatty
1 145 (137-169) 209 (206-227) 413 (395-459) 22 (20-25) 29 (29-32) 45 (43-51) 5 (4-8) 6 (5-11) 9 (5-13)
1.3 142 (135-166) 206 (202-224) 405 (388-453) 21 (20-25) 29 (28-31) 45 (43-50) 7 (4-10) 8 (5-14) 11 (5-17)
2 135 (130-160) 198 (193-217) 387 (373-438) 20 (20-24) 28 (27-30) 43 (41-48) 9 (4-15) 11 (5-20) 15 (6-25)
4 119 (118-145) 178 (169-197) 340 (335-399) 18 (18-22) 25 (24-28) 37 (37-44) 14 (5-25) 16 (6-34) 22 (7-41)
Scattered areas of fibroglandular density
1 230 (225-278) 343 (333-375) 667 (648-757) 34 (34-42) 48 (47-52) 73 (71-83) 7 (4-10) 8 (5-15) 12 (5-20)
1.3 223 (220-271) 335 (322-366) 645 (632-741) 33 (33-41) 47 (45-51) 71 (69-81) 8 (4-13) 10 (5-19) 14 (6-24)
2 209 (206-257) 317 (298-348) 597 (597-704) 31 (31-39) 44 (42-49) 66 (66-77) 11 (5-18) 13 (6-26) 18 (6-34)
4 180 (166-225) 276 (239-299) 520 (480-607) 27 (25-34) 39 (33-42) 57 (53-67) 14 (5-27) 17 (7-38) 23 (8-50)
Heterogeneously dense
1 273 (260-329) 407 (397-432) 794 (760-875) 46 (44-56) 57 (56-61) 95 (91-105) 8 (4-10) 10 (5-14) 14 (6-20)
1.3 262 (250-319) 394 (381-417) 762 (735-845) 45 (43-54) 55 (53-58) 91 (88-101) 10 (5-12) 12 (6-17) 17 (7-25)
2 238 (230-298) 367 (346-384) 693 (684-779) 41 (39-51) 51 (48-54) 83 (82-93) 12 (5-16) 15 (7-23) 21 (8-33)
4 182 (181-254) 302 (264-311) 580 (528-617) 31 (31-43) 42 (37-44) 70 (63-74) 13 (6-22) 16 (8-32) 22 (10-46)
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Table 4 Lifetime harms of screening annually, biennially or triennially per 1000 women screened by 
relative risk, breast density, and age group
Density 
and RR
False-positives vs. no screening,
median (range across models)
Benign biopsies vs. no screening,
median (range across models)
Over-diagnosis vs. no screening, median (range 
across models)*
Triennial Biennial Annual Triennial Biennial Annual Triennial Biennial Annual
Ages 50-74†
Almost entirely fatty
1 489 (424-616) 618 (613-858) 1101 (1094-1548) 79 (68-106) 91 (91-136) 127 (127-191) 11 (9-17) 12 (11-20) 17 (12-24)
1.3 484 (420-611) 612 (606-851) 1089 (1081-1536) 78 (67-106) 91 (90-135) 126 (125-190) 12 (11-21) 15 (11-26) 21 (12-31)
2 471 (412-600) 598 (590-836) 1062 (1051-1507) 76 (66-104) 89 (88-133) 123 (122-187) 17 (11-31) 22 (11-37) 30 (12-44)
4 438 (390-571) 564 (547-794) 996 (972-1429) 71 (63-99) 84 (81-126) 116 (113-177) 27 (11-53) 35 (11-63) 49 (12-75)
Scattered areas of fibroglandular density
1 781 (693-935) 1009 (991-1326) 1806 (1776-2440) 126 (111-158) 150 (147-206) 209 (206-296) 13 (11-22) 17 (11-27) 23 (12-35)
1.3 767 (683-922) 994 (972-1309) 1776 (1740-2406) 123 (110-156) 148 (144-203) 206 (202-292) 16 (11-28) 20 (11-34) 29 (12-44)
2 734 (662-894) 963 (929-1267) 1714 (1659-2329) 118 (107-152) 143 (138-197) 199 (193-283) 21 (10-39) 28 (11-48) 39 (12-62)
4 649 (613-818) 888 (818-1158) 1568 (1452-2123) 105 (99-140) 132 (122-181) 183 (169-259) 31 (11-60) 40 (12-74) 56 (13-95)
Heterogeneously dense
1 917 (822-1064) 1197 (1171-1524) 2123 (2080-2829) 163 (146-195) 178 (174-235) 266 (261-365) 16 (10-20) 20 (11-26) 28 (12-38)
1.3 894 (807-1043) 1174 (1141-1493) 2078 (2023-2771) 159 (144-191) 174 (169-230) 261 (254-358) 19 (10-25) 24 (11-32) 34 (12-46)
2 842 (775-995) 1125 (1073-1424) 1984 (1896-2642) 150 (138-183) 167 (160-220) 249 (238-342) 25 (10-34) 32 (11-44) 45 (13-63)
4 715 (703-875) 1016 (906-1248) 1778 (1585-2308) 128 (126-162) 152 (136-194) 224 (200-301) 32 (11-49) 41 (12-63) 57 (14-89)
Extremely dense
1 732 (652-849) 939 (925-1200) 1668 (1647-2225) 130 (116-156) 139 (137-185) 209 (206-288) 16 (10-17) 21 (11-22) 31 (12-32)
1.3 712 (638-827) 917 (898-1169) 1626 (1597-2167) 127 (113-152) 136 (133-181) 204 (200-281) 19 (10-21) 26 (11-27) 37 (12-39)
2 666 (608-780) 872 (839-1102) 1540 (1487-2039) 119 (108-144) 129 (125-171) 193 (186-265) 26 (10-26) 34 (11-35) 47 (13-53)
4 555 (543-663) 776 (697-933) 1359 (1223-1719) 99 (97-123) 116 (104-146) 171 (154-225) 32 (10-37) 41 (12-49) 56 (15-74)
Ages 65-74‡
Almost entirely fatty
1 145 (137-169) 209 (206-227) 413 (395-459) 22 (20-25) 29 (29-32) 45 (43-51) 5 (4-8) 6 (5-11) 9 (5-13)
1.3 142 (135-166) 206 (202-224) 405 (388-453) 21 (20-25) 29 (28-31) 45 (43-50) 7 (4-10) 8 (5-14) 11 (5-17)
2 135 (130-160) 198 (193-217) 387 (373-438) 20 (20-24) 28 (27-30) 43 (41-48) 9 (4-15) 11 (5-20) 15 (6-25)
4 119 (118-145) 178 (169-197) 340 (335-399) 18 (18-22) 25 (24-28) 37 (37-44) 14 (5-25) 16 (6-34) 22 (7-41)
Scattered areas of fibroglandular density
1 230 (225-278) 343 (333-375) 667 (648-757) 34 (34-42) 48 (47-52) 73 (71-83) 7 (4-10) 8 (5-15) 12 (5-20)
1.3 223 (220-271) 335 (322-366) 645 (632-741) 33 (33-41) 47 (45-51) 71 (69-81) 8 (4-13) 10 (5-19) 14 (6-24)
2 209 (206-257) 317 (298-348) 597 (597-704) 31 (31-39) 44 (42-49) 66 (66-77) 11 (5-18) 13 (6-26) 18 (6-34)
4 180 (166-225) 276 (239-299) 520 (480-607) 27 (25-34) 39 (33-42) 57 (53-67) 14 (5-27) 17 (7-38) 23 (8-50)
Heterogeneously dense
1 273 (260-329) 407 (397-432) 794 (760-875) 46 (44-56) 57 (56-61) 95 (91-105) 8 (4-10) 10 (5-14) 14 (6-20)
1.3 262 (250-319) 394 (381-417) 762 (735-845) 45 (43-54) 55 (53-58) 91 (88-101) 10 (5-12) 12 (6-17) 17 (7-25)
2 238 (230-298) 367 (346-384) 693 (684-779) 41 (39-51) 51 (48-54) 83 (82-93) 12 (5-16) 15 (7-23) 21 (8-33)
4 182 (181-254) 302 (264-311) 580 (528-617) 31 (31-43) 42 (37-44) 70 (63-74) 13 (6-22) 16 (8-32) 22 (10-46)
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years averted a median of 4.1 and 5.3 breast cancer deaths per 1000 women screened, 
respectively. In average-risk women with scattered fibroglandular density (RR, 1.0 or 1.3), 
biennial screening compared with no screening averted a median of 5.2 and 6.5 breast 
cancer deaths, respectively (Table 2). Screening outcomes were similar for triennial screen-
ing compared with no screening in average-risk women with low-breast density; for every 
1000 women screened, the median number of breast cancer deaths averted ranged from 
3.4 to 5.1. Screening triennially compared with biennially for average-risk women with 
low breast density resulted in a median ranging from 21% to 23% fewer false-positive 
mammograms, 13% to 17% fewer benign biopsies, and 8% to 20% fewer overdiagnosed 
cases (Table 4). Among women with fatty breasts (RR, 2.0), triennial screening, compared 
with biennial screening, averted a median of 1.6 breast cancer deaths per 1000 screened. 
In women with scattered fibroglandular density (RR, 2.0), triennial screening, compared 
with biennial screening, averted 2 breast cancer deaths per 1000 women screened. Thus, 
1000 women with fatty breasts (RR, 2.0) and 1000 women with scattered fibroglandular 
density (RR, 2.0) would have 9 rounds of triennial screening resulting in 6.4 and 7.2 breast 
cancer deaths averted, 471 and 734 false-positive mammograms, and 76 and 118 biopsy 
results, respectively; for 13 rounds of biennial screening, we noted 8.0 and 9.2 breast 
cancer deaths averted, 598 and 963 false-positive mammograms, and 89 and 143 biopsy 
results, respectively.
The benefits of more frequent screening increased as density increased and RR in-
creased to 2 or greater. For example, biennial screening, compared with no screening, 
among women aged 50 to 74 years in subgroups with an RR of 2 and heterogeneously 
dense breasts resulted in a median of 10.6 breast cancer deaths averted and 1125 
Table 4 Lifetime harms of screening annually, biennially or triennially per 1000 women screened by 
relative risk, breast density, and age group (continued)
Density 
and RR
False-positives vs. no screening,
median (range across models)
Benign biopsies vs. no screening,
median (range across models)
Over-diagnosis vs. no screening, median (range 
across models)*
Triennial Biennial Annual Triennial Biennial Annual Triennial Biennial Annual
Extremely dense
1 202 (187-239) 295 (291-312) 583 (553-631) 34 (32-41) 41 (41-44) 70 (66-76) 7 (4-9) 10 (6-11) 15 (7-17)
1.3 193 (179-231) 284 (279-298) 559 (532-604) 33 (30-39) 40 (39-42) 67 (64-72) 9 (5-10) 12 (6-13) 18 (7-20)
2 175 (161-214) 263 (253-268) 507 (491-544) 30 (27-36) 37 (35-37) 61 (59-65) 12 (5-12) 15 (7-17) 21 (9-27)
4 133 (118-180) 197 (191-221) 404 (383-412) 23 (20-31) 28 (27-31) 49 (46-49) 12 (6-16) 14 (9-24) 20 (11-38)
Abbreviations: RR, relative risk.
* Over-diagnosed cases are defined as cases that would not have been clinically detected in the 
absence of screening. The value includes DCIS and invasive over-diagnosis. Over-diagnosis is calcu-
lated by comparing cases detected in the screening scenario to those detected in the unscreened 
scenario.
† Per 1000 women compared to no screening at any age.
‡ Per 1000 women compared to biennial mammograms 50-64 with no subsequent screening.
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false-positive mammograms per 1000 women screened. If these women received annual 
rather than biennial screening, a median of 3.7 more deaths could have been averted; 
however, false-positive mammograms would increase almost 2-fold (1984 vs. 1125 false-
positive mammograms per 1000 women screened). Breast cancer deaths averted per
1000 women screened were highest with annual screening for women ages 50 to 74 
years with all levels of breast density and an RR of 4.0; averted deaths ranged from 17.2 
in women with fatty breasts to 20.5 in women with extremely dense breasts.
The Figure (top) is an exemplar model showing the ratio of harms and benefits for 
subgroups of women with different levels of risk and density screened from ages 50 to 74 
years. Compared with the ratios projected for biennial screening of average-risk women 
from ages 50 to 74 years regardless of breast density, annual screening has a similar or 
better ratio when the RR is 2 or greater across all density groups. Triennial screening has 
similar or better ratios of harms and benefits than biennial screening for average-risk 
women regardless of breast density in nearly all of the RR and density subgroups because 
false-positive mammograms are reduced with triennial screening, and the magnitude of 
breast cancer deaths averted is similar or slightly lower than with biennial screening.
Women at age 65
The different intervals among women aged 65 to 74 years had similar patterns of benefits 
and harms across subgroups as observed for screening during ages 50 to 74 years but 
with lower absolute magnitudes (Tables 2 to 4 and Figure, bottom). If women changed 
from biennial to triennial screening at age 65 years, fewer than a median of 1 less death 
per 1000 women screened was averted for all RRs and density subgroups. The exception 
was women with an RR of 4 and heterogeneously or extremely dense breasts; a median 
of 1.4 fewer breast cancer deaths were averted in this group (Table 2). For example, 
continuing biennial screening among average-risk women (RR, 1.0 or 1.3) and women 
with fatty breasts or scattered fibroglandular density averted a median of 1.8 to 2.3 
deaths for women with fatty breasts and 2.1 to 2.6 deaths for women with scattered 
fibroglandular density for every 1000 women screened (Table 2); switching to triennial 
Table 4 Lifetime harms of screening annually, biennially or triennially per 1000 women screened by 
relative risk, breast density, and age group (continued)
Density 
and RR
False-positives vs. no screening,
median (range across models)
Benign biopsies vs. no screening,
median (range across models)
Over-diagnosis vs. no screening, median (range 
across models)*
Triennial Biennial Annual Triennial Biennial Annual Triennial Biennial Annual
Extremely dense
1 202 (187-239) 295 (291-312) 583 (553-631) 34 (32-41) 41 (41-44) 70 (66-76) 7 (4-9) 10 (6-11) 15 (7-17)
1.3 193 (179-231) 284 (279-298) 559 (532-604) 33 (30-39) 40 (39-42) 67 (64-72) 9 (5-10) 12 (6-13) 18 (7-20)
2 175 (161-214) 263 (253-268) 507 (491-544) 30 (27-36) 37 (35-37) 61 (59-65) 12 (5-12) 15 (7-17) 21 (9-27)
4 133 (118-180) 197 (191-221) 404 (383-412) 23 (20-31) 28 (27-31) 49 (46-49) 12 (6-16) 14 (9-24) 20 (11-38)
Abbreviations: RR, relative risk.
* Over-diagnosed cases are defined as cases that would not have been clinically detected in the 
absence of screening. The value includes DCIS and invasive over-diagnosis. Over-diagnosis is calcu-
lated by comparing cases detected in the screening scenario to those detected in the unscreened 
scenario.
† Per 1000 women compared to no screening at any age.
‡ Per 1000 women compared to biennial mammograms 50-64 with no subsequent screening.
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Table 5 Incremental costs per quality-adjusted life year gained* by breast density, risk level, screen-
ing interval, and age for 3 models.
Density RR Screening
Frequency
Age 50-74 Age 65-74
Model E Model W Model GE Model E Model W Model GE
Fatty 1.0 Triennial 68,777 117,753 43,098 100,058 131,294 27,639
Biennial 122,007 123,132 232,710 109,587 212,665 104,235
Annual 389,195 586,116 Dom 435,881 516,979 >1,000,000
1.3 Triennial 50,231 83,220 27,022 70,716 92,938 15,785
Biennial 83,577 86,426 133,826 75,433 135,221 67,152
Annual 231,495 309,654 >1,000,000 258,193 286,643 799,501
2.0 Triennial 30,910 W Dom 10,364 42,229 58,276 3,004
Biennial 50,526 50,084† 65,297 46,300 70,911 32,912
Annual 122,540 148,375 392,745 141,183 146,961 263,493
4.0 Triennial 14,969 22,663 † 19,130 W Dom †
Biennial 22,802 23,295 19,932 21,242 30,054 5,331
Annual 54,906 56,451 95,362 69,089 62,251 76,840
Scat-tered 1.0 Triennial 69,714 72,156 18,509 W Dom 55,051 14,112
Biennial 111,605 75,673 104,454 101,612 Dom 61,723
Annual 317,991 288,199 Dom 382,578 612,349 >1,000,000
1.3 Triennial 50,010 51,493 9,683 W Dom 60,785 5,449
Biennial 75,416 53,967 63,057 72,488 73,479 39,636
Annual 186,322 171,038 488,376 224,322 201,088 450,818
2.0 Triennial 31,053 29,757 641 W Dom 38,299 †
Biennial 43,721 31,198 28,182 42,160 42,347 15,956
Annual 96,584 85,607 144,723 120,188 104,553 159,293
4.0 Triennial 15,414 12,179 † W Dom 17,507 Dom
Biennial 19,733 13,116 5,116 20,076 17,977 ‡
Annual 44,019 32,452 39,105 61,818 39,362 42,660
Het. dense 1.0 Triennial 57,924 W Dom 8,016 W Dom 75,197 611
Biennial 85,241 60,333† 50,421 85,145 96,863 23,104
Annual 222,789 185,805 268,798 279,586 290,534 179,689
1.3 Triennial 42,324 41,815 2,179 60,235 54,355 †
Biennial 61,309 42,551 31,442 61,760 60,225 11,809
Annual 137,983 116,700 134,915 169,196 174,243 97,850
2.0 Triennial 26,726 23,375 † W Dom 31,637 †
Biennial 35,235 26,574 12,543 36,446 36,762 478
Annual 75,747 57,557 56,331 99,035 85,503 44,784
4.0 Triennial 13,432 8,534 Dom W Dom 13,298 Dom
Biennial 16,745 9,256 ‡ 18,673 13,814 ‡
Annual 36,845 22,339 14,716 57,264 32,355 8,752
Dense 1.0 Triennial 50,563 52,953 3,017 W Dom 63,918 †
Biennial 68,216 55,420 27,942 75,917 77,061 8,555
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screening averted a median of 1.5 to 1.9 deaths for women with fatty breasts and 1.7 to 
2.1 deaths for women with scattered fibroglandular density. Switching from biennial to 
annual screening increased the median number of breast cancer deaths averted to 2 or 
more for women with heterogeneously or extremely dense breasts and an RR of 4.
As was the case for screening in women aged 50 to 74 years, the ratio of harms (mea-
sured as false-positive mammograms) and benefits (breast cancer deaths averted) for 
annual screening in women aged 65 to 74 years was similar to or better (lower) than 
that seen in biennial screening of average-risk women with an RR of 2 or greater in all 
density subgroups; exceptions were rare (Figure, bottom). Triennial screening also had 
a lower or more favorable ratio than biennial screening because it reduces false-positive 
mammograms, and the magnitude of breast cancer deaths averted is the same or slightly 
lower. Continuing biennial screening has a similar balance as triennial screening for most 
subgroups as seen for average-risk groups, regardless of breast density
Table 5 Incremental costs per quality-adjusted life year gained* by breast density, risk level, screen-
ing interval, and age for 3 models. (continued)
Density RR Screening
Frequency
Age 50-74 Age 65-74
Model E Model W Model GE Model E Model W Model GE
Annual 148,014 129,536 89,425 187,329 203,860 60,177
1.3 Triennial 37,937 36,486 † W Dom 45,929 †
Biennial 49,172 40,051 16,293 55,033 52,754 2,547
Annual 101,399 87,230 56,264 130,774 130,339 36,740
2.0 Triennial 24,715 20,626 † W Dom 26,367 Dom
Biennial 30,291 23,683 4,631 35,097 32,766 ‡
Annual 60,577 47,687 25,753 82,794 71,187 15,070
4.0 Triennial 13,169 7,130 Dom W Dom 10,180 Dom
Biennial 14,856 7,823 ‡ 19,207 11,669 Dom
Annual 31,433 18,224 4,407 52,645 26,834 §
Note: Incremental ratios bold if values are <$100,000, a common threshold for least costly and most 
effective strategies (dominant). Unless otherwise indicated, triennial strategies are compared to no 
screening. Breast density categories shown as: fatty, almost entirely fat; scattered, scattered fibro-
glandular density; het. dense, heterogeneously dense; and dense, extremely dense.
Abbreviations: RR, relative risk; Dom, more expensive and less effective (strongly dominated); W 
Dom, more expensive and more effective but less efficient (weakly dominated).
*Costs and quality-adjusted life years discounted at 3% per year. Quality-adjusted life years include 
disutility from participation in screening mammography.
†Strategy with no screening is strongly dominated. Triennial is the least costly strategy for compari-
son.
‡Strategy with biennial screening is the least costly.
§Strategy with annual screening is the least costly
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cost-effectiveness
When we used a common threshold of $100 000 per QALY, triennial strategies were 
the only costeffective strategies for subgroups with average risk and low breast density 
(fatty breasts or scattered fibroglandular density) in both age groups (Table 5). Biennial 
strategies were cost-effective for most density subgroups at average or intermediate risk 
(RR, 1.3 or 2.0). Annual strategies were only consistently cost-effective across models for 
subgroups with an RR of 4, regardless of density, or an RR of 2 or greater and heteroge-
neously or extremely dense breasts.
discussion
This collaborative modeling study shows that risk and density level can be useful for 
guiding tailored screening recommendations. For average-risk women in low-density 
subgroups, which comprise a large proportion of the population, triennial screening pro-
vides a reasonable balance of benefits and harms and is costeffective. Annual screening 
has a favorable balance of benefits and harms and would be considered costeffective 
for subgroups of women aged 50 years with risk levels that are 2 to 4 times the aver-
age and that have heterogeneously or extremely dense breasts. Benefits of screening 
women with heterogeneously dense breasts (at any interval) were greater than screening 
those with extremely dense breasts at each risk level, reflecting increased risk but fewer 
missed cases of cancer than screening women with extremely dense breasts. The same 
patterns are seen for women aged 65 years such that subgroups at average risk with low 
breast density can consider triennial screening. In contrast, the few women who remain 
at higher risk might benefit from annual screening. Of note, biennial screening maintains 
an acceptable balance of outcomes and is also cost-effective for women with an RR of 1.3 
or 2 as long as they are not in the highest-density groups. Screening benefits and harms 
exist on a continuum across age, risk, and density, with the optimal screening interval 
depending on women’s values and preferences for benefits and harms.
Current U.S. screening guidelines focus on the average-risk population and generally 
recommend biennial screening for women in their 50s or older (3, 4). These new model-
ing results support this recommendation for women who do not have either higher-than 
average risk and high breast density or average to low risk and low breast density. Annual 
screening has been suggested for high-risk women (4). The current results provide further 
guidance on the specific combinations of RRs and breast density after age 50 years that 
identify the subgroups in which annual screening should be considered; these subgroups 
are estimated to constitute fewer than 1% of the population at both ages 50 and 65 years 
(BCSC; Miglioretti DL. Personal communication. 2016).
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Although triennial screening is routinely used in several countries (52, 53), this interval 
has not been considered in the United States. Our modeling suggests that triennial 
screening has a similar balance of benefits and harms compared with biennial screening 
in some groups. Decisions about using triennial versus biennial screening for average-
risk women in the lowdensity subgroups result in fewer false-positive mammograms, 
Figure 1 False-positives mammograms per breast cancer death averted for women (A) aged 50-
74 and (B) aged 65-74 according to screening frequency and risk level (relative risk group, breast 
density) using an exemplar model (Model E). Values for all screening frequencies compared to the 
scenario with no mammography screening. Values for ages 65-74 assume all women received bien-
nial screening during ages 50-64. Dashed lines show this value for women with average density and 
average risk receiving biennial screening (147.7 for ages 50-74 and 105.8 for ages 65-74). Having 
fewer false-positives per death averted than this level, i.e., a value below the dashed line, would be 
more favorable.
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biopsies, and overdiagnosis with minimal effect on breast cancer deaths averted. Others 
have noted that triennial screening can be cost-effective for average-risk women or those 
with an RR of 2 or less aged 60 to 79 years with fatty breasts or scattered fibroglandular 
density(10, 11). We found that 12% of women aged 50 years and 20% of those aged 65 
years have low breast density (fatty breasts and scattered fibroglandular density) and an 
RR of 1.0 or 1.3 (BCSC; Miglioretti DL. Personal communication. 2016).
Breast cancer screening guidelines include an upper limit based on age or life expec-
tancy (3, 4, 54). Although we did not evaluate comorbidity, our study results suggest that 
screening intervals for older women should be based on competing causes of mortal-
ity, breast cancer risk, and changes in breast density associated with aging. The ability 
to tailor screening based on density may become increasingly feasible with the trend 
toward mandated standard reporting of breast density to women after a mammogram. 
Because our results show that the RR of breast cancer in combination with breast density 
has a strong influence on the net benefit of mammography at all screening intervals, 
evaluation of different risk assessment tools will be important in this context.
Although the models provide new data and have consistent conclusions, several caveats 
should be considered. First, the 3 models used common inputs but varied in how these 
data were implemented based on model structure. These variations led to differences 
in the absolute values for outcome metrics. For example, based on assumptions about 
temporal trends in underlying incidence, models with the lowest projected incidence 
estimate fewer breast cancer deaths averted than those with higher incidence. This 
analysis includes 3 of 6 Cancer Intervention and Surveillance Modeling Network breast 
models and is an extension of work conducted by all 6 groups(8). Second, because the 
analytic goal was to determine screening efficacy, the models assumed 100% adherence 
to screening and use of the most effective modern treatments. Actual benefits will fall 
short of those projected under these assumptions. Third, we did not explicitly consider 
lower-than-average risk (that is, RR <1). It will be important to extend our analyses to 
lower-risk groups because most U.S. women have an RR less than 1 across all density 
subgroups (70% of women aged 50 years and 66% aged 65 years) (BCSC; Miglioretti DL. 
Personal communication. 2016). By extension, our current findings suggest that trien-
nial screening would be a reasonable option for lower-than-average risk women with 
fatty breasts or scattered fibroglandular density. Fourth, we did not model the effect of 
screening from ages 40 to 49 years, other combinations of ages and intervals, or carriers 
of breast cancer susceptibility genes 1 and 2. Whether the lack of strategies incorporat-
ing screening women in their 40s would affect the balance of benefits and harms against 
longer (or shorter) screening intervals after age 50 years is unclear. Fifth, although 2 age 
groups and change in density between age groups were considered, our results do not 
provide guidance for women whose risk changes over time; modeling change in risk with 
aging is an important area for future research. Sixth, we used RR rather than absolute risk 
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level because our simulation models were better suited for this approach. Absolute risk 
calculators are commonly available (27, 55-57), and the suitability of these calculators to 
assign risk to personalize screening intervals should continue to be evaluated. Finally, we 
did not evaluate alternative or supplemental imaging.
Overall, this comparative modeling study illustrates consistent patterns in benefits and 
harms that could be useful for guiding shared decision making and tailoring screening 
intervals. The results show that for all screening intervals, benefits and harms change 
with risk and breast density. Further, the threshold to decide on the screening interval 
will depend on individual preference(1). Assessing breast density and breast cancer risk 
can identify subgroups of average-risk women with low breast density who can consider 
triennial screening and higher-risk women with high breast density who may benefit from 
annual screening.
Reproducible Research Statement: Study protocol: Not available. Statistical code: De-
tailed information about the models is available online at http://cisnet.cancer.gov/breast/
profiles.html and in reference (14). Data set: Input and output data from the models are 
available at reference (14) and by contacting Dr. Trentham-Dietz at trentham@wisc.edu.
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* Risk estimates were based on the comparison group consisting of the largest proportion of women, 
i.e., “average risk.” Women with reduced risk were not modeled, including women who engaged in 
regular moderate–vigorous physical activity with age at menarche >13 y or age at menopause <50 
y with almost entirely fat breast density (Breast Imaging Reporting and Data System category = “a”) 
or who breastfed for ≥1 y. Relative risks associated with breast density categories are shown in Ap-
pendix Table 3. 
DCIS = ductal carcinoma in situ; E = Erasmus Medical Center; ER = estrogen receptor; GE = George-
town University Medical Center and Albert Einstein College of Medicine; HER2 = human epidermal 
growth factor receptor 2; SEER = Surveillance, Epidemiology, and End Results; W = University of 
Wisconsin–Madison and Harvard Medical School. * Adapted from reference 14. Additional infor-
mation is available at https://resources.cisnet.cancer.gov/registry/site-summary/breast. † Combined 
output from all 3 models was analyzed using SAS software, version 9.4 (SAS Institute). 
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Sojourn time is the duration of the preclinical, screen-detectable phase of the tumor. Lead time is 
the interval from screen detection to the time of clinical diagnosis, which is when the tumor would 
have surfaced without screening. See Appendix Table 2 for the description of the implementation of 
screening benefit in the 3 simulation models. 
DCIS = ductal carcinoma in situ. * Annual mammography was defined as 9- to 18-mo intervals; bien-
nial mammography was defined as 19- to 30-mo intervals; triennial mammography was defined as 
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31- to 42-mo intervals. Data were obtained from the Breast Cancer Surveillance Consortium. † Age-
specific relative risk for breast cancer associated with breast density; reference group is women with 
average density. ‡ Corrected for missing data. 
QALY = quality-adjusted life-year.
* Values are median numbers (range across models).
† Screening was initiated at age 50 y.
‡ Women who were currently age 65 y and have been screened previously biennially from ages 50-
64 y.
§ Undiscounted.
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discussion
In developed countries, most women within the 50-70 age range have been regularly 
screened for breast cancer in the last decades. (1, 2) However, measuring the public 
health impact of breast cancer screening has been challenging for several reasons. First, 
it is unknown how many breast cancers diagnoses and breast cancer deaths would have 
occurred had there been no screening. The lack of a control group of women who are not 
screened makes it difficult to quantify the impact of screening. Second, the simultaneous 
improvements in breast cancer screening and treatment make it difficult to quantify the 
contributions of either. These are areas where models come into play. (3, 4) Models can 
simulate a population of women in the presence and in the absence of various screening 
and treatment strategies. Further, models can extrapolate the findings from randomized 
controlled trials by synthesizing data on breast cancer epidemiology, demographics, 
screening accuracy, and treatment effectiveness to estimate the magnitude of harms 
and benefits associated with many different screening strategies. The predictions by 
the Cancer Intervention and Surveillance Modeling Network (CISNET) models have 
been used to support the current United States Preventive Services Task Force (USPSTF) 
screening guidelines. (5) Overall, there are numerous reasons why models can contribute 
to a better understanding of trends in breast cancer incidence and mortality. Neverthe-
less, breast cancer microsimulation models can also be perceived as complex and be 
challenging to fully understand.
research question 1: how can model description, comparison, and 
validation contribute to a better understanding of model predictions?
Microsimulation model MISCAN-Fadia
One way to improve the understanding of model predictions is to provide a detailed 
description of the model. The tumor size-oriented MIcrosimulation SCreening ANalyses 
(MISCAN) model is characterized by exponential continuous tumor growth based on 
the tumor volume doubling time concept. The tumor FAtal DIAmeter (FADIA) concept 
represents distant metastasis of breast cancer. These concepts form an intuitive biologi-
cal entry to modeling breast cancer natural history. One advantage is that tumor size can 
be observed at diagnosis and if real data on tumor progression rates becomes available 
in the future this can be used directly in the model. A challenge however, is that trials 
evaluating the performance of screening modalities often only report test sensitivity, and 
have to be recalibrated to tumor sizes in order to be applicable in the model. Logically, 
newer and more sensitive screening tests are able to detect tumors of smaller diameter 
sizes than less sensitive (older) screening modalities such single view film mammography. 
Similarly, the efficacy of breast cancer treatment found in studies (6) is translated into a 
tumor size that can be cured by a specific treatment.
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In randomized controlled trials, randomization of participants is a key step to reduce 
the chance of systematic differences between study participants in the intervention and 
control groups. In the model this is imitated by simulating a target population twice with 
the exact same characteristics, except the screening strategy. In general, describing the 
demography, breast cancer natural history, screening and treatment part of a model and 
including the model inputs, should contribute to a better understanding of the model. In 
2018, a special issue in Medical Decision Making was dedicated to providing a detailed 
description of all CISNET breast cancer models.(7)
Comparison of DCIS models
One of the most important harms of routinely screening asymptomatic women for breast 
cancer, that has profound implications for quality of life, is overdiagnosis and overtreat-
ment. The magnitude of overdiagnoses has been a matter of extensive debate because 
the standard of care is that all tumors are treated immediately upon diagnosis. Moreover, 
overdiagnoses is difficult to measure as it not observable in individual women and esti-
mates vary widely. (8) The CISNET models project that 34-72% of DCIS diagnoses are 
overdiagnosed in a biennial 50 to 74 screening scenario.(9) The comparison of multiple 
approaches to modeling DCIS (in chapter 3) showed that models assuming a stable 
background trend in breast cancer incidence predicted the highest rates of overdiag-
noses of DCIS. The stable background trend implied that the majority of the increase 
in breast cancer diagnoses due to screening were overdiagnoses. Models with a rela-
tively long pre-clinical duration of DCIS and therefore a relatively long period to detect 
DCIS by screening, also predicted a high percentage of DCIS overdiagnoses. Models 
including invasive breast cancer which can be non-progressive, predicted relatively low 
levels of DCIS overdiagnoses. Overall, and similar to what other studies have found, the 
comparative modeling outcomes showed that even though there is uncertainty about 
DCIS natural history, the amount of overdiagnoses among DCIS cases is substantial and 
greater than the amount of overdiagnoses among invasive breast cancers. (10)
Evidently, the quality of model inputs is related to the quality of model outputs. Since 
the information about DCIS natural history is still limited, the model projections for DCIS 
overdiagnoses may therefore not be sufficiently accurate yet to inform clinical practice. A 
key step in the improvement of our understanding of DCIS natural history and the associ-
ated value of modeling DCIS is using observed data from DCIS trials. The COMET(11), 
LORD, and LORIS (12) trials monitor women with DCIS with the intent of only offering 
treatment when needed and thereby reduce the risk of overtreatment. Future steps that 
modeling groups have to make are including new trial information and predictors for 
disease progression. Predictors for progression include cytologic grade, younger age at 
diagnosis, ethnicity, or DCIS tumor size. (13, 14)
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External model validation
There is a complex interplay between multiple factors that contribute to the effects of 
screening and treatment on cancer incidence and mortality. These factors include, sen-
sitivity and specificity of screening, screening frequency, attendance to screening, treat-
ment effectiveness, treatment adherence, disease risk and natural history of the disease. 
Models can synthesize data from various sources to simulate the interplay between such 
factors and make predictions for the impact of screening and treatment. If collaborative 
modeling outcomes point to similar conclusions by different models, this should improve 
the credibility of the conclusion. To formally assess a model´s predictive ability, model 
predictions should be compared to observed clinical trial outcomes. This is called model 
validation. The comparison of model predictions to observed event data not used in 
model development, is called external validation and is seen as one of the strongest 
forms of model validation. (15)
The effectiveness of screening below age 50 is an important issue in breast cancer 
screening. While young women (< age 50) are at lower risk to develop breast cancer 
than older women, tumors grow faster and mammography performs less well due to the 
prevalence of dense breasts in younger women. (16) The different screening guidelines 
reflect the uncertainty about screening in this age group. The U.K. Age trial was specifi-
cally designed to address the question about the effectiveness of screening in women in 
the 40 to 49 age range. (17) In chapter 4, Five CISNET models, primarily built for making 
predictions of screening and treatment in the United States, made predictions for breast 
cancer screening in the United Kingdom. Predictions were compared to the findings of 
the U.K. Age trial that compared annual mammography screening of women ages 40 
to 49 years with no screening in this age group. The models underestimated the effect 
of screening on breast cancer mortality at 10-year follow-up. On average, the modeled 
breast cancer mortality reduction due to screening was 15% (range across models, 13% 
to 17%) vs. 25% (95% CI, 3% to 42%) observed in the Age trial. (18) At 17-year follow-up, 
the models predicted 13% (range across models, 10% to 17%) vs. the non-significant 
12% (95% CI, -4% to 26%) observed in the trial.
On closer inspection and comparison of model outcomes, we observed that models 
with slower tumor progression on average predicted a slight increase in breast cancer 
mortality reduction between 10 and 17-year follow-up. The models with faster tumor 
progression, and thus a shorter time to breast cancer metastases, on average showed 
a decline or stable trend in breast cancer mortality reduction. Given that the underesti-
mation at 10-year follow-up was present across all models, it might be explained by a 
common model input not related to screening. Specifically, no treatment information has 
been reported in the trial. The models used a derived treatment dissemination based on 
U.K. surgical oncology reports that may have been different from the actual treatments 
received by women diagnosed with breast cancer in the trial.
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It is known that if screening is first introduced there is a delay in the impact on cancer 
mortality. The Age trial is one example that shows that lifetime follow-up is important 
when measuring the impact of screening and treatment. If an extension of the U.K. 
screening program to women under age 50 was based on the conclusions of the trial at 
10-year follow up, one could argue that based on the breast cancer mortality reduction at 
17-year follow up this should be reversed. A different challenge of the Age trial was that 
an ongoing national screening program was in place for women aged 50 and older, and 
for justified ethical reasons women in both arms of the trial were invited to participate 
in this program. To assess the effectiveness of screening on breast cancer mortality, the 
trial restricted their analyses to breast cancers diagnosed during the intervention phase. 
With regard to screening quality in the trial, the models and the trial itself showed more 
breast cancer diagnoses due to symptoms (interval cancers) than from early detection 
by screening in the intervention group. We attributed this finding to the relatively low 
sensitivity of single view mammography at the time.
Overall we conclude that the models captured the observed long-term effect at 17-
year follow-up of screening from age 40 to 49 years on breast cancer incidence and 
mortality in the UK Age trial, suggesting that the model structures, input parameters, and 
assumptions about breast cancer natural history are reasonable for estimating the impact 
of screening on mortality in this age group. It can be noted that it is quite common to 
have relatively wide confidence intervals in randomized trials on cancer screening. The 
wide confidence intervals are partly due to the limited number of women included and 
absolute number of breast cancer deaths. In modeling studies, the outcomes and simula-
tions are not limited to a certain number of women, but models are ultimately informed 
by these observed data as well.
Which model aspects drive model predictions (MCLIR method)
A necessary step in the interpretation of collaborative model results is to understand 
how model structure and assumptions contribute to variations in cancer incidence and 
mortality predictions. However, explaining differences in model predictions is not always 
straightforward for reasons related to the nature of the disease. Modeling breast cancer 
involves the representation of unobservable processes such as tumor onset and tumor 
progression, upon which interventions are overlaid. To model breast cancer, models 
must make assumptions about the timing of tumor inception, tumor progression, and 
progression variability among tumors. These assumptions, in conjunction with model 
structure, impact 3 key determinants of screening effectiveness: 1) pre-clinical duration 
of breast cancer in which cancers could be detected by screening; 2) the sensitivity of the 
screening test; and 3) the improvement in prognosis from treatment, e.g., to what extent 
(earlier) treatment actually reduces (more) breast cancer mortality. The maximum clinical 
incidence reduction (MCLIR) method was used to isolate the effects of tumor onset, 
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tumor progression, screening test sensitivity, and breast cancer treatment by comparing 
model results before and after imposing a one-time screening intervention at age 62 
under varying assumptions about screening performance and treatment effectiveness.
Even though different models may use the same data on screening sensitivity and 
breast cancer treatment effectiveness, the implementation of screening and treatment 
varies because model structures are different. The MCLIR method was designed to gain 
insight into how model structure and assumptions influence model predictions. The 
rationale behind this method is that in the absence of screening, breast cancers will only 
be diagnosed because of clinical symptoms; referred to as clinical incidence and defined 
as breast cancers diagnosed due to symptoms. Screening is assumed to detect some of 
these cancers before symptomatic diagnosis, thereby reducing clinical incidence, and 
possibly cancer mortality. Differences in ‘clinical incidence reduction’ reflect differences 
in how models portray the pre-clinical detectable phase of breast cancer (tumor onset 
and progression) and mechanisms of screen detection (incorporation of sensitivity). On 
the other hand, differences in breast cancer mortality are expected to capture model-
specific assumptions about implementation of treatment as well as the impact of tumor 
onset and progression on breast cancer natural history.
The hypothetical ‘perfect screening test’ scenario showed that some models have 
relatively large numbers of tumors in existence at screening. On closer inspection, these 
models have in common a model structure that simulates tumor inception long before 
the start of the sojourn time (the screen-detectable phase). Moreover, the outcomes 
also indicated that the tumors in these models are, on average, slowly progressing with 
longer survival times. On the other hand, models with few cancers in existence at screen-
ing, were models with structures that simulated tumors at the start of the sojourn time 
and with assumptions of relatively fast tumor progression that resulted in shorter survival 
times on average. Overall, models may be perceived as complex, however the interplay 
between screening and treatment interventions with unobservable disease natural his-
tory is also complex in itself. The MCLIR method can isolate model parts and provide 
more insight into the factors that drive incidence and mortality predictions. Overall we 
conclude that in models, the timing of tumor inception and its effect on the length of the 
pre-clinical phase of breast cancer can have substantial impact on their predictions for 
breast cancer incidence and mortality reduction.
part 2: Quantifying the harms and benefits of age-based 
breast cancer screening in the united states.
The evidence obtained from randomized controlled trials on the effectiveness of breast 
cancer screening in the past 30 years led to the widespread use of mammography screen-
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ing. Despite this body of evidence, the magnitude of the harms and benefits of breast 
cancer screening has been debated extensively and the lack of consensus is reflected in 
the current screening guidelines. This debate has been fueled by the increase in harms 
such as false-positives and overdiagnoses. Also, the simultaneous improvements in 
breast cancer screening and treatment over time make it difficult to disentangle the 
contributions of either to the overall harms and benefits.
research question 2: What are the benefits and harms of current age-
based breast cancer screening in the united states?
Explaining the decline in U.S. breast cancer mortality
Advances in breast cancer screening and treatment have both contributed to the decline 
in U.S. breast cancer mortality in the last 30 years. In 2005, the CISNET models estimated 
that screening and treatment contributed about equally to the decline in breast cancer 
mortality between 1975 and 2000.(3) After the year 2000, two important developments 
have emerged: digital mammography screening and improvements in molecularly 
targeted treatments. To further reduce breast cancer mortality, it is useful to assess the 
relative contributions of screening and treatment to breast cancer mortality in the first 
decade of the 21st century. No single cancer registry in the U.S., nor any randomized trial, 
collected sufficient long-term information about ER/ERBB specific treatment to quantify 
the contributions of screening and treatment by molecular subtype at the population 
level.
We used 6 different CISNET models to simulate US breast cancer mortality from 2000 
to 2012 for multiple birth cohorts using national data on plain-film and digital mam-
mography patterns and performance, dissemination and efficacy of ER/ERBB2(HER2)-
specific treatment, and competing mortality. In 2000, the contribution of screening to 
overall breast cancer mortality reduction was 44% and 56% of the reduction associated 
with treatment. In 2012 this changed; screening was estimated to be responsible for 
37% and treatment for 63% of the total breast cancer mortality reduction in that year. 
Improvements in chemotherapy and hormone therapy were mainly responsible for this 
increase in the contribution of treatment. Molecular subtype tumors ER+/ERBB+ were 
mainly treated with Trastuzumab in 2012 and showed the largest relative contributions 
associated with treatment vs screening: 69% vs 31%. The ER-/ERBB- tumor group saw 
the lowest breast cancer mortality reduction (37%) and did not benefit from improve-
ments in hormone therapy nor Trastuzumab. Overall, all models conclude there has been 
a shift in in the relative contributions associated with screening and treatment to U.S. 
breast cancer mortality. Advances in screening from film to digital mammography have 
contributed to the overall decline in breast cancer mortality. Even so, the dissemination 
of new molecularly targeted therapies and the improved delivery of standard treatment 
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regimens has had a stronger impact on breast cancer mortality than screening between 
2000 and 2012.
Our analyses focused on explaining the decline in breast cancer mortality and did 
not investigate the harms associated with screening and treatment. However, in future 
perspective, one possible long-term implication of our findings could be that, if cancer 
treatments become more and more effective, more targeted, and less burdensome, 
early detection by screening could become less important. In such scenario, improved 
treatments could indirectly lead to a reduction in the number of screens and thereby 
a reduction in false-positives and overdiagnoses. It will be important to continuously 
evaluate the contributions of screening and treatment in light of new developments. In 
the meantime, improving the sensitivity and specificity of screening is the most direct 
way to reduce false positives and recall rates. The use of prognostic factors for invasive 
breast cancer or watchful waiting strategies in non-invasive cases could potentially re-
duce overdiagnoses.
Model predictions informing screening guidelines
One of the lessons learned in decades of breast cancer screening is that the harms do 
not always outweigh the benefits. In 2009, the United States Preventive Services Task 
Force used collaborative modeling outcomes to support the revision of their recommen-
dations from annual screening beginning at age 40 years to biennial screening beginning 
at age 50. (19) In 2016, the CISNET models updated the model inputs to account for 
improvements in screening and systemic treatment. We estimated the magnitude of 
harms (false-positive mammograms, benign biopsies, overdiagnosis) and benefits (breast 
cancer mortality reduction, life-years gained, quality-adjusted life-years) of eight differ-
ent screening strategies. Screening strategies varying in start age of screening (40, 45, 
50) and screening interval (annual, biennial, and hybrid), where hybrid strategies consist 
of annual screening before age 50 followed by biennial screening, were evaluated. All 
models showed that, when considering the average-risk population, screening starting 
at age 40 led to substantially more false-positives and overdiagnoses among women 
in their forties than screening starting at age 50. Starting biennial screening at age 40 
vs. 50 modestly lowered breast cancer mortality, and QALYs gained increased by 22% 
from 86 to 105 per 1.000 women screened. Overall, biennial screening strategies were 
efficient and preferred over annual strategies for average-risk women. Efficient strategies 
are strategies that result in the greatest gain in benefits per mammogram. Women at 
2-to 4-fold average risk could consider annual screening at ages 40 or 50. Sensitivity 
analyses of screening cessation at older ages showed that comorbidity levels could be 
used to tailor stopping age of screening.
Overall, these results suggest that screening starting at age 40 has some benefits, but 
increases the harms substantially. From a public health perspective considering the ratio 
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between harms and benefits, extending the 50 to 74 biennial screening recommenda-
tions to include women aged 40 to 49 is not favorable for average risk women. However, 
from a woman’s perspective the choice to start screening at age 40 may depend on the 
value she attaches to the potential benefits and harms of screening.
Radiation induced breast cancer
The ionizing radiation associated with repeated mammography may increase breast 
cancer risk and could lead to radiation induced cancer. To date, radiation induced breast 
cancer risk was based on exposure from routine screening only and assumed 4 views 
per screening. We considered radiation from routine screening for different subgroups 
of women, diagnostic work-up following an abnormal screening result, false-positive 
recalls, breast biopsies, and follow-up screening examinations. Variation in radiation 
dose was taken into account as some women receive more than the mean radiation 
dose for reasons related to breast thickness, breast augmentation, or breast movement 
during screening. Annual screening including diagnostic work-up among women aged 
40 to 74 years induced 125 breast cancers and 16 breast cancer deaths per 100.000 
women screened. Biennial screening from ages 50 to 74 resulted in 27 breast cancers 
and only 4 breast cancer deaths. Screening and diagnostic work-up among women with 
large breasts lead to 2.3 times more radiation exposure and were consequently at ap-
proximately two times greater risk of radiation induced breast cancer and breast cancer 
death than women with small or average-sized breasts. Overall, our estimates show that 
it is important to account for variation in radiation dose when quantifying the number of 
radiation induced breast cancer and breast cancer deaths
Previous analyses showed that the harms of annual compared to biennial screening 
greatly increased in terms of false-positives and overdiagnoses. We now showed that, 
especially when considering annual screening or screening initiation before age 50, the 
risk of radiation induced breast cancer and breast cancer death is substantial and should 
be taken into account by policy makers, healthcare providers, and ideally women them-
selves. Moreover, among women with large breasts who undergo more views on average 
for a complete screening examination, the radiation induced harms are even greater 
and approximately doubled. In light of the rapid adoption of digital 3-dimensional to-
mosynthesis in the United States and elsewhere, it is important to keep in mind that the 
radiation dose is similar or slightly greater than of digital mammography. It goes without 
saying that combining digital mammography with tomosynthesis doubles the amount of 
radiation exposure and risk for inducing breast cancer.
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part 3: projecting the harms and benefits of risk-based 
breast cancer screening in the united states.
In developed countries, the majority of women adhere to breast cancer screening guide-
lines. Whilst all guidelines recommend women to be screened regularly, there are differ-
ences in the start and stop age of screening as well as in screening interval. (19-21) The 
guidelines have in common the age-based approach to recommend screening. The logic 
behind this approach is that age is the strongest risk-factor for most women and ethically 
all women should have the same rights to potential benefits of screening. However, there 
is also a downside to an age-based approach to screening. For instance, a screening 
guideline of biennial screening from ages 50 to 74 essentially treats all women between 
ages 50 and 74 as being at equal risk for developing breast cancer. It is known that breast 
cancer risk varies among women of the same age.
research question 3: to what extent can risk-based breast cancer 
screening improve the harm-benefit ratio of current age-based screening 
guidelines?
Risk-stratified screening implies that women are screened in a way that is based on their 
risk level. A prerequisite is that ahead of screening some sort of risk-assessment has to 
be made. This could for instance be assessed by asking about their personal or family 
history of breast cancer, measuring their breast density, or testing for genetic risk factors 
such as SNPs or rare variants.
Tailoring breast cancer screening intervals by breast density and risk
Despite the consensus about screening women aged 50 and older that is reflected in 
the various age-based guidelines, it remains challenging to incorporate information on 
breast cancer risk into screening routines beyond age. Breast density is a risk factor 
for breast cancer, may change as women age, and affects mammography performance. 
(22, 23) We estimated the outcomes for screening strategies in the U.S. varying interval 
of screening (annual, biennial, and triennial) tailored to women aged 50 years or older 
with various combinations of breast density and relative risk. Four density levels, in line 
with the American College of Radiology’s Breast Imaging reporting were considered: 1) 
almost entirely fat, 2) scattered fibroglandular density, 3) heterogeneously dense, and 4) 
extremely dense. Additionally, increased risk levels 1.3, 2.0, and 4.0 that represent for 
example post-menopausal obesity, history of a benign breast biopsy, or personal history 
of breast cancer were included. The results showed that screening, regardless of interval 
and age group, yielded more breast cancer deaths averted, life-years gained, and quality 
adjusted life-years among women with dense breast and among women at increased 
relative risk within each density group. In other words, higher breast cancer risk was 
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associated with more benefits of screening. The number of false-positives and benign 
biopsies decreased with increasing risk and density, while overdiagnoses increased by 
risk. When considering a cost-effectiveness threshold of $100,000 per QALY, triennial 
screening was the only effective strategy for women with low breast density at average 
risk. Biennial screening was cost-effective among women at increased risk regardless of 
density, and annual screening was only cost-effective across subgroups at the highest 
(4.0) risk level and breast density categories 3 and 4 (extremely dense).
Overall, we conclude that breast density and risk level can be used to guide screening 
intervals. Across women with varying levels of risk and breast density, those with dense 
breasts at increased risk are most likely to benefit from the current USPSTF guidelines 
of biennial screening from ages 50 to 74. From a policy maker perspective, the results 
suggest that only women with extremely dense breasts at the highest risk levels should 
consider annual screening. Otherwise, annual screening is not cost-effective. Triennial 
screening was cost-effective for a relatively large group of women with low breast density 
and average risk. In international perspective, triennial screening is standard practice in 
the U.K. while in the U.S. this interval is not considered in any guidelines. The modeling 
results show that triennial screening has a similar balance between harms and benefits 
compared to biennial screening. In absolute numbers, the benefits, but also the harms 
are greater for biennial screening, but if relative measures or harm-benefit ratios are 
leading, triennial screening could be considered for low density, average-risk women. 
It remains difficult to extend this analysis to younger (<50) women as breast density is 
unknown until the first mammogram. Incorporating changes in breast cancer risk over 
time or by age could potentially increase the benefits and reduce the harms of risk-
stratified screening.
Personalizing breast cancer screening based on polygenic risk and family history
A first-degree family member diagnosed with breast cancer is a risk factor to develop 
breast cancer and relatively easy to assess. Polygenic risk can be assessed by a SNP 
test using blood or saliva and polygenic risk is presumed to remain unchanged dur-
ing life. These characteristics are the rationale behind our study assessing risk-stratified 
screening approaches using first-degree family history (FH) and polygenic risk scores 
(PRS). The models established risk groups based on first-degree family history and risk 
groups based on a 77-and 167 SNP polygenic risk score. Annual, hybrid, biennial, and 
triennial digital mammography screening strategies starting at ages 30, 35, 40, 45, and 
50 were evaluated for each risk group. Women at high risk due to a first degree family 
history of breast cancer and/or high polygenic risk could initiate screening before age 50. 
Women with below-average polygenic risk could consider triennial screening. We pro-
jected greater benefits (breast cancer deaths averted, life years gained) when targeted 
screening was based on polygenic risk scores rather than family history. The screening 
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approach combining risk from polygenic risk and family history resulted in the maximum 
improvement in benefits compared to current age-based screening guidelines.
Sensitivity analyses including additional, more recently identified SNP only modestly 
improved the benefits and harms. If the discriminatory performance of polygenic risk 
scores improves in the future, different screening scenarios may be optimal from a public 
health perspective. From an individual perspective, the attitude towards the harms and 
benefits of polygenic risk-based screening may result in a different preferred screening 
strategy. We noticed that quite some screening strategies were associated with more 
intense screening than the current biennial 50-74 screening guidelines. To remove this 
aspect and quantify the benefit from just the risk-stratification, we redistributed the 
guideline-concordant number of screens across all women. The outcomes showed that 
life-years gained and breast cancer deaths averted still increased modestly. Conversely, 
this showed that a considerable part of the projected increase in benefits was explained 
by the increase in cancer detection following from more screening examinations.
Increasing number of guidelines advise women to discuss individual breast cancer risk 
with their healthcare providers. Ongoing trials such as the WISDOM trial (24) and My-PEBS 
just started to investigate screening approaches based on genetic markers. Until results 
become available, the model estimates provide specific screening strategies based on 
genetic risk factors that could be considered in practice. Combining multiple risk factors 
such as polygenic risk, breast density, and reproductive, lifestyle, and hormonal factors 
is likely to improve risk prediction and the harm-benefit ratio for stratified screening. In 
all scenarios, obtaining genetic information should be done with utmost care and ethical 
approval. Other ethical aspects of genetic testing such as patient autonomy, accessibility 
to polygenic risk testing, and differential effects across ancestries should be considered 
before the implementation or recommendation of polygenic risk-based screening.
DIRECTIOnS FOR FUTURE RESEARCH BY BREAST CAnCER SIMULATIOn 
MODELS
Microsimulation models are commonly used to evaluate and quantify the benefits and 
harms, i.e. cost and effects of health care policies and interventions. Several applica-
tions and topics for future research related to breast cancer screening modalities, breast 
cancer detection, risk-based screening, and treatment are listed here.
Breast cancer screening modalities
· Estimate the potential impact of screening strategies combining multiple modalities 
such as mammography, tomosynthesis, magnetic resonance imaging, and/or liquid 
biopsies.
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· Estimate the impact of breast self-examination strategies in developing countries.
· Evaluate active surveillance screening strategies using liquid biopsies to monitor 
disease activity and possible treatment response.
Breast cancer detection
· Estimate the harms and benefits of currently available blood-based liquid biopsies in 
detecting circulating tumor DNA and confirming healthy tissue. 
· Estimate the required test performance for liquid biopsies to be cost effective.
· Estimate the current and future potential of computer aided detection reducing the 
harms of screening including false positives, overdiagnoses, and false reassurances.
Risk-based screening 
· Estimate the cost and effects of screening targeted to individual, age-specific, breast 
cancer risk based on a combination of risk factors including polygenic risk (SNPs), 
breast density, rare variants, and lifestyle factors.
· Find the optimal screening strategies for mutation carriers who are at increased risk 
to develop breast cancer with distinct natural history.
· Estimate the potential of combining breast cancer risk (e.g. subtype-specific risk) with 
assumptions about tumor progression rates to inform screening strategies.
Breast cancer treatment 
· Assess the impact of a new treatment or vaccine discovery that can prevent or treat 
metastatic breast cancer.
· Estimate ‘watchful waiting’ strategies for the treatment of DCIS.
Model development / methodology
· Develop models for the interaction between breast cancer risk and tumor progres-
sion.
· Develop models to predict local, regional, and distant breast cancer recurrence.
· Extend the current DCIS models by including prognostic factors for DCIS.
· Further develop the Maximum Clinical Incidence Reduction method to explore the 
effects of model structure and assumptions on predictions about the harms of screen-
ing.
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conclusions
research question 1: how can model description, comparison, and 
validation contribute to a better understanding of model predictions?
Describing the breast cancer natural history, screening, treatment, and demography 
component of micro simulation model MISCAN-Fadia provided necessary information 
to understand the workings of the model. The most important and distinct characteristics 
of the model are continuous tumor growth, the fatal diameter concept representing me-
tastasized “fatal” breast cancer, and the use of tumor size as a proxy for screen detection 
and treatment effects. We concluded that the model is quite flexible and can synthesize 
data from different sources, but also requires recalibration of several inputs before these 
can be used in this tumor-size oriented model. In this detailed model description, we 
justified modeling choices, and listed considerations as well as limitations that should 
improve transparency.
The comparison of model predictions of overdiagnoses among screen detected DCIS 
was 34% to 72% and 2% to 12% among invasive breast cancers in a biennial 50-74 
screening scenario. We concluded that regardless of differences in model structure and 
assumptions about breast cancer natural history, overdiagnoses among DCIS is exten-
sive and as long as the standard of care is treatment of DCIS upon diagnosis, many 
women are overtreated. Convergence of overdiagnoses predictions can be achieved 
when data on, currently unobservable, DCIS progression rates becomes available from 
active surveillance trials.
The models´ predictive ability was formally assessed by the comparison of breast 
cancer incidence and mortality predictions of annual screening from ages 40 to 49 to 
observed outcomes in the Age trial. The models reproduced the patterns in breast 
cancer incidence, but underestimated breast cancer mortality reduction at 10- and were 
more accurate at 17-year follow-up. We concluded that the model structures, existing 
input parameters, and assumptions about breast cancer natural history are reasonable 
for estimating the impact of screening on mortality in the 40-49 age group.
The maximum clinical incidence reduction (MCLIR) method was used to compare mod-
els and disentangle the interplay between screening and treatment interventions with 
model-specific assumptions about unobservable breast cancer natural history. Overall, 
we concluded that in models, the timing of tumor inception and its effect on the length 
of the pre-clinical phase of breast cancer had substantial impact on predictions for breast 
cancer incidence and mortality reduction.
Conclusions 301
research question 2: What are the benefits and harms of current age-
based breast cancer screening in the united states?
The models consistently showed that biennial screening starting at age 40 instead of 50 
lead to disproportionately more false-positives and overdiagnoses among average-risk 
women. Breast cancer mortality was only modestly lowered, but QALYs gained increased 
by 22%. Compared to annual screening strategies, biennial screening resulted in the 
greatest gain in benefits per mammogram and dominated annual strategies for average-
risk women. Only for women at 2-to 4-fold average risk could consider annual screening 
at ages 40 or 50. Overall, we concluded that screening starting at age 40 has some 
benefits, but increased the harms substantially.
In light of the simultaneous improvements in breast cancer screening and treatment 
in the last decade, the models incorporated the transition from film to digital mam-
mography and included molecular subtype specific breast cancer treatments to separate 
the contributions of either to breast cancer mortality reduction. In 2000, the contribution 
of screening to overall breast cancer mortality reduction was 44% vs. 56% explained by 
treatment. We showed that between 2000 and 2012 there has been a shift in relative 
contributions, screening was estimated to be responsible for 37% and treatment for 
63% of the total breast cancer mortality reduction in 2012. The models concluded that 
dissemination and improved delivery of new molecularly targeted therapies has had a 
stronger impact than screening improvements on breast cancer mortality between 2000 
and 2012.
The ionizing radiation associated with repeated mammography may increase breast 
cancer risk and could lead to radiation induced cancer. Annual screening including diag-
nostic work-up among women aged 40 to 74 years induced 125 breast cancers and 16 
breast cancer deaths per 1.000 women screened. Biennial screening from ages 50 to 74 
resulted in 27 breast cancers and only 4 breast cancer deaths. Overall, we concluded that 
it is important to account for variation in radiation amount caused by diagnostic work-up 
following an abnormal screening result, false-positive recalls, breast thickness, breast 
augmentation, breast biopsies, and follow-up screening examinations when quantifying 
the number of radiation induced breast cancer and breast cancer deaths
research question 3: to what extent can risk-based breast cancer 
screening improve the harm-benefit ratio of current age-based screening 
guidelines?
The results of screening based on breast density and risk-level showed that increased 
breast cancer risk from either source was associated with more benefits of screening. 
Conversely, the number of false-positives and benign biopsies decreased with increasing 
risk and density while the number of overdiagnoses increased by risk. When considering 
a cost-effectiveness threshold of $100,000 per QALY, triennial screening was the only 
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effective strategy for women with low breast density at average risk. Biennial screening 
was cost-effective among women at increased risk regardless of density, and annual 
screening was only cost-effective across subgroups at the highest (4.0) risk level and 
breast density categories 3 and 4 (extremely dense). Overall, we concluded that breast 
density and risk level can be used to guide screening intervals.
We projected greater benefits (breast cancer deaths averted, life years gained) when 
screening was based on polygenic risk scores rather than family history. The screening 
approach combining risk from polygenic risk and family history resulted in the maximum 
improvement in benefits compared to current age-based screening guidelines. Women 
at high risk due to a first degree family history of breast cancer and/or high polygenic risk 
could initiate screening before age 50. Women with below-average polygenic risk could 
consider triennial screening. A large part of the projected increase in benefits was ex-
plained by the increase in cancer detection following from more screening examinations. 
Nevertheless, the benefits would still modestly increase at equal number of screens.
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304 Summary (EN)
summary
Chapter 1 introduces the motivation and overall topic of this thesis: breast cancer, and 
breast cancer screening. The causes, risk-factors, incidence, survival, and breast cancer 
mortality are described. Potential benefits of early detection through screening are: 
life-years gained, improved quality of life, breast cancer deaths prevented, correct reas-
surance among women without breast cancer. Potential harms of screening include false 
reassurance, overdiagnosis, overtreatment, false-positive screening test results, and to 
some extent the temporary uncertainty after screening, and exposure to radiation that 
can induce breast cancer. The scientific body of evidence on breast cancer screening 
that has been gathered in the past decennia, has led to the widespread use of mam-
mography worldwide. However, there is no consensus about which screening strategy is 
optimal. This is the area where simulation models are used to make projections about the 
effects of various different screening strategies. In this thesis, we investigate how model 
predictions can be better understood and to what extent risk-stratification can increase 
the benefits of breast cancer screening.
part 1: breast cancer micro-simulation: methods, comparative modeling, 
and model validation.
Chapter 2 provides an overview of microsimulation screening analysis – Fatial diameters 
(MISCAN-Fadia) model. The four main components of the model: demography, breast 
cancer natural history, screening , and treatment are described in detail. The MISCAN-
Fadia model distinguishes itself from many other models by using a biological entry such 
as tumor growth and tumor size to modeling the natural history of breast cancer. The 
effectiveness of treatment and the sensitivity of screening are both linked to tumor size. 
The model adopts a ‘fatal diameter’ concept which implies that a cancer is not curable 
anymore and basically represents distant metastasis of breast cancer. The model is able 
to simulate many screening and treatment strategies in a short amount of time with 
varying adherence to screening and treatment. In each simulation, women differing in 
risk, birthyear, and life expectancy can be included. The model produces estimates of 
lifeyears gained, breast cancer eaths prevented, stage distributions, overdiagnoses, and 
interval cancer. Recent model developments include radiation induces breast cancers, 
breast density, and cancer by molecular subtype.
Chapter 3 shows how the CISNET breast cancer models simulate DCIS. Since the intro-
duction of mammpgraphy screening in the 1980’s in the United States, the incidence of 
DCIS, which is seen as a precursor of breast cancer, increased substantially. Uncertainty 
remains about the natural history of DCIS because tumor onset and tumor progression 
cannot be observed. In the 5 CISNET models, invasive breast cancer can develop from 
preclinical screen-detectable DCIS, or preclinical undetectable DCIS. A part of preclinical 
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DCIS may also regress. The models estimate that a large part of screen detected DCIS 
are overdiagnoses: 34%-72% in a biennial 50 to 74 screening strategy. Overdiagnosis 
is defined as a screen detected tumor that in the absence of screening would not have 
been found. The model predictions show no association between the amount of DCIS- 
and invasive overdiagnoses. The large differences in predictions of overdiagnosed DCIS 
cases, which is also found in other scientific literature, reflects the uncertainty around the 
natural history of DCIS. This underscores the importance of active surveillance trials such 
as the LORD, LORIS, and COMET trial that can provide more observed data on DCIS 
natural history.
Chapter 4 presents an external validation that compares model predictions to ob-
served data from the ‘U.K. Age trial’. The trial compared annual mammography screen-
ing in women aged 40 to 49 to a control group who were offered usual care, which is 
no screening in this age group. The 5 CISNET models used demography, screening 
attendance, and mammographic sensitivity from the trial in combination with extant as-
sumptions about the onset en natural history of breast cancer to predict the incidence 
and mortality in the intervention and control arm. The results show that the effect of an-
nual screening on breast cancer incidence is reproduced quite well. The average breast 
cancer mortality reduction after 10 years of follow-up was underestimated by the models 
15% (range: 13% to 17%) compared to 25% (95% CI, 3% to 42%) in the trial. After 17 
years of follow-up, the trial showed a 12% (95% CI, -4% to 26%) non-significant reduction 
and the models 13% (10% - 17%) on average. We conclude that the models reproduced 
the long term effects of the age trial reasonably well. This suggests that the existing 
model structures, model input parameters, and assumptions are suitable for estimating 
the effect of screening on breast cancer mortality in this age group.
In chapter 5, investigates how model structures and assumpations about the preclinical 
duration of breast cancer influence model predictions. The Maximum Clinical Incidence 
Reduction (MCLIR) method is used and extended to disentangle the effects of tumor 
growth rate, timing of tumor onset, screening sensitivity, and treatment effectiveness. 
The models do this in a simplified setting of a single screen at age 62 with varying 
assumptions about test sensitivity and treatment effectiveness. The MCLIR method 
compares changes in the number of breast cancer cases and deaths in 4 scenarios: 1. 
no screening, 2. a screen with perfect (100%) sensitivity and perfect treatment (100% 
cure), 3. a screen with sensitivity of digital mammography and perfect treatment, 4. a 
screen with sensitivity of digital mammography and realistic (observed) effectiveness of 
treatment. The models predict a 19% to 71% reduction in clinical incidence and 33% 
to 67% reduction in breast cancer mortality as a result of a perfect screening test and 
perfect treatment. In the scenario with sensitivity of digital mammography and realistic 
treatment effectiveness, the prediction converge: 11% to 24% clinical incidence reduc-
tion and 8% to 18% breast cancer mortality reduction. The timing of tumor onset and its 
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influence of the preclinical duration had the largest impact on model predictions. Models 
with relatively fast progressing tumors also had a shorter preclinical duration. The MCLIR 
method can shed light on the root of the differences between model predictions and can 
be applied in other disease settings where the effects of screening are modeled.
part 2 – Quantifying the harms and benefits of breast cancer screening 
among women in the united states
In chapter 6, the harms and benefits of eight screening strategies varying in starting 
age and interval are estimated by 6 cisnet models. The target population was average 
risk women and women at increased breast cancer risk due to their breast density or 
co-morbidity. Biennial screening from ages 50 to 74 prevented 7 breast cancer deaths 
on average compared to no screening. Annual screening in the same age ranges would 
prevent 3 additional breastr cancer deaths, but would increase false-positives by almost 
2.000 per 1.000 women screened over a lifetime. Starting annual screening at age 40 
showed similar harms and benefits among women with 2 to 4 times the average risk. 
Women with moderate to severe comorbidity could stop screening at age 66 or 68. All 6 
models conclude that starting screening at age 40 leads to a small benefit in terms of life 
years gained and breast cancer deaths prevented, but the increase in false positives and 
overdiagnoses is substantial. This quantitative analyses shows that biennial screening 
among average risk women is most efficient. Policy makers cab use this information to 
inform their decision about breast cancer screening policy.
In chapter 7, six breast cancer simulation models are used to assess the relative contri-
butions of screening and treatment to the trend in breast cancer mortality between 2000 
and 2012. Given the improvements in treatment and new adjuvant therapies which were 
given to breast cancer patients in these periods, the analysis focuses on combination of 
breast cancer subtypes estrogen receptor (ER) positive and human epidermal growth 
factor receptor (HER) 2. In 2000, the models estimate a 37% (27%-42%) breast cancer 
mortality reduction vs. no screening. 56% of this reduction is explained by breast cancer 
treatment and 44% by screening. However, in 2012 the total breast cancer mortality 
reduction is estimated at 49% (39%-58%) of which 37% is explained by screening and 
63% by improvemens in treatment. For 3 out of the 4 subtypes it holds that treatment 
has made a larger contribution to the decline in breast cancer mortality, except for the 
ER-/HER2- tumors where the contributions of screening and treatment are estimated as 
approximately equal. The models conclude that in 2000 to 2012 the continued decline 
in overall breast cancer mortality can be explained for a larger part by new and improved 
treatments than by screening in this period.
Chapter 8 investigates to what extent the exposure to the ionizing radiation of re-
peated mammography screening contributes to breast cancer and breast cancer death. 
Prior research was based on 4 views per screening and did not account for breast size 
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and breast thickness, nor false-positives, diagnostic work-up, and variations in radia-
tion dose caused by breast augmentation or breast positioning during screening. This 
study accounted for these factors because of their impact on the overall radiation dose 
and consequent radiation induced breast cancers. We estimated the radiation induced 
breast cancer in 8 screening strategies varying starting age (40, 45, 50) and screening 
interval (annual, biennial, hybrid). The benefits of annual screening of 100.000 women 
between ages 50 and 74 are estimated at 968 breast cancers prevented, but would 
also induce 125 breast cancer and 16 breast cancer deaths through radiation. Among 
women with large breasts, 8% receives more radiation doses during screening and this 
was estimated to cause 266 breast cancers of which 35 would lead to breast cancer 
death per 100.000 women screened. The results in this study show that it is important to 
account for variations in radiation dose from and after screening when determining the 
number of radiation induced breast cancers and breast cancer deaths.
part 3: projecting the lifetime harms and benefits of risk-based breast 
cancer screening.
In chapter 9, the effects of screening among women with varying breast density and risk 
are quantified. Three CISNET models simulate the effect of annual, biennial, and hybrid 
screening between ages 50 and 74 or 65 and 74. We distinguished four density groups 
spanning between almost entirely fat to extremely dense breast tissue. Increased breast 
cancer risk caused by other factors was modeled by including 4 relative risk groups: 1.0 
(average risk), 1.3, 2.0, 4.0. The results show that in all screening intervals, the breast 
cancer deaths prevented and life years gained increased with breast density as well as 
increases in relative risk from other factors. At the same time, false positives and unnec-
essary biopsies decreased while overdiagnoses increased. The results in this study show 
that breast density and increased risk due to other factors can be useful in the formation 
of risk-based screening guidelines.
In chapter 10 we investigated the effects of screening based on breast cancer family 
history and small DNA variations and how these relate to the results of age-based screen-
ing guidelines. Two CISNET models estimated the effects of screening strategies with 
starting ages (30, 35, 40, 45, 50) and stopping age 74, and screening intervals (annual, 
biennial, triennial, hybrid). Among women younger than age 50 with a first-degree family 
member diagnosed with breast cancer; about 9% of the population, starting screening 
before age 50 would gain 44% life years and avert 24% breast cancer deaths compared 
to starting screening at age 50. However, the increase in the number of mammograms 
among these women also led to 25% more overdiagnoses and false positives would 
double. Screening based on polygenic risk gained 19% additional life years, prevented 
11% breast cancer deaths, and overdiagnoses and false positives increased by 10% and 
26%. Screening based on breast cancer family history and polygenic risk resulted in the 
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largest increase in benefits compared to current USPSTF guideline screening. This study 
showed that risk stratified screening can lead to fewer breast cancer deaths and more life 
years gained among women who are at increased risk of breast cancer due to polygenic 
risk and family history.
Samenvatting (nL)
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samenvatting
Hoofdstuk 1 introduceert zowel de aanleiding als het overkoepelende thema van dit 
proefschrift: borstkanker en borstkankerscreening. Naast de oorzaken en risicofactoren 
worden ook de incidentie, overleving, en sterfte aan borstkanker besproken. De po-
tentiele voordelen van vroege opsporing door middel van borstkankerscreening zijn: 
gewonnen levensjaren, verhoogde levenskwaliteit, voorkomen borstkanker sterfgeval-
len, en terechte geruststelling bij gezonde vrouwen zonder borstkanker. De potentiele 
nadelen van screening zijn: onterechte geruststelling, overdiagnose en overbehandeling, 
fout-positieve uitslagen, en in mindere mate de tijdelijke onzekerheid na het screenen, 
en blootstelling aan straling wat kan bijdragen aan de ontwikkeling van borstkanker. 
Het wetenschappelijk bewijs voor borstkankerscreening wat in de afgelopen decennia 
is vergaard, heeft ertoe geleid dat wereldwijd vrouwen regelmatig worden gescreend. 
Echter is er geen consensus over welke screeningstrategie optimaal is. Dit is het ge-
bied waarin simulatiemodellen gebruikt worden om voorspellingen te maken over de 
effecten van verschillende screeningstrategien. In dit proefschrift wordt onderzocht hoe 
we voorspellingen van meerdere modellen beter kunnen begrijpen en in welke mate 
risico-stratificatie de voordelen van borstkankerscreening kan vergroten.
part 1: breast cancer micro-simulation: methods, comparative modeling, 
and model validation.
Hoofdstuk 2 geeft een overzicht van het Microsimulation Screening Analysis – Fatal 
diameter (MISCAN-Fadia) model. De vier belangrijkste componenten van het model: 
demografie, natuurlijk beloop van borstkanker, screening en behandeling worden 
uitvoerig besproken. Het MISCAN-Fadia model onderscheidt zich van veel andere 
modellen door een biologische grondslag zoals tumor groei en tumor grootte te nemen 
om het ontstaan en verloop van borstkanker te simuleren. Zowel de effectiviteit van 
behandelingen in het genezen van borstkanker en de gevoeligheid van de screening 
test wordt in MISCAN-Fadia gelinkt aan tumor grootte. Het model hanteert het ‘fatale 
diameter’ concept wat de niet meer geneesbare staat van kanker, metastase op afstand, 
symboliseert in de vorm van een fatale tumor grootte. Het model is in staat om in een kort 
tijdsbestek vele screening strategieën en behandelschema’s te simuleren met variërende 
screeningopkomst en therapietrouw . In deze simulatie kunnen vrouwen van verschillend 
geboortejaar, risico en levensverwachting tegelijkertijd worden gesimuleerd. Het model 
produceert schattingen voor onder andere gewonnen levensjaren, voorkomen borst-
kanker sterfgevallen, stadium verdelingen, overdiagnoses, en interval kankers. Recente 
ontwikkelingen omvatten het simuleren van vrouwen met verschillende borstdichtheid, 
de impact door straling geïnduceerde borstkankers, en trendanalyses in borstkanker 
naar moleculair subtypes.
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Hoofdstuk 3 laat zien hoe de CISNET borstkankermodellen DCIS simuleren. Sinds de 
introductie van mammografie screening in de jaren ‘80 in de Verenigde Staten is de inci-
dentie van DCIS, wat gezien wordt als voorstadium van en risicofactor voor borstkanker, 
sterk toegenomen. Er is onzekerheid over het natuurlijk beloop van DCIS omdat het 
ontstaan van een tumor en progressie snelheid niet observeerbaar zijn. In de 5 CISNET 
modellen kan invasieve borstkanker ontstaan uit pre-klinische screen-detecteerbare 
DCIS, of uit pre-klinische nog niet screen-detecteerbare DCIS. Daarnaast kan een deel 
van de pre-klinische DCIS ook regresseren. De modellen schatten dat een groot deel 
van de screen gedetecteerde DCIS overdiagnoses zijn: 34% - 72% bij tweejarig screenen 
tussen leeftijden 50 en 74. Overdiagnose is hier gedefinieerd als een screen gedec-
teerde tumor die in de afweigheid van screening niet gevonden zou zijn geworden. De 
model voorspellingen laten geen verband zien tussen de hoeveelheid DCIS-en invasieve 
overdiagnoses. De grote verschillen tussen voorspelde over-gediagnosticeerde DCIS 
gevallen, wat ook in andere wetenschappelijke literatuur wordt gevonden, geeft de 
onzekerheid over het natuurlijk beloop van DCIS weer. Dit onderschrijft het belang van 
active surveillance trials zoals de LORD, LORIS en COMET trial die meer geobserveerde 
data kunnen verschaffen over het natuurlijk beloop van DCIS.
Hoofdstuk 4 is een externe validatie waarbij model voorspellingen worden vergeleken 
met geobserveerde data uit de ‘U.K. Age trial’. Deze trial vergeleek jaarlijkse mammo-
grafie screening in vrouwen tussen de 40 en 49 jaar met een controle groep die de ge-
bruikelijke zorg ontvingen, wat geen screening is in deze leeftijdsgroep. De vijf CISNET 
modellen gebruikten demografie, screeningsdeelname, en mammografie sensitiviteit van 
de U.K. Age trial in combinatie met bestaande aannames over het ontstaan en natuurlijk 
beloop borstkanker om de incidentie en moraliteit in de interventie en controle arm te 
voorspellen. De resultaten laten zien dat het effect van jaarlijks screenen op borstkanker 
incidentie goed wordt gereproduceerd door de modellen. De gemiddelde voorspelde 
borstkanker mortaliteitsreductie na tien jaar follow-up was 15% (range: 13% tot 17%) en 
daarmee onderschat vergeleken met de 25% (95% CI, 3% to 42%) gevonden in de trial. 
Na 17 jaar vond de trial een 12% (95% CI, -4% to 26%) niet-significante reductie en de 
modellen gemiddeld 13% (10% - 17%). In deze externe validatie concluderen we dat de 
modellen de lange termijn effecten van de U.K. Age trial redelijk goed reproduceren. Dit 
suggereert dat de model structuren, model input parameters, en aannames geschikt zijn 
om het effect van screenen op borstkanker mortaliteit in deze leeftijdsgroep te schatten.
In hoofdstuk 5, wordt onderzocht hoe model structuren en aannames over de pre-
klinische duur van borstkanker invloed hebben op voorspellingen. De ‘Maximum Clinical 
Incidence Reduction’ (MCLIR) methode wordt gebruikt en uitgebreid om de effecten van 
tumor groeisnelheid, de timing van het ontstaan van de tumor, screening test sensitiviteit 
en behandelingseffectiviteit te ontrafelen. De modellen doen dit door de effecten van 
één screen op leeftijd 62 te simuleren met variërende aannames over screening sensiti-
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viteit en behandelingseffect. De MCLIR methode vergelijkt veranderingen in het aantal 
borstkankers (niet screen gedetecteerd) en borstkanker sterfgevallen in vier scenario’s: 
1. geen screening, 2. één screening test op leeftijd 62 met perfect (100%) sensitiviteit en 
perfecte (gegarandeerd genezende) behandeling, 3. één screening test met sensitiviteit 
van digitale mammografie op leeftijd 62 met en perfecte behandeling, 4. één screening 
test met sensitiviteit van digitale mammografie op leeftijd 62 met geobserveerde be-
handelingseffectiviteit. De modellen voorspellen een 19% tot 71% reductie in klinische 
incidentie als gevolg van een perfecte screen met perfecte behandeling en 33% tot 67% 
borstkanker mortaliteit reductie. In het scenario met sensitiviteit van digitale mammogra-
fie en realistische behandelingseffectiviteit liggen de voorspellingen een stuk dichterbij 
elkaar: 11% tot 24% reductie in klinische incidentie en 8% tot 18% borstkanker mortaliteit 
reductie. Het moment van tumor ontwikkeling en de invloed op de preklinische duur had 
het grootste effect op de model voorspellingen voor incidentie en mortaliteit. Model-
len met een relatief snellere tumorgroei lieten gemiddeld genomen ook een kortere 
preklinische duur zien. De MCLIR methode kan licht schijnen op de oorsprong tussen 
verschillen in modelvoorspellingen en kan ook worden toegepast in andere ziektes waar 
het effect van screenen gemodelleerd wordt.
part 2 – Quantifying the harms and benefits of breast cancer screening 
among women in the united states
In hoofdstuk 6 worden de voor-en nadelen van acht screening strategieën varierend in 
start leeftijd en screening interval door 6 modellen geschat. De doelgroepen zijn gemid-
deld risico vrouwen en vrouwen met een verhoogd borstkanker risico door borstdichtheid 
of co-morbiditeit. Tweejaarlijks screening van leeftijd 50 tot 74 voorkwam gemiddeld 7 
borstkanker sterfgevallen vergeleken met helemaal niet screenen. Jaarlijks screenen in 
dezelfde leeftijden zou 3 extra sterfgevallen voorkomen, maar wel tot bijna 2000 extra 
fout-positieven leiden per 1000 gescreende vrouwen. Jaarlijks screenen vanaf leeftijd 40 
heeft vergelijkbare voor-en nadelen voor vrouwen met een 2 tot 4-keer zo hoog risico als 
gemiddeld risico vrouwen. Vrouwen met matig tot ernstige co-morbiditeit zouden kun-
nen stoppen met screenen op leeftijd 66 of 68. Alle 6 modellen concluderen dat starten 
met screenen op leeftijd 40 leidt tot een kleine toename in gewonnen levensjaren en 
voorkomen borstkanker sterfgevallen, maar de toename in nadelen zoals in fout-posi-
tieven en overdiagnosen is groter. Deze kwantitatieve analyse laat zien dat tweejaarlijks 
screening voor gemiddeld risico vrouwen het meest efficient is. Beleidsmakers kunnen 
met deze uitkomsten hun overwegingen of beslissingen omtrent borstkanker screenen 
ondersteunen.
In hoofdstuk 7 wordt, gebruikmakend van 6 borstkanker simulatiemodellen, onder-
zocht wat de relatieve bijdrage van screening en behandeling is aan de trends in borst-
kankersterfte tussen 2000 en 2012. Gezien de verbeteringen in behandeling en nieuwe 
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adjuvante therapieën die in deze periode aan borstkanker patiënten zijn gegeven, 
concentreert deze analyse zich op combinaties van borstkanker subtypes oestrogeen re-
ceptor (ER) positief en human epidermal growth factor receptor (HER) 2. In 2000 schatten 
de modellen de borstkanker mortaliteitsreductie op 37% (27%-42%) vs. geen screening. 
56% van deze reductie verklaren de modellen door borstkanker behandeling en 44% is 
toe te wijzen aan screening. Echter, in 2012 wordt de totale borstkankersterfte reductie 
geschat op 49% (39%-58%) waarvan 37% door screening en 63% door verbeterde be-
handelingen. Voor drie van de vier subtypes geldt dat behandeling een grotere bijdrage 
heeft gehad in de afgenomen borstkankersterfte, behalve voor ER-/HER2- schatten de 
modellen de bijdrage van screening en behandeling als praktisch even groot. Daarmee 
concluderen de modellen dat in de periode 2000 tot 2012 de verdere afname in totale 
borstkankersterfte voor een groter deel te verklaren is door de verbeterde en nieuwe 
behandelingen dan door screening in deze periode.
Hoofdstuk 8 onderzoekt in welke mate herhaaldelijke mammografie screening leidt 
tot borstkanker of zelfs borstkankersterfte door blootstelling aan straling. Voorgaand 
onderzoek was gebaseerd op 4 röntgen foto’s per screening en hield geen rekening 
met borstgrootte en dikte, fout-positieve screening resultaten, diagnostisch vervolgon-
derzoek na een abnormaal screenings resultaat, of variaties in stralingsdosering door 
een borstvergroting of verkeerde borstpositionering. Deze studie houdt wel rekening 
met deze factoren aangezien deze allemaal invloed hebben op het aantal door straling 
geïnduceerde borstkankers. We schatten de straling geïnduceerde borstkanker inciden-
tie en sterfte voor 8 verschillende screening strategieën die variëren naar startleeftijd 
(40, 45, 50) en screening interval (jaarlijks, tweejaarlijks, hybride). De voordelen van het 
jaarlijks screenen van 100,000 vrouwen tussen leeftijd 40 en 74 worden geschat op 968 
voorkomen borstkanker doden, maar dit leidt ook tot 125 borstkankers en 16 borstkan-
ker doden die ontstaan door de straling. Voor 8% van de vrouwen met grote borsten 
die meer straling ontvangen bij screenen worden het aantal borstkankers en borstkanker 
doden geschat op 266 en 35 per 100,000 vrouwen. De resultaten uit dit onderzoek laten 
zien dat het belangrijk is om de variaties in de hoeveelheid schadelijke straling tijdens 
en na het screenen mee te nemen bij het bepalen van het aantal straling geïnduceerde 
borstkankers en borstkanker doden.
part 3: projecting the lifetime harms and benefits of risk-based breast 
cancer screening.
In hoofdstuk 9 wordt het effect van verschillende screening strategieën op vrouwen met 
variërende borstdichtheid en borstkankerrisico gekwantificeerd. Drie CISNET modellen 
simuleren het effect van jaarlijks, tweejaarlijks, en hybrid screenen tussen leeftijden 50 
en 74 of 65 en 74. We onderscheiden voor borstdichtheid 4 groepen van bijna volledig 
vetweefsel tot extreem dicht borstweefsel. Voor een verhoogt borstkankerrisico door 
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andere factoren worden ook 4 risicogroepen gemodelleerd met een relatief risico van: 
1.0 (gemiddeld risico), 1.3, 2.0, en 4.0. De resultaten laten zien dat voor alle screening 
intervallen de voorkomen borstkanker doden en gewonnen levensjaren toenemen naar-
mate zowel borstdichtheid als het borstkankerrisico toenemen. Tegelijkertijd nemen fout 
positieve screenings en onnodige biopsieën af, echter neemt het aantal over diagnoses 
wel toe. De resultaten uit deze studie laten zien dat borstdichtheid en een verhoogd 
risico bruikbaar kunnen zijn bij het opstellen van risico-gebaseerde screening richtlijnen.
In hoofdstuk 10 wordt onderzocht hoe de effecten van screening gebaseerd op familie 
historie van borstkanker en kleine afwijkingen in het DNA zich verhouden tot die van 
de op leeftijd gebaseerde screening richtlijnen. Twee CISNET modellen schatten de ef-
fecten van screening strategieën met verschillende startleeftijd (30, 35, 40, 45, 50) met 
stopleeftijd 74 en screening interval (jaarlijks, tweejaarlijks, driejaarlijks, hybride). Voor 
jonge vrouwen (<50) met een eerstegraads familielid met borstkanker; ongeveer 9% in 
de populatie, levert eerder beginnen met tweejaarlijks screenen 44% extra gewonnen 
levensjaren en 24% minder borstkanker doden ten opzichte van beginnen met tweejaar-
lijks screenen op leeftijd 50. Echter, de toename in mammogrammen leidt in deze groep 
ook tot naar schatting 26% meer overdiagnoses en het aantal fout positieven verdub-
belt. Screenen gebaseerd op polygenetisch risico, levert op populatie niveau 19% extra 
gewonnen levensjaren, 11% minder borstkanker doden, overdiagnoses stijgen met 10% 
en fout positieven met 26%. Screenen gebaseerd op familie historie van borstkanker en 
polygenetisch risico levert de meeste voordelen op ten opzichte van de huidige USPSTF 
richtlijnen. Dit onderzoek laat zien dat risico gestratificeerd screenen voor een aantal 
groepen vrouwen met een verhoogt risico op borstkanker door een familie historie met 
borstkanker en afwijkingen in hun DNA minder borstkanker doden en meer levensjaren 
kan opleveren.
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Professor of Epidemiology on Breast cancer screening based on genetic risk 
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including in-person meetings at the Dana-Farber Cancer Institute, Harvard 
School of Public Health and Harvard Medical School.
2017
(4 months)
4.0 ECTS
Reviewing manuscript for Eastern Mediterranean Health Journal. 2014 0.3 ECTS
Total 4.3 ECTS
Total Total 36.9 ECTS
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